

ACCESSION NUMBER:		0001185185-14-000776
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20131231
FILED AS OF DATE:		20140331
DATE AS OF CHANGE:		20140331
FILER:
	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AV Therapeutics
 Inc.
		CENTRAL INDEX KEY:			0001537293
		STANDARD INDUSTRIAL CLASSIFICATION:	GRAIN MILL PRODUCTS [2040]
		IRS NUMBER:				331222799
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231
	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55149
		FILM NUMBER:		14730722
	BUSINESS ADDRESS:	
		STREET 1:		20 EAST 68TH STREET
 SUITE 204
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10065
		BUSINESS PHONE:		917-497-5523
	MAIL ADDRESS:	
		STREET 1:		20 EAST 68TH STREET
 SUITE 204
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10065
	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Merica Corp.
		DATE OF NAME CHANGE:	20130731
	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Code 2 Action
 Inc.
		DATE OF NAME CHANGE:	20130618
	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AQUINO MILLING INC
		DATE OF NAME CHANGE:	20111214









    









































For the year ended December 31
 2013




















AV Therapeutics
 Inc.
























20 East 68th Street
 Suite 204
New York
 NY 10065










Securities registered pursuant to Section 12(g) of the Act: Common Stock
 par value $0.0001








Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports)
 and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site
 if any
 every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;


Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein
 and will not be contained
 to the best of registrant&#8217;s knowledge
 in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K .&#160;&#160;


Indicate by check mark whether the registrant is a large accelerated filer
 an accelerated filer
 a non-accelerated filer
 or a smaller reporting company.&#160;&#160;See the definitions of &#8220;large accelerated filer&#8221;
 &#8220;accelerated filer&#8221;
 and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.
























As of June 30
 2013
 the aggregate market value of the issued and outstanding common stock held by non-affiliates of the registrant
 based upon the last sales price of our common stock of $0.20 (unadjusted for the Company&#8217;s 70-for-one forward stock split) was approximately $40
000. For purposes of the above statement only
 all directors
 executive officers and 10% shareholders are assumed to be affiliates.&#160;&#160;This determination of affiliate status is not necessarily a conclusive determination for any other purpose.


Number of shares of common stock outstanding as of March 28
 2014 was 77
480
796.























FOR THE FISCAL YEAR ENDED DECEMBER 31
 2013











































































Market for Registrant&#8217;s Common Equity
 Related Stockholder Matters and Issuer Purchases of Equity Securities







































































Directors
 Executive Officers
 and Corporate Governance























Certain Relationships and Related Transactions
 and Director Independence
























































AV Therapeutics
 Inc. (the &#8220;Company&#8221;) is a Delaware corporation formed on November 14
 2011 under the name &#8220;Aquino Milling Inc.&#8221; Under its initial business plan
 the Company intended to purchase rice milling equipment and commence rice milling operations. On June 10
 2013
 the Company changed its name to &#8220;Code 2 Action
 Inc.&#8221; On July 30
 2013
 the Company changed its name to &#8220;Merica Corp.&#8221; The Company was unable to implement its business plan. Prior to the Reverse Acquisition (discussed below)
 Merica did not have any active business.


On December 13
 2013 (the &#8220;Closing Date&#8221;)
 the Company entered into and closed an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;)
 with AVT Acquisitions
 Inc.
 a Delaware corporation and a wholly-owned subsidiary of the Company (the &#8220;Subsidiary&#8221;) and Advanced Vaccine Therapeutics
 Inc.
 a Delaware corporation (formerly known as AV Therapeutics
 Inc.) (&#8220;AVT&#8221;). Pursuant to the Merger Agreement
 (i) the Subsidiary merged into AVT
 such that AVT became a wholly-owned subsidiary of the Company
 and (ii) the Company issued 58
000
000 shares (the &#8220;Acquisition Shares&#8221;)
 of the Company&#8217;s common stock to the shareholders of AVT
 in exchange for the cancellation of all of the issued and outstanding shares of common stock of AVT.


In connection with the Merger Agreement
 in addition to the foregoing:


(i)&#160;Effective on the Closing Date
 70
000
000 shares of common stock were returned to the Company for cancellation (the &#8220;Share Cancellation&#8221;).


(ii)&#160;Effective on the Closing Date
 Mr. Doug Cole resigned as an officer of the Company. Mr. Cole resigned as a director of the Company on February 5
 2014. In addition
&#160;the following individuals were appointed as executive officers and directors of the Company:

















Chief Executive Officer
 Chief Financial Officer
 Chairman















President
 Chief Operating Officer







Chief Scientific Officer
 Director




















(iii)&#160;On December 19
 2013
 the Company changed its name from &#8220;Merica Corp.&#8221; to &#8220;AV Therapeutics
&#160;Inc.&#8221;


In connection with the Merger Agreement
 the Company entered into and closed subscription agreements with accredited investors (the &#8220;Investors&#8221;)
 pursuant to which the Company sold an aggregate of 3
550
000 shares of common stock for an aggregate purchase price of $709
999 (the &#8220;Private Placement&#8221;).


AVT is a Delaware corporation formed on February 11
 2011.&#160;&#160;Prior to the date of incorporation
 the activities of AVT were carried out through Applied Vaccine Technology
 LLC (&#8220;AVT
 LLC&#8221;)
 a Delaware limited liability company formed in July 2007 and an entity with common ownership as AVT.&#160;&#160;The operations and net assets of AVT
 LLC were acquired by AVT on February 11
 2011 and AVT
 LLC has since been an inactive entity.


Effective on the Closing Date
 pursuant to the Merger Agreement
 AVT became a wholly owned subsidiary of the Company. The acquisition of AVT is treated as a reverse acquisition (the &#8220;Reverse Acquisition&#8221;)
 and the business of AVT became the business of the Company. At the time of the Reverse Acquisition
 Merica was not engaged in any significant active business.

References to &#8220;we&#8221;
 &#8220;us&#8221;
 &#8220;our&#8221; and similar words refer to the Company and its wholly-owned subsidiary
 AVT
 unless the context otherwise requires
 and prior to the effectiveness of the Reverse Acquisition
 these terms refer to AVT.&#160;References to &#8220;Merica&#8221; refer to the Company and its business prior to the Reverse Acquisition.




















AVT&#160;&#160;is&#160;&#160;primarily&#160;&#160;engaged&#160;&#160;in&#160;&#160;the&#160;&#160;business&#160;&#160;of&#160;&#160;developing&#160;&#160;cancer&#160;&#160;therapeutics&#160;&#160;and immunotherapeutic vaccines that can be used together with prevalent treatment modalities such as chemotherapy and radiation to treat active disease and to prevent metastases and recurrence. AVT has purchased the exclusive rights to a patented chemotherapeutic drug called &#8220;Capridine&#8221; that has been shown in preclinical models to have specific activity against prostate and colon cancer. This drug is expected to be the front line AVT product specifically in prostate cancer where limited chemotherapy is available at the present time. Our immuno-therapeutics is based on the ability of certain proprietary reagents to re-educate or reprogram a failed immune system that can target previously unidentified micro-metastases. We intend to clinically develop both of these approaches independently specifically for prostate cancer. This drug was developed and patented by certain scientists on behalf of New York Medical College
 including Dr. Raj Tiwari
 AVT&#8217;s Chief&#160;Scientific Officer
 who is also a professor at New York Medical College. The drug patents were thus issued to New York Medical College. AVT subsequently purchased an exclusive license to the drug
 including the exclusive right to commercialize the drug. Under our agreement with New York Medical College
 we agreed to pay New York Medical College 3% of net sales (as defined in the agreement) from commercialization of the drug patents
 and 30% of sublicense fees. In addition to Dr. Raj Tiwari
 Dr. Abraham Mittelman
 our Chief Executive Officer
 Dr. Jan Geliebter
 our Corporate Secretary
 and Dr. Debabrata Banerjee
 our Clinical Development Officer
 are professors at New York Medical College.


We have
 in the past
&#160;provided funding to New York Medical College to conduct research
 pursuant to our supported research and license agreement with New York Medical College (see &#8220;Our Technology&#8221; below). In the future
 we intend to expand our research efforts by identifying other promising research and funding that research through academic institutions (such as New York Medical College). Under such an arrangement
 any patents would be granted to the academic institution and AVT in turn would enter into a licensing agreement with the academic institution for rights to the patent.

Our proprietary technology is easily adaptable to infectious diseases
 thus enhancing its market potential. We do not intend to market our own products although we may decide to do so in the future. Instead
 we intend to enter into agreements with large pharmaceutical companies whereby we will receive an upfront cash sum plus an ongoing royalty stream when the drug(s) or vaccine(s) are approved by the Food and Drug Administration (&#8220;FDA&#8221;) for use in the market. We will search for a partner(s) in early Phase II/III clinical trials of any particular treatment modality drug and or vaccine.


We believe
 although no assurance can be given
 that with funding in the amount of approximately $10
000
000
 the first therapeutic pharmaceutical
 the prostate cancer specific drug and a prostate cancer vaccine can be evaluated through Phase I clinical trials in humans within the next 12 to 18 months. We do not have any definitive agreements for funding and as such
 there cannot be any assurance that we will be successful in achieving our goals.





We have acquired the exclusive license to a patented chemotherapeutic drug called &#8220;Capridine&#8221; that has been shown&#160;&#160;in preclinical&#160;&#160;models&#160;&#160;tested&#160;&#160;by the National&#160;&#160;Cancer&#160;&#160;Institute to have specific activity against prostate and colon cancer. AVT has purchased exclusive rights to two patents related to synthesis
 composition and use of these drugs
 which were developed by and awarded to scientists (including Dr. Raj Tiwari
 AVT&#8217;s chief&#160;scientific officer) on behalf of New York Medical College and subsequently licensed to AVT. A third patent developed by New York Medical College
 which AVT has also acquired an exclusive license for
 is pending. The first patent relates to the synthesis of Capridine and approximately 200 of its derivatives. The second relates to the composition of Capridine as a tumor inhibitor in combination with other agents. The patent pending relates to the delivery of peptides using a bacterial protein lysate. AVT has exclusive rights to these two patents under a licensing agreement with New York Medical College
 the patent owner.

















We also have purchased the exclusive right to two new patents related to the vaccines
 pursuant to a licensing agreement with New York Medical College
 the patent owner. The patents were developed and awarded to scientists on behalf of New York Medical College. The first is entitled &#8220;Immunogens for treatment of neoplastic and infectious diseases.&#8221; The second is entitled &#8220;Immunotherapy for prostate cancer using Bacille-Calmette-Guerin expressing prostate specific antigens&#8221;. Both of these patents were issued to New York Medical College in September of 2011
 and subsequently licensed to AVT
 significantly enhancing our existing technology. The first patent is related to a broad range of peptide-based vaccination and is a major paradigm shift in immunotherapeutic vaccine technology that can be adapted to other diseases in the future. Combining this technology with the second patent may enable us to overcome certain challenges relating to vaccine delivery. We&#160;&#160;believe&#160;&#160;that&#160;&#160;this&#160;&#160;major&#160;&#160;proprietary treatment&#160;&#160;regimen
&#160;&#160;when&#160;&#160;combined&#160;&#160;with&#160;&#160;the&#160;&#160;Capridine&#160;&#160;patents
&#160;&#160;can&#160;&#160;benefit&#160;&#160;prostate&#160;&#160;cancer patients in a novel and hopefully curative manner. We acquired exclusive rights to these patents (including commercialization rights) pursuant to a supported research and license agreement with New York Medical College. Under this agreement
 we agreed to pay New York Medical College 1 to 3% of net sales revenue (as defined in the agreement) from commercialization of the patents (varying based on the amount of net sales revenue) and 17.5% of sublicense fees. We also agreed
 for a period of four years
 to fund research by New York Medical College in the amount of $400
000 per year; however this part of the agreement ended during the year ended December 31
 2012.

AVT-licensed drugs have been tested by the NCI (National Cancer Institute) and found to be effective against a number of tumor systems. These included prostate cancer
 colon cancer and others. These drugs inhibit the DNA in the cancer cells and therefore lead to the death of these cancer cells. These drugs represent a new class of drugs that do not have a suppressive effect on the bone marrow of the animals tested. Our team of scientists are world class researchers with years of experience in the clinical trial area; they have conducted Phase I
 II
 and III studies for decades.








Our two licensed patents related to Capridine protect our research results in the U.S.
 as well as 19 countries in Europe
 Mexico
 Israel
 and Canada. We have has recently received notification that no objection has been lodged to these patent application in the European Union.


We also&#160;have&#160;exclusive rights
 pursuant to licensing agreements with the patent owner
 to two immunological patents related to vaccine development and delivery mechanism. These patents are protected in the U.S.
 but we plan to apply for protection in other jurisdictions going forward. The existing and filed patents have been written to cover both general and specific protection of AVT&#8217;s proprietary technology so that the technology can be adapted to other cancers
 autoimmune diseases
 and infectious diseases. The specific factors of the patents challenge the existing paradigms of immunological research by offering a new paradigm combining chemotherapy
 molecular biology
 proteomics
 and immune activation. This type of coverage in the patents allows the scientists at AVT to focus on one disease at a time with confidence that future research will also be protected.














US Patent 6
589
961 valid until 2021: Title: Nitroacridine derivatives also patented in 19 countries of EU
 Canada
 Mexico
 Israel valid until 2021.






US Patent 7
622
478B2 valid until 2021&#160;&#160;Nitroacridine tumor inhibitor composition valid until 2021 also patented in EU
 Canda
 Mexico and Israel.










US patent 10
378
449
 issue date 5/18/2010 
 valid until 2026
 Title: Immunotherapy for prostate cancer using recombinant Bacille Calmette-Guerin expressing prostate specific antigens.






US patent 10
379
462
 issue date 9/1/2011 
 valid until 2023 
 Title: Immunogens for the treatment of neoplastic and infectious diseases.


































Nitroacridines have been shown to have potent antitumor capabilities against mammalian tumors and are potent DNA-binding and cytotoxic agents in cancer cells
 but have not been widely pursued as a potential cancer vaccine due to their high systemic toxicity. However
 we have developed a certain Nitroacridine
 designated &#8220;C-1748&#8221;
 which
 in a prostate cancer-specific preclinical study on rodents
 has proven to have markedly lower levels of toxicity compared with its parent.&#160;&#160;The preclinical study also showed no genetic mutations in the prostate cancer cells. A separate study on beagle dogs showed similar low toxicity profile and high tumor target activity. Accordingly
 C-1748 is a unique cancer drug which is specific to prostate cancer cell types
 and which lacks systemic toxicity. Additional clinical evaluation is required to evaluate C-1748 for toxicity and synergy in combination with chemotherapy regimens.
























































Cancer vaccines are divided into two groups
 those which treat existing cancers (therapeutic vaccines)
 and those which prevent the development of cancer (prophylactic vaccines). Both types of vaccines have the potential to reduce the burden of cancer. As per evaluation of National Institutes of Health (or NIH) sponsored clinical trials
 to date
 the area of therapeutic or prophylactic cancer vaccine is an unmet clinical need.


Our scientists believe that there are two problems in cancer therapy which need to be solved. The first is that cancer antigen
 in part
 are self-aberrant proteins which means that the immune system recognize them as self and therefore do not kill them. Our immune system
 in the case of cancer needs to be reeducated to recognize that the cancer cells are not self-cells but foreign to the body. The second problem is the constant generation of random mutations in cellular proteins and the generation of large number of ever-changing antigenic epitopes. Our proprietary vaccine technology overcomes both of these limitations by using therapeutic peptides that are mimics of multivalent antigens.





The procedure that AVT&#8217;s scientists used to develop the first generation of reagents was to synthetically mimic the human immune system in the laboratory specifically as it relates to the diversity of natural antibodies. Using these antibodies
 they were able to identify synthetic peptides that mimicked the cancer-associated proteins. The synthetic peptides had the advantage that they were similar immunologically to the multiple cancer proteins
 but not identical. As a result
&#160;&#160;the&#160;&#160;host&#160;&#160;recognized&#160;&#160;the&#160;&#160;cancer&#160;&#160;proteins&#160;&#160;as foreign&#160;&#160;not&#160;&#160;self&#160;&#160;and&#160;&#160;a multivalent&#160;&#160;peptide specific&#160;&#160;immune&#160;&#160;response&#160;&#160;was&#160;&#160;generated.&#160;&#160;AVT&#8217;s proprietary technology using non-toxic peptides which mimic the cancer proteins re-educates the immune system so that the cancer cells are detected and killed. The novel proteomic and small molecule synthetic peptide platform provides identification of very specific and customized therapeutic reagents that can be manufactured synthetically. This technology is readily adapted to most forms of immunogenic cancers and to infectious diseases.


The objective of the first clinical testing of these peptides (ProVac-1
3
5) will be to render prostate cancer patients vaccinated with these peptides cancer-free. These are patients who have undergone the present standard of care for prostate cancer and these peptides are being tested for secondary prevention of prostate cancer recurrences. The next logical step for clinical development of these peptide cancer vaccines will be primary prevention of prostate cancer. Using&#160;&#160;our&#160;&#160;pipeline&#160;of&#160;patented&#160;&#160;products
&#160;&#160;our&#160;&#160;near -term&#160;&#160;objective&#160;&#160;is&#160;&#160;to&#160;&#160;combine&#160;&#160;the&#160;&#160;newly discovered&#160;&#160;prostate&#160;&#160;cancer&#160;&#160;targeted&#160;&#160;chemotherapeutic drug Capridine (which unlike the chemotherapeutic drug in use has minimal bone marrow toxicity) with peptide-based immunotherapeutic vaccine to design a completely unique curative treatment regimen for prostate cancer.




















We do not currently have any full-time employees
 but engage our personnel on a part-time independent contractor basis.





During the years ended December 31
 2013 and 2012
 we incurred $332
692 and&#160;&#160;$73
335
 respectively
 on research and development expenses.





We believe&#160;&#160;that&#160;&#160;our&#160;&#160;best&#160;&#160;interest&#160;&#160;will&#160;&#160;be served&#160;&#160;by developing&#160;&#160;our&#160;&#160;drug&#160;&#160;product internally. Accordingly
 our strategy is to complete Phase I testing and begin Phase II before soliciting a partnership with a larger pharmaceutical&#160;&#160;company.&#160;&#160;This strategy
 however
 is dependent on our ability to obtain adequate capital.&#160;&#160;We may partner with a large regional and/or global pharmaceutical companies for world-wide distribution. Under such an arrangement
 we would receive a substantial upfront cash payment followed by an ongoing royalty stream. To date
 no such companies have been identified
 and no such agreements have been reached.


The total market for AVT&#8217;s possible product mix (initially defined as a prostate cancer drug
 followed with a therapeutic vaccine
 i.e. able to also treat previous prostate disease based on multiple modalities such as drugs
 radiation
 surgery
 etc.) is vast. Prostate cancer is the initial disease for which we have developed a vaccine program. Our peptide technology may also be applicable to other illnesses
 such as breast cancer
 colon cancer
 autoimmune disorders
 and other infectious diseases. In addition
 management believes that Capridine may have applications as an adjunct to other existing chemotherapy treatments to reduce toxicity and increase therapeutic efficacy.





Regulation by governmental authorities in the U.S. and other countries is a significant factor
 affecting the cost and time of our research and product development activities
 and will be a significant factor in the manufacture and marketing of any approved products. All of our products require regulatory approval by governmental agencies prior to commercialization. In particular
 our products are subject to rigorous pre-clinical and clinical testing and other approval requirements by the FDA and similar regulatory authorities in other countries. Various statutes and regulations also govern or influence the manufacturing
 safety
 reporting
 labeling
 transport and storage
 record keeping and marketing of our products. The lengthy process of seeking these approvals
 and the subsequent compliance with applicable statutes and regulations
 require the expenditure of substantial resources. Any failure by us to obtain
 or any delay in obtaining
 the necessary regulatory approvals could harm our business.

The regulatory requirements relating to the testing
 manufacturing and marketing of our products may change from time to time and this may impact our ability to conduct clinical trials and the ability of independent investigators to conduct their own research with support from us.

The clinical development
 manufacturing and marketing of our products are subject to regulation by various authorities in the U.S.
 the E.U. and other countries
 including
 in the U.S.
 the FDA
 in Canada
 Health Canada
 and
 in the E.U.
 the European Medicines Agency (the&#160;&#160;&#8220;EMEA&#8221;). The Federal Food
 Drug
 and Cosmetic Act
 the Public Health Service Act in the U.S. and numerous directives
 regulations
 local laws and guidelines in Canada and the E.U. govern the testing
 manufacture
 safety
 efficacy
 labeling
 storage
 record keeping
 approval
 advertising and promotion of our products. Product development and approval within these regulatory frameworks takes a number of years and involves the expenditure of substantial resources.

Regulatory approval will be required in all the major markets in which we seek to develop our products. At a minimum
 approval requires the generation and evaluation of data relating to the quality
 safety
 and efficacy of an investigational product for its proposed use. The specific types of data required and the regulations relating to this data will differ depending on the territory
 the drug involved
 the proposed indication and the stage of development.

In general
 new chemical entities are tested in animals until adequate evidence of safety is established to support the proposed clinical study protocol designs. Clinical trials for new products are typically conducted in three sequential phases that may overlap. In Phase I
 the initial introduction of the pharmaceutical into either healthy human volunteers or patients with the disease (20 to 50 subjects)
 the emphasis is on testing for safety (adverse effects)
 dosage tolerance
 metabolism
 distribution
 excretion and clinical pharmacology. Phase II involves studies in a limited patient population (50 to 200 patients) to determine the initial efficacy of the pharmaceutical for specific targeted indications
 to determine dosage tolerance and optimal dosage and to identify possible adverse side effects and safety risks. Once a compound shows preliminary evidence of some effectiveness and is found to have an acceptable safety profile in Phase II evaluations
 Phase III trials are undertaken to more fully evaluate clinical outcomes in a larger patient population in adequate and well-controlled studies designed to yield statistically sufficient clinical data to demonstrate efficacy and safety.
















In the U.S.
 specific pre-clinical data
 manufacturing and chemical data
 as described above
 need to be submitted to the FDA as part of an&#160;Investigational New Drug (or IND) application
 which
 unless the FDA objects
 will become effective 30 days following receipt by the FDA. Phase I studies in human volunteers may commence only after the application becomes effective. Prior regulatory approval for human healthy volunteer studies is also required in member states of the E.U. Currently
 in each member state of the E.U.
 following successful completion of Phase I studies
 data are submitted in summarized format to the applicable regulatory authority in the member state in respect of applications for the conduct of later Phase II studies. The regulatory authorities in the E.U. typically have between one and three months in which to raise any objections to the proposed study
 and they often have the right to extend this review period at their discretion. In the U.S.
 following completion of Phase I studies
 further submissions to regulatory authorities are necessary in relation to Phase II and III studies to update the existing IND. Authorities may require additional data before allowing the studies to commence and could demand that the studies be discontinued at any time if there are significant safety issues. In addition to the regulatory review
 a study involving human subjects has to be approved by an independent body. The exact composition and responsibilities of this body will differ from country to country. In the U.S.
 for example
 each study will be conducted under the auspices of an independent institutional review board at each institution at which the study is conducted. This board considers among other things
 the design of the study
 ethical factors
 the privacy of protected health information as defined under the Health Insurance Portability and Accountability Act
 the safety of the human subjects and the possible liability risk for the institution. Equivalent rules to protect subjects&#8217; rights and welfare apply in each member state of the E.U. where one or more independent ethics committees
 which typically operate similarly to an institutional review board
 will review the ethics of conducting the proposed research. Other regulatory authorities around the rest of the world have slightly differing requirements involving both the execution of clinical trials and the import/export of pharmaceutical products. It is our responsibility to ensure we conduct our business in accordance with the regulations of each relevant territory.


In order to gain marketing approval we must submit a dossier to the relevant authority for review
 which is known in the U.S. as a&#160; New Drug Application&#160;(or NDA) and in the E.U. as a marketing authorization application
 or MAA. The format is usually specific and laid out by each authority
 although in general it will include information on the quality of the chemistry
 manufacturing and pharmaceutical aspects of the product as well as the non-clinical and clinical data. Once the submitted NDA is accepted for filing by the FDA
 it undertakes the review process that takes 10 months
 unless an expedited priority review is granted which takes six months to complete. Approval can take several months to several years
 if multiple 10-month review cycles are needed before final approval is obtained
 if at all.

The approval process can be affected by a number of factors. The NDA may be approvable requiring additional pre-clinical
 manufacturing data or clinical trials which may be requested at the end of the 10 month NDA review cycle
 thereby delaying marketing approval until the additional data are submitted and may involve substantial unbudgeted costs. The regulatory authorities usually will conduct an inspection of relevant manufacturing facilities
 and review manufacturing procedures
 operating systems and personnel qualifications. In addition to obtaining approval for each product
 in many cases each drug manufacturing facility must be approved. Further inspections may occur over the life of the product. An inspection of the clinical investigation sites by a competent authority may be required as part of the regulatory approval procedure. As a condition of marketing approval
 the regulatory agency may require post-marketing surveillance to monitor for adverse effects or other additional studies as deemed appropriate. After approval for the initial indication
 further clinical studies are usually necessary to gain approval for any additional indications. The terms of any approval
 including labeling content
 may be more restrictive than expected and could affect the marketability of a product.

We are also subject to numerous environmental and safety laws and regulations
 including those governing the use and disposal of hazardous materials. The cost of compliance with and any violation of these regulations could have a material adverse effect on our business and results of operations. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed by state and federal regulations
 accidental contamination or injury from these materials may occur. Compliance with laws and regulations relating to the protection of the environment has not had a material effect on our capital expenditures or our competitive position. However
 we are not able to predict the extent of government regulation
 and the cost and effect thereof on our competitive position
 which might result from any legislative or administrative action pertaining to environmental or safety matters.


























The field of chemotherapy for prostate cancer is an emerging area and in general very poorly developed. While no guarantees can be made
 we expect that Capridine
 if approved
 will provide very strong competition to Taxotere and any other prevalent chemotherapeutic drug and if its preclinical activity of minimal bone marrow toxicity is validated in clinical studies it could completely replace taxotere. We also expect that it could be used synergistically with prevalent chemotherapeutic agents.



Zytiga and MDV 3100 have limited use and judging from the market size provides only minimal competition for Capridine which has been found to be effective in both hormone sensitive and resistant prostate cancer. Further our mechanistic studies suggest that Capridine can convert hormone refractory prostate cancer to hormone sensitive and if validated in human studies
 Capridine can be combined with all kinds of antihormonal prostate cancer therapy including Zytiga and the recently approved MDV 3100.


Our peptide vaccine approach is unique and has very minimal competition. The approval by the FDA of the immunotherapeutic&#160;approach by Dendreon (Provenge)&#160;is encouraging to us
 given that our technology
 is cost effective well characterized and can be expanded at will.&#160;&#160;Provenge has not been met with any enthusiasm
 due to its high cost and minimal effectiveness. Our peptide approach allows for the development of &#8220;off&#160;&#160;the&#160;shelf&#8221;&#160;immunotherapeutics
&#160;rather&#160;than&#160;requiring&#160;the preparation&#160;of unique personalized vaccine for each patient. We believe that we have a competitive advantage in our target market for several reasons:











































An investment in the Company&#8217;s common stock involves a high degree of risk. In determining whether to purchase the Company&#8217;s common stock
 an investor should carefully consider all of the material risks described below
 together with the other information contained in this report before making a decision to purchase the Company&#8217;s securities. An investor should only purchase the Company&#8217;s securities if he or she can afford to suffer the loss of his or her entire investment.







We are a development stage company with no revenues and expect to incur substantial losses and have negative operating cash flows for the foreseeable future
 and we may never achieve or maintain profitability. Even if we succeed in developing and commercializing one or more of our product candidates
 we expect to incur substantial losses for the foreseeable future and may never become profitable. We also expect to continue to incur significant operating and capital expenditures and anticipate that our expenses will increase substantially in the foreseeable future as we:







































We also expect to experience negative cash flow for the foreseeable future as we fund our operating losses and capital expenditures. As a result
 we will need to generate significant revenues in order to achieve and maintain profitability.&#160;&#160;We may not be able to generate these revenues or achieve profitability in the future. Our failure to achieve or maintain profitability could negatively impact the value of our securities.&#160;&#160;Our financial statements have been prepared on the basis that we will continue as a going concern. For the years ended December 31
 2013 and 2012 we incurred net losses of $905
920
 and $286
271
 respectively.


















We are a clinical-stage company and have not demonstrated our ability to perform the functions necessary for the successful commercialization of any product candidates. The successful commercialization of any product candidates will require us to perform a variety of functions
 including:








































Our operations have been limited to organizing and staffing our company
 acquiring
 developing and securing our proprietary technology
 raising capital and undertaking development and clinical trials of our product candidates. These operations provide a limited basis for you to assess our ability to commercialize our product candidates and the advisability of investing in our securities.

We may need to finance our future cash needs through public or private equity offerings
 debt financings or corporate collaboration and licensing arrangements. Any additional funds that we obtain may not be on terms favorable to us or our stockholders and may require us to relinquish valuable rights.

Until and unless we receive approval from the US Food and Drug Administration (the &#8220;FDA&#8221;) and other regulatory authorities for our product candidates
 we cannot sell our drugs and will not have product revenues. Therefore
 for the foreseeable future
 we will have to fund all of our operations and capital expenditures from the net proceeds of the Private Placement and cash on hand. In addition
 we could be forced to discontinue product development
 reduce or forego sales and marketing efforts and forego attractive business opportunities.

We believe that the net proceeds from the Private Placement and existing cash will be sufficient to enable us to fund our projected operating requirements for approximately 6 months from the Closing Date. However
 we may need to raise additional funds more quickly if one or more of our assumptions prove to be incorrect&#160;&#160;or&#160;&#160;if we&#160;&#160;choose&#160;&#160;to expand&#160;&#160;our&#160;&#160;product&#160;&#160;development&#160;&#160;efforts&#160;&#160;more&#160;&#160;rapidly&#160;&#160;than&#160;&#160;we presently anticipate
 and we may decide to raise additional funds even before we need them if the conditions for raising capital are favorable.


We may seek to sell additional equity or debt securities
 obtain a bank credit facility
 or enter into a corporate collaboration or licensing arrangement. The sale of additional equity or debt securities
 if convertible into common stock
 could result in dilution to our stockholders. The incurrence of indebtedness would result in increased fixed obligations and could also result in covenants that would restrict our operations. Raising additional funds through collaboration or licensing arrangements with third parties may require us to relinquish valuable rights to our technologies
 future revenue streams
 research programs or product candidates
 or to grant licenses on terms that may not be favorable to us or our stockholders.&#160;&#160;We can provide no assurance that we will be successful in raising any additional capital.






We are a development stage specialty pharmaceutical company focused on the development of products
 all of which are at an early stage of development.&#160;&#160;&#160;Each of our product candidates requires extensive preclinical or clinical testing prior to the submission to the FDA of a New Drug Application
 or &#8220;NDA&#8221;
 or Pre- Market Authorization
 or &#8220;PMA&#8221;.&#160;&#160;Capridine
 our lead product candidate
 is not currently being tested in humans.&#160;&#160;We cannot predict with any certainty if or when we might submit an NDA or PMA for regulatory approval of any of our product candidates or whether such an NDA or PMA will be accepted.


Our&#160;&#160;development&#160;&#160;methods&#160;&#160;are&#160;&#160;unproven&#160;&#160;and&#160;&#160;may&#160;&#160;not&#160;&#160;lead&#160;&#160;to&#160;&#160;commercially&#160;&#160;viable products for any of several reasons.&#160;&#160;For example
 we may fail to identify appropriate targets or compounds
 our product candidates may fail to be safe and effective in clinical or additional preclinical trials
 or we may have inadequate financial or other resources to pursue discovery and development efforts for new product candidates. Our product candidates will require significant additional development
 preclinical and clinical trials
 regulatory clearances and additional investments by us or our collaborators before they can be commercialized.


















We cannot assure you that we will receive the approvals necessary to commercialize our product candidates
 or any product candidate we acquire or develop in the future
 for sale. We will need FDA approval to commercialize our product candidates in the US and approvals from the FDA equivalent regulatory authorities in foreign jurisdictions to commercialize our product candidates in those jurisdictions. In order to obtain FDA approval of any product candidate we must submit to the FDA a NDA for a new drug
 demonstrating that the product candidate is safe for humans and effective for its intended use.&#160;&#160;&#160;This demonstration requires significant research and animal tests
 which are referred to as preclinical studies
 as well as human tests
 which are referred to as clinical trials.&#160;&#160;Satisfaction of the FDA&#8217;s regulatory requirements typically takes many years
 depending upon the type
 complexity and novelty of the product candidate and requires substantial resources for research
 development and testing. We cannot predict whether our research and clinical approaches will result in drugs that the FDA considers safe for humans and effective for indicated uses. The FDA has substantial discretion in the drug approval process and may require us to conduct additional preclinical and clinical testing or to perform post-marketing studies. The approval process may also be delayed by changes in government regulation
 future legislation or administrative action or changes in FDA policy that occur prior to or during our regulatory review.&#160;&#160;Delays in obtaining regulatory approvals may:









delay commercialization of
 and our ability to derive product revenues from
 our product candidates;






















Even if we comply with all FDA requests
 the FDA may ultimately reject one or more of our NDAs or PMAs. We cannot be sure that we will ever obtain regulatory clearance for our product candidates. Failure to obtain FDA approval of our product candidates will severely undermine our business by leaving us without a saleable product
 and therefore without any source of revenues
 until another product candidate can be developed or obtained.&#160;&#160;There is no guarantee that we will ever be able to develop or acquire another product candidate.


In foreign jurisdictions
 we must receive approval from the appropriate regulatory authorities before we can commercialize any drugs. Foreign regulatory approval processes generally include all of the risks associated with the FDA approval procedures described above. We cannot assure you that we will receive the approvals necessary to commercialize our product candidates for sale outside of the US.

Preclinical and clinical trials required for our product candidates are expensive and time- consuming
 and their outcome is uncertain.

In order to obtain FDA approval to market a new drug product
 we must demonstrate proof of safety and effectiveness in humans.&#160;&#160;&#160;To meet these requirements
 we must conduct extensive preclinical testing and &#8220;adequate and well-controlled&#8221; clinical trials.&#160;&#160;Conducting clinical trials is a lengthy
 time-consuming
 and expensive process.&#160;&#160;The length of time may vary substantially according to the type
 complexity
 novelty
 and intended use of the product candidate
 and often can be several years or more per trial.&#160;&#160;Delays associated with products for which we are directly conducting preclinical or clinical trials may cause us to incur additional operating expenses.&#160;&#160;The commencement and rate of completion of clinical trials may be delayed by many factors
 including
 for example:









inability&#160;to&#160;manufacture&#160;sufficient&#160;quantities&#160;of&#160;qualified&#160;materials&#160;under&#160;the FDA&#8217;s Current Good Manufacturing Practices requirements
&#160;commonly known as cGMP
 for use in clinical trials;






































































































































delays
 suspension
 or termination of the clinical trials due to the institutional review board;























government
&#160;institutional&#160;review&#160;board&#160;or&#160;other&#160;regulatory&#160;agency&#160;delays&#160;or &#8220;clinical holds&#8221; requiring suspension or termination of the trials.




The results from preclinical testing and early clinical trials are not necessarily predictive of results obtained in later clinical trials. Accordingly
 even if we obtain positive results from preclinical or early clinical trials
 we may not achieve the same success in future clinical trials. Clinical trials may not demonstrate statistically significant safety and effectiveness to obtain the requisite regulatory approvals for product candidates.

The failure of clinical trials to demonstrate safety and effectiveness for the desired indications could delay the development of that product candidate and other product candidates. This failure could cause us to abandon a product candidate and could delay development of other product candidates. Any delay in
 or termination of
 our clinical trials would delay the filing of NDAs&#160;&#160;or&#160;&#160;PMAs&#160;&#160;with&#160;&#160;the&#160;&#160;FDA&#160;&#160;and
&#160;&#160;ultimately
&#160;&#160;our&#160;&#160;ability&#160;&#160;to&#160;&#160;commercialize&#160;&#160;our&#160;&#160;product candidates and generate product revenues. Any change in
 or termination of
 our preclinical or clinical trials could materially harm our business
 financial condition
 and results of operations.

In addition
 we or the FDA may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks.&#160;&#160;Therefore
 we cannot predict with any certainty the schedule for future preclinical or clinical trials.



Even if our preclinical or clinical trials are completed as planned
 we cannot be certain that their results will support our product candidate claims. Success in preclinical testing and early or middle clinical trials does not ensure that later clinical trials will be successful
 and we cannot be sure that the results of later clinical trials will replicate the results of prior clinical trials and preclinical testing. The&#160;&#160;clinical&#160;&#160;trial&#160;&#160;process&#160;&#160;may&#160;&#160;fail&#160;&#160;to&#160;&#160;demonstrate&#160;&#160;that&#160;&#160;our&#160;&#160;product candidates are safe for humans and effective for indicated uses. This failure would cause us to abandon a product candidate and may delay development of other product candidates.

In addition
 the product candidates that we are currently developing are based on processes and methodologies that are not currently widely employed. Our development of current and future product candidates is subject to the risks of failure and delay inherent in the development of new pharmaceutical products and products based on new technologies
 including:









delays in product development
 preclinical or clinical testing
 or manufacturing;











unplanned expenditures in product development
 preclinical or clinical testing
 or manufacturing;



































inability to manufacture on our own
 or through any others
 product candidates on a commercial scale; and
















Because of these risks
 our research and development efforts may not result in any commercially viable products.&#160;&#160;Any delay in
 or termination of
 our preclinical or clinical trials will delay the filing of our NDAs or PMAs with the FDA and
 ultimately
 our ability to commercialize our product candidates and generate product revenues. If a significant portion of these development efforts are not successfully completed
 required regulatory approvals are not obtained or any approved products are not commercially successful
 our business
 financial condition
 and results of operations may be materially harmed.


















Even if the FDA approves one or more of our product candidates
 physicians and patients may not accept and use it.&#160;&#160;&#160;Acceptance and use of our product candidates will depend upon a number of factors including:









perceptions by members of the health care community
 including physicians
 of the safety and effectiveness of our drug or product;



































effectiveness&#160;of&#160;marketing&#160;and&#160;distribution&#160;efforts&#160;by&#160;us&#160;and&#160;our&#160;licensors
 licensees and distributors
 if any.




Because we expect sales of our current product candidates
 if approved
 to generate substantially all of our product revenues for the foreseeable future
 the failure of these products to find market acceptance would harm our business
 could require us to seek additional financing
 and may even cause us to limit or cease operations.

Our&#160;&#160;products&#160;&#160;may&#160;&#160;cause&#160;&#160;undesirable&#160;&#160;side&#160;&#160;effects&#160;&#160;that&#160;&#160;could&#160;&#160;limit&#160;&#160;their&#160;&#160;use
&#160;&#160;require&#160;&#160;their removal from the market or prevent further development.

Undesirable side effects caused by our products could interrupt
 delay or halt our development programs
 including clinical trials
 and could result in adverse regulatory action by the FDA or other regulatory authorities. More severe side effects associated with our products may be observed in the future. Even if we are able to complete the development of a new product and obtain any required regulatory approval
 undesirable side effects could prevent us from achieving or maintaining market acceptance of the product or could substantially increase the costs and expenses of commercializing the product. Negative publicity concerning our products
 whether accurate or inaccurate
 could also reduce market or regulatory acceptance of our products
 which could result in decreased product demand
 removal from the market or an increased number of product liability claims
 whether or not such claims have merit.

Downturns&#160;&#160;in&#160;&#160;general&#160;&#160;economic&#160;&#160;conditions&#160;&#160;may&#160;&#160;adversely&#160;&#160;affect&#160;&#160;our&#160;&#160;financial&#160;&#160;condition
 results of operations and cash flows.


Our business may be adversely affected by downturns in general economic conditions. Economic conditions such as employment levels
 business conditions
 interest rates
 energy and fuel costs
 consumer confidence and tax rates could change consumer purchasing habits or reduce personal discretionary spending. A reduction in consumer spending may have an adverse impact on our financial condition
 results of operations and cash flows. In addition
 our ability to meet our&#160;&#160;expected&#160;&#160;financial&#160;&#160;performance&#160;&#160;is&#160;&#160;dependent&#160;&#160;upon&#160;&#160;our&#160;&#160;ability&#160;&#160;to&#160;&#160;rapidly&#160;&#160;recover&#160;&#160;from downturns in general economic conditions.


Recent global market and economic conditions have been unprecedented and challenging. Continued concerns about the systemic impact of potential long-term and wide-spread recession
 energy costs
 geopolitical issues
 the availability and cost of credit
 and the global housing and mortgage markets have contributed to increased market volatility and diminished expectations for western and emerging economies.


As a result of these market conditions
 the cost and availability of credit has been and may continue to be adversely affected by illiquid credit markets and wider credit spreads. Concern about the stability of the markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce
 and in some cases
 cease to provide credit to businesses and consumers. These factors have led to a decrease in spending by businesses and consumers alike
 and a corresponding decrease in global infrastructure spending. Continued turbulence in the US and international markets and economies and prolonged declinesin business consumer spending may adversely affect our liquidity and financial condition
 and the liquidity and financial condition of our customers
 including our ability to refinance maturing liabilities and access the capital markets to meet liquidity needs.

















Our independent registered public accounting firm&#8217;s report
 contained herein
 includes an explanatory paragraph that expresses substantial doubt about our ability to continue as a going concern
 indicating the possibility that we may not be able to operate in the future.


Our consolidated financial statements have been prepared on the basis that we will continue as a going concern. As of December 31
 2013
 our total stockholders&#8217; equity was $34
172 and we had working capital deficiency of $114
504. We expect to continue to incurring losses for the foreseeable future and must raise additional capital in order to sustain our operations while continuing the longer term efforts contemplated under our business plan. Primarily as a result of our losses and limited cash balances
 our independent registered public accounting firm has included in its report as of and for the years ended December 31
 2013 and 2012 an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern.

If we are unable to secure additional capital
 we may be required to curtail our research and development initiatives and take additional measures to reduce costs in order to conserve our cash in amounts sufficient to sustain operations and meet our obligations. These measures could cause significant delays in our clinical and regulatory efforts
 which is critical to the realization of our business plan. The accompanying financial statements do not include any adjustments that may be necessary should we be unable to continue as a going concern. It is not possible for us to predict at this time the potential success of our business. The revenue and income potential of our proposed business and operations are currently unknown. If we cannot continue as a viable entity
 you may lose some or all of your investment in our company.


We are a small company with limited resources and personnel available to establish a comprehensive system of internal controls. If we fail to maintain an effective system of internal controls
 we would not be able to accurately report our financial results or prevent fraud. As a result
 current and potential stockholders could lose confidence in our financial reporting
 which would harm our business and the trading price of our stock.


Effective internal controls are necessary for us to provide reliable financial reports and effectively prevent fraud. If we cannot provide reliable financial reports or prevent fraud
 our brand and operating results would be harmed. We may in the future discover areas of our internal controls that need improvement. For example
 because of size and limited resources
 our external auditors may determine that we lack the personnel and infrastructure necessary to properly carry out an independent audit function.


Although we believe that we have adequate internal controls for a company with our size and resources
 we are not certain that the measures that we have in place will ensure that we implement and maintain adequate controls over our financial processes and reporting in the future. Any failure to implement required new or improved controls
 or difficulties encountered in their implementation
 would harm our operating results or cause us to fail to meet our reporting obligations. Inferior internal controls would also cause investors to lose confidence in our reported financial information
 which would have a negative effect on our company and
 if a public market develops for our securities
 the trading price of our stock.


Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. generally accepted accounting principles. A material weakness is a deficiency
 or a combination of deficiencies
 in internal control over financial reporting
 such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis.

Prior to the completion of this offering
 AVT has been a private company with limited accounting personnel and other resources to address our internal control over financial reporting. If we are unable to successfully implement and maintain effective internal controls over financial reporting we risk being unable to produce accurate and timely financial statements
 and our stock price may be adversely affected.



If we fail to adequately protect or enforce our intellectual property rights or our licensors fail to secure rights to the patents we use
 the value of our intellectual property rights would diminish.


Our success
 competitive position and future revenues will depend in part on our ability to obtain and maintain patent protection for our product candidates
 methods
 processes and other technologies
&#160;to&#160;preserve&#160;our&#160;trade&#160;secrets
&#160;to&#160;prevent&#160;third&#160;parties&#160;from&#160;infringing&#160;on&#160;our proprietary rights and to operate without infringing the proprietary rights of third parties.

















To date
 we hold certain exclusive patent rights as well as rights under foreign patents and patent applications.&#160;&#160;We anticipate filing additional patent applications both in the US and in other countries
 as appropriate.&#160;&#160;However
 we cannot predict:








the degree and range of protection any patents will afford us against competitors
 including whether third parties will find ways to invalidate or otherwise circumvent our patents;











if and when patents will issue; and if granted
 whether patents will be challenged and held invalid or unenforceable;




























Our success also depends upon the skills
 knowledge and experience of our scientific and technical personnel
 our consultants and advisors as well as our licensors and contractors.&#160;&#160;&#160;To help protect our proprietary know-how and our inventions for which patents may be unobtainable or difficult to obtain
 we rely on trade secret protection and confidentiality agreements.&#160;&#160;To this end
 it is our policy to require all of our employees
 consultants
 advisors and contractors to enter into agreements which prohibit the disclosure of confidential information and
 where applicable
 require disclosure and assignment to us of the ideas
 developments
 discoveries and inventions important to our business.&#160;&#160;These agreements may not provide adequate protection for our trade secrets
 know-how or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information.&#160;&#160;&#160;If any of our trade secrets
 know-how or other proprietary information is disclosed
 the value of our trade secrets
 know-how and other proprietary rights would be significantly impaired and our business and competitive position would suffer.

If we infringe the rights of third parties
 we could be prevented from selling products and forced to pay damages and defend against litigation.

If&#160;&#160;our&#160;&#160;product&#160;&#160;candidates
&#160;methods
&#160;processes&#160;and&#160;other&#160;technologies&#160;infringe&#160;the proprietary rights of other parties
 we could incur substantial costs and we may have to:









obtain licenses
 which may not be available on commercially reasonable terms
 if at all;



























































defend litigation or administrative proceedings which may be costly whether we win or lose
 and which could result in a substantial diversion of our financial and management resources.




Any&#160;&#160;of&#160;&#160;these&#160;&#160;events&#160;&#160;could&#160;&#160;substantially&#160;&#160;harm&#160;&#160;our&#160;&#160;earnings
&#160;&#160;financial&#160;&#160;condition&#160;&#160;and operations.





The levels at which government authorities
 private health insurers
 HMOs and other organizations reimburse the cost of drugs and treatments related to those drugs will impact the successful commercialization of our products. We cannot be sure that reimbursement in the United&#160;States or elsewhere will be available for any drugs we may develop or
 if already available
 will not be decreased in the future. Also
 we cannot be sure that reimbursement amounts will not reduce the demand for
 or the price of
 our drugs. If reimbursement is not available or is available only on a limited basis
 we may not be able to obtain a satisfactory financial return on the manufacture and commercialization of existing and future drugs. Third- party payers may not establish and maintain price levels sufficient for us to realize an appropriate return on our investment in product development or our continued manufacture and sale of existing drug products.



















Our ability to commercialize our product candidates
 alone or with collaborators
 will depend in part on the extent to which reimbursement will be available from:






































Significant uncertainty exists as to the reimbursement status of newly approved healthcare products.&#160;&#160;Healthcare payers
 including Medicare
 are challenging the prices charged for medical products and services. Government and other healthcare payers increasingly attempt to contain healthcare costs by limiting both coverage and the level of reimbursement for drugs. Even&#160;&#160;if&#160;&#160;our&#160;&#160;product&#160;&#160;candidates&#160;&#160;are&#160;&#160;approved&#160;&#160;by&#160;&#160;the&#160;&#160;FDA
&#160;&#160;insurance&#160;&#160;coverage&#160;&#160;may&#160;&#160;not&#160;&#160;be available
 and reimbursement levels may be inadequate
 to cover our product candidates.&#160;&#160;If government and other healthcare payers do not provide adequate coverage and reimbursement levels for our product candidates
 once approved
 market acceptance of such products could decline.



The testing and marketing of medical products entail an inherent risk of product liability. If we cannot successfully defend ourselves against product liability claims
 we may incur substantial liabilities or be required to limit commercialization of our product candidates. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential&#160;&#160;product&#160;&#160;liability&#160;&#160;claims&#160;&#160;could&#160;&#160;prevent&#160;&#160;or&#160;&#160;inhibit&#160;&#160;the&#160;&#160;commercialization&#160;&#160;of pharmaceutical products we develop
 alone or with collaborators.&#160;&#160;We currently carry a limited amount of clinical trial insurance or product liability insurance. While we believe our current level of insurance is reasonably adequate to insulate us from potential claims
 this insurance may not fully cover potential liabilities. Even if our agreements with any future collaborators entitle us to indemnification against losses
 such indemnification may not be available or adequate should any claim arise.



Our research
 development and manufacturing activities and/or those of our third party contractors may involve the controlled use of hazardous materials and chemicals.&#160;&#160;Although we believe that our safety procedures for using
 storing
 handling and disposing of these materials comply with federal
 state and local laws and regulations
 we cannot completely eliminate the risk of accidental injury or contamination from these materials. In the event of such an accident
 we could be held liable for any resulting damages
 and any liability could materially adversely affect our business
 financial condition and results of operations.&#160;&#160;In addition
 the federal
 state and local laws and regulations governing the use
 manufacture
 storage
 handling and disposal of hazardous or radioactive materials and waste products may require us to incur substantial compliance costs that could materially adversely affect our business
 financial condition and results of operations.


If we cannot compete successfully for market share against other drug companies
 we may not achieve sufficient product revenues and our business will suffer.

Each of the markets for our product candidates is characterized by intense competition and rapid technological advances. If our product candidates receive FDA approval
 they will compete with a number of existing and future drugs and therapies developed
 manufactured and marketed by others. Existing or future competing products may provide greater therapeutic convenience or clinical or other benefits for a specific indication than our product candidates
 or may offer comparable performance at a lower cost.&#160;&#160;If our product candidates fail to capture and maintain market share
 we may not achieve sufficient product revenues and our business will suffer.
















We will compete against fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical companies
 academic institutions
 government agencies and other public and private research organizations.&#160;&#160;&#160;Many of these competitors have compounds already approved or in development in the therapeutic categories that we are targeting with our current and future product candidates. In addition
 many of these competitors
 either alone or together with their collaborative partners
 operate larger research and development programs or have substantially greater financial resources than we do
 as well as significantly greater experience in:

























































launching
 marketing and selling drugs.






Many of the organizations competing with us have substantially greater capital resources
 larger research and development staffs and facilities
 longer drug development history in obtaining regulatory approvals and greater manufacturing and marketing capabilities than we do. These organizations also compete with us to attract qualified personnel and parties for acquisitions
 joint ventures or other collaborations.

Risks&#160;Related&#160;to&#160;Our&#160;Dependence&#160;on Third&#160;Parties&#160;for&#160;Manufacturing
&#160;Research
 Development
&#160;Marketing&#160;and&#160;Distribution&#160;Activities



We depend upon independent investigators and collaborators
 such as commercial third- parties
 government
 universities and medical institutions
 to conduct our preclinical and clinical trials under agreements with us.&#160;&#160;These collaborators are not our employees and we cannot control the amount or timing of resources that they devote to our programs. These investigators may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs ourselves. If outside collaborators fail to devote sufficient time and resources to our product development programs
 or if their performance is substandard
 the approval of our FDA applications
 if any
 and our introduction of new products
 if any
 will be delayed. These collaborators may also have relationships with other commercial entities
 some of whom may compete with us. If our collaborators assist our competitors at our expense
 our competitive position would be harmed.

Reliance on third-party research and development labs entails risks to which we would not be subject if we performed the research and development ourselves. These&#160;&#160;risks include reliance&#160;&#160;on the&#160;&#160;third&#160;&#160;party&#160;&#160;for&#160;&#160;maintaining&#160;&#160;the confidentiality&#160;&#160;of the&#160;&#160;proprietary&#160;&#160;information relating to the product being developed and for maintaining quality assurance
 the possibility of breach of the research and development agreement by the third party
 and the possibility of termination or non-renewal of the agreement by the third party.



We do not intend to establish our own manufacturing facilities. We lack the resources and expertise to formulate or manufacture our own product candidates. If any product candidate we may develop or acquire in the future receives FDA approval
 we will rely on one or more third-party contractors to manufacture our product candidates. Our anticipated future reliance on a limited number of third-party manufacturers exposes us to the following risks:









While we have identified potential manufacturers
 we may be unable to reach agreement on acceptable terms or at all because the number of potential manufacturers is limited and the FDA must approve any replacement contractor. This approval would require new testing and compliance inspections. In addition
&#160;&#160;a&#160;&#160;new&#160;&#160;manufacturer&#160;&#160;&#160;would&#160;&#160;have&#160;&#160;to&#160;&#160;be&#160;&#160;educated&#160;&#160;in
&#160;&#160;or&#160;&#160;develop substantially equivalent processes for
 production of our product candidates after receipt of FDA approval
 if any.











Our third-party manufacturers might be unable to formulate and manufacture our drugs in the volume and of the quality required to meet our clinical needs and commercial needs
 if any.


























Our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce
 store and distribute our product candidates.











Drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA
 the Drug Enforcement Administration
 and corresponding state agencies to ensure strict compliance with good manufacturing practice and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.











If any third-party manufacturer makes improvements in the manufacturing process for our product candidates
 we may not own
 or may have to share
 the intellectual property rights to the innovation.




Each of these risks could delay our clinical trials
 the approval
 if any
 of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs&#160;or&#160;deprive&#160;us&#160;of&#160;potential&#160;product&#160;revenues.

We have no experience selling
 marketing or distributing products and no internal capability to do so.

We currently have no sales
 marketing or distribution capabilities. In the short-term
 we do not anticipate having the resources to allocate to the sales and marketing of our proposed products. Our future success depends
 in part
 on our ability to enter into and maintain collaborative relationships for such capabilities
 the collaborator&#8217;s strategic interest in the products under development and such collaborator&#8217;s ability to successfully market and sell any such products. We intend to pursue collaborative arrangements regarding the sales and marketing of our product candidates; however
 there can be no assurance that we will be able to establish or maintain such collaborative arrangements
 or if able to do so
 that our collaborative partners will have effective sales forces. To the extent that we decide not to
 or are unable to
 enter into collaborative arrangements with respect to the sales and marketing of our proposed products
 significant capital expenditures
 management resources and time will be required to establish and develop an in-house marketing and sales force with technical expertise. There can also be no assurance that we will be able to establish or maintain relationships with third party collaborators or develop in-house sales and distribution capabilities. To the extent that we depend on third parties for marketing and distribution
 any revenues we receive will depend upon the efforts of such third parties
 and there can be no assurance that such efforts will be successful. In addition
 there can also be no assurance that we will be able to market and sell our product candidates in the US or overseas.





Our success will depend upon the expansion of our operations and the effective management of our growth
 which will place a significant strain on our management and on our administrative
 operational and financial resources. To manage this growth
 we must expand our facilities
 augment our operational
 financial and management systems and hire and train additional qualified personnel.&#160;&#160;If we are unable to manage our growth effectively
 our business would be harmed.

We rely on key executive officers and scientific and medical advisors
 and their knowledge of our business and technical expertise would be difficult to replace.

We are highly dependent on our executive officers and scientific and medical advisors because of their expertise and experience in drug development.&#160;&#160;We do not have &#8220;key person&#8221; life insurance policies for any of our officers.&#160;&#160;The loss of the technical knowledge and management and industry expertise of any of our key personnel could result in delays in product development
 loss of customers and sales and diversion of management resources
 which could adversely affect our&#160;operating&#160;results.


If we are unable to hire additional qualified personnel
 our ability to grow our business may be harmed.

Over time
 we will need to hire additional qualified personnel with expertise in preclinical testing
 clinical research and testing
 government regulation
 formulation and manufacturing and sales and marketing. We compete for qualified individuals with numerous biopharmaceutical companies
 universities and other research institutions. Competition for such individuals is intense
 and we cannot be certain that our search for such personnel will be successful. Attracting and retaining qualified personnel will be critical to our success.



















There is a limited trading market for the Company&#8217;s common stock
 and shareholders may have difficulty trading and obtaining quotations for our common stock.


The Company&#8217;s common stock is registered under the Exchange Act and is quoted on the OTC Bulletin Board. There has been limited reported trading to date in our common stock. As a result
 investors may find it difficult to dispose of
 or to obtain accurate quotations of the price of
 our securities. This severely limits the liquidity of the common stock
 and may adversely affect the market price of our common stock. A limited market may also impair our ability to raise capital by selling shares of capital stock and may impair our ability to acquire other companies or assets by using common stock as consideration.

Our common stock is currently deemed a &#8220;penny stock
&#8221; which makes it more difficult for our investors to sell their shares.


The SEC has adopted Rule 15g-9 which establishes the definition of a &#8220;penny stock
&#8221; for the purposes relevant to us
 as any equity security that has a market price of less than $5.00 per share
 subject to certain exceptions. For any transaction involving a penny stock
 unless exempt
 the rules require that a broker or dealer approve a person&#8217;s account for transactions in penny stocks
 and the broker or dealer receive from the investor a written agreement to the transaction
 setting forth the identity and quantity of the penny stock to be purchased.


In order to approve a person&#8217;s account for transactions in penny stocks
 the broker or dealer must obtain financial information and investment experience objectives of the person
 and make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

The broker or dealer must also deliver
 prior to any transaction in a penny stock
 a disclosure schedule prescribed by the SEC relating to the penny stock market
 which
 in highlight form sets forth the basis on which the broker or dealer made the suitability determination
 and that the broker or dealer received a signed
 written agreement from the investor prior to the transaction.


Generally
 brokers may be less willing to execute transactions in securities subject to the &#8220;penny stock&#8221; rules. This may make it more difficult for investors to dispose of the Company&#8217;s common stock if and when such shares are eligible for sale and may cause a decline in the market value of its stock.

Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative
 current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally
 monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stock.

As an issuer of &#8220;penny stock
&#8221; the protection provided by the federal securities laws relating to forward-looking statements does not apply to the Company.


Although federal securities laws provide a safe harbor for forward-looking statements made by a public company that files reports under the federal securities laws
 this safe harbor is not available to issuers of penny stocks. As a result
 the Company will not have the benefit of this safe harbor protection in the event of any legal action based upon a claim that the material provided by the Company contained a material misstatement of fact or was misleading in any material respect because of the Company&#8217;s failure to include any statements necessary to make the statements not misleading. Such an action could hurt our financial condition.




Our officers and directors control
 either directly or indirectly
 a substantial portion of our voting securities. Therefore
 our management may significantly affect the outcome of all corporate actions and decisions for an indefinite period of time including election of directors
 amendment of charter documents and approval of mergers and other significant corporate transactions.



















No cash dividends have been paid on the Company&#8217;s common stock. We expect that any income received from operations will be devoted to our future operations and growth. The Company does not expect to pay cash dividends in the near future. Payment of dividends would depend upon our profitability at the time
 cash available for those dividends
 and other factors as the Company&#8217;s board of directors may consider relevant. If the Company does not pay dividends
 the Company&#8217;s common stock may be less valuable because a return on an investor&#8217;s investment will only occur if the Company&#8217;s stock price appreciates.


Because we became a public by means of a reverse acquisition
 we may not be able to attract the attention of brokerage firms.

Because we became public through a &#8220;reverse acquisition&#8221;
 securities analysts of brokerage firms may not provide coverage of us since there is little incentive to brokerage firms to recommend the purchase of our common stock.


Our certificate of incorporation allow for our board to create new series of preferred stock without further approval by our stockholders
 which could adversely affect the rights of the holders of our common stock.

Our Board of Directors has the authority to fix and determine the relative rights and preferences of preferred stock. Our Board of Directors has the authority to issue up to 50
000
000 shares of our preferred stock without further stockholder approval. As a result
 our Board of Directors could authorize the issuance of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation
 the right to receive dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares
 together with a premium
 prior to the redemption of our common stock. In addition
 our board of directors could authorize the issuance of a series of preferred stock that has greater voting power than our common stock or that is convertible into our common stock
 which could decrease the relative voting power of our common stock or result in dilution to our existing stockholders. Although we have no present intention to issue any additional shares of preferred stock or to create any additional series of preferred stock
 we may issue such shares in the future.

If and when a registration statement becomes effective
 there will be a significant number of shares of common stock eligible for sale
 which could depress the market price of such shares.

We have agreed to file a registration statement with the SEC to register the shares of our common stock issued in connection with the Private Placement. Following the effective date of such registration statement a large number of shares of common stock will be available for sale in the public market
 which could harm the market price of the stock.




Statements in this Annual Report on Form 10-K may be &#8220;forward-looking statements.&#8221; Forward-looking statements include
 but are not limited to
 statements that express our intentions
 beliefs
 expectations
 strategies
 predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations
 estimates and projections about our business based
 in part
 on assumptions made by management. These statements are not guarantees of future performance and involve risks
 uncertainties and assumptions that are difficult to predict. Therefore
 actual outcomes and results may
 and are likely to
 differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors
 including those described above under &#8220;Risk Factors
&#8221; and under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this current report and in other documents which we file with the Securities and Exchange Commission. In addition
 such statements could be affected by risks and uncertainties related to our ability to raise any financing which we may require for our operations
 competition
 government regulations and requirements
 pricing and development difficulties
 our ability to make acquisitions and successfully integrate those acquisitions with our business
 as well as general industry and market conditions and growth rates
 and general economic conditions. Any forward-looking statements speak only as of the date on which they are made
 and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this current report
 except as required under applicable securities laws. &#160;&#160;


























Our&#160;headquarters&#160;are located at&#160;20 East 68th Street
 New York
 NY 10065
 under a month-to-month verbal lease that expires in June 2014
 renewable annually. Our monthly rent is $1
200.





On May 29
 2013
 Highland Global Creek Partners
 Inc. (the &#8220;Plaintiffs&#8221;) brought an action against AVT in the Supreme Court of New York
 County of New York
 alleging a breach of a consulting contract. The Plaintiffs are seeking a judgment directing AVT to issue and deliver 80
000
000 shares of its common stock and 10
000
000 shares of its Series A Preferred Stock.&#160;In addition
 the Plaintiffs are also seeking an order enjoining AVT from taking any action requiring shareholder approval without notice to Plaintiffs and/or the Plaintiffs&#8217; participation
 as well as an order declaring that any action requiring stockholder approval taken by AVT without notice to and/or the participation of the Plaintiffs is null and void.&#160;&#160;AVT has filed counterclaims against the Plaintiffs and will contest this matter vigorously.


























5. MARKET FOR REGISTRANT'S COMMON EQUITY
 RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

The Company&#8217;s common stock is quoted on the OTCBB under the symbol &#8220;AVTH &#8221;. During the year ended December 31
 2013
 there was minimal reported trading in our common stock. There has been limited reported trading to date in 2014 in our common stock.


As of March 20
 2014
 there were approximately 47 holders of record of the Company&#8217;s common stock.



The Company has never declared or paid any cash dividends on its common stock. The Company currently intends to retain future earnings
 if any
 to finance the expansion of its business. As a result
 the Company does not anticipate paying any cash dividends in the foreseeable future.










On January 8
 2014
 the Company issued (a) 3
550
000 shares of common stock for cash proceeds from the Private Placement received in December 2013
 (b) approximately 36
600 shares of common stock in exchange for the cancellation of $7
520 in notes payable
 (c) 264
000 shares of common stock were issued for placement agent services and (d) 1
630
200 shares of common stock were issued for other services. In connection with the foregoing the Company relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933
 as amended
 for transactions not involving a public offering.


















AV Therapeutics
 Inc. (the &#8220;Company&#8221;) is a Delaware corporation formed on November 14
 2011 under the name &#8220;Aquino Milling Inc.&#8221; Under its initial business plan
 the Company intended to purchase rice milling equipment and commence rice milling operations. On June 10
 2013
 the Company changed its name to &#8220;Code 2 Action
 Inc.&#8221; On July 30
 2013
 the Company changed its name to &#8220;Merica Corp.&#8221; The Company was unable to implement its business plan. Prior to the Reverse Acquisition (discussed below)
 Merica did not have any active business.


On December 13
 2013 (the &#8220;Closing Date&#8221;)
 the Company entered into and closed an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;)
 with AVT Acquisitions
 Inc.
 a Delaware corporation and a wholly-owned subsidiary of the Company (the &#8220;Subsidiary&#8221;) and Advanced Vaccine Therapeutics
 Inc.
 a Delaware corporation (formerly known as AV Therapeutics
 Inc.) (&#8220;AVT&#8221;). Pursuant to the Merger Agreement
 (i) the Subsidiary merged into AVT
 such that AVT became a wholly-owned subsidiary of the Company
 and (ii) the Company issued 58
000
000 shares (the &#8220;Acquisition Shares&#8221;)
 of the Company&#8217;s common stock to the shareholders of AVT
 representing approximately 77% of the Company&#8217;s aggregate issued and outstanding common stock following the closing of the Merger Agreement (following the Share Cancellation and the&#160;&#160;initial closing under the Private Placement
 each as defined below)
 in exchange for the cancellation of all of the issued and outstanding shares of common stock of AVT.



















(i)&#160;Effective on the Closing Date
 70
000
000 shares of common stock were returned to the Company for cancellation (the &#8220;Share Cancellation&#8221;).


(ii)&#160;Effective on the Closing Date
 Mr.&#160;Doug Cole resigned as officer of the Company. Mr. Cole resigned as a director of the Company on February 5
 2014. In addition
&#160;the following individuals were appointed as executive officers and directors of the Company:

















Chief Executive Officer
 Chief Financial Officer
 Chairman















President
 Chief Operating Officer







Chief Scientific Officer
 Director




















(iii)&#160;On December 19
 2013
 the Company changed its name from &#8220;Merica Corp.&#8221; to &#8220;AV Therapeutics
&#160;Inc.&#8221;


In connection with the Merger Agreement
 the Company entered into and closed subscription agreements with accredited investors (the &#8220;Investors&#8221;)
 pursuant to which the Company sold an aggregate of 3
550
000 shares of common stock for an aggregate purchase price of $709
999 (the &#8220;Private Placement&#8221;).


AVT is a Delaware corporation formed on February 11
 2011.&#160;&#160;Prior to the date of incorporation
 the activities of AVT were carried out through Applied Vaccine Technology
 LLC (&#8220;AVT
 LLC&#8221;)
 a Delaware limited liability company formed in July 2007 and an entity with common ownership as AVT.&#160;&#160;The operations and net assets of AVT
 LLC were acquired by AVT on February 11
 2011 and AVT
 LLC has since been an inactive entity.


Effective on the Closing Date
 pursuant to the Merger Agreement
 AVT became a wholly owned subsidiary of the Company. The acquisition of AVT is treated as a reverse acquisition (the &#8220;Reverse Acquisition&#8221;)
 and the business of AVT became the business of the Company. At the time of the Reverse Acquisition
 Merica was not engaged in any significant active business.

References to &#8220;we&#8221;
 &#8220;us&#8221;
 &#8220;our&#8221; and similar words refer to the Company and its wholly-owned subsidiary
 AVT
 unless the context otherwise requires
 and prior to the effectiveness of the Reverse Acquisition
 these terms refer to AVT.&#160;References to &#8220;Merica&#8221; refer to the Company and its business prior to the Reverse Acquisition.





AVT&#160;&#160;is&#160;&#160;primarily&#160;&#160;engaged&#160;&#160;in&#160;&#160;the&#160;&#160;business&#160;&#160;of&#160;&#160;developing&#160;&#160;cancer&#160;&#160;therapeutics&#160;&#160;and immunotherapeutic vaccines that can be used together with prevalent treatment modalities such as chemotherapy and radiation to treat active disease and to prevent metastases and recurrence. AVT has purchased the exclusive rights to a patented chemotherapeutic drug called &#8220;Capridine&#8221; that has been shown in preclinical models to have specific activity against prostate and colon cancer. This drug is expected to be the front line AVT product specifically in prostate cancer where limited chemotherapy is available at the present time. Our immuno-therapeutics is based on the ability of certain proprietary reagents to re-educate or reprogram a failed immune system that can target previously unidentified micro-metastases. We intend to clinically develop both of these approaches independently specifically for prostate cancer. This drug was developed and patented by certain scientists on behalf of New York Medical College
 including Dr. Raj Tiwari
 AVT&#8217;s Chief&#160;Scientific Officer
 who is also a professor at New York Medical College. The drug patents were thus issued to New York Medical College. AVT subsequently purchased an exclusive license to the drug
 including the exclusive right to commercialize the drug. Under our agreement with New York Medical College
 we agreed to pay New York Medical College 3% of net sales (as defined in the agreement) from commercialization of the drug patents
 and 30% of sublicense fees. In addition to Dr. Raj Tiwari
 Dr. Abraham Mittelman
 our Chief Executive Officer
 Dr. Jan Geliebter
 our Corporate Secretary
 and Dr. Debabrata Banerjee
 our Clinical Development Officer
 are professors at New York Medical College.

















We have
 in the past
&#160;provided funding to New York Medical College to conduct research
 pursuant to our supported research and license agreement with New York Medical College (see &#8220;Our Technology&#8221; below). In the future
 we intend to expand our research efforts by identifying other promising research and funding that research through academic institutions (such as New York Medical College). Under such an arrangement
 any patents would be granted to the academic institution and AVT in turn would enter into a licensing agreement with the academic institution for rights to the patent.

Our proprietary technology is easily adaptable to infectious diseases
 thus enhancing its market potential. We do not intend to market our own products although we may decide to do so in the future. Instead
 we intend to enter into agreements with large pharmaceutical companies whereby we will receive an upfront cash sum plus an ongoing royalty stream when the drug(s) or vaccine(s) are approved by the Food and Drug Administration (&#8220;FDA&#8221;) for use in the market. We will search for a partner(s) in early Phase II/III clinical trials of any particular treatment modality drug and or vaccine.

We believe
 although no assurance can be given
 that with funding in the amount of approximately $10
000
000
 the first therapeutic pharmaceutical
 the prostate cancer specific drug and a prostate cancer vaccine can be evaluated through Phase I clinical trials in humans within the next 12 to 18 months. We do not have any definitive agreements for funding and as such there cannot be any assurance that we will be successful in achieving our goals.




Year ended December 31
 2013
 compared with the year ended December 31
 2012

There were no revenues recognized during the years ended December 31
 2013 and 2012.&#160;

Operating expenses for the year ended December 31
 2013
 totaled $905
396 and consisted of research and development of $332
692 paid mainly to consultants for providing scientific research
 consulting fees of $430
476 paid for professional services
 including legal and accounting services
 patent legal fees of $71
812 for ongoing patent maintenance
 general and administrative costs of $49
809
 consisting of rent and travel and other miscellaneous expenses
 and depreciation and amortization of $20
607
 consisting mainly of patent amortization.


For the year ended December 31
 2012
operating expenses totaled $284
343 and consisted of research and development of $73
335 paid mainly to consultants for providing scientific research
 consulting fees of $99
960 paid for professional services including legal and accounting
 patent legal fees of $61
467 for ongoing patent maintenance

 general and administrative costs of $28
976 consisting mainly of rent
 travel and other miscellaneous expenses&#160;&#160;and depreciation and amortization of $20
605
 consisting mainly of patent amortization.

The increase in expenditures for the year ended December 31
 2013 over the same period ended December 31
 2012 is mainly due to accrued salary and bonuses for research consultants as well as accounting and legal fees and&#160;an increase in consulting and professional fees relating to the reverse merger of the Company.


The net loss for the year ended December 31
 2013
 was $905
920
 including $524 in interest expense in association with the Prostagenics agreement. The net loss for the year ended December 31
 2012 was $286
271.





We have incurred net losses of $905
920 and $286
271 for the years ended December 31
 2013 and 2012
 respectively. As of December 31
 2013 the Company had cash and a stockholders&#8217; equity of $576
251 and $34
172
 respectively. At December 31
 2013
 the Company had a working capital deficiency of $114
504. During the year ended December 31
 2013
 the Company raised net proceeds of approximately $935
000 through the issuance of common stock.



Our primary ongoing uses of operating cash relate to payments to subcontractors and vendors for research and development
 salaries and related expenses and professional fees.&#160;The timing of such payments is generally even throughout the year.&#160;&#160;Our vendors and subcontractors generally provide us with normal trade payment terms.&#160;During the year ended December 31
 2013
 net cash used in operating activities amounted to $456
184 and comprised of our net loss of $905
920
 adjustments to reconcile net loss to net cash used in operating activities of $306
647
 of which $286
040 related to non-cash stock-based compensation
 and changes in operating assets and liabilities of 143
089. During the year ended December 31
 2012
 we used net cash in operating activities of $222
501
 comprised of net loss of $286
271 adjustments to reconcile net loss to net cash used in operating activities of $20
605 and changes in operating assets and liabilities of $43
165.


















During the year ended December 31
 2013
 the Company received net proceeds of $934
999 from common stock issuances. During the year ended December 31
 2012
 net proceeds of $250
000 from common stock issuances.



The Company is a development stage entity and incurred net losses of $905
920 during the year ended December 31
 2013. As of December 31
 2013 the Company had a working capital deficiency and stockholders&#8217; equity of $114
504 and $34
172. In order to execute our long-term strategic plan to develop and commercialize our core products
 we will need to raise additional funds
 through public or private equity offerings
 debt financings
 or other means. These conditions raise substantial doubt about our ability to continue as a going concern.

During the year ended December 31
 2013
 the Company issued 1
166
666 and 249
998 shares of common stock at $0.15 and $0.20 per share
 respectively
 in a private placement and received net proceeds of $225
000. During the year ended December 31
 2013
 the Company also received $709
999 in a private placement in exchange for the issuance of 3
550
000 shares of common stock at $0.20 per share.


The Company can give no assurance that the cash raised subsequent to December 31
 2013 or any additional funds raised will be sufficient to execute its business plan. Additionally
 the Company can give no assurance that additional funds will be available on reasonable terms
 or available at all
 or that it will generate sufficient revenue to alleviate the going concern. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern.

The Company&#8217;s ability to execute its business plan is dependent upon its ability to raise additional equity
 secure debt financing
 and/or generate revenue. Should the Company not be successful in obtaining the necessary financing
 or generate sufficient revenue to fund its operations
 the Company would need to curtail certain of its operational activities. The accompanying financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.



We do not have any relationships with unconsolidated entities or financial partnerships
 such as entities often referred to as structured finance or special purpose entities
 which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition
 we do not have any undisclosed borrowings or debt
 and we have not entered into any synthetic leases. We are
 therefore
 not materially exposed to any financing
 liquidity
 market or credit risk that could arise if we had engaged in such relationships.




The following discussion and analysis of financial condition and results of operations is based upon our consolidated financial statements
 which have been prepared in conformity with accounting principles generally accepted in the United States of America. Certain accounting policies and estimates are particularly important to the understanding of our financial position and results of operations and require the application of significant judgment by our management or can be materially affected by changes from period to period in economic factors or conditions that are outside of our control. As a result
 they are subject to an inherent degree of uncertainty. In applying these policies
 our management uses their judgment to determine the appropriate assumptions to be used in the determination of certain estimates. Those estimates are based on our historical operations
 our future business plans and projected financial results
 our observance of trends in the industry and information available from other outside sources
 as appropriate. Please see Note 3 to our consolidated financial statements for a more complete description of our significant accounting policies.

We intend to utilize the extended transition period provided in Securities Act Section 7(a)(2)(B) as allowed by Section 107(b)(1) of the JOBS Act for the adoption of new or revised accounting standards as applicable to emerging growth companies. As part of the election
 we will not be required to comply with any new or revised financial accounting standard until such time that a company that does not qualify as an &#8220;issuer&#8221; (as defined under Section 2(a) of the Sarbanes-Oxley Act of 2002) is required to comply with such new or revised accounting standards.
















As an emerging growth company within the meaning of the rules under the Securities Act
 and we will utilize certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies. For example
 we will not have to provide an auditor&#8217;s attestation report on our internal controls in future annual reports on Form 10-K as otherwise required by Section 404(b) of the Sarbanes-Oxley Act. In addition
 Section 107 of the JOBS Act provides that an emerging growth company can utilize the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus
 an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to utilize this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with such new or revised accounting standards as they become applicable to public companies.

. The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States which contemplate continuation of the Company as a going concern. However
 the Company is subject to the risks and uncertainties associated with a new business
 has no established source of revenue
 and has incurred significant losses from operations since inception. The Company&#8217;s operations are dependent upon it raising additional capital. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that could result from the outcome of this uncertainty.

The consolidated financial statements include the accounts of AV Therapeutics
 Inc. and its wholly-owned subsidiary
 Advanced Vaccine Therapeutics
 Inc. Intercompany balances and transactions have been eliminated upon consolidation.

. Research and development costs consist of expenditures incurred during the course of planned research and investigation aimed at the discovery of new knowledge
 which will be useful in developing new products or processes. The Company expenses all research and development costs as incurred.


We have not earned any revenue from our planned principal operations and our primary activities since inception have been the research and development of its therapeutics
 negotiating strategic alliances and other agreements
 and raising capital. Accordingly
 the Company's activities have been accounted for as those of a Development Stage Company as defined by Accounting Standards Codification (&#8220;ASC&#8221;) 915.

 - Intangible assets are comprised of patents and licenses with original estimated useful lives of 10-15 years.&#160;&#160;Once placed into service
 the Company amortizes the cost of the intangible assets over their estimated useful lives on a straight line basis.



- Effective February 11
 2011
 AVT began being taxed as a corporation.&#160;&#160;Prior to February 11
 2011
 AVT
 LLC was a disregarded entity for income tax purposes with taxable income or loss passing through to its members.&#160;&#160;AVT uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740
 Income Taxes. Under this method
 income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity's financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled.


 - We measure the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors
 the fair value of the award is measured on the grant date and for non-employees
 the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award
 usually the vesting period.




























AV Therapeutics
 Inc. and Subsidiary






























Consolidated Balance Sheets as of December 31
 2013 and 2012









Consolidated Statements of Operations for the Years Ended December 31
 2013 and 2012&#160;and for the Period From July 24
 2007 (Inception) to December 31
 2013









Consolidated Statement of Changes in Stockholders' Equity (Deficiency) for the Period From July 24
 2007 (Inception) to December 31
 2013









Consolidated Statements of Cash Flows for the Years Ended December 31
 2013 and 2012&#160;and for the Period From July 24
 2007 (Inception) to December 31
 2013













































of AV Therapeutics
 Inc.

We have audited the accompanying consolidated balance sheets of AV Therapeutics
 Inc. and Subsidiary (a development stage company) (the &#8220;Company&#8221;) as of December 31
 2013 and 2012
 and the related consolidated statements of operations
 changes in stockholders&#8217; equity (deficiency) and cash flows for the years then ended
 and for the period from&#160;July 24
 2007 (inception) to December 31
 2013.&#160; These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits.


Company is not required to have
 nor were we engaged to perform
 an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances
 but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly
 An audit also includes examining
 on a test basis
 evidence supporting the amounts and disclosures in the financial statements
 assessing the accounting principles used and significant estimates made by management
 as well as evaluating the overall financial statement presentation.&#160; We believe that our audits provide a reasonable basis for our opinion.


In our opinion
 the financial statements referred to above present fairly
 in all material respects
 the consolidated financial position of AV Therapeutics
(a development stage company) as of December 31
 2013 and 2012
 and the consolidated results of its operations and its cash flows for the years then ended and for the period from&#160;July 24
 2007 (inception) to December 31
 2013 in conformity with accounting principles generally accepted in the United States of America.


The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully discussed in Note 2 to the consolidated financial statements
 the Company is in the development stage
 has incurred net losses since inception and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.





New York
 NY


March 31
 2014




















 Inc. and Subsidiary

































December 31
 2013




December 31
 2012




























576
251



97
436







60
000











636
251



97
436







1
079



1
511







147
597



167
772







784
927



266
719






































65
432



106
735







386
618



142
226







97
000



97
000







201
705



201
705







750
755



547
666
















































Preferred stock
 $0.0001 par value:

000
000 shares authorized; none issued and outstanding













Common stock
 $0.0001 par value:
&#160;&#160; 250
000
000 shares authorized; 72
000
000&#160;&#160;and 66
289
644 shares

 respectively



7
200



6
629







3
707
680



3
543
371







1
056
159











(4
736
867



(3
830
947







34
172



(280
947

















784
927



266
719


























 Inc. and Subsidiary
















December 31
 2013





December 31
 2012




For The Period From July 24
 2007 (Inception) To December 31
 2013

































































430
476



99
960



1
892
019







332
692



73
335



2
258
109







71
812



61
467



386
557







49
809



28
976



113
346







20
607



20
605



83
482







905
396



284
343



4
733
513





















(905
396



(284
343



(4
733
513

































&#160;&#160;Interest (expense) income
 net











3
204











(1
946



(6
558











(1
928



(3
354





















(905
920



(286
271



(4
736
867



















































67
504
224



65
242
612






























 Inc. and Subsidiary





























































































































































Balance
 July 24
 2007 (Inception):































48
689
629



4
869



(4
869



























335
000











335
000























(211
376



(211
376



Balance at December 31
 2007



48
689
629



4
869



330
131







(211
376



123
624















595
000











595
000























(562
733



(562
733



Balance at December 31
 2008



48
689
629



4
869



925
131







(774
109



155
891























(121
013



(121
013



Balance at December 31
 2009



48
689
629



4
869



925
131







(895
122



34
878

















215
000







215
000























(479
710



(479
710



Balance at December 31
 2010



48
689
629



4
869



925
131



215
000



(1
374
832



(229
832







1
433
339







214
857



(215
000















12
303
336



1
230



1
844
270











1
845
500







196
667







29
480











29
500







666
667







89
933











90
000







666
667







89
933











90
000







666
672







99
933











100
000























(2
169
844



(2
169
844



Balance at December 31
 2011



64
622
977



6
463



3
293
537







(3
544
676



(244
676







166
667







24
983











25
000







666
667







99
934











100
000







833
333







124
917











125
000























(286
271



(286
271



Balance at December 31
 2012



66
289
644



6
629



3
543
371







(3
830
947



(280
947







166
667







24
983











25
000







333
333







49
967











50
000







666
666







99
933











100
000







249
998







49
975











50
000







4
293
692







(7
749











(7
320

















7
320







7
320



















709
999







709
999













(52
800



52
800



























286
040







286
040























(905
920



(905
920



Balance at December 31
 2013



72
000
000



7
200



3
707
680



1
056
159



(4
736
867



34
172


























 Inc. and Subsidiary










































July 24
 2007























December 31
 2013




December 31
 2012




December 31
 2013









































(905
920



(286
271



(4
736
867





















20
175



20
174



82
403















284
500















1
079







286
040







2
131
540





















(60
000







(60
000







203
089



43
165



452
050







(456
184



(222
501



(1
845
295











































(2
158















(230
000













(232
158































Proceeds received from issuance of common stock
 net of issuance costs



225
000



250
000



999
500







709
999







709
999















930
000















14
205





934
999



250
000



2
653
704



















478
815



27
499



576
251





97
436



69
937























576
251



97
436



576
251







































































































4
869





































7
320







7
320







52
800







52
800
























AV Therapeutics
 Inc. and Subsidiary








 &#8211; AV Therapeutics
 Inc. (the &#8220;Company&#8221;) is a Delaware corporation formed on November 14
 2011 under the name &#8220;Aquino Milling Inc.&#8221; Under its initial business plan
 the Company intended to purchase rice milling equipment and commence rice milling operations. On June 10
 2013
 the Company changed its name to &#8220;Code 2 Action
 Inc.&#8221; On July 30
 2013
 the Company changed its name to &#8220;Merica Corp.&#8221; The Company was unable to implement its business plan and prior to the Reverse Acquisition (discussed below); Merica Corp. did not have any active business.

On December 13
 2013 (the &#8220;Closing Date&#8221;)
 the Company along with AVT Acquisitions
 Inc.
 a Delaware corporation and a wholly-owned subsidiary of the Company (the &#8220;Subsidiary&#8221;) entered into and closed an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with Advanced Vaccine Therapeutics
 Inc.
 a Delaware corporation (formerly known as AV Therapeutics
 Inc.) (&#8220;AVT&#8221;). Pursuant to the Merger Agreement
 (i) the Subsidiary merged into AVT
 such that AVT became a wholly-owned subsidiary of the Company
 and (ii) the Company issued 58
000
000 shares (the &#8220;Acquisition Shares&#8221;)
 of the Company&#8217;s common stock to the shareholders of AVT
 representing approximately 77% of the Company&#8217;s aggregate issued and outstanding common stock following the closing of the Merger Agreement (following the Share Cancellation and the&#160;&#160;initial closing under the Private Placement
 each as defined below)
 in exchange for the cancellation of all of the issued and outstanding shares of common stock of AVT.


In connection with the Merger Agreement
 in addition to the foregoing:


(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Effective on the Closing Date
 70
000
000 shares of common stock were returned to the Company for cancellation (the &#8220;Share Cancellation&#8221;).


(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;AVT assumed notes payable with an aggregate value of $7
320. Shortly after the Merger in 2013
 the holders of the notes agreed to convert the notes payable into shares of the Company&#8217;s common stock at $0.20 per share. The Company has included the $7
320 in shares issuable on the consolidated balance sheet at December 31
 2013 as the 36
596 shares of common stock were not issued until January 8
 2014 due to administrative delays.


(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Effective on the Closing Date
 Mr. Doug Cole resigned as officer of the Company. Mr. Cole resigned as a director of the Company on February 5
 2014. In addition
 the following individuals were appointed as executive officers and directors of the Company:

















Chief Executive Officer
 Chief Financial Officer
 Chairman















President
 Chief Operating Officer







Chief Scientific Officer
 Director




















(iv)&#160;On December 19
 2013
 the Company changed its name from &#8220;Merica Corp.&#8221; to &#8220;AV Therapeutics
&#160;Inc.&#8221;


The Company completed its private placement memorandum (&#8220;PPM&#8221;) on September 30
 2013 authorizing the Company to sell up to 12
500
000 shares of its common stock at a price of $0.20 to accredited investors.


In connection with the Merger Agreement
 as of the Closing Date the Company entered into and closed subscription agreements with accredited investors (the &#8220;Investors&#8221;)
 pursuant to which the Company received an aggregate $709
999 and agreed to issue the Investors 3
550
000 shares of common stock (&#8220;Private Placement&#8221;).&#160;&#160;The Company&#8217;s original private placement memorandum dated September 30
 2013 permitted the Company to sell up to 12
500
000 shares of common stock at $0.20 per share. The Company included the receipt of the proceeds in shares issuable on the consolidated balance sheet at December 31
 2013 as the shares were not issued until January 8
 2014 due to administrative delays. As disclosed in Note 9
 in connection with the Private Placement
 the Company incurred costs of $52
800
 which were paid in common shares on January 8
 2014.

















AV Therapeutics
 Inc. and Subsidiary





AVT is a Delaware corporation that was formed on February 11
 2011.&#160;&#160;Prior to the date of incorporation
 the activities of AVT were carried out through Applied Vaccine Technology
 LLC (&#8220;AVT
 LLC&#8221;)
 a Delaware limited liability company formed in July 2007 and an entity with common ownership as AVT.&#160;&#160;The operations and net assets of AVT
 LLC were acquired by AVT on February 11
 2011 and AVT
 LLC has since been an inactive entity.


Effective on the Closing Date
 pursuant to the Merger Agreement
 AVT became a wholly owned subsidiary of the Company. The acquisition of AVT has been treated as a reverse acquisition in accordance with ASC 805-40 (the &#8220;Reverse Acquisition&#8221;)
 and the business of AVT became the business of the Company. At the time of the Reverse Acquisition
 Merica was not engaged in any significant active business.


 - The Company is a development stage biopharmaceutical company whose business goals are to discover
 develop and commercialize therapeutics to advance the care of patients suffering from cancer.&#160;&#160;The Company&#8217;s activities are supported by its patents
 patent applications
 provisional patent applications
 and other proprietary intellectual property surrounding capridine and immunogens for treatment of infectious diseases and in specific
 prostate cancer
 amongst others.&#160;&#160;To date
 the Company has not developed any commercial products.





As of December 31
 2013
 the Company had a working capital deficiency and stockholders&#8217; equity of $114
504 and $34
172
 respectively.&#160;&#160;Through December 31
 2013
 the Company has not generated any revenues and has incurred net losses of $4
736
867 during the period from July 24
 2007 (Inception) through December 31
 2013.&#160; These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern.&#160;The Company's main source of operating funds since inception has been its contributions from its founders and debt and equity financings.&#160; The Company intends to raise additional capital through private debt and equity investors. The Company is currently a development stage enterprise and there is no assurance that it will be successful in raising any additional funds or that any future funds raised will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America
 which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business.&#160; The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values.&#160; The financial statements do not include any adjustment that might result from the outcome of this uncertainty.






The consolidated financial statements include the accounts of AV Therapeutics
 Inc. and its wholly-owned subsidiary
 Advanced Vaccine Therapeutics
 Inc. Intercompany balances and transactions have been eliminated upon consolidation.




and its primary activities since inception have been the research and development of its therapeutics
 negotiating strategic alliances and other agreements

 the Company's activities have been accounted for as those of a Development Stage Company as defined by ASC 915.


The Company prepares the financial statements in accordance with U.S. GAAP which
 requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;&#160;The Company&#8217;s significant estimates and assumptions include the recoverability and useful lives of long-lived assets
 the fair value of the Company&#8217;s stock
 stock-based compensation
 and the valuation allowance related to the Company&#8217;s deferred tax assets. Certain of the Company&#8217;s estimates
 including the carrying amount of the intangible assets
 could be affected by external conditions
 including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company&#8217;s estimates and could cause actual results to differ from those estimates.

















AV Therapeutics
 Inc. and Subsidiary





Cash equivalents are comprised of all highly liquid investments with an original maturity of three months or less when purchased.&#160;&#160;At December 31
 2013 and 2012
 the Company had no cash equivalents.


 - Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains its cash balances in high quality financial institutions located in the United States which mitigate such risk associated with them. At times
 the Company&#8217;s cash balances may be uninsured or in deposit accounts that exceed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits.

Research and development expenses consist primarily of costs associated with the preclinical and/ or clinical trials of drug candidates
 compensation and other expenses for research and development
 including personnel
 supplies and development materials
 costs for consultants and related contract research and facility costs. Expenditures relating to research and development are expensed as incurred.


 - Property and equipment are stated at cost
 net of accumulated depreciation which is recorded using the straight line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives
 which range from 5 to 7 years. Maintenance and repairs are charged to operations as incurred.


Intangible assets are comprised of patents and licenses with original estimated useful lives of 10-15 years.&#160;&#160;Once placed into service
 the Company amortizes the cost of the intangible assets over their estimated useful lives on a straight line basis. As of December 31
 2013 the Company owns one patent that was internally developed and licenses two patents (See Note 4) and also has exclusive rights to two immunological patents related to vaccine development and delivery mechanism. Costs incurred by the Company in connection with developing patents internally are expensed as incurred.





Revenue from license fees and grants is recognized when the following criteria are met: persuasive evidence of an arrangement exists
 services have been rendered
 the contract price is fixed or determinable
 and collection is reasonably assured.&#160;&#160;In licensing arrangements
 delivery does not occur for revenue recognition purposes until the license term begins. Nonrefundable upfront fees received in exchange for products delivered or services performed that do not represent the culmination of a separate earnings process will be deferred and recognized over the term of the agreement using the straight line method or another method if it better represents the timing and pattern of performance. For the years ended December 31
 2013 and 2012 and for the period from July 24
 2007 (inception) to December 31
 2013
 the Company did not recognize any revenue.


For revenue contracts that contain multiple elements
 revenue arrangements with multiple deliverables are divided into separate units of accounting if the delivered item has value to the customer on a standalone basis and there is objective and reliable evidence of the fair value of the undelivered item.


Basic loss per share was computed using the weighted average number of common shares outstanding. Diluted loss per share includes the effect of diluted common stock equivalents. As of December 31
 2013
 and 2012
 the Company did not have any common stock equivalents outstanding.


 -&#160;The financial instruments consist of cash
 accounts payables
 accrued expenses
 and short-term credit obligations.&#160;&#160;The carrying amounts of the financial instruments approximate their respective current fair values due to their relatively short maturities.&#160;The carrying amounts of short term credit obligations approximate fair value because the effective yields on these obligations
 which include contractual interest rates
 are comparable to rates of returns for instruments of similar credit risk.

















AV Therapeutics
 Inc. and Subsidiary




Pursuant to the requirements of ASC 820
 the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:



Level 2: Financial instruments lacking unadjusted
 quoted prices from active market exchanges
 including over the counter traded financial instruments. The prices for the financial instruments are determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs
 such as interest rates and yield curves that are observable at commonly quoted intervals.

Level 3: Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little
 if any
 market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques.

 - The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors
 the fair value of the award is measured on the grant date and for non-employees
 the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award
 usually the vesting period.

 - The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740
 Income Taxes. Under this method
 income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity's financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence
 it is more likely than not some portion or all of the deferred tax assets will not be realized.


ASC Topic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition
 classification
 interest and penalties
 accounting in interim periods
 disclosure
 and transition. The Company will classify as income tax expense any interest and penalties. The Company has no material uncertain tax positions for any of the reporting periods presented. Generally
 the tax authorities may examine the partnership/corporate tax returns for three years from the date of filing. The Company has identified its federal return and its state tax return in New York as &#8220;major&#8221; tax jurisdictions
 as defined.


The FASB has issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2013-11
 Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward
 a Similar Tax Loss
 or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU state that an unrecognized tax benefit
 or a portion of an unrecognized tax benefit
 should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward
 a similar tax loss
 or a tax credit carryforward
 except as follows. To the extent a net operating loss carryforward
 a similar tax loss
 or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use
 and the entity does not intend to use
 the deferred tax asset for such purpose
 the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The amendments in this ASU are effective for fiscal years
 and interim periods within those years
 beginning after December 15
 2013. For nonpublic entities
 the amendments are effective for fiscal years
 and interim periods within those years
 beginning after December 15
 2014. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial position and consolidated results of operations.


















AV Therapeutics
 Inc. and Subsidiary










On February 5
 2010
 the Company entered into an assignment and assumption agreement (the &#8220;Prostagenics Agreement&#8221;) with Prostagenics
 LLC (&#8220;Prostagenics&#8221;)
 an entity for which two of the Company&#8217;s stockholders own a non-controlling interest (See Note 9).&#160;&#160;Pursuant to the Prostagenics Agreement
 the Company was assigned
 among other things
 the exclusive license covering certain patent rights
 technology
 know-how and preclinical research data relating to the treatment of certain cancers.&#160;&#160;Pursuant to the Prostagenics Agreement
 as consideration for the intangible assets acquired
 the Company agreed to the following:









To pay Prostagenics a fixed cash licensing fee of $200
000 in four (4) installments through April 1
 2011
 all of which has been paid;












To reimburse $284
500 of research and development expenses incurred by Prostagenics (See Note 7)












To pay Prostagenics a fixed cash licensing payment of $25
000 within fifteen (15) days upon completing a phase I clinical trial as defined by the Food and Drug Administration (&#8220;FDA&#8221;)
 and












To issue Prostagenics a convertible note payable with a face value of $1
500
000 within fifteen (15) days upon completing a phase II clinical trial as defined by the FDA.&#160;&#160;The note matures thirty-six months from the date of the




Prostagenics completes phase II clinical trial
 and contains a rate of interest of 5% per annum.&#160;&#160;The note is convertible into shares of the Company&#8217;s common stock at a 20% discount of the average closing price of the Company&#8217;s common stock for the ten (10) business days prior to the conversion
 subject to a minimum floor price of $0.50 per share.&#160;&#160;If the Company&#8217;s shares are publicly traded
 Prostagenics will have registration rights with respect to the conversion of the shares subject to a one-year lock-up period and agreed not to liquidate more than 25% of its share per quarter upon expiration of the one-year lock-up period.

The Company has not made an accounting entry related to the two contingent payments (&#8220;c&#8221; and &#8220;d&#8221; above) as it is not currently estimable when the specified performance criteria will be met.&#160;&#160;If and when the performance criteria disclosed above are met
 the Company will add the value of the consideration paid to Prostagenics to the value of the intangible assets.On June 24
 2008
 the Company entered into a Supported Research and License Agreement with New York Medical College (&#8220;NYMC&#8221;)
 a related party (the &#8220;NYMC Agreement&#8221;).&#160;&#160;Pursuant to the NYMC Agreement
 the Company was assigned
 among other things
 the exclusive royalty-bearing license covering certain patent rights
 technology
 and know-how relating to the treatment of certain cancers.&#160;&#160;Pursuant to the NYMC Agreement
 the Company made a payment to NYMC consisting of a cash licensing fee of $30
000.&#160;&#160;The Company will also be required to pay NYMC certain royalties as follows:









For any sales of &#8220;diagnostic products&#8221; the Company will be required to pay NYMC royalties of 3% of net sales revenue (as defined) for sales between $0 - $20
000
000
 2% for sales between $20
000
001 - $50
000
000
 and 1% of sales in excess of $50
000
000.










For any sales of &#8220;therapeutic products&#8221; the Company will be required to pay NYMC royalties of 1% of net sales revenue (as defined) for sales between $0 - $2
000
000
 2% for sales between $2
000
001 - $5
000
000
 and 3% of sales in excess of $5
000
000.










For any sublicense fees
 royalties from sublicenses
 maintenance fees or similar charges received from sublicenses
 the Company will be required to be pay NYMC 17.5% of such fees earned.




















AV Therapeutics
 Inc. and Subsidiary




In July of 2007
 the founders of the Company contributed a patent to the Company at no cost as the patent was previously internally developed.

As of December 31
 2013 and 2012
 intangible assets consisted of the following:









December 31
 2013




December 31
 2012








230
000



230
000







(82
403



(62
228



Intangible Assets
 net



147
597



167
772








Estimated future amortization is as follows at December 31
 2013:
















For the year ended December 31
 2014



20
174



For the year ended December 31
 2015



20
174



For the year ended December 31
 2016



20
174



For the year ended December 31
 2017



20
174



For the year ended December 31
 2018



20
174







46
727





147
597





Amortization expense amounted to $20
175 for the year ended December 31
 2013 and $20
174 for the year ended December 31
 2012. Amortization expense for the period from July 24
 2007 (inception) to December 31
 2013 was $82
403.














December 31
 2013




December 31
 2012
















2
158



2
158







(1
079







Fixed Assets
 net



1
079



1
511





 2013 and 2012
 respectively. Depreciation expense for the period from July 24
 2007 (inception) to December 31
 2013 was $1
079.





The Company has 50
000
000 authorized shares of blank check preferred stock with a par value of $0.0001. As of December 31
 2013
 none have been issued and outstanding.


At various dates between July 24
 2007 (inception) and February 11
 2011
 the date that AVT was incorporated
 AVT
 LLC received $930
000 as capital contributions from its founders.

















AV Therapeutics
 Inc. and Subsidiary





At various dates in 2010
 AVT
 LLC entered into subscription agreements with various accredited investors whereby it received $215
000 and agreed to issue the investors 1
433
339 ($0.15 per share) once AVT was incorporated. The shares were issued on February 11
 2011.


On February 11
 2011 AVT issued 12
303
336 shares of common stock to various consultants for past professional services and research and development services rendered to the Company.&#160;&#160;The grant date fair value of the shares issued was $1
845
500
 or $0.15 per share
 of which $1
170
250 was included in consulting fees and $ 675
250 was included in research and development expenses on the statements of operations for the period from July 24
 2007 (inception) to December 31
 2013.&#160;&#160;Of the total number of common shares issued
 4
000
000 shares were issued to Mr. Robert Pollack
 the Company&#8217;s current President
 and 6
470
000 were issue to Mr. Morton Coleman
 the Company&#8217;s current Vice President.&#160;&#160;As of December 31
 2013 and 2012
 there is no unamortized expense relating to these issuances.


At various dates in 2011
 AVT sold 2
196
673 shares of common stock at $0.15 per share for aggregate proceeds of $329
500. AVT incurred issuance costs of $20
000 associated with such offerings
 resulting in net proceeds of $309
500.&#160;&#160;Of the total shares issued in 2011
 30
000 were issued to Mr. Morton Coleman
 the Company&#8217;s current Vice President for $0.15 cents per share
 or gross proceeds of 4
500.


At various dates in 2012
 AVT sold 1
666
667 shares of common stock at $0.15 per share for aggregate proceeds of $250
000.


At various dates in 2013 through April 30
 AVT sold 1
166
666 shares of common stock at $0.15 per share for aggregate proceeds of $175
000.


In August 2013
 AVT sold 249
998 shares of common stock at $0.20 per share for aggregate proceeds of $50
000.





The founders of AVT advanced $3
205 on July
 24
 2007 (inception) which remained outstanding as of December 31
 2013 and 2012 and is included in notes payable &#8211; related parties on the consolidated balance sheets. The advance is non-interest bearing and the Company has agreed to repay the advance with common stock at $0.20 per share at a future date to be determined.


Through February 5
 2010
 Prostagenics received various services from three consultants (two of whom are stockholders of the Company) in connection with the continued research and development of cancer treatments supported by the patents identified in the Prostagenics Agreement.&#160;&#160;Through February 5
 2010
 Prostagenics had unpaid consulting fees accrued to these consultants in the amount of $284
500.&#160;&#160;As disclosed in Note 4
 in connection with the Prostagenics Agreement
 AVT reimbursed Prostagenics $284
500 through the assumption of such liabilities.&#160;&#160;The Company has included the $284
500 as research and development expense on the consolidated statements of operations for the period from July 24
 2007 (inception) to December 31
 2013.


Of the aggregate amount of liabilities assumed
 $125
000 and $62
500 are payable to Dr. Raj Tiwari (&#8220;Tiwari&#8221;) and Dr. Debabrata Banerjee (&#8220;Banerjee&#8221;)
 respectively
 both of whom are original founders and current stockholders of the Company.


The remaining $97
000 is payable to the estate of Daniel Miller
 an unrelated party.&#160;&#160;The Company has not reached a repayment agreement with the estate of Daniel Miller. All of the notes are due on demand and are non-interest bearing in nature.&#160;&#160;The Company has verbally agreed with both Tiwari and Banerjee to repay the outstanding notes payable immediately once the Company completes a financing of $2.5 million dollars.


The Company&#8217;s founder and current Chief Executive Officer
 Dr. Abraham Mittelman
 advanced the Company $11
000 in February 2011. The advance is non-interest bearing and the Company has agreed to repay the advance with common stock at $0.20 per share at a future date to be determined.&#160;&#160;As of December 31
 2013 and 2012
 the advance is included in notes payable &#8211; related parties on the consolidated balance sheets.

















AV Therapeutics
 Inc. and Subsidiary








Through December 31
 2013 and 2012
 the Company generated U.S. federal and state net operating loss carryovers for tax purposes of approximately $1
162
262 and $441
016
 respectively. The net operating loss carryover may be used to reduce taxable income through the year 2033. Section 382 of the Internal Revenue Code imposes certain limitations on the utilization of net operating loss carryovers and other tax attributes after a change in control. If the Company has a change in ownership
 such change could significantly limit the possible utilization of such carryovers.











December 31
 2013




December 31
 2012






































































(259
878



(97
333







(77
428



(28
999







(337
306



(126
332







(337
306



(126
332







337
306



126
332





























December 31
 2013




December 31
 2012
















State and local taxes
 net of federal effect











Total federal
 state and local tax rate
 net





































The Company assesses the likelihood that deferred tax assets will be realized. The Company contributed amortizable intangible assets with a tax basis in excess of book basis at inception. The tax basis exceeds the book basis by approximately $126
000. The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely
 a valuation allowance is established. Based upon the Company&#8217;s history of losses since inception
 management believes that it is more likely than not that future benefits of deferred tax assets will not be realized and as a result
 a full valuation allowance has been established. The tax effects of temporary differences that give rise to deferred tax assets are presented below:









December 31
 2013




December 31
 2012
















512
465



273
239







55
491



43
022







85
612











653
568



316
261







(653
568



(316
261

































AV Therapeutics
 Inc. and Subsidiary








Tiwari and Banerjee own a non-controlling interest in Prostagenics
 LLC
 described above in Note 4.





The Company rents office space from SB Lauren PC
 an entity owned by the wife of the Company&#8217;s President
 on a month to month basis for $1
200 per month. The arrangement commenced in 2012.&#160;&#160;Rent expense for each of the years ended December 31
 2013 and 2012 was $14
400 in connection with this arrangement
 of which $5
000 is included in accounts payable and accrued expenses as of December 31
 2013.





In December 2013
 the Company reached an agreement with a member of its Board of Directors
 Mr. Douglas Cole
 whereby the Company agreed to issue 200
000 shares of common stock to Mr. Cole for his past services as a Director at similar terms to the shares issued in the Private Placement.&#160;&#160;The Company has determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered.&#160;&#160;During the year ended December 31
 2013
 the Company recorded $40
000 in connection with this issuance which is included in consulting fees in the statement of operations with a corresponding accrual to shares issuable. Due to administrative delays
 the shares were issued on January 8

 2014
 Mr. Cole resigned as a director of AV Therapeutics
 Inc.





On August 27
 2013 the Company engaged Sichenzia Ross Friedman Ference LLP (&#8220;SRFF&#8221;) as its legal representative for a going public transaction. The Company agreed to pay SRFF $50
000 and 325
000 shares of common stock for providing this service. Once the Company was able to complete such transaction
 which it did in December 2013
 the Company agreed to pay $4
500 per month for general legal matters
 for which the Company will have the option to pay such fees in registered common stock valued at $6
000. The Company has determined that the fair market value of the stock was more readily available than the fair market value of the services rendered. The Company paid SRFF the $50
000 in cash during the year ended December 31
 2013 and has included the value of the common stock to be issued of $65
000 in&#160;&#160;shares issuable on the consolidated balance sheet as of December 31
 2013 with a corresponding charge to consulting fees on the statement of operations. The shares were issued on January 8
 2014.


Also
 Paradox Capital Partners
 LLC
 an entity beneficially owned by Mr. Harvey J. Kesner
 a partner at SRFF
 invested $50
000 in the Private Placement and received 250
000 shares of common stock.


Objective Equity
 LLC


On December 13
 2012
 the Company entered into an agreement with Objective Equity
 LLC (&#8220;Objective Equity&#8221;) to act on behalf of the Company as its non-exclusive placement agent and assist the Company in raising up to a maximum of $25 million.&#160;&#160;In consideration for such services
 the Company will pay Objective Equity (a) a cash placement fee of 8% of the total purchase price of securities sold
 including all amounts received by the Company upon exercise of any warrants issued in such raise and
 (b) warrants in an aggregate amount equal to 8% of the number of common shares issued by the Company in a raise.&#160;&#160;The agreement terminates on December 13
 2014. Mr. Douglas Cole
 a former Director of the Company is a partner in Objective Equity.&#160;&#160;On January 8
 2014
 the Company amended the terms of its agreement with Objective Equity whereby both parties agreed that the Company would issue Objective Equity shares of common stock with a grant date fair value equal to 8% of the total proceeds received by the Company.&#160;&#160;The Company has determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered.&#160;&#160;Of the total proceeds received to date in the Private Placement
 Objective Equity assisted the Company in the raising of the initial $660
000 and as a result
 the Company included $52
800 in shares issuable at December 31
 2013.&#160;&#160;On January 8
 2014
 the Company issued 264
000 shares of common stock.


















AV Therapeutics
 Inc. and Subsidiary









From time to time
 the Company is subject to legal proceedings arising in the ordinary course of business. Such matters are subject to uncertainties and outcomes are not predictable with assurance. Management believes at this time
 there are no ongoing matters that will have a material adverse effect on the Company's business
 consolidated financial position
 results of operations
 or cash flows
 except as disclosed below.


On May 29
 2013
 Highland Global Creek Partners
 Inc. (the &#8220;Plaintiffs&#8221;) brought an action against the Company in the Supreme Court of New York
 County of New York
 alleging a breach of a consulting contract. The Plaintiffs are seeking a judgment directing the Company to issue and deliver 80
000
000 shares of common stock and 10
000
000 shares of Series A Preferred Stock.&#160;&#160;In addition
 the Plaintiffs are also seeking an order enjoining the Company from taking any action requiring shareholder approval without notice to Plaintiffs and/or the Plaintiffs participation
 as well as an order declaring that any action requiring stockholder approval taken by the Company without notice to and/or the participation of the Plaintiffs is null and void.&#160;&#160;The Company has filed counterclaims against the Plaintiffs and has not made any formal settlement demand.&#160;&#160;To date
 the litigation has not progressed beyond the pleading stage and no discovery has taken place.&#160;&#160;The Company has not recorded a provision for a potential loss as it is unable to state that an outcome in this matter is unfavorable or estimate the amount or range of a potential loss.





During the years 2007 through 2013
 the Company considered certain executives to be consultants of the Company rather than employees.&#160; If the executives were treated as employees during the above period
 the Company would have been required to withhold and remit payroll taxes to the respective taxing authorities. This position may be subject to audit by the Internal Revenue Service and other state and local taxing authorities
 which
 upon review
 could result in an unfavorable outcome if it is determined that such individuals&#8217; compensation should have been reported on the basis of an employee rather than a consultant.&#160; The Company has recorded charges of approximately $40
392 and $8
600 for the years ended December 31
 2013 and 2012 and approximately $182
618 for the period from July 24
 2007 (inception) to December 31
 2013 in consulting and research and development fees on the statements of operations for additional compensation (including penalties and interest) on behalf of the executives should the Company be challenged by the taxing authorities and it is determined their position is without merit. As of December 31
 2013
 $ 182
618 is included in accrued expenses on the consolidated balance sheet.





On October 14
 2013 the Company entered into a consulting agreement with Dr. Abraham Mittelman to be the Company&#8217;s Chief Executive Officer for a term of 4 years.&#160;&#160;The agreement was effective on July 1
 2013. The Company shall pay Dr. Mittelman $72
000 per annum in common stock in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In connection with this agreement
 the Company incurred research consulting expense of $36
000 for the year ended December 31
 2013
 for which the entire amount remains in accrued expenses at year end.


On October 14
 2013 the Company entered into a consulting agreement with Tiwari
 to be the Company&#8217;s Chief Scientific Officer for a term of 4 years.&#160;&#160;The agreement was effective on July 1
 2013. The Company shall pay Tiwari $72
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Tiwari shall be paid a signing bonus of $20
000 to be paid over two years in equal increments not less frequently than monthly.&#160;&#160;The Company incurred expenses associated with Dr. Tiwari&#8217;s consulting services of $96
000 for the year ended December 31
 2013
 of which $56
000 related to the above agreement and the remaining $40
000 related to payment for services provided before the agreement was entered into.&#160;&#160;Of the total amount incurred by the Company
 $20
000 remains in accrued expenses at December 31
 2013.

















AV Therapeutics
 Inc. and Subsidiary





On October 14
 2013 the Company entered into a consulting agreement with Dr. Jan Geliebter to be the Company&#8217;s Secretary for a term of 4 years.&#160;&#160;The agreement was effective on July 1
 2013. The Company shall pay Ms. Geliebter $48
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Dr. Geliebter shall be paid a signing bonus of $35
000 to be paid over two years in equal increments not less frequently than monthly. The Company incurred consulting expenses associated with Dr. Geliebter&#8217;s services of $59
000 in connection with the above agreement for the year ended December 31
 2013
 which remains in accrued expenses at December 31
 2013.


On October 14
 2013 the Company entered into a consulting agreement with Dr. Robert Suriano to be the Company&#8217;s Lab Manager for a term of 2 years.&#160;&#160;The agreement was effective on July 1
 2013. The Company shall pay Mr. Suriano $24
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Dr. Suriano shall be paid a signing bonus of $10
000 to be paid over two years in equal increments not less frequently than monthly. Payments pursuant to consulting agreement shall accrue as of the date of the consulting agreement and commence once the Company has raised $2.5 million through a financing. The Company incurred expenses associated with Dr. Suriano&#8217;s consulting services of $27
000 for the year ended December 31
 2013
 of which $22
000 related to the above agreement and the remaining $5
000 related to payment for services provided before the agreement was entered into.&#160;&#160;Of the amount incurred by the Company
 $20
000 remains in accrued expenses at December 31
 2013.


On October 14
 2013 the Company entered into a consulting agreement with Banerjee&#160;to be a research consultant for the Company for a term of 4 years.&#160;&#160;The agreement was effective on July 1
 2013. The Company shall pay Banerjee $48
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Banerjee shall be paid a signing bonus of $35
000 to be paid over two years in equal increments not less frequently than monthly.&#160;&#160;Payments pursuant to consulting agreement shall accrue as of the date of the consulting agreement and commence once the Company has raised $2.5 million through a financing. The Company incurred consulting expenses associated with Dr. Banerjee&#8217;s services of $59
000 for the year ended December 31
 2013 in connection with the above agreement
 which remains in accrued expenses at December 31
 2013.


TotalCFO
 LLC


On September 17
 2013
 the Company engaged TotalCFO
 LLC to provide consulting services related to its financial reporting for a period of one year unless sooner terminated by either party upon (90) days written notice. The Company shall pay TotalCFO
 LLC (a) $2
500 per month in cash
 (b) a monthly amount of registered common shares having a grant date fair value $2
500 (to be calculated at a 25% discount to market) and (c) all pre-approved expenses.&#160;&#160;The Company incurred professional fees expense to TotalCFO
 LLC of $20
000 for the year ended December 31
 2013
 of which $10
000 was paid and $10
000 remains in accrued expenses at December 31
 2013. The amount in accrued expenses was originally to be paid in shares of registered common stock
 however since the Company has not filed a registration statement they did not have registered shares to issue. Total CFO
 LLC agreed to settle and accept shares of unregistered common stock at an amount calculated using the same per share price as the Private Placement of $0.20
 or 50
000 shares.&#160;&#160;The shares have yet to be issued do to administrative delays.


On January 8
 2014
 the Company agreed to issue Total CFO
 LLC 100
000 shares of common stock at similar terms to the shares issued in the Private Placement as a one-time bonus for consideration of their services in connection with the Company&#8217;s going-public transaction.&#160;&#160;The Company has determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered. During the year ended December 31
 2013
 the Company recorded $20
000 of consulting expense related to this arrangement. The shares were issued on January 8
 2014.

















AV Therapeutics
 Inc. and Subsidiary





RedChip Companies
 Inc.


On December 14
 2012 the Company entered into an agreement with RedChip Companies
 Inc. (&#8220;RedChip&#8221;) to assist the Company with various legal
 professional
 investor relations and other services in connection with a going-public transaction involving the Company.&#160;&#160;In December of 2013
 the Company and RedChip agreed to amend the terms of the agreement whereby the Company would issue RedChip 805
200 shares of common stock in full satisfaction for amounts owed in connection with services performed by RedChip at $0.20 per share.&#160;&#160;&#160;The Company has determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered and as a result
 the Company included $161
040 in consulting fees on the consolidated statements of operations for the year ended December 31
 2013 and a corresponding accrual to shares issuable.&#160;&#160;The shares were issued on January 8
 2014.


In addition
 in December 2013
 the Company entered into an investor relations agreement with RedChip for a term of three months commencing January 1
 2014.&#160;&#160;In connection with the investor relations agreement the Company agreed to (a) pay RedChip a $60
000 cash payment
 which was made on December 13
 2013
 and (b) issue RedChip 200
000 shares of common stock
 which were issue on January 8
 2014.&#160;&#160;The Company has included the $60
000 in prepaid expenses on its consolidated balance sheet as of December 31
 2013.





On January 8
 2014
 the Company issued (a) 3
550
000 shares of common stock&#160;in connection with the&#160;cash proceeds&#160;received in&#160;the Private Placement received in December 2013
 (b) 36
596&#160;shares of common stock in exchange for the cancellation of $7
520 in notes payable
 (c) 264
000 shares of common stock for placement agent services and (d) 1
630
200 shares of common stock for other services. In connection with the foregoing the Company relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933
 as amended
 for transactions not involving a public offering.


On March 10
 2014
 the Company entered into an agreement with John Carris Investments
 LLC (&#8220;John Carris&#8221;) to act on behalf of the Company as its non-exclusive placement agent and assist the Company in raising up to a maximum of $3.5 million.&#160;&#160;In consideration for such services
 the Company will pay John Carris (a) a cash placement fee of 10% of the total purchase price of securities sold
 including all amounts received by the Company upon exercise of any warrants issued in such raise
 (b) a non-accountable expense allowance in the amount of 2% of the aggregate consideration received by the Company
 and (c) warrants in an aggregate amount equal to 8% of the number of common shares issued by the Company in a raise.&#160;&#160;The agreement terminates on June 10
 2014.


On January 31
 2014
 the Company amended its original private placement memorandum dated September 30
 2013 to (a) increase the amount the Company is offering to $3
500
000 from $2
500
000 and (b) to add a warrant to the offering to purchase one share of Common Stock at an exercise price of $0.40 and exercisable for a period of sixty (60) months after initial exercise date.&#160;&#160;To date
 no additional proceeds other than as disclosed in Note 1
 have been raised under the Private Placement.






























Under the supervision and with the participation of our management
 including our principal executive officer and principal financial officer
 we conducted an evaluation of our disclosure controls and procedures
 as such term is defined in Rule&#160;13a-15(e) under the Securities Exchange Act of 1934
 as amended (the &#8220;Exchange Act&#8221;)
 as of December 31
 2013. Based on this evaluation
 our management concluded that
 due to the material weakness in our internal controls discussed below
&#160;&#160;our disclosure controls and procedures&#160;are not effective to provide reasonable assurance that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded
 processed
 summarized and reported within the time periods specified in the SEC&#8217;s rules and forms
 and is accumulated and communicated to our management
 including our principal executive officer and principal financial officer
 as appropriate to allow timely decisions regarding required disclosures.




Management is responsible for establishing and maintaining adequate internal control over financial reporting of the Company. Because of its inherent limitations
 internal control over financial reporting may not prevent or detect misstatements. Also
 projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions
 or that the degree of compliance with the policies and procedures may deteriorate.


Management
 with the participation of our Chief Executive Officer and Chief Financial Officer
 have evaluated the effectiveness of our internal control over financial reporting as of December&#160;31
 2013 based on criteria established in the 1992 Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation
 management concluded that
 as of December&#160;31
 2013
 our internal control over financial reporting&#160;is not effective in providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.


As of December 31
 2013
 we have identified certain matters that constituted a material weakness in our internal controls over financial reporting. Specifically
 we have difficulty in accounting for complex accounting transactions and have limited segregation of duties within our accounting and financial reporting functions. Segregation of duties within our Company is limited due to the small number of employees that are assigned to positions that involve the processing of financial information. Although we are aware that segregation of duties within our Company is limited
 we believe (based on our current roster of employees and certain control mechanisms we have in place)
 that the risks associated with having limited segregation of duties are currently insignificant. Additional time is required to expand our staff
 fully document our systems
 implement control procedures and test their operating effectiveness before we can definitively conclude that we have remediated our material weakness.






There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or 15d-15 under the Exchange Act that occurred during the quarter ended December 31
 2013 that has materially affected
 or is reasonably likely to materially affect
 our internal control over financial reporting.

























10. DIRECTORS
 OFFICERS AND CORPORATE GOVERNANCE.


Below are the names and certain information regarding the Company&#8217;s executive officers and directors. Except as set forth below
 our officers devote approximately 40-50 hours per week to AVT.


























Chief Executive Officer
 Chief Financial Officer
 Chairman

































































Abraham&#160;Mittelman


 Principal Financial Officer&#160;and&#160;Chairman&#160;of&#160;the&#160;Board

Dr. Mittelman has served as the Company&#8217;s Chief Executive Officer
 Chief Financial Officer and Chairman since December 13
 2013. Dr. Mittelman
 66
 is a practicing Oncologist with an extensive background in theoretical
 clinical and practical research experience and a keen ability to identify novel therapeutics as well as the ability to measure their clinical outcome. He is an Associate Professor of Microbiology and Immunology at New York Medical College
 a position he has held since 2000. He is also Associate Professor of Medicine
 Department of Medicine
 New York Medical College (NYMC) (since 1983) and Attending Physician in the Department of Medicine
 Division of Oncology
 at Westchester Medical Center (since 1983). His academic training as Research Fellow was at Memorial Sloan-Kettering Cancer Center
 New York City
 in Oncology. He has previously held the position of Assistant Professor of Medicine at Cornell University. Dr. Mittelman has extensive experience in managing clinical trials in investigational pharmaceuticals and immunological agents.



Cancer
 The Journal of mmunology
In addition to being an active researcher
 Dr. Mittelman is a prolific writer and has authored or co-authored more than 150 scientific papers and book chapters
 and more than 200 abstracts. Many of these papers have been presented at international conferences on cancer research.

Dr.&#160;&#160;Mittelman is the&#160;President&#160;of&#160;the&#160;New York State Society of Medical Oncology and Hematology
 and is a member of the American Society of Clinical Oncology
 the American Association&#160;for Cancer Research
 the American Society of Pharmacology
 and the Society of Biologic Therapy.&#160;&#160;He has received numerous awards for his clinical research.


Dr. Mittelman holds an MD degree from the University of Guadalajara. He previously studied in the Masters&#8217; Program
 majoring in Physics
 at New York University. His undergraduate degree is from Pratt Institute. Dr. Mittelman&#8217;s medical and scientific knowledge and experience qualify him to serve on the Company&#8217;s board of directors.

Morton&#160;Coleman

 

Dr. Coleman has served as the Company&#8217;s Vice President since December 13
 2013. Dr. Coleman
 72
 is Clinical Professor of Medicine at the Weill Medical College of Cornell University and the Director of the Center for Lymphoma and Myeloma at the New York Presbyterian Hospital-Weill Cornell Campus
 a position he has held since 1997. Dr. Coleman&#8217;s expertise is in the treatment of lymphoma
 myeloma
 Waldenstrom&#8217;s macroglobulinemia
 and associated diseases. He has played an instrumental role in devising the standard treatment for Hodgkin&#8217;s disease
 the use of infusional chemotherapy in lymphoma
 the concept of dose intensity and its use in myeloma and lymphoma
 the combined use of thalidomide in myeloma
 the role of PET scanning in lymphoma
 the innovative applications of monoclonal antibodies in lymphoma and many other developments. Dr. Coleman is chairman of the Medical Affiliate Board of Lymphoma Research Foundation and&#160;is&#160;on&#160;its&#160;Board&#160;of&#160;Directors and&#160;Scientific Review&#160;committee. He&#160;is&#160;also&#160;a member of the scientific review committees of the International Waldenstrom&#8217;s Foundation and the Research Fund for Waldenstroms
 Ltd. Dr. Coleman has served as chairman of the New Agents Committee of the Cancer and Leukemia Group B (university research consortium) and currently is on its Lymphoma Core Committee. He is the chairman of the Fund for Blood and Cancer Research and has also served as the chairman of the board of the Affiliated Physician&#8217;s Network. He has served on both the Publication and Program Committees of the American Society of Clinical Oncology and also served as the chairman of several subcommittees. He is an Associate Editor of Cancer Investigation and has served as the chairman
 consultant or member reviewer for many scientific committees and journals
 particularly in the areas of lymphoma
 myeloma and Waldenstrom&#8217;s macroglobulinemia. He has authored over 400 publications in the field of blood cancers
 and has been designated a &#8220;Top Doctor&#8221; by U.S. News Magazine and New York Magazine.
















Robert&#160;Pollock
&#160;

Mr. Pollock has served as the Company&#8217;s President and Chief Operating Officer since December 13
 2013. Mr. Pollock
 77 has over 40 years of business experience and is a graduate of City University of New York with a Physics and Engineering background. Robert is also a graduate of General Electric Management&#8217;s&#160;&#160;school
 in Crotonville
 New York. Since 2000
 he has been the Founder and Managing Partner of Continuum Partners
 a global&#160;&#160;Network&#160;&#160;Security&#160;&#160;&amp; Business&#160;&#160;Development&#160;&#160;Consultancy. His partners included three internationally recognized senior security experts with globally recognized PhD&#8217;s
 including a former NSA Deputy Director. Besides his own extensive technological
 and business development skills he works hand in hand with our PhDs and MDs in bringing their patented intellectual property to market.


Raj&#160;Kumar&#160;Tiwari

 

Dr. Tiwari has served as the Company&#8217;s Chief Scientific Officer and director since December 13
 2013. Dr. Tiwari
 57 is a Cancer Biologist with over 25 years of cancer research. He is a Professor of Microbiology &#160;and Immunology
 the Graduate Program Director
 and Professor of Otolaryngology at New York Medical College
 a position he has held since 1996. An accomplished scientist of international repute
 has over 150 publication and abstracts
 is a leader in cancer prevention and control and in inventor of several patents involving Capridine and Cancer Vaccine which are part of our intellectual property.

Dr. Tiwari was Assistant Professor of Biochemistry in Surgery
 Cornell University Medical College (1991-1996)
 New York
 Assistant Laboratory Member for the Sloan-Kettering Institute for Cancer Research (1989-1991). During the same period he served as Assistant Attending Biochemist for Memorial Hospital
 Breast Service. Dr. Tiwari has a Ph.D. in Biochemistry from Calcutta University and received his post-doctoral training at the University of Toronto
 Canada (1984-1985) and then at Sloan-Kettering Cancer Institute
 New York (1986-1989).


In addition to his academic appointments
 Dr. Tiwari reviews grant applications for the American Cancer Society
 the American-Italian Foundation
 the Dutch Cancer Society

 Journal of Clinical Oncology
 Anti-Cancer Research
 American Journal of Gastroenterology
 Journal of the National Cancer Institute
 Journal of Interferon Research
 Peptides
 FASEB Journal
 

Dr. Tiwari has published over one hundred scientific articles
 primarily in cancer biology. Dr. Tiwari has been honored a number of times for his scholarship
 including: (i) National Scholarship
 Government of India (1972-1979); (ii) Junior Research Fellowship
 Indian Council of Medical Research (1979-1982); (iii) Senior Research Fellowship
 Indian council of Medical Research (1982-1983); (iv) Post-Doctoral Fellowship
 University of Toronto (1983-1985); and (v) Post- Doctoral Fellowship
 the National Institute of Health (1992). He is the author of several awarded patents.

Dr. Tiwari is a member of the American Association for Cancer Research
 the American Association for the Advancement of Science
 the Society for Interferon Research
 the Harvey Society and the New York Academy of Sciences.&#160;&#160;&#160;&#160;&#160;Dr. Tiwari is&#160;also&#160;&#160;a&#160;&#160;member&#160;&#160;of&#160;&#160;the Molecular Biology Study Section which reviews and awards grants for breast cancer from the US Army Medical Research Command. His research has been funded by grants from the National Institute of Health (NIH)
 the US Army Medical Research Command (Breast and Prostate Cancer Initiative)
 and the American Institute for Cancer Research. Dr. Tiwari&#8217;s medical and scientific knowledge and experience qualify him to serve on the Company&#8217;s board of directors.


Jan&#160;Geliebter



Dr. Geliebter has served as the Company&#8217;s Secretary since December 13
 2013. Dr. Geliebter
 58
 brings to the Company experience in areas including research of prostate cancer
 thyroid cancer
 vaccines
 and infectious diseases.

Dr.&#160;&#160;Geliebter is the Professor of Microbiology and Immunology
 Associate Professor of Medicine
 Associate Professor of Otolaryngology
 and Medical Microbiology Course Director at New York Medical College. He joined New York Medical College as Assistant Professor of Microbiology and Immunology in 1996. Previously
 Dr. Geliebter was Assistant Professor of Urology&#160;&#160;at Albert&#160;&#160;Einstein&#160;&#160;College&#160;&#160;of Medicine&#160;&#160;(1993&#160;&#160;&#8211; 1996). Prior&#160;&#160;to this
&#160;&#160;he held&#160;&#160;the position&#160;&#160;of Assistant&#160;&#160;Investigator&#160;&#160;for the Howard&#160;&#160;Hughes&#160;&#160;Medical&#160;&#160;Institute&#160;&#160;(1988&#160;&#160;&#8211; 1993). During the same period
 Dr. Geliebter was an Assistant Professor for The Rockefeller University. In his early graduate career
 he served as a Research Associate for Albert Einstein College of Medicine (1984 &#8211; 1987) and a Postdoctoral Fellow (1981 &#8211; 1984).
















In addition to his academic appointments

 Cancer Investigation
 Cancer
 and Peptides


Dr. Geliebter&#160;&#160;has published&#160;&#160;over fifty (50) scientific&#160;&#160;articles. He has been awarded&#160;&#160;three (3) patents and currently has two (2) patents pending.&#160;&#160;&#160;Dr. Geliebter has been honored for his scholarship&#160;&#160;by&#160;&#160;the&#160;&#160;American&#160;&#160;Cancer&#160;&#160;Society
&#160;&#160;National&#160;&#160;Cancer&#160;&#160;Institute
&#160;&#160;Albert&#160;&#160;Einstein College of Medicine
 Pfeiffer Foundation
 and New York Medical College.&#160;&#160;Dr. Geliebter holds a PhD in Microbiology&#160;&#160;and Immunology from SUNY
 Downstate Medical Center.


Dr. Geliebter is a member of the American Association for Cancer Research
 the American Association for the Advancement of Science
 and the New York Academy of Sciences. His research has been funded by grants from the Pfeiffer Foundation
 American Institute for Cancer Research
 Retirement Research&#160;&#160;Foundation
 Zita&#160;&#160;Spiss&#160;&#160;Foundation
&#160;&#160;Zalmin&#160;&#160;Arlin&#160;&#160;Cancer Research Fund
 National Institute of Health
 and the National Cancer Institute.




Debabrata&#160;Banerjee

 


Dr. Banerjee has served as the Company&#8217;s Clinical Development Officer since December 13
 2013. Dr.&#160;&#160;Banerjee
 57
 brings to the Company extensive research experience that will be especially useful in the final phases of compound readiness for clinical trials. His research interests range from gene therapy and cancer to stem cells.

Dr. Banerjee is an Associate Professor of Medicine and Pharmacology for the Rutgers University
 New Jersey
 and an Adjunct Associate Professor at the New York Medical College
 positions he has held since 2002.&#160;&#160;Prior to this
 he was an Associate Lab Member at the Sloan-Kettering Institute of New York. Prior to this
 he held the position of Research Scientist
 Molecular Pharmacology Laboratory (1989&#160;&#160;&#160;&#8211;&#160;&#160;1992)&#160;&#160;&#160;at the same institution. Dr. Banerjee obtained a PhD in Biochemistry from Calcutta University and also served as an Adjunct Lecturer for the Department of Biochemistry&#160;&#160;at Calcutta University&#160;&#160;(1988 &#8211; 1989).&#160;&#160;Before this
 he was a Senior Scientist for Research on Hematology and Blood Transfusion&#160;&#160;of Calcutta (1987 &#8211; 1989). Dr. Banerjee completed his Postdoctoral Fellowship training in the Department of Biology
 McGill University
 Canada (1983 &#8211; 1987).

In addition
 to his academic appointments

 Oncogene
 Clinical Cancer Research
 Gynecologic Oncology
 Journal of Cancer Chemotherapy
 British Journal of Cancer
 Stem Cells
 and Blood. 

Dr. Banerjee has published over fifty scientific articles primarily in cancer
 gene therapy
 and stem cell biology. He has been awarded two (2) patents. Dr. Banerjee is a member of the American Association for Cancer Research
 the American Society for Gene Therapy
 a Life Member for the Indian Society for Human Genetics
 and the Cancer Institute of New Jersey. His research has been funded by grants from Pharmamar
 S.A.
 National Institute of Health
 National Cancer Institute
 and the New Jersey Science and Technology Commission.




Dr. Mittelman serves as Chairman and Chief Executive Officer. Due to the small size and early stage of the Company
 we believe it is currently most effective to have the Chairman and Chief Executive Officer positions combined.

Our board of directors is primarily responsible for overseeing our risk management processes.&#160;The board of directors receives and reviews periodic reports from management
 auditors
 legal counsel
 and others
 as considered appropriate regarding our company&#8217;s assessment of risks. The board of directors focuses on the most significant risks facing our company and our company&#8217;s general risk management strategy
 and also ensures that risks undertaken by our Company are consistent with the board&#8217;s appetite for risk. While the board oversees our company&#8217;s risk management
 management is responsible for day-to-day risk management processes. We believe this division of responsibilities is the most effective approach for addressing the risks facing our company and that our board leadership structure supports this approach.&#160;



















The Company&#8217;s directors are appointed for a one-year term to hold office until the next annual general meeting of the Company&#8217;s shareholders or until removed from office in accordance with the Company&#8217;s bylaws and the provisions of the Delaware General Corporation Law. The Company&#8217;s directors hold office after the expiration of his or her term until his or her successor is elected and qualified
 or until he or she resigns or is removed in accordance with the Company&#8217;s bylaws and the provisions of the Delaware General Corporation Law.






To our knowledge
 our directors and executive officers have not been involved in any of the following events during the past ten years:




























being subject to any order
 judgment
 or decree
 not subsequently reversed
 suspended or vacated
 of any court of competent jurisdiction
 permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business
 securities or banking activities or to be associated with any person practicing in banking or securities activities;&#160;









being found by a court of competent jurisdiction in a civil action
 the SEC or the Commodity Futures Trading Commission to have violated a Federal or state securities or commodities law
 and the judgment has not been reversed
 suspended
 or vacated;









being subject of
 or a party to
 any Federal or state judicial or administrative order
 judgment decree
 or finding
 not subsequently reversed
 suspended or vacated
 relating to an alleged violation of any Federal or state securities or commodities law or regulation
 any law or regulation respecting financial institutions or insurance companies
 or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or









being subject of or party to any sanction or order
 not subsequently reversed
 suspended
 or vacated
 of any self-regulatory organization
 any registered entity or any equivalent exchange
 association
 entity or organization that has disciplinary authority over its members or persons associated with a member.






The Board of Directors acts as the Audit Committee and the Board has no separate committees. The Company has no qualified financial expert at this time because it has not been able to hire a qualified candidate. Further
 the Company believes that it has inadequate financial resources at this time to hire such an expert.



We have not adopted a Code of Business Conduct and Ethics that applies to our principal executive officer
 principal financial officer
 principal accounting officer or controller
 or persons performing similar functions because of the small number of persons involved in the management of the Company.




Because we did not have a class of equity securities registered pursuant to Section 12 of the Exchange Act during the year ended December 31
 2013
 we were not subject to Section 16(a) of the Exchange Act.




















During its last two fiscal years
 Merica did not pay any compensation to its officers or directors.

The following table sets forth all compensation paid in respect of AVT&#8217;s chief executive officer for the years ended December 31
 2013 and 2012. No other executive officer of AVT received compensation in excess of $100
000 for either of AVT&#8217;s last two completed fiscal years.





























































































36
000 (1)





36
000



















20
000





























76
000 (1)





96
000











The Company&#8217;s executive officers provide services to the Company on an independent contractor basis. The Company is party to consulting agreements with Dr. Mittelman
 Dr. Tiwari
 Dr. Geliebeter and Dr. Banerjee. The consulting agreements have four year terms
 effective July 1
 2013. Pursuant to the consulting agreements
 the Company agreed to pay Dr. Mittelman
 Dr. Tiwari
 Dr. Geliebeter and Dr. Banerjee&#160;$72
000
 $72
000
 $48
000 and $48
000 annually
 respectively.





The Company had no outstanding equity awards as of December 31
 2013.





No director of the Company received any compensation for services as director for the year ended December 31
 2013.








The following table sets forth certain information
 as of March 26
&#160;&#160;2014 with respect to the beneficial ownership of the outstanding common stock by (i) any holder of more than five (5%) percent; (ii) each of the Company&#8217;s executive officers and directors; and (iii) the Company&#8217;s directors and executive officers as a group. Except as otherwise indicated
 to our knowledge each of the stockholders listed below has sole voting and investment power over the shares beneficially owned.
















Beneficial ownership is determined in accordance with the rules of the SEC. Unless otherwise indicated in the table
 the persons and entities named in the table have sole voting and sole investment power with respect to the shares set forth opposite the shareholder&#8217;s name.

























15
659
079

















5
568
166

















3
426
564

















11
401
892

















6
681
800

















6
681
800

















49
419
101














The percentage of class beneficially owned is based on 77
480
796 shares of common stock issued and outstanding as of March 28
 2014. Beneficial ownership has been determined in accordance with Rule 13d-3 under the Exchange Act.&#160;&#160;Pursuant to the rules of the SEC
 shares of common stock which an individual or group has a right to acquire within 60 days pursuant to the exercise of options or warrants are deemed to be outstanding for the purpose of computing the percentage ownership of such individual or group
 but are not deemed to be beneficially owned and outstanding for the purpose of computing the percentage ownership of any other person shown in the table.


13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
 AND DIRECTOR INDEPENDENCE





In December 2013
 the Company reached an agreement with a member of its Board of Directors
 Mr. Douglas Cole
 whereby the Company agreed to issue 200
000 shares of common stock to Mr. Cole for his past services as a Director at similar terms to the shares issued in the Private Placement.&#160;&#160;The Company has determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered.&#160;&#160;During the year ended December 31
 2013
 the Company recorded $40
000 as consulting fees
 representing the fair market value of the stock
 which is included in consulting fees in the statement of operations. Due to administrative delays
 the shares were issued on January 8

 2014
 Mr. Cole resigned as a director of AV Therapeutics
 Inc.


On December 13
 2012
 the Company entered into an agreement with Objective Equity
 LLC (&#8220;Objective Equity&#8221;) to act on behalf of the Company as its non-exclusive placement agent and assist the Company in raising up to a maximum of $25 million.&#160;&#160;In consideration for such services
 the Company will pay Objective Equity (a) a cash placement fee of 8% of the total purchase price of securities sold
 including all amounts received by the Company upon exercise of any warrants issued in such raise and
 (b) warrants in an aggregate amount equal to 8% of the number of common shares issued by the Company in a raise.&#160;&#160;The agreement terminates on December 13
 2014. Mr. Douglas Cole
 a former Director of the Company is a partner in Objective Equity.&#160;&#160;On January 8
 2014
 the Company amended the terms of its agreement with Objective Equity whereby both parties agreed that the Company would issue Objective Equity shares of common stock with a grant date fair value equal to 8% of the total proceeds received by the Company.&#160;&#160;The Company has determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered.&#160;&#160;Of the total proceeds received to date in the Private Placement
 Objective Equity assisted the Company in the raising of the initial $660
000 and as a result
 the Company included $52
800 in shares issuable at December 31
 2013.&#160;&#160;On January 8
 2014
 the Company issued 264
000 shares of common stock.


AVT rents office space from SB Lauren PC
 an entity owned by the wife of Robert Pollock
 AVT&#8217;s President
 for $1
200 per month. The arrangement commenced in 2012.


On February 5
 2010
 AVT entered into an assignment and assumption agreement (the &#8220;Prostagenics Agreement&#8221;) with Prostagenics
 LLC (&#8220;Prostagenics&#8221;)
 an entity for which Dr. Tiwari and Dr. Banerjee own a non-controlling interest. Pursuant to the Prostagenics Agreement
 the Company was assigned
 among other things
 the exclusive license covering certain patent rights
 technology
 know-how and preclinical research data relating to the treatment of certain cancers.
























The following is a summary of fees for professional services rendered by Marcum LLP
 our registered independent public accounting firm for the year ended December 31
 2013:

















57
500




































&#160;&#160;Audit fees represent fees for professional services performed by Marcum LLP for the audit of our annual financial statements and the review of our quarterly financial statements
 as well as services that are normally provided in connection with statutory and regulatory filings or engagements.







The aggregate fees billed to Merica for Merica&#8217;s fiscal years ended December 31
 2013 and 2012
 by 
 Merica&#8217;s registered independent public accounting firm
 were as follows:














December 31
 2013




December 31
 2012
















7
500



10
500
















































































Agreement and Plan of Merger
 dated December 13
 2013
 among Merica Corp.
 AVT Acquisitions
 Inc. and AV Therapeutics
 Inc. (1)















































































Supported Research and License Agreement between New York Medical College and Applied Vaccine Therapeutics
 LLC (1)















Assignment and Assumption between AVT Acquisition Corp. and AV Therapeutics
 Inc. (2)















Subsidiaries: Advanced Vaccine Therapeutics
 Inc. (Delaware corporation)


























































































(1) Filed as exhibit to 8-K filed on December 17
 2013 and incorporated herein by reference.
(2) Filed as an exhibit to 8-K/A filed on December 27
 2013 and incorporated herein by reference.
(3) Filed as an exhibit to 8-K filed on July 31
 2013 and incorporated herein by reference.
(4) Filed as an exhibit to 8-K filed on December 26
 2013 and incorporated herein by reference.
(5) Filed as an exhibit to S-1 filed on December 29
 2011 and incorporated herein by reference.




















Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934
 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.






AV THERAPEUTICS
 INC.









Dated:&#160;&#160;March 31
 2014




















(principal executive
 financial and accounting officer)






Pursuant to the requirements of the Securities Exchange Act of 1934
 this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
























Chief Executive Officer
 Chief&#160;Financial Officer and Chairman

March 31
 2014



(principal executive
 financial and accounting 





















March 31
 2014










































    













I
 Abraham Mittelman
 certify that:

1.&#160;&#160;&#160;&#160;I have reviewed this report on Form 10-K of AV Therapeutics
 Inc.;

2.&#160;&#160;&#160;&#160;Based on my knowledge
 this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made
 in light of the circumstances under which such statements were made
 not misleading with respect to the period covered by this report;

3.&#160;&#160;&#160;&#160;Based on my knowledge
 the financial statements
 and other financial information included in this&#160;report
 fairly present in all material respects the financial condition
 results of operations and cash flows of the registrant as of
 and for
 the periods presented in this report;











designed such disclosure controls and procedures
 or caused such disclosure controls and procedures to be designed under our supervision
 to ensure that material information relating to the registrant
 including its consolidated subsidiaries
 is made known to us by others within those entities
 particularly during the period in which this&#160;report is being prepared;












designed such internal control over financial reporting
 or caused such internal control over financial reporting to be designed under our supervision
 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;












evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures
 as of the end of the period covered by this report based on such evaluation; and












disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected
 or is reasonably likely to materially affect
 the registrant&#8217;s internal control over financial reporting; and





5.&#160;&#160;&#160;&#160; The registrant&#8217;s other certifying officer(s) and I have disclosed
 based on our most recent evaluation of internal control over financial reporting
 to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):










all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record
 process
 summarize and report financial information; and












any fraud
 whether or not material
 that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&#160;













Dated:&#160; March 31
 2014









































    














In connection with the Annual Report of AV Therapeutics
 Inc. (the &#8220;Company&#8221;) on Form 10-K for the period&#160;ended December 31
 2013 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;)
 I
 Abraham Mittelman
 Chief Executive and Financial Officer of the Company
 certify
 pursuant to 18 U.S.C. section&#160;1350
 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 that:





















The information contained in the Report fairly presents
 in all material respects
 the financial condition and results of operations of the Company.













Date: March 31
 2014



















































      


      




      


      




      


      
      




      


      
      




      


      
      




      

        



      




      

        



      




      

        



      




      

        



      




      


      




      

        



      
      




      

        



      
      




      


      
      




      

        



      
      




      

        



      




      

        



      




      

        



      




      

        



      




      


      




      

        



      
      




      


      
      




      

        



      
      




      

        



      




      

        



      




      

        



      




      

        



      




      


      




      

        



      
      




      


      
      




      

        



      




      

        



      




      

        



      




      

        



      




      


      




      

        
        



      
      




      

        



      
      




      

        



      
      




      


      
      




      

        



      




      

        



      




      

        



      




      

        



      




      


      




      

        
        



      
      




      

        
        



      
      




      

        
        



      
      




      

        



      
      




      

        
        



      
      




      

        
        



      
      




      

        



      
      




      

        
        



      
      




      

        
        



      
      




      

        



      
      




      

        
        



      
      




      

        
        



      
      




      

        



      
      




      

        
        



      
      




      

        
        



      
      




      

        



      
      




      

        
        



      
      




      

        
        



      
      




      

        



      
      




      

        



      
      




      


      
      




      

        



      




      

        



      




      

        



      




      

        



      




      


      




      

        
        



      
      




      

        
        



      
      




      

        



      
      




      

        
        



      
      




      

        
        



      
      




      

        



      
      




      

        
        



      
      




      

        
        



      
      




      

        



      
      




      

        



      
      




      

        



      




      

        



      




      

        



      




      

        



      




      

        
        



      
      




      

        
        



      
      




      

        



      
      




      

        
        



      
      




      

        
        



      
      




      

        



      
      




      

        
        



      
      




      

        
        



      
      




      

        



      
      




      

        
        



      
      




      

        
        



      
      




      

        



      
      




      

        



      
      




      

        



      
      




      

        
        



      
      




      

        



      
      




      

        
        



      
      




      

        



      
      




      

        
        



      
      




      

        
        



      
      




      

        
        



      
      




      

        



      
      




      

        



      
      




      

        



      




      

        



      




      

        



      




      

        



      




      

        
        



      




      

        
        



      




      

        
        



      




      

        
        



      




      

        
        



      




      

        
        



      




      

        
        



      




      

        
        



      




      

        
        



      




      

        
        



      




      

        
        



      




      

        
        



      




      

        
        



      




      

        
        



      




      

        
        



      




      

        
        



      




      

        
        



      




      


      




      

        



      
      




      

        



      
      




      

        



      
      




      

        



      
      




      

        



      
      




      

        



      
      




      


      




      


      




      

        



      
      




      

        



      




      

        
        



      
      




      

        



      




      

        



      
      




      

        



      
      




      

        



      
      




      

        



      
      




      

        



      
      




      

        



      
      




      

        



      
      




      

        



      
      




      

        



      
      




      

        



      
      




      

        



      
      




      

        



      
      




      

        
        



      
      




      

        
        



      
      




      

        
        



      
      




      

        
        



      
      




      

        
        



      




      

        



      
      




      

        
        



      
      




      

        
        



      
      




      

        



      




      

        



      




      

        



      




      

        



      
      




      

        



      
      




      

        



      
      




      

        



      
      




      

        
        



      
      




      

        
        



      




      

        



      
      




      

        



      
      




      

        



      
      




      

        



      




      

        



      




      

        



      




      

        



      
      




      

        



      
      




      

        
        



      




      

        



      
      




      

        



      




      

        



      




      

        



      




      

        



      




      

        



      
      




      

        
        



      
      




      

        
        



      
      




      

        
        



      




      

        
        



      
      




      

        



      




      

        



      
      




      

        



      
      




      

        



      




      

        



      
      




      

        



      
      




      

        
        



      
      




      

        
        



      
      




      

        
        



      
      




      

        



      
      




      

        



      
      




      

        



      
      




      

        



      




      

        
        



      
      




      

        
        



      
      




      

        
        
        



      
      




      

        
        
        



      
      




      

        
        



      




      

        
        



      
      




      

        
        



      
      




      

        
        
        



      
      




      

        
        
        



      
      




      

        
        



      




      

        
        



      
      




      

        



      
      




      

        



      




      

        
        



      
      




      

        



      
      




      

        



      




      

        



      
      




      

        
        



      
      




      

        



      




      

        



      
      




      

        
        



      




      

        
        



      
      




      

        



      
      




      


      



    




        


        




    


    

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  


  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  


  
  
  
  
  
  
  
  
  
  
  
  
  


            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; TEXT-DECORATION: underline&quot;&gt;NOTE 1.&amp;#160;&amp;#160;&amp;#160;ORGANIZATION AND NATURE OF OPERATIONS&lt;/font&gt;&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Organization&lt;/font&gt; &amp;#8211; AV Therapeutics
 Inc. (the &amp;#8220;Company&amp;#8221;) is a Delaware corporation formed on November 14
 2011 under the name &amp;#8220;Aquino Milling Inc.&amp;#8221; Under its initial business plan
 the Company intended to purchase rice milling equipment and commence rice milling operations. On June 10
 2013
 the Company changed its name to &amp;#8220;Code 2 Action
 Inc.&amp;#8221; On July 30
 2013
 the Company changed its name to &amp;#8220;Merica Corp.&amp;#8221; The Company was unable to implement its business plan and prior to the Reverse Acquisition (discussed below); Merica Corp. did not have any active business.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-17&quot; style=&quot;MARGIN-LEFT: 36pt&quot;&gt;&lt;/font&gt;On December 13
 2013 (the &amp;#8220;Closing Date&amp;#8221;)
 the Company along with AVT Acquisitions
 Inc.
 a Delaware corporation and a wholly-owned subsidiary of the Company (the &amp;#8220;Subsidiary&amp;#8221;) entered into and closed an Agreement and Plan of Merger (the &amp;#8220;Merger Agreement&amp;#8221;) with Advanced Vaccine Therapeutics
 Inc.
 a Delaware corporation (formerly known as AV Therapeutics
 Inc.) (&amp;#8220;AVT&amp;#8221;). Pursuant to the Merger Agreement
 (i) the Subsidiary merged into AVT
 such that AVT became a wholly-owned subsidiary of the Company
 and (ii) the Company issued 58
000
000 shares (the &amp;#8220;Acquisition Shares&amp;#8221;)
 of the Company&amp;#8217;s common stock to the shareholders of AVT
 representing approximately 77% of the Company&amp;#8217;s aggregate issued and outstanding common stock following the closing of the Merger Agreement (following
            the Share Cancellation and the&amp;#160;&amp;#160;initial closing under the Private Placement
 each as defined below)
 in exchange for the cancellation of all of the issued and outstanding shares of common stock of AVT.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In connection with the Merger Agreement
 in addition to the foregoing:&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;(i)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Effective on the Closing Date
 70
000
000 shares of common stock were returned to the Company for cancellation (the &amp;#8220;Share Cancellation&amp;#8221;).&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;(ii)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;AVT assumed notes payable with an aggregate value of $7
320. Shortly after the Merger in 2013
 the holders of the notes agreed to convert the notes payable into shares of the Company&amp;#8217;s common stock at $0.20 per share. The Company has included the $7
320 in shares issuable on the consolidated balance sheet at December 31
 2013 as the 36
596 shares of common stock were not issued until January 8
 2014 due to administrative delays.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;(iii)&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Effective on the Closing Date
 Mr. Doug Cole resigned as officer of the Company. Mr. Cole resigned as a director of the Company on February 5
 2014. In addition
 the following individuals were appointed as executive officers and directors of the Company:&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;75%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
              &lt;tr&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;25%&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Name&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                  &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;49%&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Title&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;25%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Abraham Mittelman&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
                  &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;49%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Chief Executive Officer
 Chief Financial Officer
 Chairman&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;25%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Morton Coleman&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
                  &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;49%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Vice President&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;25%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Robert Pollock&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
                  &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;49%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;President
 Chief Operating Officer&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;25%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Raj Kumar Tiwari&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
                  &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;49%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Chief Scientific Officer
 Director&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;25%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Debabrata Banerjee&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
                  &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;49%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Clinical Development Officer&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;25%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Jan Geliebter&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
                  &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;49%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Secretary&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
            &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;(iv)&amp;#160;On December 19
 2013
 the Company changed its name from &amp;#8220;Merica Corp.&amp;#8221; to &amp;#8220;AV Therapeutics
&amp;#160;Inc.&amp;#8221;&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company completed its private placement memorandum (&amp;#8220;PPM&amp;#8221;) on September 30
 2013 authorizing the Company to sell up to 12
500
000 shares of its common stock at a price of $0.20 to accredited investors.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In connection with the Merger Agreement
 as of the Closing Date the Company entered into and closed subscription agreements with accredited investors (the &amp;#8220;Investors&amp;#8221;)
 pursuant to which the Company received an aggregate $709
999 and agreed to issue the Investors 3
550
000 shares of common stock (&amp;#8220;Private Placement&amp;#8221;).&amp;#160;&amp;#160;The Company&amp;#8217;s original private placement memorandum dated September 30
 2013 permitted the Company to sell up to 12
500
000 shares of common stock at $0.20 per share. The Company included the receipt of the proceeds in shares issuable on the consolidated balance sheet at December 31
 2013 as the shares were not issued until January 8
 2014 due to administrative delays. As disclosed in Note 9
 in connection with the Private Placement
 the Company incurred costs of $52
800
 which were paid in common shares on January 8
 2014.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-18&quot; style=&quot;MARGIN-LEFT: 36pt&quot;&gt;&lt;/font&gt;AVT is a Delaware corporation that was formed on February 11
 2011.&amp;#160;&amp;#160;Prior to the date of incorporation
 the activities of AVT were carried out through Applied Vaccine Technology
 LLC (&amp;#8220;AVT
 LLC&amp;#8221;)
 a Delaware limited liability company formed in July 2007 and an entity with common ownership as AVT.&amp;#160;&amp;#160;The operations and net assets of AVT
 LLC were acquired by AVT on February 11
 2011 and AVT
 LLC has since been an inactive entity.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Effective on the Closing Date
 pursuant to the Merger Agreement
 AVT became a wholly owned subsidiary of the Company. The acquisition of AVT has been treated as a reverse acquisition in accordance with ASC 805-40 (the &amp;#8220;Reverse Acquisition&amp;#8221;)
 and the business of AVT became the business of the Company. At the time of the Reverse Acquisition
 Merica was not engaged in any significant active business.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Nature of Business&lt;/font&gt; - The Company is a development stage biopharmaceutical company whose business goals are to discover
 develop and commercialize therapeutics to advance the care of patients suffering from cancer.&amp;#160;&amp;#160;The Company&amp;#8217;s activities are supported by its patents
 patent applications
 provisional patent applications
 and other proprietary intellectual property surrounding capridine and immunogens for treatment of infectious diseases and in specific
 prostate cancer
 amongst others.&amp;#160;&amp;#160;To date
 the Company has not developed any commercial products.&lt;/font&gt;

  
  
  
  
  
  
  
  
  
  
  
  

 Mr. Doug Cole resigned as officer of the Company. Mr. Cole resigned as a director of the Company on February 5
 2014. In addition
 the following individuals were appointed as executive officers and directors of the Company:&lt;br /&gt;
    &lt;br /&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;75%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
              &lt;tr&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;25%&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Name&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                  &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;49%&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;Title&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;25%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Abraham Mittelman&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
                  &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;49%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Chief Executive Officer
 Chief Financial Officer
 Chairman&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;25%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Morton Coleman&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
                  &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;49%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Vice President&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;25%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Robert Pollock&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
                  &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;49%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;President
 Chief Operating Officer&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;25%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Raj Kumar Tiwari&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
                  &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;49%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Chief Scientific Officer
 Director&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;25%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Debabrata Banerjee&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
                  &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;49%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Clinical Development Officer&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;25%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Jan Geliebter&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;1%&quot;&gt;
                  &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                &lt;/td&gt;
                &lt;td align=&quot;left&quot; valign=&quot;middle&quot; width=&quot;49%&quot;&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Secretary&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;


 Chief Financial Officer

  




  
  

            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; TEXT-DECORATION: underline&quot;&gt;NOTE 2.&amp;#160;&amp;#160;&amp;#160;LIQUIDITY AND FINANCIAL CONDITION&lt;/font&gt;&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;As of December 31
 2013
 the Company had a working capital deficiency and stockholders&amp;#8217; equity of $114
504 and $34
172
 respectively.&amp;#160;&amp;#160;Through December 31
 2013
 the Company has not generated any revenues and has incurred net losses of $4
736
867 during the period from July 24
 2007 (Inception) through December 31
 2013.&amp;#160; These conditions raise substantial doubt about the Company&amp;#8217;s ability to continue as a going concern.&amp;#160;The Company&apos;s main source of operating funds since inception has been its contributions from its founders and debt and equity financings.&amp;#160; The Company intends to raise additional capital through private debt and equity investors. The Company is currently a development stage enterprise and there is no assurance that it will be successful in raising any additional funds or that any future funds raised will be sufficient to enable the Company to
              fully complete its development activities or attain profitable operations. The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America
 which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business.&amp;#160; The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values.&amp;#160; The financial statements do not include any adjustment that might result from the outcome of this uncertainty.&lt;/font&gt;

  

            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; TEXT-DECORATION: underline&quot;&gt;NOTE 3.&amp;#160;&amp;#160;&amp;#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Principles of Consolidation &amp;#8211;&lt;/font&gt; The consolidated financial statements include the accounts of AV Therapeutics
 Inc. and its wholly-owned subsidiary
 Advanced Vaccine Therapeutics
 Inc. Intercompany balances and transactions have been eliminated upon consolidation.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Basis of Presentation -&lt;/font&gt; The Company&amp;#8217;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;).&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Development Stage Company-&lt;/font&gt; The Company has not earned any revenue from its planned principal operations &lt;font style=&quot;BACKGROUND-COLOR: #ffffff; DISPLAY: inline&quot;&gt;and its primary activities since inception have been the research and development of its therapeutics
 negotiating strategic alliances and other agreements
 and raising capital.&lt;/font&gt; Accordingly
 the Company&apos;s activities have been accounted for as those of a &quot;Development Stage Company&quot; as defined by ASC 915.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Use of Estimates&amp;#8212;&lt;/font&gt;The Company prepares the financial statements in accordance with U.S. GAAP which
 requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&amp;#160;&amp;#160;The Company&amp;#8217;s significant estimates and assumptions include the recoverability and useful lives of long-lived assets
 the fair value of the Company&amp;#8217;s stock
 stock-based compensation
 and the valuation allowance related to the Company&amp;#8217;s deferred tax assets. Certain of the Company&amp;#8217;s estimates
 including the carrying amount of the intangible assets
 could be affected by external conditions
 including those unique to the Company and general economic conditions. It is reasonably
            possible that these external factors could have an effect on the Company&amp;#8217;s estimates and could cause actual results to differ from those estimates.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Cash -&lt;/font&gt; Cash equivalents are comprised of all highly liquid investments with an original maturity of three months or less when purchased.&amp;#160;&amp;#160;At December 31
 2013 and 2012
 the Company had no cash equivalents.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Concentration of Credit Risk&lt;/font&gt; - Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains its cash balances in high quality financial institutions located in the United States which mitigate such risk associated with them. At times
 the Company&amp;#8217;s cash balances may be uninsured or in deposit accounts that exceed the Federal Deposit Insurance Corporation (&amp;#8220;FDIC&amp;#8221;) insurance limits.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Research and Development -&lt;/font&gt; Research and development expenses consist primarily of costs associated with the preclinical and/ or clinical trials of drug candidates
 compensation and other expenses for research and development
 including personnel
 supplies and development materials
 costs for consultants and related contract research and facility costs. Expenditures relating to research and development are expensed as incurred.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Property and Equipment&lt;/font&gt; - Property and equipment are stated at cost
 net of accumulated depreciation which is recorded using the straight line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives
 which range from 5 to 7 years. Maintenance and repairs are charged to operations as incurred.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Intangible Assets&lt;/font&gt; - &lt;font style=&quot;BACKGROUND-COLOR: #ffffff; DISPLAY: inline&quot;&gt;Intangible assets are comprised of patents and licenses with original estimated useful lives of 10-15 years.&amp;#160;&amp;#160;Once placed into service
 the Company amortizes the cost of the intangible assets over their estimated useful lives on a straight line basis. As of December 31
 2013 the Company owns one patent that was internally developed and licenses two patents (See Note 4) and also has exclusive rights to two immunological patents related to vaccine development and delivery mechanism. Costs incurred by the Company in connection with developing patents internally are expensed as incurred.&lt;/font&gt;&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Impairment of Long-Lived Assets&lt;/font&gt; - The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. The Company has not identified any such impairment losses.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Revenue Recognition -&lt;/font&gt; Revenue from license fees and grants is recognized when the following criteria are met: persuasive evidence of an arrangement exists
 services have been rendered
 the contract price is fixed or determinable
 and collection is reasonably assured.&amp;#160;&amp;#160;In licensing arrangements
 delivery does not occur for revenue recognition purposes until the license term begins. Nonrefundable upfront fees received in exchange for products delivered or services performed that do not represent the culmination of a separate earnings process will be deferred and recognized over the term of the agreement using the straight line method or another method if it better represents the timing and pattern of performance. For the years ended December 31
 2013 and 2012 and for the period from July 24
 2007 (inception) to December 31
 2013
 the
            Company did not recognize any revenue.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;For revenue contracts that contain multiple elements
 revenue arrangements with multiple deliverables are divided into separate units of accounting if the delivered item has value to the customer on a standalone basis and there is objective and reliable evidence of the fair value of the undelivered item.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Loss per Share -&lt;/font&gt; Basic loss per share was computed using the weighted average number of common shares outstanding. Diluted loss per share includes the effect of diluted common stock equivalents. As of December 31
 2013
 and 2012
 the Company did not have any common stock equivalents outstanding.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Fair Value of Financial Instruments&lt;/font&gt; -&amp;#160;The financial instruments consist of cash
 accounts payables
 accrued expenses
 and short-term credit obligations.&amp;#160;&amp;#160;The carrying amounts of the financial instruments approximate their respective current fair values due to their relatively short maturities.&amp;#160;The carrying amounts of short term credit obligations approximate fair value because the effective yields on these obligations
 which include contractual interest rates
 are comparable to rates of returns for instruments of similar credit risk.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Pursuant to the requirements of ASC 820
 the Company&amp;#8217;s financial assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Level 1: Financial instruments with unadjusted quoted prices listed on active market exchanges.&amp;#160;&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Level 2: Financial instruments lacking unadjusted
 quoted prices from active market exchanges
 including over the counter traded financial instruments. The prices for the financial instruments are determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs
 such as interest rates and yield curves that are observable at commonly quoted intervals.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Level 3: Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little
 if any
 market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Stock-Based Compensation&lt;/font&gt; - The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors
 the fair value of the award is measured on the grant date and for non-employees
 the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award
 usually the vesting period.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Income Taxes&lt;/font&gt; - The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740
 &quot;Income Taxes.&quot; Under this method
 income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity&apos;s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred
            tax assets reported if based on the weight of the available positive and negative evidence
 it is more likely than not some portion or all of the deferred tax assets will not be realized.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;ASC Topic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise&apos;s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition
 classification
 interest and penalties
 accounting in interim periods
 disclosure
 and transition. The Company will classify as income tax expense any interest and penalties. The Company has no material uncertain tax positions for any of the reporting periods presented. Generally
 the tax authorities may examine the partnership/corporate tax returns for three years from the date of filing. The Company has identified its federal return and its state tax return in New York as &amp;#8220;major&amp;#8221; tax jurisdictions
 as defined.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Recent accounting pronouncements&lt;/font&gt; &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;-&lt;/font&gt; The FASB has issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2013-11
 Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward
 a Similar Tax Loss
 or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU state that an unrecognized tax benefit
 or a portion of an unrecognized tax benefit
 should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward
 a similar tax loss
 or a tax credit carryforward
 except as follows. To the extent a net operating loss carryforward
 a similar tax loss
 or a tax credit carryforward is not available at the reporting
            date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use
 and the entity does not intend to use
 the deferred tax asset for such purpose
 the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The amendments in this ASU are effective for fiscal years
 and interim periods within those years
 beginning after December 15
 2013. For nonpublic entities
 the amendments are effective for fiscal years
 and interim periods within those years
 beginning after December 15
 2014. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption of this standard is not expected to have a material
            impact on the Company&amp;#8217;s consolidated financial position and consolidated results of operations.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Subsequent Events-&lt;/font&gt; The Company evaluates events that have occurred after the consolidated balance sheet date to the date the financial statements are issued. See Note 11.&lt;/font&gt;


 Inc. and its wholly-owned subsidiary
 Advanced Vaccine Therapeutics


          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Development Stage Company-&lt;/font&gt; The Company has not earned any revenue from its planned principal operations &lt;font style=&quot;BACKGROUND-COLOR: #ffffff; DISPLAY: inline&quot;&gt;and its primary activities since inception have been the research and development of its therapeutics
 negotiating strategic alliances and other agreements
 and raising capital.&lt;/font&gt; Accordingly


 requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&amp;#160;&amp;#160;The Company&amp;#8217;s significant estimates and assumptions include the recoverability and useful lives of long-lived assets
 the fair value of the Company&amp;#8217;s stock
 stock-based compensation
 and the valuation allowance related to the Company&amp;#8217;s deferred tax assets. Certain of the Company&amp;#8217;s estimates
 including the carrying amount of the intangible assets
 could be affected by external conditions
 including those unique to the Company and general economic conditions. It is reasonably


 2013 and 2012




 compensation and other expenses for research and development
 including personnel
 supplies and development materials


 net of accumulated depreciation which is recorded using the straight line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives

  
  

 the Company amortizes the cost of the intangible assets over their estimated useful lives on a straight line basis. As of December 31

  
  
  
  
  
  

 services have been rendered
 the contract price is fixed or determinable
 and collection is reasonably assured.&amp;#160;&amp;#160;In licensing arrangements
 delivery does not occur for revenue recognition purposes until the license term begins. Nonrefundable upfront fees received in exchange for products delivered or services performed that do not represent the culmination of a separate earnings process will be deferred and recognized over the term of the agreement using the straight line method or another method if it better represents the timing and pattern of performance. For the years ended December 31
 2013 and 2012 and for the period from July 24
 2007 (inception) to December 31
 2013
 the
            Company did not recognize any revenue.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;For revenue contracts that contain multiple elements


 2013
 and 2012


 accounts payables
 accrued expenses
 and short-term credit obligations.&amp;#160;&amp;#160;The carrying amounts of the financial instruments approximate their respective current fair values due to their relatively short maturities.&amp;#160;The carrying amounts of short term credit obligations approximate fair value because the effective yields on these obligations
 which include contractual interest rates
 are comparable to rates of returns for instruments of similar credit risk.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Pursuant to the requirements of ASC 820
 the Company&amp;#8217;s financial assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Level 1: Financial instruments with unadjusted quoted prices listed on active market exchanges.&amp;#160;&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Level 2: Financial instruments lacking unadjusted
 quoted prices from active market exchanges
 including over the counter traded financial instruments. The prices for the financial instruments are determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs
 such as interest rates and yield curves that are observable at commonly quoted intervals.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Level 3: Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little
 if any


 the fair value of the award is measured on the grant date and for non-employees
 the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award


 &quot;Income Taxes.&quot; Under this method
 income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity&apos;s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred
            tax assets reported if based on the weight of the available positive and negative evidence
 it is more likely than not some portion or all of the deferred tax assets will not be realized.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;ASC Topic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise&apos;s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition
 classification
 interest and penalties
 accounting in interim periods
 disclosure
 and transition. The Company will classify as income tax expense any interest and penalties. The Company has no material uncertain tax positions for any of the reporting periods presented. Generally
 the tax authorities may examine the partnership/corporate tax returns for three years from the date of filing. The Company has identified its federal return and its state tax return in New York as &amp;#8220;major&amp;#8221; tax jurisdictions


 Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward
 a Similar Tax Loss
 or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU state that an unrecognized tax benefit
 or a portion of an unrecognized tax benefit
 should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward
 a similar tax loss
 or a tax credit carryforward
 except as follows. To the extent a net operating loss carryforward
 a similar tax loss
 or a tax credit carryforward is not available at the reporting
            date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use
 and the entity does not intend to use
 the deferred tax asset for such purpose
 the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The amendments in this ASU are effective for fiscal years
 and interim periods within those years
 beginning after December 15
 2013. For nonpublic entities
 the amendments are effective for fiscal years
 and interim periods within those years
 beginning after December 15
 2014. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption of this standard is not expected to have a material

  

            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; TEXT-DECORATION: underline&quot;&gt;NOTE 4.&amp;#160;&amp;#160;&amp;#160;INTANGIBLE ASSETS&lt;/font&gt;&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On February 5
 2010
 the Company entered into an assignment and assumption agreement (the &amp;#8220;Prostagenics Agreement&amp;#8221;) with Prostagenics
 LLC (&amp;#8220;Prostagenics&amp;#8221;)
 an entity for which two of the Company&amp;#8217;s stockholders own a non-controlling interest (See Note 9).&amp;#160;&amp;#160;Pursuant to the Prostagenics Agreement
 the Company was assigned
 among other things
 the exclusive license covering certain patent rights
 technology
 know-how and preclinical research data relating to the treatment of certain cancers.&amp;#160;&amp;#160;Pursuant to the Prostagenics Agreement
 as consideration for the intangible assets acquired
 the Company agreed to the following:&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; id=&quot;list&quot; width=&quot;100%&quot; style=&quot;TEXT-ALIGN: justify; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
              &lt;tr valign=&quot;top&quot; style=&quot;TEXT-ALIGN: justify;&quot;&gt;
                &lt;td align=&quot;right&quot; style=&quot;WIDTH: 36pt&quot;&gt;
                  &lt;div&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;a)&amp;#160;&amp;#160;&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;justify&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;To pay Prostagenics a fixed cash licensing fee of $200
000 in four (4) installments through April 1
 2011
 all of which has been paid;&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
            &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; id=&quot;list-0&quot; width=&quot;100%&quot; style=&quot;TEXT-ALIGN: justify; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
              &lt;tr valign=&quot;top&quot; style=&quot;TEXT-ALIGN: justify;&quot;&gt;
                &lt;td align=&quot;right&quot; style=&quot;WIDTH: 36pt&quot;&gt;
                  &lt;div&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;b)&amp;#160;&amp;#160;&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;justify&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;To reimburse $284
500 of research and development expenses incurred by Prostagenics (See Note 7)
&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
            &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; id=&quot;list-1&quot; width=&quot;100%&quot; style=&quot;TEXT-ALIGN: justify; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
              &lt;tr valign=&quot;top&quot; style=&quot;TEXT-ALIGN: justify;&quot;&gt;
                &lt;td align=&quot;right&quot; style=&quot;WIDTH: 36pt&quot;&gt;
                  &lt;div&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;c)&amp;#160;&amp;#160;&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;justify&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;To pay Prostagenics a fixed cash licensing payment of $25
000 within fifteen (15) days upon completing a phase I clinical trial as defined by the Food and Drug Administration (&amp;#8220;FDA&amp;#8221;)
 and&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
            &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; id=&quot;list-2&quot; width=&quot;100%&quot; style=&quot;TEXT-ALIGN: justify; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
              &lt;tr valign=&quot;top&quot; style=&quot;TEXT-ALIGN: justify;&quot;&gt;
                &lt;td align=&quot;right&quot; style=&quot;WIDTH: 36pt&quot;&gt;
                  &lt;div&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-SIZE: 10pt&quot;&gt;d)&lt;/font&gt;&amp;#160;&amp;#160;&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;justify&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;To issue Prostagenics a convertible note payable with a face value of $1
500
000 within fifteen (15) days upon completing a phase II clinical trial as defined by the FDA.&amp;#160;&amp;#160;The note matures thirty-six months from the date of the&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
            &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Prostagenics completes phase II clinical trial
 and contains a rate of interest of 5% per annum.&amp;#160;&amp;#160;The note is convertible into shares of the Company&amp;#8217;s common stock at a 20% discount of the average closing price of the Company&amp;#8217;s common stock for the ten (10) business days prior to the conversion
 subject to a minimum floor price of $0.50 per share.&amp;#160;&amp;#160;If the Company&amp;#8217;s shares are publicly traded
 Prostagenics will have registration rights with respect to the conversion of the shares subject to a one-year lock-up period and agreed not to liquidate more than 25% of its share per quarter upon expiration of the one-year lock-up period.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company has not made an accounting entry related to the two contingent payments (&amp;#8220;c&amp;#8221; and &amp;#8220;d&amp;#8221; above) as it is not currently estimable when the specified performance criteria will be met.&amp;#160;&amp;#160;If and when the performance criteria disclosed above are met
 the Company will add the value of the consideration paid to Prostagenics to the value of the intangible assets.On June 24
 2008
 the Company entered into a Supported Research and License Agreement with New York Medical College (&amp;#8220;NYMC&amp;#8221;)
 a related party (the &amp;#8220;NYMC Agreement&amp;#8221;).&amp;#160;&amp;#160;Pursuant to the NYMC Agreement
 the Company was assigned
 among other things
 the exclusive royalty-bearing license covering certain patent rights
 technology
 and know-how relating to the treatment of certain cancers.&amp;#160;&amp;#160;Pursuant to the NYMC Agreement
 the Company made a payment to NYMC consisting of
            a cash licensing fee of $30
000.&amp;#160;&amp;#160;The Company will also be required to pay NYMC certain royalties as follows:&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; id=&quot;list-3&quot; width=&quot;100%&quot; style=&quot;TEXT-ALIGN: justify; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
              &lt;tr valign=&quot;top&quot; style=&quot;TEXT-ALIGN: justify;&quot;&gt;
                &lt;td align=&quot;right&quot; style=&quot;WIDTH: 36pt&quot;&gt;
                  &lt;div&gt;
                    &lt;font style=&quot;display: inline; font-size: 10pt; font-family: Symbol
 serif;&quot;&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;justify&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;For any sales of &amp;#8220;diagnostic products&amp;#8221; the Company will be required to pay NYMC royalties of 3% of net sales revenue (as defined) for sales between $0 - $20
000
000
 2% for sales between $20
000
001 - $50
000
000
 and 1% of sales in excess of $50
000
000.&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
            &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; id=&quot;list-4&quot; width=&quot;100%&quot; style=&quot;TEXT-ALIGN: justify; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
              &lt;tr valign=&quot;top&quot; style=&quot;TEXT-ALIGN: justify;&quot;&gt;
                &lt;td align=&quot;right&quot; style=&quot;WIDTH: 36pt&quot;&gt;
                  &lt;div&gt;
                    &lt;font style=&quot;display: inline; font-size: 10pt; font-family: Symbol
 serif;&quot;&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;justify&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;For any sales of &amp;#8220;therapeutic products&amp;#8221; the Company will be required to pay NYMC royalties of 1% of net sales revenue (as defined) for sales between $0 - $2
000
000
 2% for sales between $2
000
001 - $5
000
000
 and 3% of sales in excess of $5
000
000.&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
            &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; id=&quot;list-5&quot; width=&quot;100%&quot; style=&quot;TEXT-ALIGN: justify; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
              &lt;tr valign=&quot;top&quot; style=&quot;TEXT-ALIGN: justify;&quot;&gt;
                &lt;td align=&quot;right&quot; style=&quot;WIDTH: 36pt&quot;&gt;
                  &lt;div&gt;
                    &lt;font style=&quot;display: inline; font-size: 10pt; font-family: Symbol
 serif;&quot;&gt;&amp;#183;&amp;#160;&amp;#160;&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
                &lt;td&gt;
                  &lt;div style=&quot;TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;justify&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;For any sublicense fees
 royalties from sublicenses
 maintenance fees or similar charges received from sublicenses
 the Company will be required to be pay NYMC 17.5% of such fees earned.&lt;/font&gt;
                  &lt;/div&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
            &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;justify&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In July of 2007
 the founders of the Company contributed a patent to the Company at no cost as the patent was previously internally developed.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;As of December 31
 2013 and 2012
 intangible assets consisted of the following:&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;75%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
                  &lt;tr&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;December 31
 2013&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;December 31
 2012&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Patents&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;230
000&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;230
000&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Accumulated amortization&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(82
403&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(62
228&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Intangible Assets
 net&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;147
597&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;167
772&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;75%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
                  &lt;tr&gt;
                    &lt;td align=&quot;left&quot; colspan=&quot;4&quot; valign=&quot;bottom&quot; width=&quot;74%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline&quot;&gt;&lt;font style=&quot;DISPLAY: inline&quot;&gt;Estimated future amortization is as follows at December 31
 2013:&lt;/font&gt;&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;61%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;61%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;61%&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;For the year ended December 31
 2014&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20
174&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;61%&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;For the year ended December 31
 2015&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20
174&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;61%&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;For the year ended December 31
 2016&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20
174&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;61%&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;For the year ended December 31
 2017&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20
174&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;61%&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;For the year ended December 31
 2018&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20
174&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;61%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Thereafter&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;46
727&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;61%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;147
597&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;justify&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Amortization expense amounted to $20
175 for the year ended December 31
 2013 and $20
174 for the year ended December 31
 2012. Amortization expense for the period from July 24
 2007 (inception) to December 31
 2013 was $82
403.&lt;/font&gt;

  

000 in four (4) installments through April 1
 2011

  


  

000 within fifteen (15) days upon completing a phase I clinical trial as defined by the Food and Drug Administration (&quot;FDA&quot;)

  

500

  
  
  

 subject to a minimum floor price of $0.50 per share.  If the Company&apos;s shares are publicly traded

  

000
000
 2% for sales between $20
000
001 - $50
000
000
 and 1% of sales in excess of $50
000


000
000
 2% for sales between $2
000
001 - $5
000
000
 and 3% of sales in excess of $5
000


 royalties from sublicenses
 maintenance fees or similar charges received from sublicenses

  

 2013 and 2012
 intangible assets consisted of the following:&lt;br /&gt;
    &lt;br /&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;75%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
                  &lt;tr&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;December 31
 2013&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;December 31
 2012&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Patents&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;230
000&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;230
000&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Accumulated amortization&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(82
403&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(62
228&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Intangible Assets
 net&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;147
597&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;167
772&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

  
  
  
  

 2013:&lt;br /&gt;
    &lt;br /&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;75%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
                  &lt;tr&gt;
                    &lt;td align=&quot;left&quot; colspan=&quot;4&quot; valign=&quot;bottom&quot; width=&quot;74%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline&quot;&gt;&lt;font style=&quot;DISPLAY: inline&quot;&gt;Estimated future amortization is as follows at December 31
 2013:&lt;/font&gt;&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;61%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;61%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;61%&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;For the year ended December 31
 2014&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20
174&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;61%&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;For the year ended December 31
 2015&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20
174&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;61%&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;For the year ended December 31
 2016&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20
174&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;61%&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;For the year ended December 31
 2017&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20
174&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;61%&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;For the year ended December 31
 2018&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;20
174&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;61%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Thereafter&lt;/font&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;46
727&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;61%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;147
597&lt;/font&gt;
                    &lt;/td&gt;
                    &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

  
  
  
  
  
  

            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; TEXT-DECORATION: underline&quot;&gt;NOTE 5.&amp;#160;&amp;#160;&amp;#160;PROPERTY AND EQUIPMENT&lt;/font&gt;&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company&amp;#8217;s property and equipment include the following:&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;75%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
                &lt;tr&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;December 31
 2013&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;December 31
 2012&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Fixed Assets&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2
158&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2
158&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Accumulated Depreciation&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(1
079&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(647&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Fixed Assets
 net&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1
079&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1
511&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
              &lt;/table&gt;&lt;br/&gt;&lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Depreciation expense amounted to $432 and $431 for the years ended December 31
 2013 and 2012
 respectively. Depreciation expense for the period from July 24
 2007 (inception) to December 31
 2013 was $1


    &lt;br /&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;75%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
                &lt;tr&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;December 31
 2013&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;December 31
 2012&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Fixed Assets&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2
158&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2
158&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Accumulated Depreciation&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(1
079&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(647&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Fixed Assets
 net&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1
079&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1
511&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

  
  
  
  

            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; TEXT-DECORATION: underline&quot;&gt;NOTE 6.&amp;#160;&amp;#160;&lt;/font&gt; &lt;font style=&quot;DISPLAY: inline; TEXT-DECORATION: underline&quot;&gt;STOCKHOLDERS&amp;#8217; EQUITY (DEFICIENCY)&lt;/font&gt;&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company has 50
000
000 authorized shares of blank check preferred stock with a par value of $0.0001. As of December 31
 2013
 none have been issued and outstanding.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;At various dates between July 24
 2007 (inception) and February 11
 2011
 the date that AVT was incorporated
 AVT
 LLC received $930
000 as capital contributions from its founders.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;At various dates in 2010
 AVT
 LLC entered into subscription agreements with various accredited investors whereby it received $215
000 and agreed to issue the investors 1
433
339 ($0.15 per share) once AVT was incorporated. The shares were issued on February 11
 2011.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On February 11
 2011 AVT issued 12
303
336 shares of common stock to various consultants for past professional services and research and development services rendered to the Company.&amp;#160;&amp;#160;The grant date fair value of the shares issued was $1
845
500
 or $0.15 per share
 of which $1
170
250 was included in consulting fees and $ 675
250 was included in research and development expenses on the statements of operations for the period from July 24
 2007 (inception) to December 31
 2013.&amp;#160;&amp;#160;Of the total number of common shares issued
 4
000
000 shares were issued to Mr. Robert Pollack
 the Company&amp;#8217;s current President
 and 6
470
000 were issue to Mr. Morton Coleman
 the Company&amp;#8217;s current Vice President.&amp;#160;&amp;#160;As of December 31
 2013 and 2012
 there is no unamortized expense relating to these issuances.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;At various dates in 2011
 AVT sold 2
196
673 shares of common stock at $0.15 per share for aggregate proceeds of $329
500. AVT incurred issuance costs of $20
000 associated with such offerings
 resulting in net proceeds of $309
500.&amp;#160;&amp;#160;Of the total shares issued in 2011
 30
000 were issued to Mr. Morton Coleman
 the Company&amp;#8217;s current Vice President for $0.15 cents per share
 or gross proceeds of 4
500.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;At various dates in 2012
 AVT sold 1
666
667 shares of common stock at $0.15 per share for aggregate proceeds of $250
000.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;At various dates in 2013 through April 30
 AVT sold 1
166
666 shares of common stock at $0.15 per share for aggregate proceeds of $175
000.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In August 2013
 AVT sold 249
998 shares of common stock at $0.20 per share for aggregate proceeds of $50
000.&lt;/font&gt;

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; TEXT-DECORATION: underline&quot;&gt;NOTE 7.&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style=&quot;DISPLAY: inline; TEXT-DECORATION: underline&quot;&gt;NOTES PAYABLE&lt;/font&gt;&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The founders of AVT advanced $3
205 on July
 24
 2007 (inception) which remained outstanding as of December 31
 2013 and 2012 and is included in notes payable &amp;#8211; related parties on the consolidated balance sheets. The advance is non-interest bearing and the Company has agreed to repay the advance with common stock at $0.20 per share at a future date to be determined.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Through February 5
 2010
 Prostagenics received various services from three consultants (two of whom are stockholders of the Company) in connection with the continued research and development of cancer treatments supported by the patents identified in the Prostagenics Agreement.&amp;#160;&amp;#160;Through February 5
 2010
 Prostagenics had unpaid consulting fees accrued to these consultants in the amount of $284
500.&amp;#160;&amp;#160;As disclosed in Note 4
 in connection with the Prostagenics Agreement
 AVT reimbursed Prostagenics $284
500 through the assumption of such liabilities.&amp;#160;&amp;#160;The Company has included the $284
500 as research and development expense on the consolidated statements of operations for the period from July 24
 2007 (inception) to December 31
 2013.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Of the aggregate amount of liabilities assumed
 $125
000 and $62
500 are payable to Dr. Raj Tiwari (&amp;#8220;Tiwari&amp;#8221;) and Dr. Debabrata Banerjee (&amp;#8220;Banerjee&amp;#8221;)
 respectively
 both of whom are original founders and current stockholders of the Company.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The remaining $97
000 is payable to the estate of Daniel Miller
 an unrelated party.&amp;#160;&amp;#160;The Company has not reached a repayment agreement with the estate of Daniel Miller. All of the notes are due on demand and are non-interest bearing in nature.&amp;#160;&amp;#160;The Company has verbally agreed with both Tiwari and Banerjee to repay the outstanding notes payable immediately once the Company completes a financing of $2.5 million dollars.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company&amp;#8217;s founder and current Chief Executive Officer
 Dr. Abraham Mittelman
 advanced the Company $11
000 in February 2011. The advance is non-interest bearing and the Company has agreed to repay the advance with common stock at $0.20 per share at a future date to be determined.&amp;#160;&amp;#160;As of December 31
 2013 and 2012
 the advance is included in notes payable &amp;#8211; related parties on the consolidated balance sheets.&lt;/font&gt;

  
  
  
  
  
  
  
  
  
  
  
  
  

            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; TEXT-DECORATION: underline&quot;&gt;NOTE 8.&amp;#160;&amp;#160;&amp;#160;INCOME TAXES&lt;/font&gt;&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Through December 31
 2013 and 2012
 the Company generated U.S. federal and state net operating loss carryovers for tax purposes of approximately $1
162
262 and $441
016
 respectively. The net operating loss carryover may be used to reduce taxable income through the year 2033. Section 382 of the Internal Revenue Code imposes certain limitations on the utilization of net operating loss carryovers and other tax attributes after a change in control. If the Company has a change in ownership
 such change could significantly limit the possible utilization of such carryovers.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The income tax provision (benefit) consists of the following:&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;75%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
                &lt;tr&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center&quot;&gt;
                    &lt;div style=&quot;TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;December 31
 2013&lt;/font&gt;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center&quot;&gt;
                    &lt;div style=&quot;TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;December 31
 2012&lt;/font&gt;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Current tax expense:&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;left&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;left&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;Federal&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;State&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total current tax expense&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Deferred tax expense:&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;Federal&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(259
878&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(97
333&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;State&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(77
428&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(28
999&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total deferred tax expense&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(337
306&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(126
332&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total income tax expense&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(337
306&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(126
332&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Valuation allowance&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;337
306&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;126
332&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Provision for income tax&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
              &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;A reconciliation of the federal statutory rate and the Company&amp;#8217;s effective tax rate are as follows:&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;75%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center&quot;&gt;
                    &lt;div style=&quot;TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;December 31
 2013&lt;/font&gt;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center&quot;&gt;
                    &lt;div style=&quot;TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;December 31
 2012&lt;/font&gt;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Federal statutory rate&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(34.00&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)%&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(34.00&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)%&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;State and local taxes
 net of federal effect&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(10.13&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(10.13&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total federal
 state and local tax rate
 net&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(44.13&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(44.13&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Valuation allowance&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;44.13&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;44.13&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Effective income tax rate&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;0.00&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;0.00&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
              &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;justify&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company assesses the likelihood that deferred tax assets will be realized. The Company contributed amortizable intangible assets with a tax basis in excess of book basis at inception. The tax basis exceeds the book basis by approximately $126
000. The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely
 a valuation allowance is established. Based upon the Company&amp;#8217;s history of losses since inception
 management believes that it is more likely than not that future benefits of deferred tax assets will not be realized and as a result
 a full valuation allowance has been established. The tax effects of temporary differences that give rise to deferred tax assets are presented below:&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;75%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
                &lt;tr&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center&quot;&gt;
                    &lt;div style=&quot;TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;December 31
 2013&lt;/font&gt;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center&quot;&gt;
                    &lt;div style=&quot;TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;December 31
 2012&lt;/font&gt;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Net operating loss carry forwards&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;512
465&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &amp;#160;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;273
239&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &amp;#160;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Depreciation and amortization&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;55
491&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &amp;#160;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;43
022&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &amp;#160;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Accrued Wages&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;85
612&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Deferred tax asset&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;653
568&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &amp;#160;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;316
261&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &amp;#160;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Valuation allowance&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(653
568&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(316
261&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Net deferred taxes&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

  
  
  
  

    &lt;br /&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;75%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
                &lt;tr&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center&quot;&gt;
                    &lt;div style=&quot;TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;December 31
 2013&lt;/font&gt;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center&quot;&gt;
                    &lt;div style=&quot;TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;December 31
 2012&lt;/font&gt;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Current tax expense:&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;left&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;left&quot; colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;Federal&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;State&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total current tax expense&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Deferred tax expense:&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;Federal&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(259
878&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(97
333&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&amp;#160;State&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(77
428&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(28
999&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total deferred tax expense&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(337
306&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(126
332&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total income tax expense&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(337
306&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(126
332&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Valuation allowance&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;337
306&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;126
332&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Provision for income tax&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  

    &lt;br /&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;75%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center&quot;&gt;
                    &lt;div style=&quot;TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;December 31
 2013&lt;/font&gt;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center&quot;&gt;
                    &lt;div style=&quot;TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;December 31
 2012&lt;/font&gt;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Federal statutory rate&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(34.00&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)%&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(34.00&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)%&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;State and local taxes
 net of federal effect&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(10.13&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(10.13&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total federal
 state and local tax rate
 net&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(44.13&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(44.13&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Valuation allowance&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;44.13&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;44.13&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Effective income tax rate&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;0.00&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;0.00&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

  
  
  
  
  
  
  
  
  
  

    &lt;br /&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;75%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;
                &lt;tr&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center&quot;&gt;
                    &lt;div style=&quot;TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;December 31
 2013&lt;/font&gt;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: center; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center&quot;&gt;
                    &lt;div style=&quot;TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;December 31
 2012&lt;/font&gt;&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; width=&quot;12%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Net operating loss carry forwards&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;512
465&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &amp;#160;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;273
239&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &amp;#160;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Depreciation and amortization&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;55
491&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &amp;#160;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;43
022&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &amp;#160;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Accrued Wages&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;85
612&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Deferred tax asset&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;653
568&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &amp;#160;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;316
261&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;
                    &amp;#160;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr style=&quot;background-color: #CCEEFF;&quot;&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Valuation allowance&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(653
568&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(316
261&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;47%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;div style=&quot;TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;
                      &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Net deferred taxes&lt;/font&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td align=&quot;right&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td valign=&quot;bottom&quot; width=&quot;11%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;
                  &lt;/td&gt;
                  &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;
                    &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

  
  
  
  
  
  
  
  
  
  
  
  

            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; TEXT-DECORATION: underline&quot;&gt;NOTE 9.&amp;#160;&amp;#160;&amp;#160;RELATED PARTY TRANSACTIONS&lt;/font&gt;&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Tiwari and Banerjee own a non-controlling interest in Prostagenics
 LLC
 described above in Note 4.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Lease Commitments&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The Company rents office space from SB Lauren PC
 an entity owned by the wife of the Company&amp;#8217;s President
 on a month to month basis for $1
200 per month. The arrangement commenced in 2012.&amp;#160;&amp;#160;Rent expense for each of the years ended December 31
 2013 and 2012 was $14
400 in connection with this arrangement
 of which $5
000 is included in accounts payable and accrued expenses as of December 31
 2013.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Director Compensation&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In December 2013
 the Company reached an agreement with a member of its Board of Directors
 Mr. Douglas Cole
 whereby the Company agreed to issue 200
000 shares of common stock to Mr. Cole for his past services as a Director at similar terms to the shares issued in the Private Placement.&amp;#160;&amp;#160;The Company has determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered.&amp;#160;&amp;#160;During the year ended December 31
 2013
 the Company recorded $40
000 in connection with this issuance which is included in consulting fees in the statement of operations with a corresponding accrual to shares issuable. Due to administrative delays
 the shares were issued on January 8
 2014.&amp;#160;&amp;#160;&lt;font style=&quot;BACKGROUND-COLOR: #ffffff; DISPLAY: inline&quot;&gt;On February 5
 2014
 Mr. Cole resigned as a director of AV Therapeutics
 Inc.&lt;/font&gt;&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Sichenzia Ross Friedman Ference LLP&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On August 27
 2013 the Company engaged Sichenzia Ross Friedman Ference LLP (&amp;#8220;SRFF&amp;#8221;) as its legal representative for a going public transaction. The Company agreed to pay SRFF $50
000 and 325
000 shares of common stock for providing this service. Once the Company was able to complete such transaction
 which it did in December 2013
 the Company agreed to pay $4
500 per month for general legal matters
 for which the Company will have the option to pay such fees in registered common stock valued at $6
000. The Company has determined that the fair market value of the stock was more readily available than the fair market value of the services rendered. The Company paid SRFF the $50
000 in cash during the year ended December 31
 2013 and has included the value of the common stock to be issued of $65
000 in&amp;#160;&amp;#160;shares issuable on the consolidated balance sheet as of December 31
 2013
            with a corresponding charge to consulting fees on the statement of operations. The shares were issued on January 8
 2014.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Also
 Paradox Capital Partners
 LLC
 an entity beneficially owned by Mr. Harvey J. Kesner
 a partner at SRFF
 invested $50
000 in the Private Placement and received 250
000 shares of common stock.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Objective Equity
 LLC&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On December 13
 2012
 the Company entered into an agreement with Objective Equity
 LLC (&amp;#8220;Objective Equity&amp;#8221;) to act on behalf of the Company as its non-exclusive placement agent and assist the Company in raising up to a maximum of $25 million.&amp;#160;&amp;#160;In consideration for such services
 the Company will pay Objective Equity (a) a cash placement fee of 8% of the total purchase price of securities sold
 including all amounts received by the Company upon exercise of any warrants issued in such raise and
 (b) warrants in an aggregate amount equal to 8% of the number of common shares issued by the Company in a raise.&amp;#160;&amp;#160;The agreement terminates on December 13
 2014. Mr. Douglas Cole
 a former Director of the Company is a partner in Objective Equity.&amp;#160;&amp;#160;On January 8
 2014
 the Company amended the terms of its agreement with Objective Equity whereby both parties agreed that
            the Company would issue Objective Equity shares of common stock with a grant date fair value equal to 8% of the total proceeds received by the Company.&amp;#160;&amp;#160;The Company has determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered.&amp;#160;&amp;#160;Of the total proceeds received to date in the Private Placement
 Objective Equity assisted the Company in the raising of the initial $660
000 and as a result
 the Company included $52
800 in shares issuable at December 31
 2013.&amp;#160;&amp;#160;On January 8
 2014
 the Company issued 264
000 shares of common stock.&lt;/font&gt;

  
  
  
  

 Mr. Douglas Cole
 whereby the Company agreed to issue 200

  
  
  
  

500 per month for general legal matters
 for which the Company will have the option to pay such fees in registered common stock valued at $6

  
  
  
  
  

 including all amounts received by the Company upon exercise of any warrants issued in such raise and
 (b) warrants in an aggregate amount equal to 8% of the number of common shares issued by the Company in a raise.  The agreement terminates on December 13
 2014. Mr. Douglas Cole
 a former Director of the Company is a partner in Objective Equity.  On January 8
 2014

  
  
  

            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; TEXT-DECORATION: underline&quot;&gt;NOTE 10.&amp;#160;&amp;#160;&amp;#160;COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Legal Matters&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;From time to time
 the Company is subject to legal proceedings arising in the ordinary course of business. Such matters are subject to uncertainties and outcomes are not predictable with assurance. Management believes at this time
 there are no ongoing matters that will have a material adverse effect on the Company&apos;s business
 consolidated financial position
 results of operations
 or cash flows
 except as disclosed below.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On May 29
 2013
 Highland Global Creek Partners
 Inc. (the &amp;#8220;Plaintiffs&amp;#8221;) brought an action against the Company in the Supreme Court of New York
 County of New York
 alleging a breach of a consulting contract. The Plaintiffs are seeking a judgment directing the Company to issue and deliver 80
000
000 shares of common stock and 10
000
000 shares of Series A Preferred Stock.&amp;#160;&amp;#160;In addition
 the Plaintiffs are also seeking an order enjoining the Company from taking any action requiring shareholder approval without notice to Plaintiffs and/or the Plaintiffs participation
 as well as an order declaring that any action requiring stockholder approval taken by the Company without notice to and/or the participation of the Plaintiffs is null and void.&amp;#160;&amp;#160;The Company has filed counterclaims against the Plaintiffs and has not made any formal settlement demand.&amp;#160;&amp;#160;To date
            the litigation has not progressed beyond the pleading stage and no discovery has taken place.&amp;#160;&amp;#160;The Company has not recorded a provision for a potential loss as it is unable to state that an outcome in this matter is unfavorable or estimate the amount or range of a potential loss.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Payroll Taxes&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;During the years 2007 through 2013
 the Company considered certain executives to be consultants of the Company rather than employees.&amp;#160; If the executives were treated as employees during the above period
 the Company would have been required to withhold and remit payroll taxes to the respective taxing authorities. This position may be subject to audit by the Internal Revenue Service and other state and local taxing authorities
 which
 upon review
 could result in an unfavorable outcome if it is determined that such individuals&amp;#8217; compensation should have been reported on the basis of an employee rather than a consultant.&amp;#160; The Company has recorded charges of approximately $40
392 and $8
600 for the years ended December 31
 2013 and 2012 and approximately $182
618 for the period from July 24
 2007 (inception) to December 31
 2013 in consulting and research and development fees on the
            statements of operations for additional compensation (including penalties and interest) on behalf of the executives should the Company be challenged by the taxing authorities and it is determined their position is without merit. As of December 31
 2013
 $ 182
618 is included in accrued expenses on the consolidated balance sheet.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Employee Agreements&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On October 14
 2013 the Company entered into a consulting agreement with Dr. Abraham Mittelman to be the Company&amp;#8217;s Chief Executive Officer for a term of 4 years.&amp;#160;&amp;#160;The agreement was effective on July 1
 2013. The Company shall pay Dr. Mittelman $72
000 per annum in common stock in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In connection with this agreement
 the Company incurred research consulting expense of $36
000 for the year ended December 31
 2013
 for which the entire amount remains in accrued expenses at year end.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On October 14
 2013 the Company entered into a consulting agreement with Tiwari
 to be the Company&amp;#8217;s Chief Scientific Officer for a term of 4 years.&amp;#160;&amp;#160;The agreement was effective on July 1
 2013. The Company shall pay Tiwari $72
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Tiwari shall be paid a signing bonus of $20
000 to be paid over two years in equal increments not less frequently than monthly.&amp;#160;&amp;#160;The Company incurred expenses associated with Dr. Tiwari&amp;#8217;s consulting services of $96
000 for the year ended December 31
 2013
 of which $56
000 related to the above agreement and the remaining $40
000 related to payment for services provided before the agreement was entered into.&amp;#160;&amp;#160;Of the total amount
            incurred by the Company
 $20
000 remains in accrued expenses at December 31
 2013.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On October 14
 2013 the Company entered into a consulting agreement with Dr. Jan Geliebter to be the Company&amp;#8217;s Secretary for a term of 4 years.&amp;#160;&amp;#160;The agreement was effective on July 1
 2013. The Company shall pay Ms. Geliebter $48
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Dr. Geliebter shall be paid a signing bonus of $35
000 to be paid over two years in equal increments not less frequently than monthly. The Company incurred consulting expenses associated with Dr. Geliebter&amp;#8217;s services of $59
000 in connection with the above agreement for the year ended December 31
 2013
 which remains in accrued expenses at December 31
 2013.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On October 14
 2013 the Company entered into a consulting agreement with Dr. Robert Suriano to be the Company&amp;#8217;s Lab Manager for a term of 2 years.&amp;#160;&amp;#160;The agreement was effective on July 1
 2013. The Company shall pay Mr. Suriano $24
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Dr. Suriano shall be paid a signing bonus of $10
000 to be paid over two years in equal increments not less frequently than monthly. Payments pursuant to consulting agreement shall accrue as of the date of the consulting agreement and commence once the Company has raised $2.5 million through a financing. The Company incurred expenses associated with Dr. Suriano&amp;#8217;s consulting services of $27
000 for the year ended December 31
 2013
 of which
            $22
000 related to the above agreement and the remaining $5
000 related to payment for services provided before the agreement was entered into.&amp;#160;&amp;#160;Of the amount incurred by the Company
 $20
000 remains in accrued expenses at December 31
 2013.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On October 14
 2013 the Company entered into a consulting agreement with Banerjee&amp;#160;to be a research consultant for the Company for a term of 4 years.&amp;#160;&amp;#160;The agreement was effective on July 1
 2013. The Company shall pay Banerjee $48
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Banerjee shall be paid a signing bonus of $35
000 to be paid over two years in equal increments not less frequently than monthly.&amp;#160;&amp;#160;Payments pursuant to consulting agreement shall accrue as of the date of the consulting agreement and commence once the Company has raised $2.5 million through a financing. The Company incurred consulting expenses associated with Dr. Banerjee&amp;#8217;s services of $59
000 for the year ended December 31
 2013 in
            connection with the above agreement
 which remains in accrued expenses at December 31
 2013.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;TotalCFO
 LLC&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On September 17
 2013
 the Company engaged TotalCFO
 LLC to provide consulting services related to its financial reporting for a period of one year unless sooner terminated by either party upon (90) days written notice. The Company shall pay TotalCFO
 LLC (a) $2
500 per month in cash
 (b) a monthly amount of registered common shares having a grant date fair value $2
500 (to be calculated at a 25% discount to market) and (c) all pre-approved expenses.&amp;#160;&amp;#160;The Company incurred professional fees expense to TotalCFO
 LLC of $20
000 for the year ended December 31
 2013
 of which $10
000 was paid and $10
000 remains in accrued expenses at December 31
 2013. The amount in accrued expenses was originally to be paid in shares of registered common stock
 however since the Company has not filed a registration statement they did not have registered shares to issue. Total CFO
 LLC agreed to settle and
            accept shares of unregistered common stock at an amount calculated using the same per share price as the Private Placement of $0.20
 or 50
000 shares.&amp;#160;&amp;#160;The shares have yet to be issued do to administrative delays.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On January 8
 2014
 the Company agreed to issue Total CFO
 LLC 100
000 shares of common stock at similar terms to the shares issued in the Private Placement as a one-time bonus for consideration of their services in connection with the Company&amp;#8217;s going-public transaction.&amp;#160;&amp;#160;The Company has determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered. During the year ended December 31
 2013
 the Company recorded $20
000 of consulting expense related to this arrangement. The shares were issued on January 8
 2014.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;RedChip Companies
 Inc.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On December 14
 2012 the Company entered into an agreement with RedChip Companies
 Inc. (&amp;#8220;RedChip&amp;#8221;) to assist the Company with various legal
 professional
 investor relations and other services in connection with a going-public transaction involving the Company.&amp;#160;&amp;#160;In December of 2013
 the Company and RedChip agreed to amend the terms of the agreement whereby the Company would issue RedChip 805
200 shares of common stock in full satisfaction for amounts owed in connection with services performed by RedChip at $0.20 per share.&amp;#160;&amp;#160;&amp;#160;The Company has determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered and as a result
 the Company included $161
040 in consulting fees on the consolidated statements of operations for the year ended December 31
 2013 and a corresponding accrual to shares
            issuable.&amp;#160;&amp;#160;The shares were issued on January 8
 2014.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In addition
 in December 2013
 the Company entered into an investor relations agreement with RedChip for a term of three months commencing January 1
 2014.&amp;#160;&amp;#160;In connection with the investor relations agreement the Company agreed to (a) pay RedChip a $60
000 cash payment
 which was made on December 13
 2013
 and (b) issue RedChip 200
000 shares of common stock
 which were issue on January 8
 2014.&amp;#160;&amp;#160;The Company has included the $60
000 in prepaid expenses on its consolidated balance sheet as of December 31
 2013.&lt;/font&gt;

  
  
  
  
  
  

 2013. The Company shall pay Dr. Mittelman $72

  

 to be the Company&apos;s Chief Scientific Officer for a term of 4 years.  The agreement was effective on July 1
 2013. The Company shall pay Tiwari $72
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Tiwari shall be paid a signing bonus of $20

  
  
  
  

 2013. The Company shall pay Ms. Geliebter $48
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Dr. Geliebter shall be paid a signing bonus of $35

  

 2013. The Company shall pay Mr. Suriano $24
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Dr. Suriano shall be paid a signing bonus of $10

  
  
  
  

 2013. The Company shall pay Banerjee $48
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Banerjee shall be paid a signing bonus of $35

  

 LLC (a) $2
500 per month in cash
 (b) a monthly amount of registered common shares having a grant date fair value $2

  
  
  
  
  
  
  
  
  

 2014.  In connection with the investor relations agreement the Company agreed to (a) pay RedChip a $60
000 cash payment
 which was made on December 13
 2013
 and (b) issue RedChip 200
000 shares of common stock
 which were issue on January 8

  
  
  

            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&lt;font style=&quot;DISPLAY: inline; TEXT-DECORATION: underline&quot;&gt;NOTE 11.&amp;#160;&amp;#160;SUBSEQUENT EVENTS&lt;/font&gt;&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;

 2014
 the Company issued (a) 3
550
000 shares of common stock&amp;#160;in connection with the&amp;#160;cash proceeds&amp;#160;received in&amp;#160;the Private Placement received in December 2013
 (b) 36
596&amp;#160;shares of common stock in exchange for the cancellation of $7
520 in notes payable
 (c) 264
000 shares of common stock for placement agent services and (d) 1
630
200 shares of common stock for other services. In connection with the foregoing the Company relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933
 as amended
 for transactions not involving a public offering.&lt;/font&gt;&lt;/font&gt;
            &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On March 10
 2014
 the Company entered into an agreement with John Carris Investments
 LLC (&amp;#8220;John Carris&amp;#8221;) to act on behalf of the Company as its non-exclusive placement agent and assist the Company in raising up to a maximum of $3.5 million.&amp;#160;&amp;#160;In consideration for such services
 the Company will pay John Carris (a) a cash placement fee of 10% of the total purchase price of securities sold
 including all amounts received by the Company upon exercise of any warrants issued in such raise
 (b) a non-accountable expense allowance in the amount of 2% of the aggregate consideration received by the Company
 and (c) warrants in an aggregate amount equal to 8% of the number of common shares issued by the Company in a raise.&amp;#160;&amp;#160;The agreement terminates on June 10
 2014.&lt;/font&gt;
          &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;
            &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On January 31
 2014
 the Company amended its original private placement memorandum dated September 30
 2013 to (a) increase the amount the Company is offering to $3
500
000 from $2
500
000 and (b) to add a warrant to the offering to purchase one share of Common Stock at an exercise price of $0.40 and exercisable for a period of sixty (60) months after initial exercise date.&amp;#160;&amp;#160;To date
 no additional proceeds other than as disclosed in Note 1
 have been raised under the Private Placement.&lt;/font&gt;

  
  
  
  
  

 including all amounts received by the Company upon exercise of any warrants issued in such raise
 (b) a non-accountable expense allowance in the amount of 2% of the aggregate consideration received by the Company
 and (c) warrants in an aggregate amount equal to 8% of the number of common shares issued by the Company in a raise.  The agreement terminates on June 10


500
000 from $2
500

  
  





















        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        




        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        




        
        
        


        
        
        
        




        
        
        



        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































    


    

    


    


    


    


    


    


    


    

    


    

    


    


    


    


    


    


    


    

    



 $0.0001 par value: 50
000




 $0.0001 par value: 250
000
000 shares authorized; 72
000
000 and 66
289
644 shares issued and outstanding



    


    


    


    


    


































    


    


    

    


    


    


    


    


    


    


    


    

    






    


    


    


    


    


    


    


    

    

    

    

    


    


    


    

    


    

    


    


    

    


    


    


    


    


    

    


    

    


    





    


    


    

    

    


    

    


    


    


    


    


    

    


    


    


    


    

    


    


    


    


    

    






    


    


    


    


    

    

    


    

    


    


    


    

    


    


    


    


    






    

    


    

    


    


    


    










    


    


    


    


    


    


    


    


    


    


    


    



















 Credit Risk












 Finite-Lived



































    

    


    










    


    


    


    

    


    


    


    


    

    


    

    


    


    
































    

    









    


    





    

    


    

    


    


    


    


    

    


    


    


    


    

    


    


    


    

    


    










 state and local tax rate



    


    


    

    


    


    


    


    


    


    


    






    


    



 Equity Interest Issued or Issuable












 Recognized Identifiable Assets Acquired and Liabilities Assumed
 Current Liabilities



 Convertible



 Value




 Shares



    





    


 Shares



    

    


    

    




    


    






    


    



 Plant and Equipment







    

    


    


    


    


    



 Term of Consideration


    







 Maturity Date




 Interest Rate




 Convertible



    


    









    

    


 including payment terms
 frequency of payments and other terms of consideration


    

    


    


    













    


 Value



 Shares






 Shares



 Value


    

    



 Shares
 Share-based Compensation



 Stock Issued
 Shares




 Equity Issuance



 Stock Issued
 Value


    






    


    


 Related Parties











    






    


    

    

    

    


    










    


    



 Rent Expense
















    


 Shares


    


 Stock Issued
 Shares



    






    


    


    



 Damages Sought



    





    




    

    


    


    



 Converted Instrument



 Original Debt







    


    


    


    


    


    


    


    






    


    


    


    


    


    


    


    


    


    


    


    


    


    


    


    


    

    

    


    

    

    


    








    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    








    








    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    








    

    

    


    

    

    


    








    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    








    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    








    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    


    

    

    

    

    

    

    

    

    

    

    

    

    

    

    

    

    

    







    


 Interest Rate





    

    






 Convertible





    


 Credit Risk


    




    











 Plant





    










    


    


    




    





 Shares
 Share-based Compensation









 Deferred Tax Asset



 Recognized Identifiable Assets Acquired and Liabilities Assumed
 Current Liabilities








    




    


    

    


    


 Finite-Lived






    







    


    


    

    





 Depletion and Amortization
 Property
 Plant


    

    




    


 Converted Instrument



    





    

    





 Shares



 Property


    




    




    




    


 Equity Interest Issued or Issuable






 Plant and Equipment


    


    







    




    

    


    

    

    

    


    





 Equity Issuance








    




    

    

    





    


 Rent Expense


    

    


 Maturity Date












    

    

    


    


    








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































    
  
      

          

        
        
        
        
        

      


















 2014



          



 2014



          



 2014

          



 2013



          



 2012



          



 2013



          



 2013

          



 2013

          



 2012

          



 2013

          



        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


Operating Leases
 Rent Expense
 Minimum Rentals
        
        
        
        
        
        
        

200
        
        
        
        
        
        


Operating Leases
 Rent Expense
        
        
        
        
        
        
        

400

400
        
        
        
        
        


Accrued Rent
 Current
        
        
        
        
        
        
        

000
        
        
        
        
        
        


Other Commitments
 Description
        
        
        
        

 including all amounts received by the Company upon exercise of any warrants issued in such raise
 (b) a non-accountable expense allowance in the amount of 2% of the aggregate consideration received by the Company
 and (c) warrants in an aggregate amount equal to 8% of the number of common shares issued by the Company in a raise.  The agreement terminates on June 10
 2014.
        
        
        
        

 Mr. Douglas Cole
 whereby the Company agreed to issue 200
000 shares of common stock to Mr. Cole for his past services as a Director at similar terms to the shares issued in the Private Placement.

500 per month for general legal matters
 for which the Company will have the option to pay such fees in registered common stock valued at $6
000
        

 including all amounts received by the Company upon exercise of any warrants issued in such raise and
 (b) warrants in an aggregate amount equal to 8% of the number of common shares issued by the Company in a raise.  The agreement terminates on December 13
 2014. Mr. Douglas Cole
 a former Director of the Company is a partner in Objective Equity.  On January 8
 2014
 the Company amended the terms of its agreement with Objective Equity whereby both parties agreed that the Company would issue Objective Equity shares of common stock with a grant date fair value equal to 8% of the total proceeds received by the Company.
        


Stock Issuable
 Shares
 During Period (in Shares)
        
        
        
        
        
        
        
        
        

000
        
        
        
        


        

476

960

892
019
        
        
        
        
        
        

000
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        

000
        
        
        


Stock Issued During Period
 Shares
 Issued for Services (in Shares)
        
        
        
        
        

000

630
200
        
        
        

000
        
        
        


        

812

467

557
        
        
        
        
        
        
        

000
        
        
        


Stock Issued During Period
 Value
 Issued for Services
        
        
        
        
        
        
        
        
        
        

000
        
        
        


Development Stage Entities
 Stock Issued
 Value
 Issued for Cash
        
        
        
        
        
        
        
        
        
        
        
        
        

000


Development Stage Entities
 Stock Issued
 Shares
 Issued for Cash (in Shares)
        
        
        
        
        
        

550
000
        
        
        
        
        
        

000


        

500
000
        

500
000

500
000

500
000
        
        
        
        
        
        
        

000
000
        


        
        
        
        
        
        
        
        
        
        
        
        

000
        
        


Stock Issuable
 Value
 During Period.
        
        
        
        
        
        
        
        
        
        
        

800
        
        




        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 including but not limited to
 furniture and equipment
 that is not directly or indirectly associated with the manufacture
 sale or creation of a product or product line.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 pending or threatened litigation
 including arbitration and mediation proceedings.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance
 maintenance
 and taxes.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 including but not limited to
 long-term and short-term purchase commitments
 recorded and unrecorded purchase obligations
 supply commitments
 registration payment arrangements
 leases
 debt
 product warranties
 guarantees
 environmental remediation obligations
 and pensions.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 lawyers and accountants. The term is often expanded to include other professions
 for example
 pharmacists charging to maintain a medicinal profile of a client or customer.
              
 -Subparagraph (SX 210.6-07.2(a)
(b)
(c)
(d))
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 but is not limited to
 shares issued for services contributed by vendors and founders.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 but is not limited to
 services contributed by vendors and founders.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    


















begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0#9;-]]]`$``/`9```3``@6T-O;G1E;G1?5'EP97-=
M+GAM;"B!`(HH``````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#




M`$`M54P(_4```!,`@``P`(`E]R96QS+RYR96QS(*($`BB@``(`````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````(R2ST[#
`S&[TB\0^3[ZFY(*&ENTQ(NR%4'L`D[A^UC:,D
M0/?VA`.2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q
V)[UVIXK9]6#Z!B(F=I
M%
QRI9$P4<IA:-&3
_F?6*73HQ`GA,[RW;E
M0V8+J<_;J)IRTF#%?.<TQ')^R)C`YXFVEQ/]/^V.'$B2XG02.#S/-^*<T#K

`4$L#!!0`!@`(````(0#)


@H@0!
M**```0``````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````

MSLR2NKO_?=A7/T-
NZ&O#2V6I@I]
[2[?EN;[T]?+V]
D7UN1Z3H9)RF\<TZ-7=5^CBLQ:

:#T[9`!RWP2MF0KY`?DS8-01S6/C4P/#6P]JF!
MX:E!MU9L=KZXJ@KDB[M2#86HAV8@E
+#=K8J7.Q]`^YECN&]);HWSV&-G.

O][[_='8KRYVM1_%0`




MRW#`5ZBIJ\_5^$'D48

M2J(7P9@1W_%=XLPQ!J1LC;F18BP:/BT6SNJ%!C

M&5'B1X[_2![F'G7T(M3





$%``&``@`







KLH!IO=P6D(&PW6C8;F4^D45*0M-:+WN#?A;L



Q8D

T'):SN#^[%[$+






U=K]F8(.;1

MT43$`R;HK?GM@9(!L#=%\QT-Y?]&H&HJ=I&;@P@9]D@)U0R6!L*D
=R=W2





KM.1OMK
MOP\RAS#_H##['X7NT%AA.E+H
7L3XRR*HE

0
M4UO7GP@$/ZP.K?
V[KO?L`&MJZ




.B_(R/8K?+-YE5;-Z.V:GF



2WF/0@*907V)94(*2R(S5R^$J`N$I@-[`.4U_(E@K
M01'8L

%A*






N$_Y5<H(85'@0$]3PN;5FTPS+`CVK%JH3Q<T8M&(
M32,.C;@TXM&(3R,!C80M8O+5V,R0EBH1[22FD:07$87MGYN9Y7^LJ$R7!2(
M



'
MU
%WF@1UF.BN7K%#!E!'3][6-&+1B$TC#HVX-.+1B$\C`8V$-!*U$_M?H5
MU9CVD?0BHCX@BX(^/KGT8

G*
MI;UX-.+32$`C(8U$-!+32-*+B$IAVV
/5!*^FW9;28R9-
_T;;DUL_^:G7#W



M`P!02P

M+W-H965T
S

_-
B)-0








MJ)CSP=08S:WI[75*A6[N@SY;$6LPL^WQ9/8)E;E0H4^A\@?-:Y`KN4FHH5L9
M\_.%




ME^B4..DRBDK:)=3JS;I(YT)YEU$N5.@(R5$T:DF.8B.#14.BWEGL+

MEEPYV0U


5H
MU4KJ
REGQHV5E7F2G/,T1QSVV.745*96#U(^)`((!%(H)$#(D$$BDD
DCD
)AQ,=(@)%0(-QEQMBB'V61
M&6&5&
)1E*
9!C)

MM6[+


MQ

HSD&FTB.PW
MEL?]`[_Q]*_D-TMIP*6ARQ$+OT'$P2HN1CR,^`(10W'72@'6#$2823&2(*1


M\3$283$2(21&
)1E*

M;3]CEN2OT^D)LG



M3M5;L[GKL3K1]L7FSU?:KEK2%^5'`X*?J^K4_L

M`P04``8`````$`=


MUT:H)L=)%&/$&Z8*T:QR_/O74V^


/ZHV$;RQ@83S6MJ@=]4HC5'
M-\ENL9-4KS=MCRG9@L52U


MM!'8D0!Z7?
U/M?O*Q:JR,.T,G)U
M38J71VX8-!1LHM1C

M)49L8ZR2?X


\*!SQH_9G#C'
MX'UB2T?][I/G03/T[4V3[`)]\6ZX0P6EW4[EQ)=4@PNJH



M:&5E='

2YX;6R455UOFS`4?9^T_V#YO7PED!:%5$U0MTJK-$W[


4--Z\]*4:I@]5*Q79-A#W2S@G
M=.#N!Q?T@E
EM2R-!W2^$WH9\XU_XP/3:EEPB
#:CA0K

MSO;ZY!OI6NX_*5Y\X2T#LR%--@%;*9\L]*&P4[#9O]A]WR?@JT(%*\FN
=_D



ONH[#./D/EOF!!=X#


5\\J!SJ(Y7=[PV!Q-
9)=NW!U;U@JF(;UC0:4;FS5S^(\?9L2O=
M1;8^SN;780I5O/^N`#=HB

O`6T!Z4ZS=N8&37W[:M--`G
M^L\:?@L
ZCSP`%Q*:8:!/6#\T:Q^`P``__\#`%!+`P04``8`````$`!@[!







V_

\U+AL8(/



^8X]6_
M_`T``/__`P!02P,$%``&``@````A`#*#=$M!!@``Z2(``!D```!X;]W;W)K


X$(;O5]IWB+B?$`@YJM.C(9QAI=5J

M=*9

MP


MEQ2B#3HQ!5Z*XCM#_0


M9G%LJV:VAGMK=+&]^SXQ1XC51[0YIO=9Y`7AQ/0SB[V/2_N
8;P?@CF*#/
&&1S6
%5+
'6(
ML?MX0\Q9/PA!O6?8(A9B7[(68C
0
W+?+

MK+#&$&25R\GHG0+ILY/*6*
$;')&)B=)6W!EA4HQ=GMM7L=4'=Q2,(E8\D

\@(B2)2$8(\K*'W





2F$8=&
M7!KQ:
0?0(P-6J0%`U!O(/
(2X(72;V(
K
=!BSSB('




C+HUX-.+32$`C(8U$`XBQN:]]1979

W\-1-DL*=P!-
M[=8-D(QV6_QUHT96NHXM`^71CP:\6DDH)&01M@;`QLPU'AJO(3?G[HG*?E
M:[I/S^=JDA1O[/1^!4_QG;5[L^;P4Y`D=W4MG`@W+<[[$V$`;NI;\TA/WM]

M2P

FV))4T))P4

M^N&(OJ0)9X)ET@



![0X(B+QB'TYD%BV\4:8
/
M6.+5DK.=`U4#
46-50VB!3#OG1D=K==S5L&C(KE3++$+Y0XN!.S/RRH(ITO_
M!7*:-)A[@X'7%H-:A`]J6DD@HROI=)+WD158159)5U+NS1?=
./382;]

KY






V
M+GAM;)2676^;
!2&[R?M/R#N&P*$$*(D54G5K=(F3=








\*#9Y0M_*0:HU_3S]

UM;L)




93O#GAN-=-P
6E

MZ0$7ZZ]JW\```#__P,`4$L#!!0`!@`(````(0786$C[@(``)4(```9````

W+GAM;)R676^;
!2&[R?M/UB^+Y\A3:.0







D%C-8J!9CA6[

X(1&9SU(=EEV3.;

==G_




N)+%@4SD:=7_?W0^(%IZ(/L.678]EQ$
L0L(N7=M


4?83+B


';;
MGP6\91D






M?;=6%5/

MYJNR:&0K=]T




+D:37Q4+X
266F?ADB6E)\P55#X(JKVVZ%.SHXK8K4D10


[Y)WM1M;+)=4+!
MCC#''2DB*(S/Z2)RA0V!B#%.C`7+8XM;AG8+A+49VF%R*0UQ^;U4G`[!IA
M22/0:*8[K:=MKU&3)2A.
SKY$SJHG#V060`)&8_-CK:UW5;XL6@/2Q@UB:*U
M(8/:XCECQ$G&C`P)0J
H

:#N?
+;W;NH(!`LZA.:C4%`GX5/-







2P81F+1[DE89N@MG




MD#
KL7@3.-W
Y4J6AY(DB:9I




YF8OK+X;R?C[+OBWPF1F9'^:(]
MP
;&]L[&[G9SC+P\GM+?MTOICT?UC/SF_R63'/WBP7)EF(6L=K9\O+T;?
MO1Q-\D7SD1X

_%G?-L;_8VMK:


MI/)P
IY/1L


$
M:7P]O!P5F5.9K7S
I_4GFM-%;1\-\\OA:+@8%NVE]OIFK^?9-+_+F:PY!K_/












@[YFZZ['^0L#Y1U6QX20)JA0N65UN3NVNYCPYV''P&.SK?:;#M

W?E.8^SGGS%VZYW@`7WKAJXR2`')A\3'S5WQ]+.BIFSGR^UM$JLX'T@B

)*B

M*`9SR6A!H@4\K02((8$5X
_2%[8$004]T)_

M$6U^P63WX

Z;7=YEJSC9)%DODA:B
HTO

=C[8PDR*I?78]2ENQ^Z'PYG7JB@J39@
(JJ'B)[K=4


M_7J5WPY)#_D(^L.7-JAUFWPUGY*6^






$





='03U
MN:\0O

[S?]]?'7E
MC13R/YKH


MO6RXJB1N7Q-M$&-\EEPVS=89
*B]7J?`3*$IU#R*1F!(6_T\1;BS564L-F7G
M2JN+:T8
^Z.EN6M^\#5(-


%GXI$1LV$+JJ#




?D+T6+U8=@9'5/`=FJ/K`.^M1[-MB
M-*1@V&YK/2](`J@3MTG#VO`]AN]-@J?.RBL8S]W3@FRMB0(D`:#5L/#J*4!








K^GOD?]B6^[8

1E#'?-R$'Z.Y=6=+?(E&Z48MHS`ZD[;]S

M.?X11QK$]/*$FN$#SRO99F`2C%%3
9CT(L8BMQ]^0%PGHBCU\3`F=
FB



`9A
M)@D

Q#P(E?GV+^:93A!G\PF5$S

I3





MX@;-6


B&*]LMYH:B8W

3F1Y@P7*0HK??;#N:IB[BLZ]`&TVB/PC)^3




MG?E.75'E10ZJDC[BG':X/%*$GFU6OK$70$?$20;H*!'(Q(^HB2LL@O83X
M2JBX



M$/.(

1%IZ;20D6Z4SK:LETYQ#5!(C?V



MH'HL*\%BGR!*\2








M
8VB@9Y/YGS`GI
RBJ9XCQM][NA*#`QQ8B\+J8ZQ#Y++O/SO.F)0I8S6)M

MM&KP.7@[%3B.0P[9XYZ9KC88T4P!6ZLPSE
(::@/FL=6A1A2#.AB0(
9D'*@

ME6'C+D0KQD/OT3QI3\T(
3^=GHQ&S']+%P7'BN9XVD


M4XTUUA%I+%!;ERK%;M

M4[+B1\(!0%BPKFD2FE(BH+@8N
4MP1`1()89@JZ&/[('2/&`9E.*9%;(\ZQ$





MI&*M5I08`TW93D*B'PX




[)3WE&ZI3
MGA=E'%7FGNW0^JZU'8H



]U\ES`SZZVCHN]`AF/LNVO
M$C5,N61I=,[VYU#F.._+@D


9UNXO_Z




QA







?[.'G'Z6KWWP4+M.QEDV?POQ0&#&66AHYE!B&AAV?7'WE=X6(



UX@:2T5*Y/3&]QFA,
M#G[4)9R?0TRSG('N]8HFGA;0[H.'GI\Y8G*

C$K4N.3)3C/9(D.:+Y*N:`L87[=7



:S\W?6='0ZX5N3W'BT



M(0)TPU%?6O+
THMM`B5

R9'H/0&
M7(Q[^1'5RE9&U&8`1PZ@?
:5MQ%IK8@B+

M
]1`)_2XYPV4$/LA##.9D4M_]^MT_)*LZBT]*^
5;;H
6\A?T&-G.E.O+EGM
MM;QT\H-`E-*=[#

\T1-.22N
@UF,!-1=@G&%AA+IPAH]<,A'V\1#%V$O)7<H:3K=S=N)A],;8%
M90.W4)&UL2.L0CXCP5#!JFM7502I_$K2+RR^M#U`FBD*,1,!&!5MH&+0M6





K`ZR/3



(I/DWMI)UKU0JO^&

%F-?)H9-BR)KTM?-[CDTX&\:56P


M23[;+AM5OK[RI:K#A`N1E.%'(AB@[O)L9*)FXZ







P4QF6?K

M`!C8`[=0Y2US_#6=5D[

G=D*0AFJ

C-E_::

E%DT/@.NA8T(YYQH5/J#U&];@\F-U]M=S]











//Q[LYSB2WFG0G*4E.DT$)2
M3W1X@@1K6;_RRV+EB:[-0W)U]D4'<<FTX9(*S-1GXWO)FDVNS0F%9RZ2KD9


6TG:R3CK

MI$\!I*BT\T+OUI
D9U@U:Q%+\)9@#4,V<Q)57&(6#*L5(C8[LC8&VB/_
MX4-OL$=BS+*XRM!%YR*?%79(U3KCXGM:.$[
&86QQN6MU)O14S#R[G).\4$

0$N:6*Z_F=V*9#@J\Z@-I2GXN@)252*7M=


0QV7T@




[-[]E_6`R`YZI@*E$8/



'.P

M2():4`U9$9$0G=0_F;





M&*3#7T^=*)SB(`$6V@PL-N7K2I40DDNH$Z_B70?S9X35VT

M]`BQT!.MO0A:#6W90:[TN?+[H.%2D+Y=\PA6T3&.Y'(+6&_4F^UE57Y#?8-Z
M0PQV^


WL/U]_=MJ


=85UEY)C2(1

ME`6:?WWRN^9?3)Z

MTP/Y)MT[EFTW).X8:%.)7-=^GGW-QNR8/O0W@3G35


1NNUCJ=Q.)UW^/Q):KZ#E%I\IU#6
M.C=@Q.1#RV2<=D`:H1F=1V[UE'CMRO__L0AH-:/1RTJFGJX]G1_=WW_:=N#





M+&0\V(*88(R-!K=%O



M




6Z2W5

7]*S
MP!LO9-
HR

4M($0E$1B1
MS4/D

M\_6CYB]G

*S
4+
0B3/W$M^
\
?48!KQ#D





TNUDX*([TK-,N9PMX]E3[I2@!E4-[1%]!M



MXF:.+4))@H2D$45$3-[R`!:+0I[01S+ZB6:1F'%+DQ+N.;MK^FKUG/\N]@
MVFJXI:(MQV:K


0L^BYD7*R^ZA$X;5)%1@:S![0Z!2[&`


[H
C5Y
MKW)G*@-;.T$*B^`


M_$`E`LY^$)]3V(K+?((GSK8#0Q'2K)




?(



(VE)F5
)DQFG%YB2)L]PKQ!8=]]%42P-?G%HT'WZ7VC*W`N`SI
F0

_N'7H)'



M=&`?#9/W9NK0$I?RX/

$C/4OQZS3WA93G8_#I^7A^^T3

M@**'T&()-BM8WE$ZBT$.
ZTZ;20%[.3VW#13N3X:%9\WU\LM)))'/.0\38
M[NH)?\MF17]IL]5^SWE$6.W7@KFBMBJ8%_'U3AH:OWL2W$!4_I:!XESI#0*-

KCTW+M7'-F'DET

1PO)_

3-5L(#

M=BZ,N*?0+9(%/B@1(EB/6&7-4L$G)W9<L,6R9YD\3JP#I-TQ_/?P[!37P55`
M8\(@K+_H/.A+K#@X-9YTT#\WG!F218NZVPU[IK%HV?!;I*U4+7.X&9ZC`63



M.=P=\4LPF9/$GWYT-\28L]^^M$A)82)__1CBA.?7F$X6YJH2][I(4C1RW!



]D*2=?U)*
MT-/6QAQ%&M&85E@7R3$Y3M:3`=:/WQ[YU3*&I1*6:_@GR@:*-0SA5JI$*:
M+3XR4%_9#+SLCG!1@-`:
6C]!`C:=REWJ'N`B4Z47F+#0CY3568?-?&B?



CHJ@6

M!
9M1?8Y
.%Y+F
M7B$-*QN&$IKTRM4'MA*_K#I^;3QV6+0P_-_#7\/`G4VK';;=JI25#UZ99X





S(VBY*Z++)5?'\W^KA
M;E&0G!DR:U%VG!SBG=P

M8D42





M=3_SS22I`W83V+K-LCN='%.

?U5Y;-H?RQY)A




3A&W)MX=]Q3I*#M2*$^/+

-TRY=


M7



MO:


O=!

M0=!


M`$Y2J`A=4/:KSED$A


\?&Q

;]
']/:Z9NLRQET(9W#3GK16



MTF8X7@5NV.V5XK?PDRO/7P+(CJ5#@AY??0


'CYN'
M
0&*M:1JD<E-'H51B935:V0:M







M_MT9:






LW

M\X`09_(13M(\@LO&.9Q?8:M7A`HB3A*XD+UB^/YB\6W.RZYB1BMC[[0IVK7W



M

M1]A8U#8#X

M5);6G1A.[5/%6U0G:ZV-UE1:_[`!2H?\.

MR974HZZZECZO7NYBJ])2[PYI]184@A9..H0G*_B_A=IY389@'?%`F7*CU1@'
MY!I`$
ZYL6/L`O/S8(ANGE&1QYQM!-+SW%#FRZ=*C1;JDH49_F$VN_GJ_P0`
M``#__P


M]WU5L7TK6#G^XTS]ZX-Q






.O

M&.GW/`?



%-GLS@V&4MMS%XB

BUD_C12H%<C.58)`DE6)0@D677<

FQ2A!(LBI!(

UF0YG)F5SX_92@[6CLL@7
$%I.RJR&`(Z[;DW
VU:Z]C


L1S]L)F)Z/(-G3

M

`#EH@`#@57G%*'`Q(
M-@
?*%@_ZY80H[)I.18=BAE6?H%_A52&ESZ/4G-)-^HQ=JAH

MB;=C6=!
M4

M)UM5FC!O73\G8#E=$;628U^EMB^_YQA\;[O606HQH$?*QL:&[)!H+U3#*V[
M84MAD4R@RCLG6W[U43%$RQ7&&`8C'Y-,AF/VVCV%GOFN4/7&*\+42X]GM;
MB#0PPU%$V,+B4SQOMGG:.6MD1KPJWLR&G6KL-#C#_753E;H,UNGL6%G_EY:







MDFU)@$T(Y)8N_H:N?


1VB-

M\GE%\P35,;CKSN1X*ZW\^HO







M3V_O#.UBTI]/+O2A/;J8CN:W%R-]
;^]-:9]K;_X#Z@


P(8+XYD0O2C_*9*;_P(``/__
M`P!02P
$%``&``@````A`/MBI6V4!@``IQL``!





;5B;6%=W_S2



MD!+M[E'JV'6/^H)+/E'H'D4=3$M-
J0C)Y`6BW9I!'Z9E^D

MTWJ''+I(2`C




U9^2F

TD4F
MI`.)$B[AO&B&2VEK//3^RIXV&_H
M\G'2]B9P5(;'*`&O2]U









MD5T]`3F-=70XYB?M20.EU6*;P0AHVI42[Y;J
W)B9*C::M$DZ+\


M
0UK-O]*7Z#7S8#@NU-!D[EEF?9\=O^([%8%'I-6Y8&T/+4B\-V*&+
)
O6O
M)`5!13#:&E\U2&-N=T4CYO4R6I1DK,3R3X69T2^GPCA]ZB*QMF\J60?E='


0O`YZ4KU]YKD
Q+1N$9X#)Z^P'L$D=I

R2F`N(.$8'PAH2)9OR-?

;



M'4S8





.XC!XY'AO&UX:QOZ6P



$%``&``@````A`-]);YK)

6)X1Z/SM[6W?W'V;X$(HAGGZR`
M[;__[ES].-IYGR?<V?)^?ER_[=WSE85X=4Y.\<




*5*N!M[]\1V


.3T$6*]RO$/KMM%EJ6L


M




*

LG!G+%--XDN.L



4C/-D
/^
#9Q=XUHP3@NR&AI

103**90S*80[&`
M8@G%HHU%!LHME#LLH243.RV^8%DXENUB^SRXY8H6I

M*/I0#*`PH1A,8)B#,4$BBD4,RCF4R@6$*Q$D(+%T
:BOA'KCR21$TE&]C.

8TVITAOF;;*^P89!'J5=LEIM5.J)

H:@!X4!
M11^*`10F%$




3)(#J.TL/$
MP*2/R0`3$Y
A)B-
QIA

)EB

`*DS4F&TRV

!)B8F0TQ&F(PQ

-IAL
=EE$CG#^%/*
M!S)
/-Q



MG(0:P!1V)C-OOUJ6#$AFZ6=R$T+SJ2VI?YT:\?CGS_VN]Z
X5=OR\-0W!J-^


M^OVI/[8'UG0T-@COO115[6V9RWYO_5'5Y?[_'#*$*^[$%$[&5'OQN3DP9Y9A
MV;_A92*\T&OKQ1Y
)QI44IMN#NHT&HUDTVJHM6L.E-:;<(\LN,580
MIXLHA-LE)L94?I#'&6KG.:26;<F,WV4FQDQF@CN8L,LH-8ZZA-KLN(LH3A)(
MI)#(NH1:D;R+7HBB84F7TDL;$R/:3W1BX:5DD2C&I:JP5$-KFKPN.$ZVA/C


]#(929&G
M!;

DA



)!Q(N)#Q(^)`((!%RPN**F4PZD@&?
MQ_`)2122&20R'6$)!B6#KH^$.H%PVA5,,IN?L$9G6`@X4#A80'1\2`21
M3G#!6*..7J#&!())%)(9)#(=82D&$I,2(IAQPU*^:!=)RNF2D?9NPXHY
.




Y%I$UA)+H]V_B!D

+T)N



9)(=1F;W2U\BIUD&
FU

)[9EJ6L
MF*X@-!KT
.)C)



^!@)
!)B)
)(C)$$(RE&
M

W!7ER

1((



!1D*
M1!B)

&(
MBQ$/(SY&`HR$&(DP$F

KOB
ME9HX&K!;VB=^D9V_J<MC<V/YI:SI`GKS[SO]X*@J\*C`<&O95FW;]@#SC]A




M56W/Z;
#3H(&

7.9.;?=QL#\25ER#Q
`OE87FO[%F?[];TLG#?2L)Q6.Q?-


MH



MLNA$X'40^2R&)TO25CO!'.^W#;TZ
-8A-*NQF#EH`X)]:64AAF+_7ZVAR$+D

M$9IWF-[3O0M8][[6G4624+TC8YS'-F*:'R
T\ZM'S`M8-X^



10I)1VP[









))])34&LZ%
L@![2E\DNLOD7S#8
MOAJ=M`7XSHP
Y^A8BA_TM
7D4`BH=@@)R;PFV?L*\Q0
!1G+:\-(:0D!P*=1


NL;S%1GTFNF2!T

L%!.U2]]U


]XZGD,]X7N<?#?F^A\7LM!NL=:_@O%J4=C/PH


MWH#SOP```/__`P!02P
$%``&``@````A`7C/`3B!```7A8``!D```!X;]W


MU=IFH[%M\2H3N[PZK.V__HR_S6VK:=-JEQ:BXFO[@S?V]\W//ZW.HGYICIRW


M&3@*



MA^(3@^RYS2CS;M[1ND-:017TD
FB'L&
9V//9YY6KH2#BBPAKZNAFX1H^/(_




5N/UMB1??%VZO]LWE-2'8X]++<'&='$


6




*Q)%S


;81
MC*
8HP2C%*


M'+\A1A%&









3D]^84UCUT3:P(`B8$D0%(@&9`<2`&DM`D+
ME`0-U1




\9G%PVS%?7A-]Y-OA*^34Q+DEBL2#`-KR
I'?/_+B6$I':.%XVXF`A=-=E9F5TP1I0@2A%EB')$!:*2(9XB<0K;*3HS
M+?2A;4\+^QS7TP)0[`%*$*6(,D0YH@)1R1/N4]@Z.WSVB<7J#H\K2B8Q@Q=

48ZH0%0RQ&
6JL..
M^6*A(^[@W9IH4,AGUHFVHHMD\D7-P2^$#V^
(QNV+F3.E1L/BM[K!+


M=*)


M4IIJYUX)I_2[`1DT7)G1%;D/PI5;\UL#]XH?+L0#^YY^?.I';6K0AOJA)ZE]












M*HV`AD;I0XOCI@O1;HXN;


M5J3G-'?D-(D4R)`5E
B2DX47R(@Y&O(L1*#X_E$)Q$#:NLMH43#A@4U&P[




#PLH
CI4AGL0
J*VC*=&0

M:$606H^]'2M#/(D64-O(R44+L846HG`Q@KW1TD!1Q*#GY-@:XDG$@-H&FHL8
M8@LQT
7#??9&0P/$Q@V18VF()W$#:AMH+FZ(+=P0AZL9E.`VW:&A`:+803NE




L.S$RC*GJR2[

V8&W
!J%W!89@
WNS^[9OP`]+

F81IP``\B58X&5`0_IC3
:/_!E#2FPI<O;4;[OER8<V.0+L!
M[3J.PY-D0+SW%!@&EQ^9!'=(LD*6G

/`?

'
A


MF)U1


MZ%]K^$](.%!Q!.#2&+]?@#`;_CS+?P```/__`P!02P








DG!$
M/!N#X

M#TI#DDY*&

MUJNVYW7H08F`)`'R2D:`])KA^'3Q@J
3F[/B#.3HM7#UTAT19?7BD*1+]LKH
MOJ&7

M2$XG&3LC\.ZS#)F6*V&W:7`EO.7=15D).23ITC;`Z+ZQELVFP?7B^XC1RX.2
MB$.20



_W]2`KG^B6`&OD]KJ#

1]+2$TP






M]?DA=F9UDQTWV;X\YBOG1UX[GYY__NGIHZR^UKL\;V9@X5BOG%W3G!X7BWJ]

UQ4:YW1;K


[


MW:?%-\C


M?1*\
+R/[&[3




&_?U:UP8(GQ/AP*BICP`^D&?12H
M&UK4!F[8VU:@!%+ZC%QB08#?A*F



4[
M
2LA\@%%FR\I@8QVB+*MIVD0MXEOV:4^?/#@8T2BRU+2JSB$XO+:TKH0CN

J:LIF@]._278FJ200L


PB%J`?#_)

15F
M$IMX-R4VO0U15@AUY2X5AJ/3BWET64@(PB
67[*N3XT-7&9%J
]F]0TN]R)I

4CR/D1(_^=;%&JO
7\Z.@:R=S8=T,<HX'^CHC^<_C]6_^&TQ=R
M02C3P$F`_V294G/
(AW09%+&CA!
2@GG$9N!H?IV2!)BEP_;Q2%1M
TVT;D

BF1-02UWS
MKB3#T7\
LCZLF(G]80+?A4FST6FU'MJ=Q_HN#Q\NM/N%S=?[8K4+&_A1V/R/

CWI49H:][)7&0$0;D

*Q.)=YA6(L(PL
M*A;=UE6(,+]O:I`A-E=5R#[&XJ$&%VMV7$
H51[\I
1[C2OHQ8IC`SAS+3
M_:P2%U%XTN$B*H\FI?

RYG\#]
MA9Q16LR9L!(]



FA^T;A_
\SV\J









5'8+?[N[^%:'=+]&/]

MD_LW7VZ_WOSYXW%V]W?G]OOOWQYUO
_UE*)G]O[+?QJW#Y_UDBKF7?D\2OI\
M]T

%;^S[-^]7GKSTKM6E&)1S




F

MNF:8\'5.?




2[WV!O+9FR;



M&R2V2.R0
&.$?3
6SM@X8^6
G3.6SM@Z8^V
O3
6S]@\8_6
W;.]?\*9A,^
M&5A8PN--33VT%A$8Q.-531VT5A&8QMK;&.-;=0-)4\EJO_.&:1FNED765_1
MS1$==G

41BA
0X)LZ?


41BA
0X)O;U?'5]40X.[@1#IDC
D)@C

&.$M3/VSE@\8_.
U3-VSU@^8_N
]3/VSUA`8P.-
M%;3$P8)W3V
'C24TMM!80V
/C44T-M%816
7C64TMK'&-M;8QEJAC9FJULWA


M%L_8/&/UC-TSEL_8/F/]C/TS%M#80&
%C1TTEM#80F
-C3TT%M'81&
5C5TT
MEK'&

VP%C-%_8Q$`XDF$BTDVDATD.@B

86&FMH
M[*&QB
8F&JMH[**QC
8VUMC&&MM82VS
/Z4R#:VOKK^BH2
;97
M+WLY
%[)(+$N_TTT1E@[8^\L$:_@+=-8/F/[C/4S]L]80&
#C14T=M!80F
+

M&HPT&6DQTF:DPTB7D1XC?48&C`P9&3$R9F3R)21&2-S1A:,+!E9,;)F9,/(
MEI$=(VKV6,@U]3LS#B$5+/'.?%GO?/KO$O:CETYE#2'DRIV?EH.*U7LG./P
M4L7..0XSS:&FBIWWY9#3'':JV'E?#C]5[)SC
%3%SCD.1\TAJ8J=]^705
6.


6ZT40P7O-75&&HPT&6DQTF:DPTB7

MQ[+-'JV4](IFCQ=64OS!B/UYGO_IRE&MA*LOU1EI
-)DI

M&1DP
F1DQ

&9DQ


M5DMGP=
-(]3GG3!R


^
0

MSG'8J3EXSG'XJ3EXSG$8JKOF.
?AJ.Z:XQR'I;JXSCD.3]7LF*.+Z\RDGN:?


=1KJ
]!CI
S)@9
C(B)$Q(Q-&IHS


M3I#X)
KYMCI'3!F9
3)G9







M4K/QG./P4K/QG.



]!D9
#)D9
3(F)$)(U-&9HS
&5DPLF1D

M#8YH
M)BI
U(AY$N(SU&^HP
&!DR
F)DS
&G;J3C?3D,U8UTG.-P
M5#?2<8[#4MU(QSD.3U7OF*,;Z9@I]C1;[]&-_]%O<?KY&3GY8.)]UH9%].I

=)FI

&1DQ





C!F9
M


M)CI
_(@)$A(R-&
MQHQ
&)DR
F-DSLBD24C*T;6C&P8V3*R8T2UCA*IUIFI.YC4Q@(+-KG?:5&
M%N6D3A8Q#BM5Z_QX'%ZJUCG'8:9JG7


;X7'U
MG'H9D08C349:C+09Z3#29:3'2)^1`2-#1D:
C!F9
#)E9
;(G)$%(TM&5HRL


$(V.&FKJGS`W+8J?EVSG'XJ?EVSG$8JOEVSG$XJOEVSG%8
MJOEVSG%XJOEVS%&U
^

MSDB#D28C+4;:C'08Z3+28Z3/R(1(2,C1L8)$I]%%]6+X)Z)4=
&9DQ
F=D

IK#1DMUC
?YA#4'(::0]&:0]&:0]%:JFA:Z=ES+-OHT1HV_M%Z)5[R
M)C-:+P=FUQ*HX*RK,])@I,E(BY$V(QU&NHST&.DS,F!DR,B(D7&[!N]7+Z^
M#`[UA&.FC
P8F3.R8&3)R(J1-2
;1K:


MSCD.2U7MG./P5-6..:IV9HH]S5:[6OHUU1[AX6`]F&RJ56*HL-H1:7!*DY$6
^WOGB'T(1(2,C1L:,3!B9,C)C
M9,[(@I$E(ZL$B3_`E*M:GC$[=;K.`-'-=L'IOLD`)464@A-DRP]CQXA:'*51
MBS-3=S`.^]3BO^'?VIQSGDV\$5/U.*<\VSCRSD.)\TAI5J<'X]#2[4XYSC$




MI

B0D1$C8T8FC$P9F3$R9V3!R)*1%2-K1C:
M;!G9

XY#C_-(:B:G??E4%3-SCD.2=7L
MG./05

&9DQ

MD14C:T8VC&P9V3&B6D?15.O

M#B=5ZYSS;&7^?7*'K\S;RE7E[+H:7'Q1H_-N'$ZJT3G'(:8:G7



M;?3@K;Y6*5KH)OZN.B
-1IJ
M!AI
])AI
M(CY$^(P-&AHR

MPB_I3#AFRLB


:E#.C$
9;O10DTU\XY
MSR*^G/.LX\N



M
H3JY/HZN%XR3@A=L]G?!1F$3!B9
C)C9


M1!

KZ7B4I_N$%S\CS!B9
[)@9
G(BI$U(QM&MHSL&%&[XQ%0NS/CD%'M
M'N?$'SO?7EY6@ZMMFG'G/3ELU(P[YSA\U(P[YSB



4?=SHS#4G5[G)
:6#GX










M'+4Z

MR4B+D38C'4:ZC/08Z3

S!E9
+)D
M9




MS[:ZSHS7M'J$!^/U\#M4M6H

#!D9
M

MAS?WOW__]?#FQ^U7G5MG[RZU:M+]]]^C6S+C__-X]\?'$UT_^NWN\?'NY]
_




M

)1@#Q:)3QEU29&?WX_W=PB3RI2
MI:3@%8W1.Y7H;O7YTW+'Q8O


MH]CXLA:4I


S/GN
MJV#I=U91<!OJINPYOQ%0Y]3_0H6^[W53TT%?@HOI1G9%NH7WWVC;)

M


PP

:%%^*#&2@(9KJ2/




ML`FL9UO/:$!#1$!FL*H-%M!SXH@`&YP3'&UJ9V`3J][_S9T]_G3GB



)#69$-_$+%AE?0*FL'28#2#(R#


3
N


BEWH_OG]=#=W':E(
M$9.





M[LZ62O7$$-)UHKU4//]GG'P=E

@AU


M/SU'9G1&9DP7AO)@#$V:H)]F=`L-.D.^&\$'\V&-:YB-S[CA




=#RYJP6



3X/;6]\:O3+:@
FR:WQT)E:E'3\]0F/B#V<4)YW?'




$%``&``@````A`
_@.X@-#```V#H``!D`




M3)!#O5V=X/R/KYNW(T7;K2\)MUL=OGY[^VW=[-X@Q)?-=G/ZLPTZ'NW6B_)E
MWQQ67[;0[Q]!O%I3[/8/$7ZW61^:8_-\NH%P$W.BLL]WD[L)1'J\?]I`#W3:


MN0\*'R@?E#ZH'



\3[K$DJ6



5+9;6T5I%4Z_%BK7(4ZI+


M

MVMF_D(Y*HE+&JE@LG@9='5Z1!E-



VZ@D/$


















MY-6&X=
?1;.YM[?*T<15'WE982L9NR0K


M
X\-T/'
#!=Z#<]Y1&HVQ<9U,KR)3=B[+W
M%2PX--WOE/@D_?$?CJ[G-O?N%KO'81]7

M)'B_=*'?(.WI.!S1+X#*(_!:)?CTG1:\)`D^?4?2$))EY@:OB_`(8%'V'H%G

M2AW


_[S_^]]N
MW^O#E^:UJHX#8-@W=\/7X_%M/AHUZ]=JMVJNZK=J#]\\UX?=Z@@_'EY&S=NA
M6CVU2;OM*!R/IZ/=:K






P(6R_PXA-`VL
M5HY)U-BSP,+$!#!O.R=-/7&ZD$X=@:0R02R%$@ND$(@I8LPD6!E^QTB:1J8
MC+``=0)$P9A+L
`@5Z4H\*2



'#-ZKSE_U&XS[W+ZC6;@\
MB(#]NOFCQOX2T@71=28&F:A.PU0@F4'



M=V08Y9K1)A)7+ND+&]5#7S)Z+J+N)R^?QH%I/V''IXM:$
0
(O9WC')V@L0F



MMZ*0^DQ%+K5NS']]*3'M/5NT$8*+L4J'W@$VU@=\N$6.Q1*$F*E-5'33GF.4
MFHE./L

^

H]PV5%;
B:NW8D%1O15+5I&KKAM^
MH?KGEP=S;M!U.GDBOQ58!!@%9G*BO.T[ME$T?Q

990(J%40IF$EA+*)51(J&00&W-X[@QST7.7
MEH5OUP39K2!&R)U\!'W\[
5&D
H90N[3%X*L\+E-_.CYBXT@ZA(A
X&Y4/K@



MW]=@U)F^AKCL


XQBII9G)

MXBT?'%;^UD:**8J1&R%DLI*C*/PJ

8#V.#+]E3E7*:U67
M&.54RBG1SHVBMU)):R'=IQE?5)0*C\Z891KW7&HG;N1/X3C05%\8;1VX)B
M&T6S-9%0*J%









MWP)T7\&+_&^KE^J?J\/+9M\

(/O0Z\

$%``&``@````A

M/FCT=5FTN,.'?@)T%IVH7O/,FEG`M)SO2ZB`R&ZTZ+`PGYUHY]BFM9P/`OU=
MHDLW^M_H3OBR;<O];V6#0&U8)[(+QB_DM!L3R!(MK3L9%B!/UICCP[Y6]7_

MRX


M$&UX52L.7


<O+3]87C-NM=?'<^
MWL@&1EEL#LD65NI?LZBQAQGD28F:B7G4='Q8X=*$TQXP
C&^F`IC[H[6
:C

90/QXLOP!``#__P
`4$L#




KKZ@(F7LI3V7VG1DVC

?R'Q5YDW=UOMN!.8L-E'L\\2:6&!I/MV5X`&A



M
A(KS\3
S`2_(=U:6$A?Y[[M3*VOD/PYEUE@&4UB*21(IA.SL0XD.I#JP$H'

M&QW82H!!SPGT$$
0

MR`8A6QE12()J]C-((F9@


MQ5&(CN(H*ZTCLL=UQS)_7=1L;QX@P(
2R@HK

)?I.=

MXO5(PA'5D%;D4R;D0OI(HXW5T59HM#4:;3



M:J

MUE/[*B6*6XRA!$
IAE886F-H@Z&M`JF
D2Y67O8?


M&$
)AE(



M#BH&6I%)N)1H'FQ';YY2(4$+KYHLI(MZ(`BLZ5+RG$/`GY3GVK%B28Y=0('$


MAA
N=2LD3
OY%[<-BGYM

M=O0


=
M^$$&Z+]#S7\```#__P,`4$L#!!0`!@`(````(0`/T5.)-@,``@*```9````

!!]7VG_`?F]$)-[%%*E


=<6X\0AU
M1#)CJD40Z#CC!=.^K'@)_Z12%<S`H]H&NE*<)?90D0?A8#`)B9*XA`6J@^&
M3%

X


#XX1B18IE#`/#I%0);

\




M0UA$C;5Y'UB'6)-C^VBQ=N\)0?

M5M!



YX
M;6RL5EUOFS`4?9^T_X!X;P@A7Z`D51+4K=(F35.W/3O@)%8!(]MIVG^_:XR-
M3=*ME?I2RLFYQ\?W^IJ[N'TN^\)



H;X+*(A@-A].@1*3RE4+WJ)!]WN2X91FIQ)70HDP7`!_OF1


M





M9@LYV8S[;=


DC:[@ZW&R!NM7`L9)VFROO\`D@0L8^('Y`8:S

X@'.QIU3H

$%``&``@````A`.(06GWG`@``@@@``!D```!X

;*=IOWWN[8)@R9KZ0O$E^-S?*ZOK[.Y?N*U]TBE8J))




MI9?3@AQJ_4

`HT?S0U3)FI8`#P]SDQI0$;(


MVT7@G`SRL+SL

MIEU//@L&/)9RD7


M+W-H965T



ML]8)^LOH4;:^.W+/CU\$R[ZSDD*VH4Y8@4?.G]#U6X8F..SU3C_HOP43D:W
MY)K7_SXE;+=7D&Y8V$Q%;9ZSV5*6048&9!C$@IS^$\.D4#%L#


M:!
9HHV/C
X8&;.5[DSAG:88#A,.4

M
IX@.D
-KEJP8?26.1/:.(T(#?W0#HV=%BRPJRX4&
_I6S1YKBW0[$T]P^A
MJA=VU/=[9WM4,82Z79M-PKDI$LF7%YB@H=L^-HC=-B$@Z7#B5W]%2@LQW*
M6/I

M*`@&)KLJ\1E../2MR.\W&&)V$EB;!CA-4@G?2``
:S
F)Y-=FS/X$]2!NW=
MR=I)"^)3GX.FEG2`]^'
^N+DZ^/MF)4L^^79NK
[69-/Q^?_IKTT!M.O-_




;:+/*W`6ISUQZM
;_P```/__`P!02P,$%``&``@````A`F;7
R;!```
MM!

&B@U.X%ZB
(R_F6]F


MRZ+BY7SZ%(OL!!#/29J4[P3J.EF\^G;(11$]I\#[S0^CN
:FAPY\EL2%D&)?


%BK[/ZB3KPHW!V?!^=T_*GN/S%D\.QA';/

H:(`




M;BU7:Z'

738^9-Y&


MT@E9S@+!*$4@;V

5<P$:I`'D;/&PJP/Z?M`R(T0E#'IC+`<$-DH%R-N(9E
!9J@`RIH_
MAQN`6\)&XT@E4;HESG`[@3&2$(Y*U'JTRM65-W).HB(N/%@7_A:2J=6)SQ



MS)H%N]`*5@ZL+K

JLJ$)I85W[V&'0Y'3)Y:_
ME;1JI9&:GK,6XF].Q:7IK)6YC[DRJU_?+M]R5E[`Q$MQ+MHO830,RGS]XUBQ
M.GLY`^Y/E&1Y9UO\&)DOB[QF#3NTS`7R4#'F-






M
)):/J@=A(7NR.)^\A#S]1J_4YDXM8E,7'/XBWD)[[AE!:/K@=U(6FCSN_

=H6NF:=Q?'H;MIPD9CFNM$9JUU00S8

/@VD\Z$)19H'5!3-SZ`R[

-3U2BEU6\RJB

JR#
JOGV5
M:-R^Q


M-N%A3#!$B4P\5\8E


M!:BCDU&!'.PQS9B\A-9UWXE


%'5[LI

_1\^Q@([1%NW?

M3SJ=R
1]9=))9A&



D?67TLJB8XTP/4-1:46,N/'_)'RRY0
M;_B`P5KX:'^/<%'*@IO^6-.-@?&VNX'=]!_]MK]#P``__\#`%!+`P04``8`

M``$`````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````G)%!3\
@&(;O)OZ'
MAGM+::=92
L2-3NYQ



M\3Z;@'H4^#?Q!&#]\\_9U\```#__P,`4$L#!!0`!@`(````(0:;QG)/`
`

O87!P+GAM;B!`$HH``!````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````)Q646^;

MQ4ZW[N7D@M.@41MA-VKVZV=@;4F'V90W8]]W]]UW/G/.Q=-#/MBR4F:3ZS1
M\=`:,)Z(-./W$VM%9D=GUD`JRE.:\XFUHY)Z\)]_\Z)2U&P4F5
#K0++B?6



M'





\)N2[=(32D)P\CID<OXY/4$\?X)O5A.AZE
E<J\<E+]

M!@`(````(0#9;-]]]`$``/`9```3``````````````````````!;0V]N=&5N





M965T

M````$`=


R+GAM;%!+`0(M`!0`!@`(````(0`0:;)#K@(``*T&```9


M+GAM;%!+`0(M`!0`!@`(````(0`R@W1+008``.DB```9````````````````

&UL4$L!`BT`%``&``@````A`C0-YG+


M+GAM;%!+`0(M`!0`!@`(````(0`_Z;MF.5P``#9'`0`4````````````````
M`)9-``!X;]S:&%R9613=')I;F=S+GAM;%!+`0(M`!0`!@`(````(0`DWZ[0
M:PL``-!D```-``````````````````&J``!X;]S='EL97

M%``&``@````A`/MBI6V4!@``IQL``!
`````````````````E[4``'AL+W1H
M96UE+W1H96UE






M971S+W-H965T


M;6Q02P$+0`4``8`````$`;QY2=T&``#O'0``&`````````````````#W











RYX;6Q02P$+0`4``8`````$`5K5

P:```9````````````




52P4&`````#(`

 'defref_avth_NOTE6STOCKHOLDERSEQUITYDEFICIENCYDetailsLineItems'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_PreferredStockSharesAuthorized'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_PreferredStockParOrStatedValuePerShare'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_PreferredStockSharesIssued'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_PreferredStockSharesOutstanding'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_ProceedsFromContributedCapital'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_avth_StockIssuableValueDuringPeriod'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_avth_StockIssuableSharesDuringPeriod'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_SharesIssuedPricePerShare'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_ProfessionalFees'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_ResearchAndDevelopmentExpense'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_EquityIssuancePerShareAmount'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForCash'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_PaymentsOfStockIssuanceCosts'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_avth_NOTE1ORGANIZATIONANDNATUREOFOPERATIONSDetailsScheduleofExecutiveOfficersandDirectorsLineItems'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_avth_DescriptionOfExecutiveOfficersAndDirectors'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_avth_NOTE1ORGANIZATIONANDNATUREOFOPERATIONSDetailsScheduleofExecutiveOfficersandDirectorsLineItems'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_avth_DescriptionOfExecutiveOfficersAndDirectors'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_avth_NOTE1ORGANIZATIONANDNATUREOFOPERATIONSDetailsScheduleofExecutiveOfficersandDirectorsLineItems'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_avth_DescriptionOfExecutiveOfficersAndDirectors'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_avth_NOTE1ORGANIZATIONANDNATUREOFOPERATIONSDetailsScheduleofExecutiveOfficersandDirectorsLineItems'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_avth_DescriptionOfExecutiveOfficersAndDirectors'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_avth_NOTE1ORGANIZATIONANDNATUREOFOPERATIONSDetailsScheduleofExecutiveOfficersandDirectorsLineItems'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_avth_DescriptionOfExecutiveOfficersAndDirectors'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_avth_NOTE1ORGANIZATIONANDNATUREOFOPERATIONSDetailsScheduleofExecutiveOfficersandDirectorsLineItems'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_avth_DescriptionOfExecutiveOfficersAndDirectors'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_avth_ScheduleOfEffectiveIncomeTaxRateReconciliationAbstract'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_avth_EffectiveIncomeTaxRateContinuingOperationsBeforeValuationAllowance'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations'




'@-W
M]K9TO?#+46Z@Y.-/?O!\+`F?.QX861Y-CC*GCQ)OG5J/K_8_B#_L':<?;EY
MU'J-7@IO3CZ`8EF!.'+LE&'X
A4@.RHLBZ9\N?C

M?R7EH-A2\]9'T'[`



M.QQ^/BX=8DL$5
5N=3<R



M.!2PL&0ZO+AD_*2I&PN

:X#^QA=4U-
MFQJB3
H@H\TNV#;S\:.QC1\-[G#Z

9]J!)$1
MC7$?V,.BBYHV%42;?-$U^`FHHA.0^].A^-,NU%U,BPPRVNR;3T?/YK;^-'D





M/K

ME.RB=



@\`?-J?G]`8S`F-_F&W108XLF._L55
MZ`L)YQ*+69SA!GJYDSLBI9,[FHIHC/W\!BM!4!?:U!!M,ED\/=P^BY4IJ
3





M:%-$M


M



MN



R7LQM7.8;G(7QN_RSG'6

MT;3S:_U&/$AG%?`N


:U@GXPB-3F6=#G
M\%])IL`S4:OJ!__2C[T%=)7CM
\H?Z


M+V%VW*L$!=^@\WM21Q_=^:[+3GE:8\67







G2@9(D_#'M$?+M4@
MU

M.&ZJEH/E4OO!N-((XQ^VX
YZ3SZ^B
'OJV3W8;ER091\_F*%X(K!I1N;X*ZE
MCT.M


B'/I+^!-_`SW_YP5\W8)&L







XBX9.H
MCC3;D&=NW&=Y=:(6H8D\)&'$RMXP-W)E[[G/B*N8;N*06@)?1Z\'VNG0/&P]

VA


A34-BG'+

5C9\_I'[M[A
-6/H$-(.&4M5HC$W\-.U?LH13;_X+6Q-^C

MMM831M)RJ=NG-#(NY%Y0*8_]4@
3?Q\9$2[OX7`@/+L+P!



M

O+^`1C:(+AZ^91\-S!%R/M?UO
KK%-K1+I4
W*\4G%T*12
M\:L\'E%-&9N=+#OQNR=XW-T#.P!P2N1KS#C8.@(;(NRQKRR;U-!?6X_940(&
M3VHRB$A4W/?898$H[MU9ETV4`N7SGRF51W)N%/
[1;
)9[@-%-)+Y.G/P4
M$O=L`O*P:#I([&(Q*#;:@R1J9

PAK7V(9.K9!_\R'+/+V^OK\]9


$/?4GS_!?#\

+I=A3T71^RWO)6(9L/J2RQIP_V4K^$S!UA3?EGR]

]_6&X
9LF/OX.G##2S-:32


M6CA`QT0$[4-#&[W#*`T&9]XB04I:G/$-M&!;%'0S+W+\&*=TR-DO$%$5Q4;D


LIJQAT





QJDWN8@#

5F3L*(CA3'B


MTE
E*HKTW

ZZ%5)N(-J4M1377LIR$=$!C1W!J.BV#B4ZZUFY5G12
M-F_2K@'9



M@++6]^NM=QJZD65)
Z4\
O8
6#H#&Q)(JC9=EO/[:=7TT2&/6*.2I!JB8))3





MM:65&`N05K5G6HF!8






TPU6W9#1A%+[[NW0WO825DL*OAGP(*1?5'!0I
M(=5%#?I%+/UUIOV\$3.469%PK%3`G4#J2-WTGW&8'0MX\#%22A=$!Q`\#.`+
MV^3$M)6=*J/%ZD6:%).'(V+
E[J;:SW7!)%.;\M@2X?&I)+*LS*\6G61R@%
M9]+


FFRB)#7NTF3)51@K6:G8:JB
MU.'QTO]G[TF4VT:._16\E\V6MU:2`5X@K
15U&5SK6LIVEYO*I6@$%&P1H

YVIR_WN?8FV574X68.
M+C[=PHGNZ6R$HQ

M`='+
B\=

W5@VJY4\BU(N6[%ZL+V/?II%D'A0CX_$KH%9;!`V4W'OG!KR83MJ`=P9=

M9Q
'N]\L+;`$$;



O]7`PJ1O];
+?`.[]BK@GVTY4(0;DE^E$(:#N6.8A827[EX53O-NZERT271?


MUC;!S0\&.(JR6TJ;7FY6`;ZU/[QI$+HR.6-LI&))]$2*W&;$-L'4
%;YSGZA
M3JBRW*F(8V



*E..RV^OSM;&H2'4GD\@ZWH

MF*C/Y6D)TN^)G=VJ.4GD=?0VEMP6@[QDBV4QWYNI=LZR]4J;VAHRB_%T41XO


M0U(TP
X#



62:Q$#@E
MI*(A2/CE0FI+79ZE2=!J:&D.@;=@5/KW$-P*

H.CJD!9







M6^U@9?

2Q.Z
J65

MFW/+



MFR]SM(@ON'[UDVV_5=Y85A@G7AGO':CDZ8&5S)OKH%'A[:CO\WH'S`&_





'HWO#Z\/+\(WPB^&0W?O6=?


4S\Y/;T:#\?`&D*=Q.SY;CW1]
SX7I*.?U=G\

OE_`Z;3*G19!B$ZY'B$I7?*49S?HM
M23H6
EU6X15XTZO76N)Q8

M`5'#`U4@W/LN(.RZPMQ4K0

M([B(`/T



/]&/RQ
9NSS1HZ9&P5
MZ6+

Z*JFG#.X^&]P!Z8QSEB4!Q'.2I!.0K57A\L$US

ZOSN6
_0;CN



RF68P:WX7NA!`W

)@7
YU-\*)T_*8<KT<[*@1P4





M`1WE:D3ZMGR$&8PI




3;OEM?#`7MOMM=U.:
14W)UF8)H3


M(7




'P2+Y::1^K!'A\

M8:456FB4)1`9567Q6FL-V[=@$;7KT=7\J=LZZ





MCOM@S%E5[SA7UZT[=#1+)1U=L=.6+B*.+2`'8M#JB&)5V1K$6G@ZQ^AF4U

*66FIF4=1(170@`$A
G0E_L'G;$E!N1T<<A(1ZLX'C=
M#R(`*$`L^2B&RX!5D&'@&C[+F.\@[!*!*@5-&+&F*JM/IUTBW'7WOFT=(_9V


I=Q*L=WRY#^/N#ZV(BNRMNAY04;@W[#D8]1GX!B28GUZ
MV'WD`1R--?-,;2Q_0C4,`H5^B+W`LZM@Q'4[%@=3-XT?E/56@2[S:F@WAJ!D
MG0$^!^U*'6O7!VEV4'II8$W+99U/FC$*.'@KC_'3FY
(=/0$
029CH(/F`-
M%RRO&G3!F.


8^[?P^!
`?THS''
D)!G$GW-:]DT62D

M
*0DM19R[!:&@BO0^O^WXI$L;\2=`\2\IN



O+EQ'$D?_BJ,6O<;K@C9+5&773WK)6/
M7O=6E6MM]\S;?W50(F2QFR(U/.SR?/I?9@*\#U$295$R)G9G7)((`HG
)P]D
M)N)
NDR8:EH
%YM^/\972R96?*TX&#OAHT`2PI=OLV&I!K7E\TH(=8/DQG3
M?;H6,ZAX$UDM+BBW(/7/?412K-X25[;2&#O*STGW/?XI)3`
M=+*';)XA$Y]D\PS9/&.)3
C$4=D\0^:.RMQ1V3Q#8J%LGB%14**@;)XA(;#N

MW_-^&+MIS3.E+9UTKR2Z7I7+,R:73)*.LFM4YRISH]PY-0D=IVL?XQDEAO

[.5M(K






F7F6
MO4LTD!+\C+J.!B(VGAM/



D]FW%//$#V0.Z$8)-B!@H=5:8Y5M)+
MC?PI
'0M_%*P!C!8K$-?[K0_CR[_]]=[T&%7)Y=W7^[N/RG_-:7_E
P^0#MX
MRQSKFF/.0M8)#)B:F](NS![


M





/OHOEWC?
$
M-/'1.:!'R?2RBSUC5(UB==0!+#B'EF*QU;BR:%2-NX%-AFDOTHHF\2L6_(HW
MU_9X)H%'&]^BI`$T:R83?^YSAM'Q!`[%@NXD(3@G$QI=2PSHNH'9CZ$/.CS#


.IJ1GGIG&2-+5JZ3E6\C





V&R._#$

P)

MB$FP:^



7?;

M@)O1(2L$E@A?5X`GP:GG


6'RJW`A\)V-
00;22X*GW!
6CY2D1ANQU&B[*&T[B0L!$NJ&+C9`

L$X69@:`&3\3%E]MVX8^%V*#$

^Q0SLWPH'+
M--

M











M`W#5K

M
O0R0==X&!LS




M$550RH*#T*1P*7'J/YM-9C`YY






U2&
`_QU7%P.Q4R9OUPXDRPDW^`:A/#A)#:1

M

M1`10PQ(X#3TJ#G^:XUEXQ;JQ^'DBBA-87

M-R8BHAV5%\M


M+2]XLM'O5@RXX1'E

-JS;LT


YH




YSG&--=QO?[E`PVVG
M!W_

M`EUDM!2@&!WBH/UTJH05-9W.DO.3DE:4JS5WC#6E#!Y
-+2C!U[WIQ=DPYE1

MPGP-4`W3




M-/IEPUS9



@=*8HR)=DGK:
\A.



LAOS075CEKV892]F
MV8M9]F)^BU[




9
M
3_6J+ZVE+\M^^5D9K\$$<2PGT_8W`9P5DNTO2';VV&:%P0`@]=,$*D+
M6@!47;\F4EYU83)$=939'@83?K29ZB*`8X4=+L.<NT\9:\HX!YY%!-FF@OT

















M2E)D09


B2X^D7^26^F`
M

MF@(



)ZT37V-4)L9R.(
M78JP8!-XFNW&%^+X/7P`+8O`58K`38I1M0.\!2D#2\):(5`T4ZBXB^=UO\

:27X6T&2YIRU
(?



MNKK]]NO)Y[O'Q[NOGQ1U\6/9S-9DK&7TRVCNJKEE*:RM@52=U2EU:(2:V@U
M`:69*:*Y%/SZ/?Y[O[J^CXDWQA[&R

MVDHE@[H58F
A`U2SRZOQB66_@*



X^6Q[
TM%<)2R_9BO=GDH\F$W_N\ZQQ;8Y-9_^3<R'1,KHUT$JOD2OV2$#K
MT)3E$2IQ^%B(=.^5DAN3,J-S=T+(XS.UU6MW]U#A-C8Z]K%^.T]9`U$E!`I


ME94+4$S1;1]XI%11RYC@BO3+!@UW0L).;]CJGP\/0CT?OG!+A*R!B!(AWX)\




A])`GT#BF!?GTB2*7




MF+;K.^R1_?`^X\9?A-SU#^W9FWWZYN-4[J8/
\UA
]NDJWE]R_#NV?2_/RS@
MT0]T-2\\3Y]
NL






'1&?Z^
.

M]%
JNFC&
=C
_^E7S?
=PWN]TCS6`*X#YG\UQ/7^*',808SEYOSN,DZS!9


6`FM^-^^Y@!#<+T!=K@A
MYBIF4?#&TR*QJ,#:%U7L%Y*M6^LW&QCOG_`EBD2IUHA[\^VS4$#:9W\^^(N%
M#6O48T8VMUY8*__@BWYQE[^L)V_OS(=




SR%Y9R.2+Z5X@N!)


Z;[*(TW
M8!9X[`ON69J@CQII


T

2)E@'97Q1WO
1NN




M]FJN9WHO819AS%Q=7][=CQYO[T`I^Y;.'!PJI@HKO#CZ=2V2%.K;G05ZWG?X
MMO&))FM=%'0PQ%S33]REB](8(C0\AW#W=-J?7

MC-NADU2

\\D&8;)!V


M%WM'RQ%O3U_DO
8@

MNHP1!D4V7TMO`![6NFM)S&[H.^.O6.]_K=Q.O@+?WZW[ZQP+O7KPQW8MHN
M@.+J'8






M9IK8-;'!OHC@SFO!WA\)ZR\VPT9CSNM]O\9BOCO9V#16_]6#
E)1QN0CT)


_/U5


.M^]&'Z[4;8UV^YO$

M*U!E!:HLN6I8RJ

MD^$?



T9:$Y:!'X#']_

2Q?N^
,
M_OE('1W@.=M9V`Z<PL_;2E?OEPJ`-(

]%0V90W+,]67'_L3AR#=E;1GAS&
M4!&Z7!:#D;3)!!XP/'KHF8&T.O+&8PR?H6=B6TF6%!\
X%%:#3J/D(R2?P1


MJD










A8)]



MR[.YQ')XEH5U8E!VFNLI8Z8Y-$N8A)?*


063#8\Z
M:I1(?#10^88[+-0\2'U,.-3^@EF\`,0HQX$R4H&!Z*/P@\XO/&D=GP![4QO#
MCFO*9\UBSE^`0O$G@P_CSR8O0&PI8]N;)9#*=HPG`S-=0U6-;PN2L$IP3&:R
MEYL^W&Q!-#PZ'Q(_&&Z<!94C.29+!G-
IBI?#5
DSF840JH&K=*BE.(XV`#
M%@Z\5YO



,^W5JNY_@(_[=+.YA

N
N6GT&$R4^56'V8
MRN0C_A716


)D)!YQ^_J

MPZDR9;!7FDD_YB$9K
D4D5UP7$W
/YYHCO-J/V
0C@*]V@\%S
6%[?(Z(VVQ





H.J=Z%*


LZB6\A;QOM;_J6Z?V7FF5TJ445%D_P


AG@YL!XIV0*`F74)6?KWQ#HAS4C-QI&I;GW82BXHH([%H
\)(+))8




M78%4BF[[8Y
M4:^[(&*3[J99B7IIQ;H#VNUE7[NL-CU@499`N`GU)!!NGW@2






]?W+4._V3MOM
VN&YP3(+O!D:<P^SP(\[[=-.IJO]/NC41L:W
MFEDO+^%0PN%V22CA4
*AK-278?Z*';*$G]&B:'_*':&X/WDD^^M_R%B;C+7M


MV%YY)X?74V)KBKC1[6'V1A4WN$U






;





M1X/EZ@9\ZC!X6JSE3U0QW#A&3MWEMB\;0&3P08;.A+?OE4#-AQKS0%#N^Z


M2.P&*C`9^'F7@9_C(JMY+]1@(R-`S;RG24*BA
3MDO!@(+'(
90N&-(;%0P
MO*;^L^_+R\#2Q7@+O$/-N6E`K])]4:B-[C_
M!
+M$T\80[M)!^27(-_S:G#_L_?O;=DR=-6WRZI7N%'K4?5X8[
6W7=]@C



M\[VR:AL04FMTRSG9OK?Y[7ME?_.=X-\N6G++_N8U$E



M2622R+02[63$^F#



;_U$R?KBJ&N9GVBV9-]M@LEZ&LE:DD0UGO,I159/WO@YYM9"KV:UQ
M)#!*8-PN0\%&(L\$`F


-?Q'



C2_]B3]Z
AN7OO*AYGNL3




[@WF'NQ4]@?!WL&((]=EWN5


C%
@[8@Z6%4)=G%





M['\EX5#X79)*.%0PJ'LO7#_!4[W@H_HT71_I0[0G%_\DCVU_^0L389:]OS

M].8^J
U&!K3VN









M9.#G709^CHNLYKU0@XV


M80YM)-`^;)-?S;LNLW5NHHG=
1/O/\7=#5XXOMNI?8TR-HZ1%UU?9=/=54




MG3C&F.F*-K;I\F;EF^TQI7=:YE#M)_$Y-1__^`+D-#QPXR:Q]VZX(5^8YC(%



MP398J38+DX^YGAQF?6PN%?9@:\YZC?:N-#+MZ_;OHZGZPVF=@^$GFAO=+=



M2&'=
%_#
0@?8!2K8)1PE0[&%CBN3.\\ATT.P+,*X*\]&9/;`=_=]3C.U$
M?4@S\J\XZ*70#AYQ?9




9@.3\#NT&V%8']_/T*UD4]8..1_P1K4=2AL)+BB,&L)W!D=*4




LP.O$6_%%H2:

4CXX:]&B`



Y*C!

709S


M9U)&HB0M/'UR\0!)*)\!9HU.



O[KT'6=9





MJ7SA/]-/CY[HOPKY\F00K=4P!7GM3:JGJN%QGFEV5_(&%J%&)JB-!BIBB[






HN)ED7'\=2?O5V!:H+2.L$9)

?RJP`[QXZ68B&4,,PP_`LD-;T0JJ[R-/'3UV!''+A
M#
I0I#G.P$O$[*X%9J3]B-H`*H@F*!+=2(3\'2?P8I3$V
_!





6


*M!3)]#]:J!4I9..K<^7J



M61@(RPU27@374\+$`FY)[-1Q%R'#S4S=+.O@H?L^F[
=D3&QV7)Y3O&5JN
MUE
4+
UR*'])ELV8X42B8KBAX3



*I@:+_BF`
T42SN\+
_&

MO+CI3A;PJL$HQ]-P46BRW;0Y1['\90'WS$TRUX+U^TL3@I3IM@ZI8!QCD-




X==CBT[`L/0RA:T$^@/54@(2E\?H6\E.5(?K
MV(E9&#A2U34MQ_X;&X[9-R^D2B!?`M`'K3^C;:5@X.6B:YH
;T=)@.\I:D8
M=BD^0LQ7-NN#,2\/=M_6*]JX:EH
2^K8+KN`%I
*A@%-=F[^X_2F[S
.41


M)OZ6TC1B[Q(3+)3SF1E9#*4?DS3^XC6J4``):







=W2G8G5DQ8NV`&!)











M3:ZIU%Q;5S
5NWG%2PC+*P)EM&'E!M=#RXHV:E$\LD3C33+P*JJAVH&H#FY.
/R6@<ND
O+'.H125G4((L:8MFO:UY&4`=\
Q3JDE7CE/17F`


SN15WWO:F=P@M8


MQ&R+O+F=S4)V''3:O=JN)ES!.BL.N-R*!
S[(/^RXL)2!^/;3RI5\EL^'G(*



M:_N36\8;^VFZ*@7U9'?0ZI\/HD&**\38C\F
;E4)XL
3+'@PS;`.^&C8`ML7


M01X:-@D2WOI&
SS;Z+3SY#5M


MJ_EY0A1K+RG_BE7Q4V


$+)AF*XSRON4EV
N[MR6OQ?[-
V,%;6&4,3<RB+?:FW'^A)!=XE3K;:+G.IJSG&WWU_'.\:IY:SKBHV]2]O
MZV!AI_A?P/JW%IA3/E(X/DQGZVL;@



N%O)HU[*FVD-M0$
M3&=GE1E\:Z49I!BBA/-XV5W':)MU
.Q?2\.&&3Z$)D5_55A_L]4186NQ3
MNHYT$^BJ:Y*I),]TOLF:4R12_N/G'V/'Y-KD_P%02P,$%`````@`=89_1!_W
M.AW'P``.Y0``!4`'`!A=G1H+3(P
3
Q
C

90VUB^RX+V]*6)8_0MK4]:%VE)O/U/

^QJLM$V+_E6SX`S09^8
8/H[_?O8



MT+?HSQ-@YA`UV)!R+D*M396

JT)&)7
PR*08!`U7\_1.7;CZ






MG.+BYO9.J#E

M:AJRJ=OLJDL6\8D
G

XSX8
JY9

MMO@6.!

M\/(#E_2LQ:K49?-5D
U

P
M&

JMZY)JAI=FNW





M)K.1Z%%#;]IBS/F[1V:Z-O4^#W@6AMQZ\8[W(F0;+MNJOY]L)
Y)=%H#/A


*FY-0W!_SJ*K32SI.(?!H&



-`9?4(





M9-56^'5`78`ATH




]-RQL%&\45?JI)!#
JZD-PU

TE^'^X=

MNJB
GT&(/OJV_I*M$&Q('*7?:)51(''<3Q0Z[=;RN;-<


NVDQ
K/.=BAR$


M91&3KPBQI/K_XD:.=]86PE:184



QII1)2\2I!M\`CC*^JHCJ2H

R

#








6=_G^\ETJ[#_))[\'OV-R0]]UEH2F*\LE

MG

I/;

^-J\&@V

R

8+\9X6-Z-XB'P[7TQZ/_\T&?4'LSF1LKCK#X:$O7'O3KS/].94



MYQU^5\A#*Z?:.W&W#_)V@]4*)1;;@^@9/OC/D.U[MN
ZR6IMI1PU!KU3ET







MDGS

;SP[L.


T4C


ML-R4-.S;,GQ4X87\V0B1=#8CU`-TZ9(#)CE7BTEA0CQZ,#59DAE]PG3:T@


M#/W+90*&Y4XM9VEZ/6OK1!:(V;)
E
[=7I:?4MC`C
V9$9$D$`GG\7UH!\Z6
M=`-L_Z=(U'A&53KC%D:M)2S/71(W+]Y#X;YQK-#)L+:!$Z*TUQ$^1


0K'X(+
M#?3`1^)BF?K




MIV4C*ENR.G-H9P[MS*&=.;0SAW;FT

!/B3(9&4Q=S+)[$


[ZVLMJEP;K/@%R'`$EU8C(;4;
MCOP0EH:
&)T[DR`/67!XYH-$T.*$F'93.3O6A4(5*8\W]E*8^=Y@SN1)'704



MQ,OMCF'+QWK#7NPE$/,[^FE9`07KS(22.M8-ZKCS+=65'6$O\D=8X\WV].
KR`:=R36^.HBBUMNSLC%++FE+&N\*
M):CA@0BH$N/)`$'!HV.CO


=I.^U:G
KA`/+*I+][]A#I@X:4:;]T\5
M&DZA4.Z@52K9B-=Q&F@X:PA7=ESJ_!PCH9:WQ'6`'BG9BZ\^PKFPKL3!M0Y
MD5`DNR]*2,@UTU(2\E`H+V11*GEB1SX6J8'\Y;TI16NPD4!(FS'#44SPO)V


ML!IJ!1%

:!32&JT%90QH&=\@K'^;667#FFHR7;`;&=IZ2-



EQVF
MRP[398?ILL-TV6&Z[#!==I@N.TR7':;+#M-EA^FRPW39823YZ++#=-EAU-'0

M8;KL


MJE/7^=LK#O?IO)+:Y)6TU^/(7Z#=ZEK



M;2H.!.M\V





!69W!&4IR/4TMK!H3+V)H
M_L[D?0V+Z3F(JFWF#%6IH.\U:J)%TANBB0J2*@(OVS`@EV$3R\?'4_(?LI0_

ICX^3P6W



MVE:8NZA

]TQCU)F/\$9ZN


3/A\?C2
Y_?SVYL;8W8W

=NFQ45F)E#)I
MLC%6&9WCO'70?853LB;MGI_@W#F






\9ST






B.O99C;[.U

K\'`GPWW]V!JX8XG4:'`78XV)W?Y$KKATR1#/


&=)








DY87;B:6&H3+TXZ`9(R7IB0X3=^.&

M'VH=!$)VB?+T=5KM$KDP&RL;9G/TE*UD?Q`
\F(:&33%;X&9XAD2&Z&XJPW@

M]_.[/VX7+Z'[W:/]UUOWW]''^'$6_GOQZPVZ04^CEY\^_O3S']^:WV[O'^W^



Y/
0%R^SKE
?U&X*J[.HT



'3Q=*];`80KY5NI/(^X6ZA@LY8S`I`@I
M[E//)\4=8L=;3[8H+:X:5E*T%8C1;X62Y5\9T$#:.


MG/F


Y$Z
M#9Q'*T)3U[(3$Q$6Y6/]9AEO!-A@-J+O$HAQ)CB@S\:AOFTF[;/I12A`812:

M)%MK-%E]\HF#RJ&SNZ6HKF'#TQ-MKI2@@X2+`ZB[_WGDVU]F:!L']H.%&S2\

MA9;F$H]&9^58F6HIZ3#
EW_'W\4;M-SEH
A\
?*]]0(%FSZZ![G:KK'WNB(!







[+KX(

M327]*GY2U](DB/AA+2IY?Z#[I62*//@N;CQ
KRS`#EUY*3K7&@EJ:'B!Q7D^


M;V]NC-G=9#@WK\?FT.P9XX71ZTUNQPMS?#V=C





DGP4?RDQOB.JA240
$Q
M)21FQ&83)Z$





#EB-]$S#52L[M`
M

M2['N2JR[$NNNQ+HK


MIJ^/\Q5UPPYF_LX)


MC3S'#HUU@/;Y#OFS/98_WVJ_)HP,'K:/-YN_2!RXRFL?/-.?3@LQ
]C-'3
MG1]\N4%+XB[2\UT7%?MQE\T5!7):S:T2H&&.1[E


/&596]

RY]')-C]F
$8

CHJX%GGDZT?2WF`EIMHD7:1IZ
M/-/[MX_A^(2_!.*95W3[V.4&E9F


J1*Q5^11M/'+$XEGX6]22CDV*KER8BP!DVE*OH23A


@2(QS9\$


/@)\N-04NQ<DK6[;N@F-IRA
%R?9Z/K'2IJ&N:[J3I
M3/H(
C_W*


4R!\





J45%46


B(D^_UN:\ETTT%AHJ7AF8J6








M6IWH.8

M'
WHO


AH.-FNZ-U_^$+EI&&&.4KWG0#9^&LX


M

M`BFZPZXJ452$&I0B?W;:0*$=.-LH8T$%O;7
B-
;X%-M0:2AR`Y+K:!X?*75

C-K6-/:K=F=PL6.')4V(77UQ&LB









[+CR'E$






MO4KSY%CW3LN1@Z%\'D_X1ICJOS(%1N6:1.E%P=\U$VAE]JIE`Y4HC6&]






-G:.L')+3Y)J/%9Q!J*VW8N&AX\/T




SL1
MU3K:-5:K-)+:7H]C8X*J0DETL\@RR=+AO_X!X`62N$DD.9MQ([5$I%(982
MB;SPU_^UOP\^P!BF00Y7X/89A

M8(K^C?Y^G^?;[]^^?7Q\/%BB3[-EF
(LV:5+F.%?@/W]OP'\?_____=7/
EQ

F
MBK/_^A
UV=-M&ATDZ=W;+P\/OWI;??BGXLOOG_`O6M\_?D6^/GKW[MU;\M?Z

D-C//%
M^BR
T4X(@^@RR4(L_[/;+





SB1QA#,-X64
MB)4''QFN#BF&@!&BJ3Z'NP#-




^5#KAWVH6QKQ_:1VD$G..$
LQ*2S2;


M4BQ;WWU9_Q6+UK??[GWYYW=[WW[]=?4Q6^[VT+4LVT)2LQ0]N[Z3\82A:_3T

PM4\/@ZV(;I93.)0Y$QE^V[/P8/G3:R_!B3W
HS!LAC@

M.N$




MES`EIL7T/A?NS/9+.5304G7.U#=G\`9=6$Z2*`K2#&QA6MR''4NC'O/Y/A@A
ME8:4%-&3%#;NK'8V3^3O1DMWVO$V*B*8,]+X_J^K,96OK0Q6%\TV'!GA
G

M*U9


[G0W&F\KV39.#AXX4

'M\
$_AHT/1


(A1Q3TTJ4:24MFD.

(=%W.N.H)3UNM+L2+]LV@8P`0_++S^'==+JE`6Y59.II






M[8




0D




'\*E?0=;








5
J5!AF.LB=7N
.QS?H2$]

1[=.A%T8X?9W&/1-@G[`C/V4P=4\'JJ/
MQYK+;E_3D;#FJ'(*.JZ]22OXN(LB$47\6_PSB3CMLL)O(E/XUM7&R&)4:Y4Q


)\D(4HRHV4_


FY0+U^M@Y\7V.90J2O

.2E#C??B9/%1_W4M5[:
M*EL[[]#+UVYJ\_2!SY;+9!?GV67PC.OZ\$MPRV6Z@[28VY$^)4SL.\K-$.5=
MX
NA8%N


KM/T

OK#\5XP9T[T$G9-4=;?G[+DPA4D=(

PVW9:CB3$&JZ'.
M+P_Z
D`?8YHT

@7HYD


M.R3(D35_%\8Q5B\XID0F=GK6*2U*G7-
:DST;*[L44M5!%DUS16[8+QB

JG


=%OCRBEF'F`A;4*NP[LX7(?+
M(

1O)-ZI/AU#FGI-;(90V+Q[


I;1OF/CZ(7:.Q%



MKQ581L=KX

M@:VFR^*5#_'V-ZZ+_B23WN049Y[`2Q_3$L)-UZ.43,8,70FVN4'O-;80=U



N%X3/`*@(5(UY+;L
M1$T9R0@PN##)FGM.
)\3W232$^VO+ECJC!5(EQC:2RZ7PN55CEIP$LZIUW=
M)4.'(V3E,$#&`7J@1UI,E;VTMG1PU2?\8!;4F\ZTSO1=AH(ZLNE_#KIDXPJ
M*D==BIGK2ER]%!:O0N-V$B3)Y0[&.AGQ][30\R+TX+.4%]6`F#^(I;4#S*
M/!PD$:W6)-I$
W;A*4TUJ?+5Q

0]T$69HMU)R?PV8+(*<[L1/C4<..((1F,R_.:
MX:KZ$0:]42`EDL-






6D

-[!
M*[A



M




MY3;MQH@R7X`M@9$\M)K-YK--43P*X'I0TS2![X?#CE:ZTFI*%0W0728R
=


N
M%/_W
(;K

M[9TA



93G*.
66R_K=-'
M0:EUXJ_%M^X3#/B
XO5!I%:I'\D@DGBQN#D]6EQ]F%W



MP(U_H9.F

:2^!@'UN=/8F[DP*

M2;)Z#*.(=\0Q4BQCF+M6+RHK8K%





M9CB:R_9WSM/GALG'



4!OC#EV5S


3#W+KC]'B)4/&%-9M
MFAE8SL`Q3R:4+]Z
@\-J7&4X:<B0A@VA2B[BMH
M8IL*AEOK5R]!A-O?H6PLR;9-G70#D+&JOX7KM:.[E?`A&6B
@GOQ?5R-`88


M19/.ZE56WK1'QXR[3).'



@

M


M2HA?@%\)4


-0Y]DGFS_



'5+%Y=P1R#/MFE


M0$8!
ZOGW0`1^6*26DVNX1)]B
M?39?6J.D8-TOV$8XW8TFW!M%E;JHJ\?%-#!PUX;YP:XTA:S]0=1G<C5_?'
MXG<[#;'P3;

MO%9E9B?6FQIN_.YP9##`_`;5\.*Q91]4AQGK.P](JI)G?&M&H#V*$J?J4
67

E);EPO:RN8A12E;94_E*5!D0=KP
GC?%HWW-3&@%

!@ZZ:FL8.\SV


MEL@_@9A!D(\AQNMGG9:R8E)F-^GR:[NWNP+97_








G%660H'_3!8T)!X_3\KZX_

0$MNV:$@

M13GZ7QV`$B#.R:=`@@8FJ(#Z6%TR0!Y:6?JF=+4DR.?:Q2:F\.U6G!AB.8E(







`8HA;
MMZJ
?_RRV


MLBLBHP48JN621\T$5$2!+ZI28HTCKU1!+[;5LJK$%Y?[GD&\72R(K0H2KL]N
M!1Q59;C5)(







MQ0MCNM


M0DZ5/SU23
$DA7[6=



M.;DV)VN8X4S-(


M/FUQS(`;;2D'D:@*W66X'.=6$0J7Q&*'`@U
D]^%*I7\[WO\U.MQLL&3D?C3


INA?,Y
M.4U%&'&K=?BR63[04,';H]YUZ];HNA%,%8[3HBBECS]7QK8]/(YVZ5\K6LK%
M(]727[WQ5:*M6%Q<)!A/ME%/\ZKYH.G7[.C'BET'R2+DSFC!109K?GM'WV
MN7-9R;V08:%:HNE5=WP9^_@5E_U^]]HR5=@?(?_Y_IR]LOL_?FI4?H8'X+=











9E=-T=+'
M


)<LWMCN;
.U($9NK
@V#HKRXO0TXG!&(!339
TK-(;3



,DHXLDGT5XT&TT8?&T
MTKPVPATZ/'?W<-#Z^.?C`9H.*C'





%!X[.CP`%!B`X(`6(&&

MNY(8!S7P@X

MJ0;FS=.^Q*ESL!8Q1=H





M'13=%T]_PI=&
P^7&(QE+X(0&:';X.@`-&-!
=C'@,UMK4]`W*J3)(!AXJ

MPD&@B8&39G;J^(D:W#50]D`-I]7VCO
4K+/&=_J2T6V&ITDY%_E\;307:7@7
M(F



MV5

\R+;G
K#

S8!-&SX4\+M8?@QBI)SS=(KU$FFL9;H-H
M\1C#=#HM8XJ*9;DS1)-7'U-!`P4X4'R-Y;2!$@B3`D3$*#^7`8'2EKCF8`




M8LX)PKVM%8_@;#C]?1?FST@LMTD\I;(13VCU%!.BPI&DXE/0?-M7/DY]#R(V
M




MO469:Y2+(-^E2)[*



RVB#Y0$M1G

NTV.5*C`FKF%R%XB^.Y-T:\5&(




M%3+8O]2KH


^

M1F$2XYRJE)#Q
GC&CP_

1K7Y9[`W4V?MOPE]'NET?4;;F
MUV*R4_/6!7,''2N[
`QK6P\
MV4V2!]'QV4(O+4T9F&

BIG=

XA6=8]^I(*69U`SR*@#T9&R
MEV.FH/'C%:B@D'_0`6L
R).*#2
6LX10D6C.C@`U_3G0$!S]3^S?8O2GQ]
<*&-U]%BZ685U+IM#3,VRT33Y
M91HFZ35,'\*EEHM#!8Y-QX8/NKZFPP&U6@_?-<:C./*$X\H=MT5BE@I:FP%


MC?*XX=0C
2(7#(L`SY)=O$*2KZ
=VT.L].ID3

M+U%L/1R8NDQ`U1=`UL-)3@RYFNHAPM1
Y5=ND\JT:7K4I:FZTODAO+M')%A]



5^DH'/
M'Z?:=0J^&'HEY_$#S-#?2(`(/V
T8FVR*6RKMJH9CER%74`#-;B74[`\4!(H






T19N%B?X'!W]#&


79]^@


2NC
!6:NEIKF;4:Z])%.PA=CHSC)\@!I\'9F=G




M)C

MQHUO0@$QMC;FL\=AV&XMIA[#3#P;+$^8.[.
G
=:P(AE4=*T!$H&
S4L-;
MC_-1QRIPJ24R

AL&:!C

\

M8E:]*EZYN98KH2;5O&R&.76



MJ^VA#!M7;9_!VW07I
\CV-L
&]C@M5MZZ3_E<




MDAH&:EHJNF&8;R4U(S%JS)*:Q3+'+V,8$3W(3D.(O80TE72)0#?+30NX5R
MQ::.'T%$)FY:2EO

(B+@IDBDL=YXG-/




5%3U/`8-&/R(I8?O(9GPER5[BA1SECFA

M[R;KHHN&BM*_24`UR#-EP&

M&[XXCH=R87C6P\]A?G^9A@]!#B^C8$ET\QDT]19+H+EH+2I&246E8@B@!`%J




(X@[.[%)(S`9\3%_#QER3]_!&NPF40'2=1!.^T
MXIDCS&/33A^.+N\TJ#C1`L$$)'-30PL?P0=X`E#.`
HI_-!`X\E.(_$C

/.K*S/\3FFZ(UO*)-P[FS`-Q%*%Q?
7Q5U@

MI42@24_C/
R?YS$R5C9$0&:W69X&RUSI0%49.UZI((-YTLAA+I+`8#:C3X


*42$WV'B()@C\%






%NVC.9HVO@N1C3;+


G:I.1&MWH(_)/B\Q41)XY
P6T9)MDOE5QS)


8@TL;9E=MG\7!-M_





,8&,(]_
MY!M0?N34!J&Q95&\OQKMID(K&/ZKRW$[$MB<D4HK@:+79[E2(`1%ZM!14YI

!&3H
4ABT.A\(-ZXLISI#`8YTBS*YR<%:Z\X
M/G&)%U7P50+TR1!26+_\E%4FHLWK9QO%


95F'T^3N$JS/%/?%.7&@+P


W&`S:H5^`&A)H0+FR:/07S;24-4EFE9_4KJ?R
MH%E\H[Y$&ZV7$.Z$





M57:&*$!29Q!U%FM6)1QSUY:C`28@J
9C?V.O':!;EJHMD[E3-0AD^81$E[S%
M^C3+PPUA6MPHJ\P0^KO5*T6%VQJKXC%#M::K7J1T#4;A__0?[*?@@BK
:+
M!+.N)XQK1&+7!`F=XA\H

3F1X``P[?H^+C363?3O-2FFTVN%FI9XIVH#BU/
M'!
#&C2Y=(=MGKD@8_2?7<

\L@4\$%OH--0T7`L5-5QB&[;7&A'BR@2YV*!#=V<<:'
M%$FZ4G_WDO\%RH-L/POLPR&@'9]+S(E4LLAI'7ONY8PQ37\P9/Q;7B`@KJ
6Y?W




O



1X%J6.'J2QV&



2B^=G8/

0-PJWN);7X=W<;@.E]@;LUJ%PN[$C-0FA8VC2EHH`;G
M/.];FP`L%AM2T6K=D*@@O;'JJJ=/R&

MB\$P\CO1




MC\W\_+E.C2_N?(N4]/Q'YN7%;G
+T\6:CH[H%2(4$S3OFY?W[20%U1Q[H)B%
M^%G(/


S$SECZ;G*%+UB-M!

MIVV:P&'+;3SG^E4@YD(X[EG^FFTWT0VR











/
MZX_*%O*N8R0LAK0#(;U%F70A[H$[#V
X1S\*CL01I*9Q;:V[J,@%PC\*2#?
M_H]SWP^?44SI:*^RUA#E,M!?/U=+0;]_[H-
DCVYO\%4$L#!!0````(`'6&








M-+\V(R

\

OL\EPM%AB*JN;X6B
T9L.;MAYKAY.MCI\
MQ/\LY\:-@=!D9S;[=7DG)![V)W
ZF%V-5L9O/.LK\VWI^GF^&$V
U6@X-Y!R
MK1;&=&D
.#=E\E#2S*-X[W^#Q'%EKO`*6*+E@'9
O

MZPN\&!UT6=,DH/CXACR]-6P;2]R0^ANY\@PL$(+I[BGY[8&*T81[H.UUL#

P0631



M!1LH-B?J\97




7A+T[W\4/N

_3)(D.5U0.--
M@D8;)E.O3ZDM[\#^VP/[;.HTB'S



_^HB!@:/=I.M$9;]Z7GK1^@XZA`E8INBZT9



5Y



JX+7
@.P3UPO/B%AWK6S#I9WV/@Q`
K'0L.UH%\6WG6'D
M(QLK_PT5Z$O@JE.;M@P4.&XPYXD*N6+!Q:WJ8K35Q.?6*#2N5V^3%(CG4Y

M].\C_?M(_S9


BK5ZFZLAD1./SB6W
M0



MLGTHLIUI]0*IV7QH0AM59(EH#V&QXE7%FI2$RIXD-I9/DNTIS@&$=U8070
MQFX?Z$2AFN7.I(MMFHI28E=((+T\`;N\0#\8]VA2V8!KM;H$_V\1LIJ([
M&L9DY









V$D23FEMM'H'%?6X+5[`7&*2D#`M\]$


M$



M'0N7FIH**\GJH5VW9`*V4E
15C2&YHX\D9(XD%/95\MX/5][8BUR<T\-W(RQ\
MOP

M-VM@21T#T,(#8;02NH!VN-H$N-?7J92(O6[BME5.+&JJ7U=3

M;
^UH0


M(.4+P



MO





5=_)&8-:!R'=43%0QU*Q^]H87%1%]O

;VWW1P(V(!QL[A.\_!




M7R/1L8/#EQ4J``\;'5KX7%(^JH:XMTTLD*P)HXY$JTO.4K+`CDC*:W6Q/U
M(349WW/1CS9([40-@
S

1S62_U)C6&C97.*@NCQ&7VUVOZ
.%`F\.6<UW$'3G4*6?JM.






P#H),8:JCETB5?GG<3TI-0=U<4I@G+U`)Q[<.6YX5W3QS@-1VT^Y*F5
MAG:_IT&HG;9!D?

MTFQ*C1)0)#1M;TB+QE[DMT.)8D[TO+:U28



'P<7T[J=?OIU]7407


M_'/PP?S#
&HOZKEMQ$3IG/.]P-
M7(Y/D.`:-M)DA+ZV0&'<F;IG8(X$Q7*((TW[3Y#+JV1!XWVYR$B;^@8:70;




O

M--R77RB`DE=_(7[T/UXTH4QD..0$[[


OTLE6HGO-W+TH-%X4`;JVC=5



MM

)C=V60%T)=B\E$S7MW9J
M-+

#2^JUV%.U-1VK4+V[Z5B\+:4]#



VDF

AA_IF31$XEU
M_PRH$.0!X)_8`48K_]83]AG/?<\&8!V,T91C?XYKQZ5QJQ:MM/+`-)2[\2A3
M3^MC`^Z<-YP5L'S<8/O
XFJIH\=J@V[;HR.VN^UHCFZJCB\G/GUR[=\K:==
M4N'DA56D70

M#K9WR^NK*V-Q


V9^\)&JF#P29[*R_AZLV#J-?
8_\.E


4.1W69+5DVD/^FJ6

K-)65S\

`
U9V1U:U:SG.T\%2!^LY
MLM[=

M








(7.\]%Q=X=D#\6HOS7DUF=R'MB+I=
M575X



M!Y[C@W+G5H&G6YB+D76ESX_;-UQYZMW^I\MJ8^B2C]TH6G:+[WISBC]9!2


16@EJBL@GB




D
+VI5%KNB4[_B4R@QE
26!8A+[
TM/]

MKY_

'M=Q812G9/&GI_IM
42CUL[BK8E4*EM

G-6T]*:I8GG!+-C4/JRWI.:48`TI.5
MMTOQ2M\(W_QP]H%/^)GO=D+_L[/5$]:58^?M&W[A/W^W


L9F41B$EKN&[K8I@-
DOR^4
\*496WSAE
\-T`=

*8

R[-VFX@JYR
37))&=J69QTRG*

M
A&)]L7QPN

I_G

:&^
Z1

M


M&AVLK


A-!
M6R$TS3'01

[+U/-;]H)/32OY+9SZ7GK!^@X



M@D)T&X`_(NS%N



9SI[KWO(Q:O9PME9Z+Q:Z\--A/;9+A]*V$CB:;I?+
M0L_S?=^'N-)7V?:%S_C*EDV-$XSS`%8`@L5+
.P5=.$NVN%/+$=Q$$\-[39C

G4-\E5B[H
)H-JVZ0





MI3*X69'X!6[O'



7D)


MJ49=#4*.PG;%G8/S^@SV%EP?[G$*+TWEA+J+-$%P






_%6J
M8T(NL[4_I@CA\T(X/PNQT06\^
G\1MS\X-J^MY6&7S@LF%;G);VL?3N0%

B%Q=A'4
'W3QE23\_



M75MSVSBR?C]5YS]@_;+9FK%ER782NR:IHG5Q.-$MDIS$V=I*020DP:9`!2!M



M'?P(H8='&+D+::+3<O<B;]`-EK76VS\KQ2\/%L,)`#$\(%^``/LD_?)T^3Y







M#?X3Q$T6E#Z14I75U:^52?C9

M'MM@]0UGLH:9X_DLI(C_0\@%Y2.P+AIPV2`6#CH-L!(OI;=@5\)NI6E_NK9K



UR14KB:VXUUZ3^$\1R



M;A&-!2TE[%(6OMM&HC%%:N:%EV6X_@A3`9=WT/.QBQRWGTUWR#
D6QS)5N


MBX(\+)7KRW2Q




MVQ


M!JB'')\XV









MJ@);*J6_!XFZM


M'KKG4UB$2N$
2&UQ

M












M7C`7+H=9JJ8`4W\^'WK8$;YU`T6IO%'FI/@[$=:-'3PX-L#MRP
VT_3H7/=A
MI

M65V'I4Q@=!PNW^TAAB!U)N)3';I'GA]]FQV+0EJ&^QU:ZN@ZH=5KM!4_/0*
M2YQW[KK[=.!WX3Q*C6SX-.E847),4?S;U9G.C]-
?4
SSHW;Z0YTP.M])&R



1JWF)0#3%UYK2&%$SAMX2!`WA22
M%A);71

M.



RFD5'\+V:61L1![T[[-MVQ=Z*MM_0W*%N!
]#$SR

O1Y:O]73P(V(!DK5:A`O?0::$CDP%5V+

NYS%(50DL99JV:*2'W3%*3GIU9N+R[9#@8-X(B=L\ZAZ9HUT.
MM.H[%Z`XX3I8_<H!G]QNZ)BTM\ZJ#J1SJLROL_!<$RXS3)5.Q5$E7;(H5%N




M/33=!:KW`PCK(D)/U*\8KN@F2J4S)*U.D/E3=`OEGDH:S^0&RKQ*MH3/;SZ5


+BTNX:&IJF:A9.%:=A%/+?N!0@R4/9


M@0````!A=G1H+3(P
3
Q
C
Q+GAM;%54!0`#7=4Y4W5XP`!!4.```$.0$`


`%0`8```````!````I($I
`Q0````(`'6&?T3CS(H(A#<``-FJ`P`5`!@```````$```D

3
Q
C



 'defref_avth_GoingConcernDisclosureTextBlockAbstract'
<a class=a href=javascript:void(0); onclick=top.Show.showAR( this
 'defref_avth_GoingConcernDisclosureTextBlock'

M;VL-D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]D-3`X,C5C,E\Q938R7S1C,39?.6%C8E]F,60S
M935A.#DT-C8B#0H-E1H:7
@9&]C=6UE;G0@:7
@82!3:6YG;&4@1FEL92!7



C5C
E\Q938R7S1C
39?.6%C8E]F
M







T0B5V]R:W-H965T
&-E;%=O<FMS:&5E=#X-B`@



T0B5V]R:W-H965T
&-E;%=O<FMS:&5E=#X-B`@


T0B5V]R:W-H


O4VAE970P-BYH=&UL(B\^
&-E;%=O<FMS:&5E







M5$5?





1$524U]%455)5%E?

T0B
#I7;W)K<VAE9713




&-E

M;64^3D]415\Q





O4VAE970Q.YH=&UL(B\^#0H@(`\+W@Z17AC96Q7


O4VAE970Q


5]/4D=!3DE:051)3TY?



M3F%M93Y.3U1%7S1?24Y404Y'24)
15]!4U-%5%-?5&%B;&4\+W@Z3F%M93X-








M1$E465]!3D1?1DE.04Y#24%

#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1)7;W)K




M:&5E=#X-B`@(#QX.D5X8V5L5V]R:W-H965T/@T*(`@(#QX.DYA;64^3D]4


O4VAE970S
#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1)7;W)K<VAE971S+U-H965T


1$52
M4U]%455)5%E?1$5&

#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1)7;W)K<VAE971S+U-H
M965T
S0N:'1M;(O/@T*(`@/]X.D5X8V5L5V]R:W-H965T/@T*(`@/'@Z


M965T
S8N:'1M;(O/@T*(`@/]X.D5X8V5L5V]R:W-H965T/@T*(`@/'@Z


M(#QX.DYA;64^3D]415\X7TE.0T]-15]405A%4U]$971A:6QS7U-C






T0B5V]R










]


]

]

]


]

S`L(#(P
3





]





T1T;W`^1&]C=6UE;G0@5'EP93PO=&0^#0H@(`@(`@(#QT




3(M
M



]


]






]


]

]
M






]






]

]




]

]
T1T97AT/D1E8R`S
M


]



3



]


]


#@R-6
R7S%E-C)?-&
Q-E\Y86-B7V8Q9#-E-6$X.30V-@T*



]

M:60]


#$S/&)R/CPO

]


M86QI9VX]




]

]
T1N=6UP/C8P+#`P


]
T1R;W4^#0H@


]
T1N


]



T1T;W`^26YT86YG






]


]


]
T1N=6UP/C8U+#0S


]
T1R;SX-

]
T1N=6UP/C
X-BPV
M
















]
M



]
2DZ/]S=')O


]


M97




]
T1P;!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M+`D







]
T1N=6UP/C
L
M-S`W+#8X





]
T1N=6T^*#
L.#




]
T1N=6UP/C
T+#$W


]




M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#4P.#(U8S)?
64V
E\T8S$V
M7SEA8V)?9C%D

O4VAE970P
RYH=&UL#0I#


M87-C:6DB#0H-
MCQH=&UL/@T*(`\:&5A9#X-B`@(`\345402!H='1P+65Q=6EV/3-$0V]N





M1'1L(&-O;'-P86X]
T0Q(')O=W-P86X]





]

]
T1N=6UP/B0@



]
T1N=6UP/C4P+#`P

#`L









]





]

]
T1N=6UP/C(U




]
T1N=6UP/C8V+#(X


BPP
#`L

C@Y+#8T



]

M96UE;G1S(&]F($]P97)A=&EO;G

]

]


]
T1T:#Y$96
N(#

S$L(#(P
M
3







]

\



M+#@Y
BPP




L
S
U/'-P86X^

BPR-3@L
M





]
T1N=6UP/C0Y


]
T1N=6UP/C$Q




M






]



T1T







]


]
T1N=6UP

M;7`^
RPR






M





#$I



M


I

#0L
C(T/'-P

M
C0R+#8Q

;V-A=&EO;CH@9FEL93HO+R]#.B]D-3`X
C5C
E\Q938R7S1C
39?
M.6%C8E]F

T1#;VYT

]
T13:&]W+FIS



M92!3=&%T96UE;G1S(&]F($-H86YG97



]





C`Q


]
T1T:#Y#

M(&EN($IU;F4@
C`Q

]


C`Q
B!;365M


]


3



M=7-T(#(P
3

M/3-$=&@^0V]M;6]N(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@(`@(`@



]


#$Q(%M-96UB


M




]




M87)Y(#(P
3




M($9E97












]



]
T1T

C`Q
2!;365M

]


#$Q(%M-96UB97)=/&)R/CPO=&@^#0H@(`@(`@(#QT

]
T1T

#$R(%M-96UB97)=


]

M


C`Q

]



]
T1P;!V86QI9VX],T1T;W`^0F%L86YC92!A=!$
M96
N(#

]
T1T97AT



]
M




]



]




]



]
T1T97AT



]
M




]




]




]
T1T




]





]





]





]



]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT




M9VX]
T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K('1O(&9O=6YD97)S



]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]




]
M




]



]




]



]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT




]


]
T1T97AT



]
M





]





]



]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT



]
M




]



\+W1D/@T*



]



]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT



]
M


S4L


]



]




]




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^

S
U+#`P
M

]

]
T1T97AT



]
M




]



]



]




]




]
T1T97AT



]
M




]


C$Q+#



2P@
M

]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]




]
T1N



]



]



]




]
T1N=6T^*#(Q
2PS-S8I


]
T1T




]





]
T1N=6UP/C$R
RPV



M870@1&5C+B`S
2P@

]
T1T




]





]
T1N=6UP/C0X+#8X.2PV




]




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]




]
T1T




]





]




]




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]




]
T1T




]




]





]



]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P



M9VX]



]





]





]





]



]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P






]





]





]
T1R8SX-B`@(`@


]
T1T97AT



]
M





]





]





]

C4L
3


]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P

#QS




]





]





]


2P@


]





]





]
T1N=6UP/C0X+#8X.2PV




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]




]
T1T




]





]





]








]



]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT



]
M




]


]




]




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^



M
T1T;W`^0F%L86YC92!A=!$96,N(#,Q+`R
#`Y/]T9#X-B`@(`@(`@




]





]


]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]




]
T1N
M=6UP/CDR-2PQ





]






]




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^




]



]



]


]
M




]



]



]




]




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]




]


3$@870@)#`N

]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT



]
M




]



]



]




]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT



]
M




]
T1P;!V
M86QI9VX],T1T;W`^#0H@(`@(`@(#PO=&0^#0H@(`@(`@(#QT9!C;&%S


]



]



]




]




]


34L
#`P


]
T1T





]





]





]





]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT



]
M




]



]




]




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]



]
T1P;!V86QI
M9VX],T1T;W`^0F%L86YC92!A=!$96
N(#
Q+`R,#$P/]T9#X-B`@(`@


]





]



M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]




]
T1T





]





]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]




]
T1T





#$P/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT



]
M






]





]



]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT



]
M




]


M;65N=!O9B!S:&%R97,@:7-S=6%B;&4@,B\Q,2\R,#$Q(&%T(0P+C$U('!E

]




]
T1T




]


]



]




]

M/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$;G5M/B@R
34L


]




]
T1T




]





]




3$O
C`Q
2!A=`D,XQ

]



]




]




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]




]
T1T




]





]





]






M+S(P

]




]
T1T




]




]





]



]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
M




]



]




]


M
BPS
#
L
S



]



]



]




]




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]





]



]



T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N




]




]





]
T1N=6UP/C(Y+#0X


]
T1N=6UP/C@Y+#DS


]
T1T97AT



]
M




]



]




#`P/'-P86X^

3`P+#`P
M

]
T1T




]





]




]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT



]
M




]



]



]




]


I



]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]




]
T1T




]





]





]




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]




]
T1N
M=6T^*#(L


]




]




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]
T1T97AT



]
M




]


RPU





]



]




]
T1T




]




]

M96
N(#

]
T1T97AT



]
M




]





]



]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT



]
M




]



]


]



M


]
M




]







]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT



]
M




]
T1N=6UP/C$R-2PP




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^





]




]





]





]





]



]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT



]
M




]


]





]





]





]



]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P



]





]





]


C@V+#(W



M1&5C+B`S
2P@
C`Q

]
T1T97AT



]
M




]




]





]


]





]



]



]




T1T;W`^0F%L86YC

#$R/]T9#X-B`@(`@(`@




]





]



]




]
T1T




]





]





]





]



]
T1N=6UP/C8V+#(X.2PV-#0\



]





]






]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT


M;7`^







]




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]






#`L






]



]


]
T1N





]





]





]



]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT




M9VX]


]





]





]




]




]





]
T1T




]





]





]

M(`@(`@/'1D(&-L87-S/3-$;G5M/B@W+#
R


]
T1R;SX-B`@(`@


]
T1T97AT



]
M



]



]




]




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]




]
T1T




]




]



]





]





]



]



]
T1N=6T^*#4R+#@P
M

]
T1T









]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT



]
M





]




]





]



]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT



]
M




]



]




]





M86QA;F-E(&%T($1E8RX@
S$L(#(P
3


]



]



]




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]


M(#
L-S`W+#8X


]





]




]
T1T




]
T1N=6UP/B0@
S0L


I(&%T($1E
M8RX@
S$L(#(P
3

]
T1T97AT



]
M




]





]



]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT



]
M




]


#`P+#`P



'0O:'1M



]

M+B`S
2P@
C`Q




M(&-L87-S/3-$=&@^1&5C+B`S
2P@
C`Q


M

M1&5C+B`S
2P@
C`Q



M/]T:#X-B`@(`@(`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
2P@
C`Q
3QB

M87-H(&EN($IU;F4@
C`Q

#$Q/&)R/D-O;6UO;B!3=&]C:R!;

M

M1&5C+B`S
2P@
C`Q


C`Q


#$R/&)R


#$R(%M-96UB97)=/&)R/CPO=&@^#0H@(`@(`@(#QT

]
T1T:#Y$96
N(#


]
T1T:#Y$96
N(#

]
M
T1T:#Y$96
N(#


S$L(#(P
3







M












34\

M(#`N







]
M




]



]



]










]










]



]

]

]
T1T:#Y$96
N(#

S$L(#(P
3




]


]



]


C`L

C`L


]

C@T+#4P


]


T1T









]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


M

]
M
T1N=6T^*#8P+#`P


]

]
T1N=6UP/C(P
RPP





]
M


M;G5M/B@R

]



]



]
T1N


M1&YU;3XH



]

M86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$;G5M/B@R
S`L
#`P*3QS


]

C

]
T1R;SX-


]



]
T1N=6UP/CDY.2PU




]












M9&5D(&)Y(&9I;F%N8VEN9R!A8W1I=FET:65S/]T9#X-B`@(`@(`@/'1D



C4P+#`P



M;F-R96%S92!I;B!C87-H/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$;G5M





]










]
M



M9VX]




]


R


]

M:60@:6X@8V]M;6]N('-T;V-K/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$

BPX




@


T1T;W`^





]




]



]



]




]
T1N=6UP


M=%]D-3`X
C5C
E\Q938R7S1C
39?.6%C8E]F



M87-C:6DB#0H-CQH
M=&UL/@T*(`\:&5A9#X-B`@(`\345402!H='1P+65Q=6EV/3-$0V]N=&5N



M*B!$;R!.;W0@4F5M;W9E(%1H:7

]


3XQ
B!-
M;VYT:'

M(`@(`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
2P@
C`Q



]



]



]


05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@

M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4




M+!);F,N(AT:&4@)B
X
C(P.T-O;7!A;GDF(S@R


C`Q
2!U


M










M97(@*'1H92`F(S@R

#M!5E0F(S@R



#M!
M8W%U:7-I=&EO;B!3:&%R97
F(S@R
C$[*2P@;V8@=&AE($-O;7!A;GDF(S@R
M





M:6]N(&]F(&%L;!O9B!T:&4@:7-S=65D(&%N9!O=71S=&%N9&EN9R!S:&%R
M97



05DZ(&EN;&EN93L@1D].5U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q
'!T)SY);B!C





05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@



M960@=&\@=&AE($-O;7!A;GD@9F]R(&-A;F-E;&QA=&EO;B`H=&AE(8C.#(R
M,#M3:&%R92!#86YC96QL871I;VXF(S@R,C$[*2X\+V9O;G0^(`@(`-B`@

6QE/3-$)T1)4U!
05DZ(&EN;&EN93L@1D].
M5U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q
'!T)SXH
M:6DI)B
Q-C`[)B
Q-C`[)B
Q-C`[)B
Q-C`[)B
Q-C`[)B
Q-C`[)B
Q-C`[
M)B
Q-C`[)B
Q-C`[)B
Q-C`[)B


M86)L92!W:71H(&%N(&%G9W)E9V%T92!V86QU92!O9B`D-RPS
C`N(%-H;W)T


R
!I;B!S:&%R97,@:7-S=6%B;&4@;VX@=&AE(&-O;G-O
M;&ED871E9!B86QA;F-E('-H965T(&%T($1E8V5M8F5R(#








M.B`Q
'!T.R!&3TY4+49!34E
63H@=&EM97


T1L969T('9A;&EG;CTS1&UI9&1L92!W:61T:#TS1#$E

M)B

T1L969T/B`-





M3E0M4TE:13H@

M(`@(`@(`@(`@(`@(`@/]D:78^(`T*(`@(`@(`@(`@(`@(#PO

T1M:61D;&4@=VED=&@]
M

T1L969T/B`-B`@(`@


M(`@(`@(`\+W1R/B`-B`@(`@(`@(`@(`@/'1R/B`@(`@#0H@(`@


05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@

T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4+5-)


M/3-$)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`@(`-B`@
M(`@(`@(`@(`@(`\+W1D/B`@(`T*(`@(`@(`@(`@(`@(#QT9!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$-#DE/B`@(`T*






M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T


M(`@(`@(`@(#PO=&0^(`@#0H@(`@(`@(`@(`@(`@/'1D(&%L:6=N
M/3-$;&5F=!V86QI9VX]
T1M:61D;&4@=VED=&@]
T0Q)3X@(`T*(`@(`@

T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E
63H@=&EM97

M/B8C
38P.SPO9F]N=#X@(`@(`T*(`@(`@(`@(`@(`@(#PO=&0^(`@
M#0H@(`@(`@(`@(`@(`@/'1D(&%L:6=N/3-$;&5F=!V86QI9VX],T1M
M:61D;&4@=VED=&@],T0T.24^(`@#0H@(`@(`@(`@(`@(`@(`\9&EV

05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@

T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&

M(`@(`@(`@(`@(`\='(^(`@(`-B`@(`@(`@(`@(`@(`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&UI9&1L92!W:61T:#TS1#(U)3X@(`-


M(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-


M/B`-B`@(`@(`@(`@(`@(`\+W1D/B`@(`T*(`@(`@(`@(`@(`@
M(#QT9!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$
24^

M(`\+W1D/B`@(`T*(`@(`@(`@(`@(`@(#QT9!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$-#DE/B`@(`T*(`@(`@(`@(`@
M(`@(`@/&1I=B!S='EL93TS1=415A4+4E.1$5.5#H@
'!T.R!$25-03$%9

M(&%L:6=N/3-$;&5F=#X@#0H@(`@(`@(`@(`@(`@(`@(#QF;VYT('-T

05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SY#:&EE9B!38VEE;G1I9FEC($]F

M9!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,C4E/B`@
M(`T*(`@(`@(`@(`@(`@(`@/&1I=B!S='EL93TS1=415A4+4E.1$5.
M5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2


05DZ(&EN;&EN93L@1D].5U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SY$96)A
M8G)A=&$@0F%N97)J964\+V9O;G0^(`@(`-B`@(`@(`@(`@(`@(`@
M(#PO9&EV/B`-B`@(`@(`@(`@(`@(`\+W1D/B`@(`T*(`@(`@(`@
M(`@(`@(#QT9!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H
M/3-$

M1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`@(`-B`@(`@(`@
M(`@(`@(`\+W1D/B`@(`T*(`@(`@(`@(`@(`@(#QT9!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$-#DE/B`@(`T*(`@(`@
M(`@(`@(`@(`@/&1I=B!S='EL93TS1=415A4+4E.1$5.5#H@
'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4


05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SY#;&EN:6-A;!$979E
M;&]P;65N=!/9F9I8V5R/]F;VYT/B`@(`@#0H@(`@(`@(`@(`@(`@
M(`\+V1I=CX@#0H@(`@(`@(`@(`@(`@/]T9#X@(`-B`@(`@(`@

M(`@(`@(`@(#QT9!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I
M9'1H/3-$
C4E/B`@(`T*(`@(`@(`@(`@(`@(`@/&1I=B!S='EL93TS

M(`@(`@(`\+V1I=CX@#0H@(`@(`@(`@(`@(`@/]T9#X@(`-B`@
M(`@(`@(`@(`@(`\=&0@86QI9VX]
T1L969T('9A;&EG;CTS1&UI9&1L



M86QI9VX]

M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU

M3BU224=(5#H@




38P.TEN8RXF(S@R
M

M;&4]


M($1)4U!
05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T.R!-05)'24XM4DE'


#M04$TF(S@R
C$[
M*2!O;B!397!T96UB97(@
S`L(#(P
3


BPU
#`L

@8V]M


M/3-$)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5U325I%.B`Q
'!T)SY);B!C;VYN96-T:6]N('=I=&@@=&AE




M.#(R

F(S@R




C`Q

M;R`Q
BPU
#`L

C`@




2P@
C`Q
R!A

M(#(P

@9&ES8VQO

M(%!L86-E;65N=P@=&AE($-O;7!A;GD@:6YC=7)R960@8V]S=',@;V8@)#4R
M+#@P,P@=VAI8V@@=V5R92!P86ED(&EN(&-O;6UO;B!S:&%R97
@;VX@2F%N


M/3-$)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5U325I%.B`Q




@0594+B8C
38P.R8C
M


0R!H87



M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4



#4M
M-#`@*'1H92`F(S@R
C`[4F5V97)S92!!8W%U:7-I=&EO;B8C.#(R




@82!D979E
M;&]P;65N=!S=&%G92!B:6]P:&%R;6%C975T:6-A;!C;VUP86YY('=H;W-E

L('!R;W9I



N)B
Q-C`[)B
Q-C`[5&\@9&%T92P@=&AE($-O;7!A


;V-A=&EO;CH@9FEL
M93HO+R]#.B]D-3`X
C5C
E\Q938R7S1C
39?.6%C8E]F
60S935A.#DT-C8O




]


T0Q(')O=W-P
M86X]

25%5241)5%D@04Y$($9)3D%.0TE!


3(@36]N=&AS($5N9&5D/]T:#X-B`@

M/D1E8RX@
S$L(#(P
3




]

]


05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@


BXF(S$V
#LF(S$V
#LF(S$V
#M
M25%5241)5%D@04Y$($9)3D%.0TE!3!#3TY$251)3TX\+V9O;G0^/]F;VYT


M8VL[($U!4D=)3BU



M96-T:79E;'DN)B
Q-C`[)B


S8L.#8W(&1U

#$S+B8C
38P.R!4:&5S92!C;VYD
M:71I;VYS(')A:7-E('-U8G-T86YT:6%L(&1O=6)T(&%B;W5T('1H92!#;VUP
M86YY)B
X
C$W.W



















N)B
Q


M;VUE(&]F('1H:7
@=6YC97)T86EN='DN/]F;VYT/B`@#0H@(`@(`@(`@

MB`@(`\+W1A8FQE/@T*(`\+V)O9'D^#0H\+VAT;6P^#0H-BTM+2TM+3U?

64V
E\T8S$V7SEA8V)?9C%D
V4U83@Y-#8V
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T
Z+V0U
#@R-6
R7S%E-C)?
M-&

3`N:'1M






]






]
T1R;SX-B`@(`@

24=..B!J
M=7-T:69Y.R!415A4+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%2

05DZ(&EN;&EN93L@1D].5U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q
'!T)SX\9F]N=!S
M='EL93TS1=$25-03$%9.B!I;FQI;F4[(%1%6%0M1$5#3U)!5$E/3CH@=6YD
M97)L:6YE)SY.3U1%(#
N)B
Q-C`[)B
Q-C`[)B
Q-C`[4U5-34%262!/1B!3
M24=.249)0T%.5!!0T-/54Y424Y'(%!/3$E#2453/]F;VYT/CPO9F]N=#X@

05DZ(&EN;&EN
M93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q
M
'!T)SX\9F]N=!S='EL93TS1=&3TY4+5-464Q%.B!I=&%L:6
[($1)4U!

M;F






1494.B`P


T0G




M
C`[52Y3+B!'04%0)B
X









05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@
M5&EM97


M;V8@17-T:6UA=&5S)B
X


@:6X@86-C;W)D86YC92!W:71H




M:&4@9&%T92!O9B!T:&4@9FEN86YC:6%L('-T871E;65N='
@86YD('1H92!R


Q-C`[)B
Q-C`[5&AE($-O;7!A
M;GDF(S@R

M97

M86EN(&]F('1H92!#;VUP86YY)B
X
C$W.W

M='
L(&-O=6QD(&)E(&%F9F5C=&5D(&)Y(&5X=&5R;F%L(&-O;F1I=&EO;G
L
M(&EN8VQU9&EN9R!T:&]S92!U;FEQ=64@=&\@=&AE($-O;7!A;GD@86YD(&=E
M;F5R86P@96-O;F]M:6



M86-T;W)S(&-O=6QD(&AA=F4@86X@969F96-T(&]N('1H92!#;VUP86YY)B
X
M
C$W.W



05DZ(&EN;&EN93L@1D].
M5U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q
'!T)SX\
M9F]N=!S='EL93TS1=&3TY4+5-464Q%.B!I=&%L:6
[($1)4U!
05DZ(&EN





2P@
C`Q
M
R!A;F0@
C`Q

M='


M4TE:13H@

13H@:71A;&EC
M.R!$25-03$%9.B!I;FQI;F4G/D-O;F-E;G1R871I;VX@;V8@0W)E9&ET(%)I




M:70@86-C;W5N='




05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T.R!-

M;&4]
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@5&EM97
@3F5W








1494.B`P


T0G

M96-I871I;VX@=VAI8V@@:7




M92!C:&%R9V5D('1O(&]P97)A=&EO;G
@87


05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@


T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E
63H@5&EM97
@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P









M(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-


13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4G






@979E;G1U






13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4G/E)E=F5N=64@4F5C

M;F0@9W)A;G1S(&ES(')E8V]G;FEZ960@=VAE;B!T:&4@9F]L;&]W:6YG(&-R









C`P

2P@
C`Q



M05DZ(&EN;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5U325I%.B`Q







M07
@;V8@1&5C96UB97(@
S$L(#(P
3




M/3-$)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5U325I%.B`Q
'!T)SX\9F]N=!S='EL93TS1=&3TY4+5-4
M64Q%.B!I=&%L:6
[($1)4U!

M:6YA;F-I86P@26YS=')U;65N='


M86)L97
L(&%C8W)U960@97AP96YS97
L(&%N9!S:&]R=UT97)M(&-R961I




05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T.R!-05)'

M
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@5&EM97
@3F5W(%)O

M;65N='
@;V8@05-#(#@R



T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@5&EM97
@3F5W(%)O;6%N.R!&

N)B
Q-C`[/]F;VYT/B`@(`-B`@(`@


M3BU

M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q,'!T)SY,979E
M;`R.B!&:6YA;F-I86P@:6YS=')U;65N='
@;&%C:VEN9R!U;F%D:G5S=&5D

L


24=..B!J=7-T
M:69Y.R!415A4+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.


M;'D@=')A9&5D(&]N(&$@;6%R:V5T(&5X8VAA;F=E+B!4:&ES(&-A=&5G;W)Y
M(&EN8VQU9&5S('-I='5A=&EO;G














M3BU












@:7





@;6]R92!L:6ME;'D@=&AA


05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E
63H@5&EM97

M;W!I8R`W-#`M
3`M






TQ,TT

L


N


M='

C`[;6%J
M;W(F(S@R


M+4%
24=..B!J=7-T:69Y.R!415A4+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B



#M!4U4F(S@R
C$[*2!.;RX@
C`Q
RTQ




@5&%S:R!&;W)C92DN(%1H92!A;65N9&UE;G1S(&EN
M('1H:7











M;F%N8VEA;!S=&%T96UE;G1S(&%S(&$@;&EA8FEL:71Y(&%N9!S:&]U;&0@

M(&%M96YD;65N='


#$S+B!&;W(@

@=VET

M;65N='


@;V8@

'!T.R!$25-03$%9.B!B;&]C:SL@


05DZ
M(&EN;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U3
M25I%.B`Q
'!T)SX\9F]N=!S='EL93TS1=&3TY4+5-464Q%.B!I=&%L:6
[
M($1)4U!




3$N/]F;VYT/B`@(`@#0H@(`@(`@(`@(`\+V1I








#$S/&)R/CPO=&@^#0H@(`@(`\+W1R/@T*(`@(`@



6QE/3-$)T1)4U!
05DZ(&EN
M;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%
M.B`Q
'!T)SX\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[(%1%6%0M
M1$5#3U)!5$E/3CH@=6YD97)L:6YE)SY.3U1%(#0N)B
Q-C`[)B
Q-C`[)B
Q
M-C`[24Y404Y'24)
12!!4U-%5%


05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E
63H@5&EM97

M8G)U87)Y(#4L(#(P
3`L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A;B!A

M96YI8W
L($Q
0R`H)B
X


@87-S:6=N960L(&%M





T0P(&ED/3-$;&ES=!W:61T:#TS1#$P,4@




T1R
M:6=H=!S='EL93TS1=724142#H@

M(`@/&1I=CX@(`@(`T*(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL

#LF(S$V
#L\+V9O;G0^
M(`@(`T*(`@(`@(`@(`@(`@(`@/]D:78^(`T*(`@(`@(`@(`@

M)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5U325I%.B`Q


#`L
#`P(&EN(&9O=7(@*#0I

3$L(&%L;!O9B!W
M:&EC:!H87
@8F5E;B!P86ED.SPO9F]N=#X@#0H@(`@(`@(`@(`@(`@
M(`\+V1I=CX@#0H@(`@(`@(`@(`@(`@/]T9#X@(`-B`@(`@(`@

T1L:7-T+3`@
M=VED=&@]
T0Q


3!P=#L@


05DZ(&EN;&EN93L@1D].5U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q
'!T)SYB*28C
38P
M.R8C
38P.SPO9F]N=#X@(`@#0H@(`@(`@(`@(`@(`@(`\+V1I=CX@
M#0H@(`@(`@(`@(`@(`@/]T9#X@(`-B`@(`@(`@(`@(`@(`\

M3D1%3E0Z(#!P=#L@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@
M5&EM97

M92`D
C@T+#4P

M97



T0P(&ED/3-$;&ES=TQ('=I9'1H/3-$,3`P)2!S='EL93TS
M1=415A4+4%
24=..B!J=7-T:69Y.R!&3TY4+49!34E
63H@=&EM97
@;F5W

3!P=#L@1D].

24=..B!J=7-T


M=CX@(`@(`T*(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$

M($9/3E0M4TE:13H@

M(`@(`@(`@(`@(`@(`@/]D:78^(`T*(`@(`@(`@(`@(`@(#PO
M=&0^(`@#0H@(`@(`@(`@(`@(`@/'1D/B`@#0H@(`@(`@(`@(`@









M/3-$



M86QI9VX]


T0G
M5TE$5$@Z(#


'!T)SYD*3PO9F]N=#XF(S$V
#LF(S$V
#L\+V9O;G0^(`@
M(`-B`@(`@(`@(`@(`@(`@(#PO9&EV/B`-B`@(`@(`@(`@(`@
M(`\+W1D/B`@(`T*(`@(`@(`@(`@(`@(#QT9#X@(`T*(`@(`@(`@
M(`@(`@(`@/&1I=B!S='EL93TS1=415A4+4E.1$5.5#H@
'!T.R!-05)'
M24XM3$5&5#H@


M($9/3E0M4TE:13H@

M+#4P


24=..B!J=7-T:69Y.R!415A4
M+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#
V










@=VEL;!H879E(')E9VES=')A
M=&EO;B!R:6=H=',@=VET:!R97-P96-T('1O('1H92!C;VYV97)S:6]N(&]F
M('1H92!S:&%R97

C4E




05DZ(&EN;&EN93L@1D].5U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q
'!T)SY4:&4@




#LF(S$V
#M)9B!A

M;W9E(&%R92!M970L('1H92!#;VUP86YY('=I;&P@861D('1H92!V86QU92!O

M:&4@=F%L=64@;V8@=&AE(&EN=&%N9VEB;&4@87-S971S+D]N($IU;F4@
C0L
M(#(P

#M.64U#)B
X





N)B
Q-C`[)B

@06=R965M96YT


M
S`L
#`P+B8C
38P.R8C
38P.U1H92!#;VUP86YY('=I;&P@86QS;R!B92!R


T0P(&ED/3-$;&ES=TS('=I
M9'1H/3-$,3`P)2!S='EL93TS1=415A4+4%
24=..B!J=7-T:69Y.R!&3TY4
M+49!34E
63H@=&EM97

M3E0M4TE:13H@




'!T





T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@5&EM97
@

@;V8@
M)B
X
C(P.V1I86=N;W-T:6

F(S@R
C$[('1H92!#;VUP86YY


E

@
M8F5T=V5E;B`D
`M(0R

@8F5T=V5E
M;B`D
C`L
#`P+#`P
2`M(0U,PP
#`L

PP,#`L,#`P+CPO9F]N=#X@(`T*(`@(`@(`@
M(`@(`@(`@/]D:78^(`T*(`@(`@(`@(`@(`@(#PO=&0^(`@#0H@



T1R:6=H=!S='EL93TS1=724142#H@
S9P


05DZ(&EN;&EN93L@1D].5U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q
'!T)SY&;W(@

B4@9F]R
M('-A;&5S(&)E='=E96X@)#(L
#`P+#`P
2`M(0U+#`P,PP




T1R:6=H=!S='EL93TS
M1=724142#H@





05DZ(&EN
M;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%
M.B`Q


L(&UA:6YT96YA;F-E(&9E97


L('1H92!#;VUP86YY

@




05DZ(&EN
M;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%
M.B`Q
'!T)SY);B!*=6QY(&]F(#(P





M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU

M4D=)3BU224=(5#H@
'!T)SX@(`@#0H@(`@(`@(`@(`\9F]N=!S='EL

@;V8@1&5C96UB97(@
S$L(#(P
M
3
@86YD(#(P


T0P('=I9'1H

M($9/3E0M4TE:13H@
3!P=#L@1D].5U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SX@(`T*(`@(`@(`@(`@(`@(`@/'1R
M/B`@(`-B`@(`@(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#0W)2!S='EL93TS1=0041$24Y'+4)/5%1/33H@
G!X)SX@

M5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`@(`T*(`@(`@(`@(`@
M(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`@(#QT9!V86QI
M9VX]
T1B;W1T;VT@=VED=&@]

M
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O

38P.SPO9F]N=#X@(`@#0H@(`@

M#0H@(`@(`@(`@(`@(`@(`@(`@/&1I=B!S='EL93TS1=415A4+4E.
M1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@

M(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI

M
3!P=#L@1D].5U714E'2%0Z(&)O;&0G/D1E8V5M8F5R(#,Q+`R
#$S/]F
M;VYT/B`@#0H@(`@(`@(`@(`@(`@(`@(`@/]D:78^(`@(`-B`@



M;&4]
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W

M(S$V
#L\+V9O;G0^(`@#0H@(`@(`@(`@(`@(`@(`@(#PO=&0^(`-

38P.SPO9F]N=#X@(`-B`@

3(E



S$L(#(P
3(\
M+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(`@(`\+V1I=CX@(`@(`T*
M(`@(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@
M(`@(#QT9!N;W=R87`]
T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$

T0G5$585U!3$E'3CH@;&5F=#L@4$%$1$E.1RU3U14


Q-C`[/]F;VYT/B`@(`-



T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N

\+V9O;G0^(`@#0H@(`@(`@
M(`@(`@(`@(`@(`@/]D:78^(`@(`-B`@(`@(`@(`@(`@(`@
M(`@/]T9#X@(`T*(`@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
T1R
M:6=H=!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@(`T*(`@(`@(`@

05DZ(&EN;&EN93L@
M1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T
M)SXF(S$V
#L\+V9O;G0^(`@(`T*(`@(`@(`@(`@(`@(`@(`\+W1D
M/B`@#0H@(`@(`@(`@(`@(`@(`@(#QT9!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1=415A4+4%
24=..B!L969T)SX@(`-B`@



T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&



M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^(`@(`T*(`@(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@
M(`@(`@(`@(`@(`@(#QT9!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O

M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B`@(`T*(`@(`@(`@(`@(`@(`@

M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXD/]F;VYT
M/B`@(`@#0H@(`@(`@(`@(`@(`@(`@(#PO=&0^(`-B`@(`@(`@
M(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S
M='EL93TS1=415A4+4%

M
C
P+#`P

24=..B!L

M
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O

38P.SPO9F]N=#X@(`@#0H@(`@
M(`@(`@(`@(`@(`@(#PO=&0^(`-B`@(`@(`@(`@(`@(`@(#PO



T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4+5-)

M)B
Q-C`[/]F;VYT/B`@(`-B`@(`@(`@(`@(`@(`@(`@/]T9#X@

M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^(`@(`T*(`@(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@
M(`@(`@(`@(`@(`@(`@(#QT9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
M
T0Q

T0G0D]21$52+4)/5%1/33H@8FQA8VL@
G!X('-O;&ED
M.R!415A4+4%



T1B;W1T
M;VT@=VED=&@]

M('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXI/]F;VYT/B`@
M(`@#0H@(`@(`@(`@(`@(`@(`@(#PO=&0^(`-B`@(`@(`@(`@


M(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`@(#QT9!V86QI9VX]
T1B
M;W1T;VT@=VED=&@]
T0Q

T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@
G!X('-O;&ED.R!415A4+4%


3!P

M86QI9VX]
T1B;W1T;VT@=VED=&@]


M5%1/33H@-'!X)SX@(`@(`T*(`@(`@(`@(`@(`@(`@(`@(#QD:78@



M#0H@(`@(`@(`@(`@(`@(`@(#PO=&0^(`-B`@(`@(`@(`@(`@

M/3-$



M13H@

M8F]T=&]M('=I9'1H/3-$

T0G0D]21$52+4)/5%1/33H@8FQA



T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E
63H@=&EM97


M(`@(`@(`@(`@(`@(#QT9!N;W=R87`]
T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$


Q-C`[
M/]F;VYT/B`@(`-B`@(`@(`@(`@(`@(`@(`@/]T9#X@(`T*(`@
M(`@(`@(`@(`@(`@(`\=&0@86QI9VX],T1R:6=H=!V86QI9VX]
T1B
M;W1T;VT@=VED=&@]

M;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`@(`T*(`@(`@
M(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`@(#QT
M9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q)2!S='EL93TS1=3U)$15(M

24=..B!L969T)SX@

M8F]T=&]M('=I9'1H/3-$


CPO9F]N=#X@#0H@(`@(`@(`@(`@(`@(`@(#PO



05DZ(&EN;&EN
M93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
M
'!T)SXF(S$V
#L\+V9O;G0^(`@(`T*(`@(`@(`@(`@(`@(`@(`\

M25I%.B`Q
'!T.R!&3TY4+49!34E
63H@=&EM97





M;6]R=&EZ871I;VX@:7
@87

24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@

05DZ(&EN;&EN93L@1D].5U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\
M+V9O;G0^(`@(`T*(`@(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@
M(`@(`@(`@(`@(`\+W1R/B`@(`@#0H@(`@(`@(`@(`@(`@(`\
M='(^(`@(`T*(`@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-C$E/B`@(`-B`@(`@(`@(`@(`@(`@(`@(`\
M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T


M/B`@(`-B`@(`@(`@(`@(`@(`@(`@/]T9#X@(`T*(`@(`@(`@
M(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4


M)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`@(`T*(`@(`@
M(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`@(#QT



T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM
M97

38P.SPO9F]N=#X@
M(`@#0H@(`@(`@(`@(`@(`@(`@(#PO=&0^(`-B`@(`@(`@(`@

T1B;W1T;VT@
M=VED=&@]
T0Q)2!S='EL93TS1=415A4+4%,24=..B!L969T)SX@(`@#0H@


M(#QT9!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V,24^(`@(`T*(`@(`@

T1B;W1T
M;VT@=VED=&@]

Q-C`[/]F;VYT/B`@
M(`-B`@(`@(`@(`@(`@(`@(`@/]T9#X@(`T*(`@(`@(`@(`@




3!P


M1TXZ(&QE9G0G/B`@(`-B`@(`@(`@(`@(`@(`@(`@(`\9F]N=!S

Q-C`[/]F;VYT/B`@(`-



T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N

M9&EV/B`@(`@#0H@(`@(`@(`@(`@(`@(`@(#PO=&0^(`-B`@(`@

M=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE


M(`-B`@(`@(`@(`@(`@(`@(`@/]T9#X@(`T*(`@(`@(`@(`@
M(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

M

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
M63H@=&EM97







M(`@(`@(`@(`@(`@/'1D(&%L:6=N/3-$;&5F=!V86QI9VX]
T1B;W1T
M;VT@=VED=&@]
T0V

T1L
M969T/B`@(`@#0H@(`@(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL

M8V5M8F5R(#
Q+`R,#$U/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`@
M(`@/]D:78^(`@(`-B`@(`@(`@(`@(`@(`@(`@/]T9#X@(`T*
M(`@(`@(`@(`@(`@(`@(`\=&0@86QI9VX],T1R:6=H=!V86QI9VX]
M
T1B;W1T;VT@=VED=&@]

M('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^(`@(`T*(`@(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@
M(`@(`@(`@(`@(#QT9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q)2!S
M='EL93TS1=415A4+4%,24=..B!L969T)SX@(`-B`@(`@(`@(`@(`@
M(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M


M/3-$


05DZ(&EN
M;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%
M.B`Q
'!T)SXR






M;&4]
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W




M;VYT/B`@(`-B`@(`@(`@(`@(`@(`@(`@/]T9#X@(`T*(`@(`@
M(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
24@


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E
63H@=&EM97

M
38P.SPO9F]N=#X@(`@#0H@(`@(`@(`@(`@(`@(`@(#PO=&0^(`-
MB`@(`@(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$Q)2!S='EL93TS1=415A4+4%


C`L


M15A4+4%
24=..B!L969T)SX@(`@#0H@(`@(`@(`@(`@(`@(`@(`@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@
M=&EM97

38P.SPO9F]N

M(`@#0H@(`@(`@(`@(`@(`@(`@(#QT9!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$-C$E/B`@#0H@(`@(`@(`@(`@(`@
M(`@(`@/&1I=B!S='EL93TS1=415A4+4E.1$5.5#H@
'!T.R!$25-03$%9


2P@
C`Q-SPO9F]N=#X@(`T*(`@(`@(`@
M(`@(`@(`@(`@(#PO9&EV/B`@(`@#0H@(`@(`@(`@(`@(`@(`@

M:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

M)B
Q-C`[/]F;VYT/B`@(`-B`@(`@(`@(`@(`@(`@(`@/]T9#X@

M(#PO=&0^(`-B`@(`@(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O

M(`@(`-B`@(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$

M($9/3E0M4TE:13H@

T1B;W1T;VT@=VED=&@]
T0Q)2!S
M='EL93TS1=415A4+4%,24=..B!L969T)SX@(`@#0H@(`@(`@(`@(`@


M(`@(`T*(`@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
T1L969T('9A

M63H@8FQO8VL[($U!4D=)3BU

'!T
M)R!A;&EG;CTS1&QE9G0^(`@(`-B`@(`@(`@(`@(`@(`@(`@(`@

05DZ(&EN;&EN93L@1D].5U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SY&;W(@=&AE('EE
M87(@96YD960@1&5C96UB97(@
S$L(#(P
3@\+V9O;G0^(`-B`@(`@(`@
M(`@(`@(`@(`@(`\+V1I=CX@(`@(`T*(`@(`@(`@(`@(`@(`@
M(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`@(#QT9!A;&EG;CTS1')I

M(`-B`@(`@(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W

M(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`@(#QT9!V86QI9VX]
T1B
M;W1T;VT@=VED=&@]
T0Q


M(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`@(#QT
M9!N;W=R87`]
T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
24@


05DZ(&EN;&EN93L@1D].
M5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF
M(S$V
#L\+V9O;G0^(`@(`T*(`@(`@(`@(`@(`@(`@(`\+W1D/B`@
M#0H@(`@(`@(`@(`@(`@(`\+W1R/B`@(`@#0H@(`@(`@(`@(`@
M(`@(`\='(^(`@(`T*(`@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8Q)2!S='EL93TS1=0
M041$24Y'+4)/5%1/33H@


M;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SY4:&5R96%F=&5R/]F
M;VYT/B`-B`@(`@(`@(`@(`@(`@(`@(`\+V1I=CX@(`@(`T*(`@
M(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`@


M=&0^(`-B`@(`@(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O

M(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/


M9'1H/3-$



T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E
63H@=&EM97

M-SPO9F]N=#X@(`@(`T*(`@(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@





M(`@#0H@(`@(`@(`@(`@(`@(`@(#QT9!V86QI9VX]
T1B;W1T;VT@
M=VED=&@]
T0V


Q-C`[/]F;VYT/B`@(`-B`@(`@(`@(`@(`@
M(`@(`@/]T9#X@(`T*(`@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
M,T1R:6=H=!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q)2!S='EL93TS1=0
M041$24Y'+4)/5%1/33H@-'!X)SX@(`@(`T*(`@(`@(`@(`@(`@(`@

M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^(`@(`T*(`@(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@
M(`@(`@(`@(`@(`@(#QT9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q

M15A4+4%

M(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$


M(')I9VAT)SX@(`-B`@(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL

30W+#4Y-SPO9F]N=#X@#0H@(`@
M(`@(`@(`@(`@(`@(#PO=&0^(`-B`@(`@(`@(`@(`@(`@(`@

24=..B!L969T.R!0041$24Y'+4)/5%1/33H@

M/3-$)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`@(`T*(`@
M(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`\

M4D=)3BU

'!T)R!A;&EG;CTS1&IU

M
C`L

S$L(#(P
M








3(@36]N=&AS($5N9&5D/]T:#X-B`@

M/D1E8RX@
S$L(#(P
3



]




M($9/3E0M4TE:13H@

M


M+49!34E
63H@=&EM97

M3E0M4TE:13H@

T1B;W1T;VT@=VED=&@]

T0G4$%$




05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@

M(#

T1B;W1T
M;VT@=VED=&@]





05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T.R!-

Q+`R,#$R/]F
M;VYT/B`@(`@#0H@(`@(`@(`@(`@(`@(`@(#PO9&EV/B`@(`T*(`@

T1B;W1T;VT@=VED=&@]
T0Q

M(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

M4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5U325I%.B`Q


Q-C`[/]F;VYT/B`-B`@

B!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q
B4^
M(`@(`T*(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-0

M3E0M4TE:13H@


05DZ(&EN;&EN
M93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
M

M(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT


Q-C`[/]F;VYT/B`-B`@(`@(`@(`@(`@

M/3-$
B!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q
B4^(`@(`T*(`@(`@
M(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[

3!P

6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`-B`@(`@(`@
M(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`\+W1R/B`@



M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU

M3BU224=(5#H@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E
63H@=&EM97



M9'1H/3-$


M;&4]
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W

M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$


M;&4]
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W

34X/]F;VYT/B`@#0H@(`@
M(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\



05DZ(&EN;&EN93L@1D].5U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
M
#L\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@
M(`@(`@(`@(`@(`@(#QT9!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O

M;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@
M(`@(`@(#QT9!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1=415A4+4%
24=..B!L969T)SX@#0H@(`@(`@(`@(`@(`@(`@(#QF

05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXD/]F;VYT/B`@(`T*
M(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@
M(`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1=4
M15A4+4%


05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXR+#$U.#PO9F]N=#X@
M(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@

24=..B!L969T)SX@(`T*(`@(`@




05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@

M4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5U325I%.B`Q
'!T)SY!8V-U;75L871E9!$97!R96-I871I;VX\+V9O
M;G0^(`@#0H@(`@(`@(`@(`@(`@(`@(#PO9&EV/B`@(`T*(`@(`@
M(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D


M;&4]


M=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE






M($9/3E0M4TE:13H@

M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T


M/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@

M(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI

M





M:6=N/3-$8F]T=&]M('=I9'1H/3-$


M;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`-B`@(`@
M(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT

M05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5U325I%.B`Q

M
2PP-SD\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-
MB`@(`@(`@(`@(`@(`@(#QT9!N;W=R87`]
T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$


05DZ(&EN;&EN93L@1D].5U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\
M+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@
M(`@(`@(`@(`@(#QT9!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O


Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@
M(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$

T0G0D]21$52+4)/5%1/33H@8FQA


3!P


M/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@



M(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@


05DZ(&EN;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5U325I%.B`Q
'!T)SY$97!R96-I871I;VX@97AP96YS
M92!A;6]U;G1E9!T;R`D-#,R(&%N9`D-#

@96YD
M960@1&5C96UB97(@
S$L(#(P
3
@86YD(#(P





M+2TM+2TM/5].97AT4&%R=%]D-3`X
C5C
E\Q938R7S1C
39?.6%C8E]F
60S






M/DY/5$4@-BX@4U1/0TM(3TQ$15)3)R!%455)5%D@*$1%1DE#245.0UDI/&)R


]
T1T:#Y$96
N(#




T1T;W`^4W1O8VMH;VQD


T0G1$E34$Q!63H@:6YL:6YE.R!4

38P.R8C
38P

T0G1$E34$Q!63H@:6YL:6YE.R!415A4

X
C$W.R!%
M455)5%D@*$1%1DE#245.0UDI/]F;VYT/CPO9F]N=#X@(`@#0H@(`@(`@


05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
M63H@5&EM97






05DZ(&EN;&EN93L@1D].5U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q

C`P-R`H:6YC97!T:6]N*2!A;F0@

3$L(#(P


S`L



05DZ(&EN;&EN93L@
M1D].5U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q
'!T
M)SY!=!V87)I;W5S(&1A=&5S(&EN(#(P,3`L($%65P@3$Q#(&5N=&5R960@

@86-C

@
2PT
S
L
S
Y

M(%1H92!S:&%R97

3$L(#(P
3$N



@)#$L.#0U+#4P


@:6YC

M('1H92!S=&%T96UE;G1S(&]F(&]P97)A=&EO;G
@9F]R('1H92!P97)I;V0@

Q
M+`R,#$S+B8C,38P.R8C,38P.T]F('1H92!T;W1A;!N=6UB97(@;V8@8V]M

#`P+#`P




M8VL[($U!4D=)3BU



M-S


S(Y+#4P

PP,#`@87-S;V-I871E9!W:71H

#DL-3`P+B8C
38P.R8C





M=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE



24=..B!J=7-T:69Y.R!415A4+4E.
M1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@

M=R!2;VUA;CL@1D].5U325I%.B`Q,'!T)SY!=!V87)I;W5S(&1A=&5S(&EN
M(#(P
3


24=..B!J
M=7-T:69Y.R!415A4+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%2


@;V8@8V]M;6]N


M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#4P.#(U8S)?
64V
E\T8S$V7SEA8V)?
M9C%D


M/@T*(`\:&5A9#X-B`@(`\345402!H='1P+65Q=6EV/3-$0V]N=&5N=U4







@4$%9
M04)

3XQ
B!-;VYT:'

M
2P@
C`Q

]



]
T1P;!V86QI9VX],T1T;W`^1&5B=!$:7-C;&]S


T0G1$E34$Q!

M+B8C
38P.R8C
38P.R8C
38P.SPO9F]N=#X\9F]N=!S='EL93TS1=$25-0
M3$%9.B!I;FQI;F4[(%1%6%0M1$5#3U)!5$E/3CH@=6YD97)L:6YE)SY.3U1%
M4R!005E!0DQ%/]F;VYT/CPO9F]N=#X@(`-B`@(`@(`@(`\+V1I=CX\


M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU

M($U!4D=)3BU224=(5#H@
'!T)SX@(`@#0H@(`@(`@(`@(`\9F]N=!S

M5!A9'9A;F-E9`D
RPR

C0L(#(P


@;V8@1&5C96UB97(@
M
S$L(#(P
3
@86YD(#(P
3(@86YD(&ES(&EN8VQU9&5D(&EN(&YO=&5S('!A

X

@;VX@=&AE(&-O;G-O;&ED



T0G5$58

M8FQO8VL[($U!4D=)3BU

'!T)SX@




M=&5D(&)Y('1H92!P871E;G1S(&ED96YT:69I960@:6X@=&AE(%!R;W-T86=E

Q-C`[)B


M97

38P.R8C







M/3-$)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5U325I%.B`Q


3(U+#`P

X
C(P.U1I=V%R
M:28C.#(R

C`[
M0F%N97)J964F(S@R




05DZ(&EN;&EN93L@1D].5U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5U325I%.B`Q

6UE;G0@86=R965M96YT('=I=&@@
M=&AE(&5S=&%T92!O9B!$86YI96P@36EL;&5R+B!!;&P@;V8@=&AE(&YO=&5S
M(&%R92!D=64@;VX@9&5M86YD(&%N9!A<F4@;F]N+6EN=&5R97-T(&)E87)I

38P.R8C




05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@5&EM
M97

X
M
C$W.W

M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9#4P.#(U8S)?
64V
E\T8S$V7SEA8V)?
M9C%D

O4VAE970Q-2YH=&UL#0I#;VYT96YT





M;R!.;W0@4F5M;W9E(%1H:7

]


]
T1T:#Y$96
N(#
Q




24=..B!J=7-T
M:69Y.R!415A4+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.


05DZ(&EN;&EN93L@1D].5U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q
'!T)SX\9F]N=!S='EL
M93TS1=$25-03$%9.B!I;FQI;F4[(%1%6%0M1$5#3U)!5$E/3CH@=6YD97)L
M:6YE)SY.3U1%(#@N)B
Q-C`[)B
Q-C`[)B

24=..B!J=7-T:69Y.R!415A4+4E.1$5.5#H@
'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))

M1D].5U325I%.B`Q,'!T)SY4:')O=6=H($1E8V5M8F5R(#,Q+`R
#$S(&%N




C`S
RX@4V5C=&EO;B`S.#(@;V8@=&AE($EN

M;G


@82!C:&%N9V4@
M:6X@;W=N97)S:&EP+!S=6-H(&-H86YG92!C;W5L9!S:6=N:69I8V%N=&QY




M4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5U325I%.B`Q



T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM
M97

38P.SPO9F]N=#X@
M(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@

M/3-$





G!X
M)SX@(`@(`T*(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$

M($9/3E0M4TE:13H@
3!P=#L@1D].5U714E'2%0Z(&)O;&0G/B8C,38P.SPO
M9F]N=#X@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@
M(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

M;&4]

M4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5U325I%.B`Q




M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SX\9F]N=!S





M9VX]
T1B;W1T;VT@=VED=&@]
T0T-R4^(`@(`-B`@(`@(`@(`@(`@
M(`@(`@/&1I=B!S='EL93TS1=415A4+4E.1$5.5#H@
'!T.R!$25-03$%9


M(`@(`@(#QT9!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^(`@(`T*(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS

Q-C`[/]F;VYT/B`@#0H@(`@(`@
M(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@
M86QI9VX]
T1L969T(&-O;'-P86X]
T0R('9A;&EG;CTS1&)O='1O;2!W:61T

T1L969T/B`@(`T*



T1B;W1T;VT@=VED=&@]
T0Q)3X@(`@#0H@(`@



M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU

M24=(5#H@
'!T)R!A;&EG;CTS1&QE9G0^(`@#0H@(`@(`@(`@(`@(`@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E
63H@=&EM97

38P
M.SPO9F]N=#X@(`@#0H@(`@(`@(`@(`@(`@(`@(#PO9&EV/B`@(`T*
M(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@

T1B;W1T;VT@=VED=&@]
M
T0Q)2!S='EL93TS1=415A4+4%,24=..B!L969T)SX@(`T*(`@(`@(`@
M(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/




M


M;VYT/B`-B`@(`@(`@(`@(`@(`@(`@/]D:78^(`@#0H@(`@(`@
M(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@
M86QI9VX]
T1R:6=H=!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@(`@

Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@
M(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$



T1B;W1T
M;VT@=VED=&@]
T0Q



M4TE:13H@




T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&

38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@
M(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D('9A;&EG


M(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`-

M(`@(`@(`@/'1D(&%L:6=N/3-$;&5F=!V86QI9VX]
T1B;W1T;VT@=VED
M=&@]


M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU

M3BU224=(5#H@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E
63H@=&EM97

M
38P.R8C
38P.U-T871E/]F;VYT/B`@(`-B`@(`@(`@(`@(`@(`@
M(`@/]D:78^(`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@
M(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
T1R:6=H=!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1=0041$24Y'+4)/5%1/33H@
G!X

T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&

38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@
M(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D('9A;&EG





M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T


M/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@
M(`@(`@(`\=&0@86QI9VX],T1R:6=H=!V86QI9VX]
T1B;W1T;VT@=VED
M=&@]




05DZ(&EN;&EN93L@1D].5U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
M
#L\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@
M(`@(`@(`@(`@(`@(#QT9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q
M

T0G0D]21$52+4)/5%1/33H@8FQA8VL@
G!X('-O;&ED.R!4
M15A4+4%


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@
M=&EM97





Q-C`[/]F;VYT/B`@#0H@(`@
M(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@/]T

M86QI9VX]


05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T.R!-


05DZ(&EN;&EN93L@
M1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T

M(`@(`@(`@(`@(`@/]D:78^(`@#0H@(`@(`@(`@(`@(`@(`\
M+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
T1R:6=H

M)B
Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@
M#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$


M)B
Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@
M#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$

T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P




M4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`-B`@(`@(`@(`@
M(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!A;&EG

M=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1=415A4+4%
24=..B!L969T)SX@#0H@

05DZ(&EN
M;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%
M.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO
M=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!V86QI9VX]
T1B;W1T
M;VT@=VED=&@]
T0Q



M4TE:13H@



M(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(#PO
M='(^(`@#0H@(`@(`@(`@(`@(`@/'1R/B`@#0H@(`@(`@(`@(`@
M(`@(`\=&0@86QI9VX]
T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS


05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@

05DZ
M(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U3
M25I%.B`Q

M(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^(`T*(`@(`@(`@(`@(`@(`@(`\
M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T


M/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@

M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T


M/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@


T1B;W1T
M;VT@=VED=&@]
T0Q)2!S='EL93TS1=415A4+4%,24=..B!L969T)SX@(`T*
M(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I

M13H@

M+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`-B`@(`@(`@(`@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E
63H@=&EM97

M
38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*
M(`@(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS



M;W(Z(-#0T5%1D8[)SX@(`T*(`@(`@(`@(`@(`@(`@/'1D(&%L:6=N
M/3-$;&5F=!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0T-R4^(`@(`-B`@
M(`@(`@(`@(`@(`@(`@/&1I=B!S='EL93TS1=415A4+4E.1$5.5#H@
M
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.


Q
M-C`[)B
Q-C`[1F5D97)A;#PO9F]N=#X@#0H@(`@(`@(`@(`@(`@(`@

M=&]M('=I9'1H/3-$


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM
M97

38P.SPO9F]N=#X@
M(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@
M(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS


24=..B!L969T)SX@

M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`@#0H@(`@(`@(`@

MB`@(`@(`@(`@(`@(`@(#QT9!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1=415A4+4%

05DZ(&EN;&EN93L@1D].
M5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF
M(S$V
#L\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-
MB`@(`@(`@(`@(`@(`@(#QT9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
M
T0Q



3!P

6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5U325I%.B`Q,'!T)SXI/]F;VYT/B`@(`T*(`@(`@(`@
M(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(#PO='(^(`@
M#0H@(`@(`@(`@(`@(`@/'1R/B`@#0H@(`@(`@(`@(`@(`@(`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0W)2!S
M='EL93TS1=0041$24Y'+4)/5%1/33H@

M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T



M(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI

M



M=#X@(`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@



M(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@
M(#QT9!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E

M)B
Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@
M#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$

T0G0D]21$52+4)/5%1/33H@8FQA8VL@
G!X('-O;&ED
M.R!415A4+4%
24=..B!L969T)SX@(`-B`@(`@(`@(`@(`@(`@(`@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@
M=&EM97

38P.SPO9F]N
M=#X@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@
M(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL












M9VX]



M13H@




S-RPS
#8\


M('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXI/]F;VYT/B`@
M(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@

M/3-$




M(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-



M;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXH,3(V+#,S,CPO9F]N
M=#X@(`@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@

24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@
G!X)SX@(`-B`@(`@(`@(`@(`@(`@(`@/&9O

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM
M97


M


M(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI
M9VX]
T1R:6=H=!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@(`@(`T*

Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\
M+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$



Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\
M+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$


T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4


6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXI/]F;VYT/B`@
M(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@

M/3-$

M
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O

38P.SPO9F]N=#X@(`T*(`@(`@
M(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D

M=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXH,3(V+#,S,CPO9F]N=#X@(`@
M(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@

24=..B!L969T)SX@(`T*(`@(`@



05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T

05DZ(&EN;&EN
M93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
M
'!T)SY686QU871I;VX@86QL;W=A;F-E/]F;VYT/B`@(`T*(`@(`@(`@
M(`@(`@(`@(`\+V1I=CX@(`-B`@(`@(`@(`@(`@(`@(#PO=&0^
M(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!A;&EG;CTS1')I9VAT('9A



Q-C`[/]F;VYT/B`@#0H@(`@
M(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@
G!X('-O;&ED.R!415A4+4%
24=..B!L969T)SX@

T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4

38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@(`@
M(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1=3U)$15(M0D]45$]-.B!B

M(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI

M



3!P

M(`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX],T1R:6=H=!V86QI
M9VX]
T1B;W1T;VT@=VED=&@]



05DZ
M(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U3
M25I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@
M(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!V86QI9VX]
T1B
M;W1T;VT@=VED=&@]
T0Q

T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@
G!X('-O;&ED.R!415A4+4%

T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P

S(\+V9O;G0^(`@(`T*(`@(`@(`@(`@(`@(`@/]T

T1B;W1T;VT@=VED=&@]

M/'1R/B`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#0W)2!S='EL93TS1=0041$24Y'+4)/
M5%1/33H@-'!X)SX@(`-B`@(`@(`@(`@(`@(`@(`@/&1I=B!S='EL
M93TS1=415A4+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.


M(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!A


Q-C`[
M/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@
M(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
24@

T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$58

M=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE




M(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI

M

M/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX],T1R:6=H=!V
M86QI9VX]
T1B;W1T;VT@=VED=&@]




24=..B!L969T

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
M63H@=&EM97

38P.SPO
M9F]N=#X@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@
M(`@(`@(`@(#PO='(^(`@#0H@(`@(`@(`@(`@(#PO=&%B;&4^/&)R

05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@




T0G1D].5U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T.R!&3TY4+5-)6D4Z




M(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
M,T1R:6=H=!V86QI9VX]
T1B;W1T;VT@=VED=&@]




M8V5M8F5R(#
Q+`R,#$S/]F;VYT/CPO9F]N=#X@(`@#0H@(`@(`@(`@
M(`@(`@(`@(#PO9&EV/B`@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@

M86QI9VX]
T1B;W1T;VT@=VED=&@]


05DZ(&EN;&EN93L@
M1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T

24=.


T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E
63H@=&EM97

M($9/3E0M5T5)1TA4.B!B;VQD)SXF(S$V
#L\+V9O;G0^(`T*(`@(`@(`@
M(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D(&-O
M;'-P86X]
T0R('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS


'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P

M
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O

05DZ
M(&EN;&EN93L@1D].5U714E'2%0Z(&)O;&0G/D1E8V5M8F5R(#,Q+`R
#$R
M/]F;VYT/CPO9F]N=#X@(`@#0H@(`@(`@(`@(`@(`@(`@(#PO9&EV

24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@
G!X)SX@(`-B`@(`@(`@(`@(`@(`@(`@/&9O;G0@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@

38P.SPO9F]N=#X@(`T*


M(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI

M


M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
24^(`@(`-B`@(`@(`@(`@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E
63H@=&EM97

M
38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*
M(`@(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS

6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5U325I%.B`Q,'!T)SXI)3PO9F]N=#X@(`@#0H@(`@(`@(`@
M(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI
M9VX],T1R:6=H=!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q)3X@(`@(`T*
M(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I

M13H@



M13H@


#PO9F]N=#X@(`-B`@(`@(`@(`@(`@
M(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!N;W=R87`]
M
T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

T0G


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM
M97


M(`@(`@(`@/'1D(&%L:6=N/3-$;&5F=!V86QI9VX]
T1B;W1T;VT@=VED
M=&@]


M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU

M3BU224=(5#H@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E
63H@=&EM97




Q
M-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@
M(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M

T0G0D]21$52+4)/5%1/33H@8FQA8VL@
G!X('-O;&ED.R!4
M15A4+4%
24=..B!L969T)SX@(`-B`@(`@(`@(`@(`@(`@(`@/&9O

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM
M97

38P.SPO9F]N=#X@
M(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@
M(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS





24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M

T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N

M
T1R:6=H=!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1=0
M041$24Y'+4)/5%1/33H@
G!X)SX@(`-B`@(`@(`@(`@(`@(`@(`@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@
M=&EM97

38P.SPO9F]N


M;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`-B`@(`@
M(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT


SPO9F]N=#X@(`-B`@(`@(`@(`@
M(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!N;W=R
M87`]
T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

M


05DZ
M(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U3
M25I%.B`Q
'!T)SXI/]F;VYT/B`@(`T*(`@(`@(`@(`@(`@(`@/]T
M9#X@(`@(`T*(`@(`@(`@(`@(`@(#PO='(^(`@#0H@(`@(`@(`@

M9VX]
T1B;W1T;VT@=VED=&@]
T0T-R4^(`@(`-B`@(`@(`@(`@(`@
M(`@(`@/&1I=B!S='EL93TS1=415A4+4E.1$5.5#H@
'!T.R!$25-03$%9



M:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$


T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E
63H@=&EM97

M/B8C
38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@
M(`T*(`@(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T


6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5U325I%.B`Q,'!T)SXI/]F;VYT/B`@(`T*(`@(`@(`@
M(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D(&%L

24^(`@(`-

T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4+5-)

38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@(`@(`@
M/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O


M5U325I%.B`Q,'!T)SXH-#0N,3,\+V9O;G0^(`@#0H@(`@(`@(`@(`@
6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXI/]F;VYT/B`@(`T*
M(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@
M(#PO='(^(`@#0H@(`@(`@(`@(`@(`@/'1R/B`@#0H@(`@(`@(`@
M(`@(`@(`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#0W)2!S='EL93TS1=0041$24Y'+4)/5%1/33H@
G!X)SX@(`-B`@



M(`@/]D:78^(`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@
M(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
T1R:6=H=!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1=0041$24Y'+4)/5%1/33H@
G!X

T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&

38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@
M(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D('9A;&EG






M;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@
M(`@(`@(`@(`\=&0@86QI9VX],T1R:6=H=!V86QI9VX]
T1B;W1T;VT@
M=VED=&@]
T0Q)2!S='EL93TS1=0041$24Y'+4)/5%1/33H@,G!X)SX@(`-


05DZ(&EN;&EN93L@1D].
M5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF
M(S$V
#L\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-
MB`@(`@(`@(`@(`@(`@(#QT9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
M
T0Q

T0G0D]21$52+4)/5%1/33H@8FQA8VL@
G!X('-O;&ED
M.R!415A4+4%

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
M63H@=&EM97




Q-C`[/]F;VYT/B`@
M#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@

T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0W
M)2!S='EL93TS1=0041$24Y'+4)/5%1/33H@-'!X)SX@(`-B`@(`@(`@
M(`@(`@(`@(`@/&1I=B!S='EL93TS1=415A4+4E.1$5.5#H@
'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4





M4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`-B`@(`@(`@(`@
M(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!V86QI
M9VX]
T1B;W1T;VT@=VED=&@]
T0Q)2!S='EL93TS1=3U)$15(M0D]45$]-





T1B
M;W1T;VT@=VED=&@]

M#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@
M(`@(`\=&0@86QI9VX],T1R:6=H=!V86QI9VX]
T1B;W1T;VT@=VED=&@]
M
T0Q)2!S='EL93TS1=0041$24Y'+4)/5%1/33H@-'!X)SX@(`-B`@(`@

!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`@(`-B`@(`@(`@(`@(`@
M(`@(`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@






T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E
63H@5&EM97








M;VX@:7


X
C$W.W
@:&ES




M=!B92!R96%L:7IE9!A;F0@87


M:6YG/3-$




M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@


M4TE:13H@
!S;VQI9#L@5$585U!3$E'3CH@8V5N=&5R


M3E0M4TE:13H@

S$L(#(P
3
\+V9O;G0^




M



M(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/


S$L(#(P
3(\+V9O;G0^/]F;VYT/B`@(`-B`@
M(`@(`@(`@(`@(`@(`@/]D:78^(`@#0H@(`@(`@(`@(`@(`@




T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P

38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@
M(`@(`T*(`@(`@(`@(`@(`@(`@/'1D(&-O;'-P86X]
T0R('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@(`@#0H@(`@(`@(`@(`@(`@

M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@



T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@

38P.SPO9F]N=#X@(`T*
M(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@
M(`@/'1D(&-O;'-P86X]
T0R('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R

M1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`-B`@(`@(`@(`@



T1B;W1T;VT@=VED=&@]
M
T0T-R4^(`@(`-B`@(`@(`@(`@(`@(`@(`@/&1I=B!S='EL93TS
M1=415A4+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%

M/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`@(#PO9&EV/B`@(`T*(`@

T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&

38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@
M(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D('9A;&EG



24=..B!L969T)SX@(`T*(`@(`@(`@(`@(`@(`@
M(`F(S$V,#L@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@
M(`@(`@(`@(`@(`\=&0@86QI9VX]

Q-C`[/]F;VYT/B`@
M#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@
M(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

T0G

M(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@
M(#QT9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q

T0G5$58

M=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE



M(`@(`@(`@(`@(`@(8C
38P.R`-B`@(`@(`@(`@(`@(`@(#PO

T1B;W1T;VT@=VED=&@]
T0T-R4^(`@(`-B`@(`@
M(`@(`@(`@(`@(`@/&1I=B!S='EL93TS1=415A4+4E.1$5.5#H@
'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))


M:6=N/3-$8F]T=&]M('=I9'1H/3-$



T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E
63H@=&EM97

38P
M.SPO9F]N=#X@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@
M(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q

6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B`@#0H@(`@(`@(`@(`@(`@(`@(8C
38P.R`-B`@(`@(`@
M(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!A
M;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`@

05DZ
M(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U3
M25I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@
M(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!V86QI9VX]
T1B
M;W1T;VT@=VED=&@]



L

T1B;W1T;VT@=VED=&@]
T0Q)2!S='EL93TS
M1=415A4+4%,24=..B!L969T)SX@(`T*(`@(`@(`@(`@(`@(`@(`F
M(S$V

M

M(`@(`@(`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#0W)2!S='EL93TS1=0041$24Y'+4)/5%1/33H@
G!X)SX@(`-B`@




M13H@




T1B;W1T
M;VT@=VED=&@]

05DZ(&EN;&EN
M93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
M
'!T)SXF(S$V
#L\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^
M(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!V86QI9VX]
T1B;W1T;VT@
M=VED=&@]


Q-C`[
M/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@
M(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
3$E



05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXM/]F;VYT/B`@(`T*
M(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@

T1B;W1T;VT@=VED=&@]
M

M(`@#0H@(`@(`@(`@(`@(`@/'1R/B`@#0H@(`@(`@(`@(`@(`@
M(`\=&0@86QI9VX]
T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0W


05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M


05DZ(&EN
M;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%
M.B`Q

T1R:6=H=!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X@(`@(`T*(`@(`@(`@(`@

Q
M-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@
M(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M



Q
M-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@
M(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M


T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E
63H@=&EM97

M/C8U
RPU-C@\+V9O;G0^(`@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@

M86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q)2!S='EL93TS1=415A4+4%,24=.
M.B!L969T)SX@(`T*(`@(`@(`@(`@(`@(`@(`F(S$V
#L@#0H@(`@
M(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\
M=&0@86QI9VX],T1R:6=H=!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q)3X@
M(`@(`T*(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-0

M3E0M4TE:13H@




M3E0M4TE:13H@


M(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D

24=..B!L969T)SX@(`T*(`@(`@(`@(`@(`@
M(`@(`F(S$V,#L@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@

T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#0W)2!S='EL93TS1=0041$24Y'+4)/5%1/33H@,G!X)SX@
M(`-B`@(`@(`@(`@(`@(`@(`@/&1I=B!S='EL93TS1=415A4+4E.
M1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@


M(`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX],T1R:6=H=!V86QI
M9VX]
T1B;W1T;VT@=VED=&@]



05DZ
M(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U3
M25I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@
M(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!V86QI9VX]
T1B
M;W1T;VT@=VED=&@]
T0Q

T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@
G!X('-O;&ED.R!415A4+4%

T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P

L-38X/]F;VYT/B`@(`@#0H@(`@(`@(`@(`@(`@(`\


3!P



M($9/3E0M4TE:13H@


M*#
Q-BPR-C$\+V9O;G0^(`@(`-B`@(`@(`@(`@(`@(`@(#PO=&0^





M13H@


M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$


M=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`-B`@
M(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@

M4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5U325I%.B`Q
'!T)SXD/]F;VYT/B`@(`T*(`@(`@(`@(`@(`@


T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$


05DZ(&EN;&EN93L@1D].5U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\
M+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@
M(`@(`@(`@(`@(#QT9!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O


Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@
M(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$

T0G0D]21$52+4)/5%1/33H@8FQA


3!P














]
T1T:#Y$96
N(#
Q



]
M

24=..B!J=7-T:69Y.R!415A4+4E.1$5.5#H@
'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4

05DZ
M(&EN;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U3
M25I%.B`Q
'!T)SX\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[(%1%
M6%0M1$5#3U)!5$E/3CH@=6YD97)L:6YE)SY.3U1%(#DN)B
Q-C`[)B
Q-C`[
M)B
Q-C`[4D5
051%1!005)462!44D%.4T%#5$E/3E,\+V9O;G0^/]F;VYT


M

3$

24=..B!J=7-T:69Y.R!415A4+4E.
M1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@



M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU

M($U!4D=)3BU224=(5#H@
'!T)SX@(`@#0H@(`@(`@(`@(`\9F]N=!S

@


C`Q
BXF(S$V
M
#LF(S$V

M9&5D($1E8V5M8F5R(#
Q+`R,#$S(&%N9`R

30L-#`P(&EN

2P@
C`Q
RX\+V9O;G0^


M#0H@(`@(`@(`@(`\9F]N=!S='EL93TS1=&3TY4+5-464Q%.B!I=&%L
M:6
[($1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5U325I%.B`Q


M

M4$Q!63H@8FQO8VL[($U!4D=)3BU

M

C`Q





Q-C`[)B
Q-C`[5&AE


2P@
C`Q





C`Q-XF(S$V,#LF
M(S$V,#L\9F]N=!S='EL93TS1=04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F
M.R!$25-03$%9.B!I;FQI;F4G/D]N($9E8G)U87)Y(#4L(#(P
30L($UR+B!#


13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[($9/



M24=..B!J=7-T:69Y.R!415A4+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C



S(U+#`P







#`@:6XF(S$V
#LF(S$V
#MS:&%R97
@:7-S=6%B;&4@;VX@
M=&AE(&-O;G-O;&ED871E9!B86QA;F-E('-H965T(&%S(&]F($1E8V5M8F5R
M(#,Q+`R


M(&]F(&]P97)A=&EO;G
N(%1H92!S:&%R97



M/3-$)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5U325I%.B`Q


M=F5S=&5D(0U,PP
#`@:6X@=&AE(%!R:79A=&4@4&QA8V5M96YT(&%N9!R
M96-E:79E9`R-3`L


05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@


M3$Q#/]F;VYT/B`@(`@#0H@(`@(`@(`@/]D:78^/&)R+SX\9&EV('-T

M($1)4U!
05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T.R!-05)'24XM4DE'

T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@5&EM97
@3F5W(%)O;6%N.R!&



@:71S(&YO;BUE

M)B
Q-C`[)B


M87-E('!R:6-E(&]F('-E8W5R:71I97





38P.R8C
38P.U1H92!A9W)E96UE;G0@

RP@






38P.R8C
38P.T]F




#$S
M+B8C
38P.R8C




'0O:'1M





3XQ
B!-;VYT:'


2P@
C`Q
M

]

]
T1T


24=..B!J=7-T:69Y.R!415A4+4E.
M1$5.5#H@

M;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q,'!T)SX\9F]N=!S='EL93TS
M1=$25-03$%9.B!I;FQI;F4[(%1%6%0M1$5#3U)!5$E/3CH@=6YD97)L:6YE
M)SY.3U1%(#$P+B8C,38P.R8C,38P.R8C,38P.T-/34U)5$U%3E13($%.1!#
M3TY424Y'14Y#2453/]F;VYT/CPO9F]N=#X@(`-B`@(`@(`@(`\+V1I


1494.B`P




M($UA;F%G96UE;G0@8F5L:65V97



24=..B!J=7-T:69Y.R!415A4+4E.1$5.5#H@
'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))


M(&]F($YE=R!9;W)K+!A;&QE9VEN9R!A(&)R96%C:!O9B!A(&-O;G-U;'1I



3`L
M
#`P+#`P






M9G

M86YD+B8C
38P.R8C
38P.U1O(&1A=&4L(`@(`-B`@(`@(`@(`@('1H

M+B8C
38P.R8C


@87
@:70@:7
@=6YA8FQE



N/]F;VYT/B`@(`-B`@(`@(`@(`\+V1I


1494.B`P




05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@5&EM97
@

@
M
C`P-R!T:')O=6=H(#(P
3
L('1H92!#;VUP86YY(&-O;G-I9&5R960@8V5R


#L@268@=&AE(&5X96-U
M=&EV97



M=!I;B!A;B!U;F9A=F]R86)L92!O=71C;VUE(&EF(&ET(&ES(&1E=&5R;6EN
M960@=&AA=!S=6-H(&EN9&EV:61U86QS)B
X
C$W.R!C;VUP96YS871I;VX@

PS.3(@86YD(0X+#8P
!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M
M8F5R(#,Q+`R

C`P-R`H:6YC97!T

2P@
C`Q



M=&AO=70@;65R:70N($%S(&]F($1E8V5M8F5R(#
Q+`R,#$S+`D(#$X
BPV
M
3@@:7



1494

'!T)SX@(`@#0H@(`@(`@(`@(`\
M9F]N=!S='EL93TS1=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN
M;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%
M.B`Q,'!T)SY%;7!L;WEE92!!9W)E96UE;G1S/]F;VYT/B`@(`T*(`@(`@

24=..B!J=7-T
M:69Y.R!415A4+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.


M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q,'!T)SY/;B!/8W1O
M8F5R(#$T+`R
#$S('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(&-O;G-U

M(&)E('1H92!#;VUP86YY)B
X
C$W.W
@0VAI968@17AE8W5T:79E($]F9FEC
M97(@9F]R(&$@=&5R;2!O9B`T('EE87)S+B8C
38P.R8C
38P.U1H92!A9W)E
M96UE;G0@=V%S(&5F9F5C=&EV92!O;B!*=6QY(#$L(#(P
3
N(%1H92!#;VUP




M96YS92!O9B`D
S8L



M($U!4D=)3BU



M($-O;7!A;GDF(S@R

M(&$@=&5R;2!O9B`T('EE87)S+B8C
38P.R8C
38P.U1H92!A9W)E96UE;G0@
M=V%S(&5F9F5C=&EV92!O;B!*=6QY(#$L(#(P
3
N(%1H92!#;VUP86YY('-H





@
M;V8@)#DV+#`P
!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P
M,3,L(&]F('=H:6-H(0U-BPP


M;65N=!W87,@96YT97)E9!I;G1O+B8C
38P.R8C
38P.T]F('1H92!T;W1A



24=..B!J=7-T:69Y.R!415A4+4E.
M1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@

M=R!2;VUA;CL@1D].5U325I%.B`Q,'!T)SY/;B!/8W1O8F5R(#$T+`R
#$S

M96YT('=I=&@@1'(N($IA;B!'96QI96)T97(@=&\@8F4@=&AE($-O;7!A;GDF
M(S@R

38P
M.R8C
38P.U1H92!A9W)E96UE;G0@=V%S(&5F9F5C=&EV92!O;B!*=6QY(#$L
M(#(P
3



@

M97AP96YS97




M1V5L:65B=&5R)B
X
C$W.W

@;V8@)#4Y+#`P

M96YD960@1&5C96UB97(@
S$L(#(P
3
L('=H:6-H(')E;6%I;G
@:6X@86-C

2P@
C`Q


05DZ(&EN;&EN93L@
M1D].5U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q
'!T

M86YO('1O(&)E('1H92!#;VUP86YY)B
X
C$W.W
@3&%B($UA;F%G97(@9F]R
M(&$@=&5R;2!O9B`R('EE87)S+B8C
38P.R8C
38P.U1H92!A9W)E96UE;G0@
M=V%S(&5F9F5C=&EV92!O;B!*=6QY(#$L(#(P
3
N(%1H92!#;VUP86YY('-H

C0L

M;!I;F-R96UE;G1S(&YO=!L97-S(&9R97%U96YT;'D@=&AA;B!M;VYT:&QY
M('=I=&@@82!F:79E(@U*2!P97)C96YT(&%N;G5A;!I;F-R96%S92!P;'5S

M=6%L(&EN8W)E;65N='




M9R!A9W)E96UE;G0@86YD(&-O;6UE;F-E(&]N8V4@=&AE($-O;7!A;GD@:&%S
M(')A:7-E9`D,BXU(&UI;&QI;VX@=&AR;W5G:!A(&9I;F%N8VEN9RX@5&AE
M($-O;7!A;GD@:6YC=7)R960@97AP96YS97

2P@
C`Q
RP@;V8@
M=VAI8V@@(`@(`T*(`@(`@(`@(`@)#(R+#`P,!R96QA=&5D('1O('1H

#`P(')E

C`L
#`P
M(')E;6%I;G

2P@
M
C`Q
RX\+V9O;G0^(`@(`-B`@(`@(`@(`\+V1I=CX\8G(O/CQD:78@


M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU

M24=(5#H@

M($)A;F5R:F5E)B

@969F96-T:79E(&]N($IU;'D@
2P@
C`Q
M


M(&%N;G5M(&EN(&5Q=6%L(&EN8W)E;65N='



N


S4L




#LF(S$V









T0G5$58

M8FQO8VL[($U!4D=)3BU

'!T)SX@
M(`@#0H@(`@(`@(`@(`\9F]N=!S='EL93TS1=&3TY4+5-464Q%.B!I
M=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5U325I%.B`Q,'!T)SY4;W1A;$-&3RP@3$Q#/]F;VYT


05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@


T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E
63H@5&EM97
@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P

C`Q
RP@=&AE($-O;7!A;GD@96YG86=E





@:&%V:6YG(&$@9W)A;G0@9&%T92!F
M86ER('9A;'5E(0R+#4P,`H=&\@8F4@8V%L8W5L871E9!A=!A(#(U)2!D


S$L(#(P
3
L(&]F
M('=H:6-H(0Q,PP
#`@=V%S('!A:60@86YD(0Q,PP







M
38P.R8C
38P.U1H92!S:&%R97
@:&%V92!Y970@=&\@8F4@:7-S=65D(&1O






3$
@
3`P+#`P

M8F5R(#

#$T


M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T.R!-05)'24XM4DE'2%0Z(#!P




M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU

M24=(5#H@

30L(#(P
3(@=&AE($-O





M;B!C;VYN96-T:6]N('=I=&@@82!G;VEN9RUP=6)L:6
@=')A;G-A8W1I;VX@
M:6YV;VQV:6YG('1H92!#;VUP86YY+B8C
38P.R8C
38P.TEN($1E8V5M8F5R
M(&]F(#(P
3




2!H87,@9&5T97)M:6YE9!T:&%T('1H92!F86ER('9A


@

38Q+#`T
!I;B!C;VYS=6QT:6YG(&9E97,@;VX@=&AE(&-O;G-O;&ED
M871E9!S=&%T96UE;G1S(&]F(&]P97)A=&EO;G
@9F]R('1H92!Y96%R(&5N
M9&5D($1E8V5M8F5R(#


Q
M-C`[)B


M($1)4U!
05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T.R!-05)'24XM4DE'

T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@5&EM97
@3F5W(%)O;6%N.R!&


M:7`@82`D-C`L

#$T+B8C
38P.R8C
38P.U1H92!#;VUP86YY(&AA



M.#(U8S)?
64V
E\T8S$V7SEA8V)?9C%D
V4U83@Y-#8V#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T
Z+V0U
#@R-6
R7S%E-C)?-&
Q-E\Y86-B7V8Q





^+RH@1&\@


$5-

]
M


T1T




]


05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@

M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4



M
RPU-3`L

#MI;B!C;VYN
M96-T:6]N('=I=&@@=&AE)B

#MS:&%R97
@;V8@8V]M


@

@
M86YD(AD*2`Q+#8S,PR





@;V9F97)I


M;CL@1D].5U325I%.B`Q,'!T)SY/;B!-87)C:`Q
P@,C`Q-P@=&AE($-O



M





M
3`L(#(P

#$S('1O(AA*2!I
M;F-R96%S92!T:&4@86UO=6YT('1H92!#;VUP86YY(&ES(&]F9F5R:6YG('1O
M(0S+#4P
PP,#`@9G)O;2`D,BPU,#`L,#`P(&%N9`H8BD@=&\@861D(&$@



#LF(S$V
M




;V-A=&EO;CH@9FEL93HO+R]#.B]D-3`X
C5C
E\Q938R7S1C
M
39?.6%C8E]F



M@T*/&AT;6P^#0H@(#QH96%D/@T*(`@(#Q-151!(&AT='`M97%U:78]
T1#

]
T13:&]W



]







]

24=..B!J=7-T:69Y.R!415A4
M+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P

05DZ
M(&EN;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U3
M25I%.B`Q
'!T)SX\9F]N=!S='EL93TS1=&3TY4+5-464Q%.B!I=&%L:6
[
M($1)4U!








'0^)SQD:78@<W1Y;&4]
T0G5$58

M8FQO8VL[($U!4D=)3BU

'!T)SX\
M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4














]

]


M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T.R!-05)'24XM4DE'2%0Z(#!P






L('1H92!F86ER('9A;'5E(&]F
M('1H92!#;VUP86YY)B
X
C$W.W

M;G-A=&EO;BP@86YD('1H92!V86QU871I;VX@86QL;W=A;F-E(')E;&%T960@
M=&\@=&AE($-O;7!A;GDF(S@R






M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU

M4D=)3BU224=(5#H@
'!T)SX\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI

M

13H@:71A;&EC.R!$25-0

M('=I=&@@86X@;W)I9VEN86P@;6%T=7)I='D@;V8@=&AR964@;6]N=&AS(&]R

@=VAE;B!P=7)C:&%S960N)B
Q-C`[)B
Q-C`[070@1&5C96UB97(@
M
S$L(#(P
3
@86YD(#(P

]
'0@0FQO8VM=/]T9#X-
MB`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1=415A4
M+4%
24=..B!J=7-T:69Y.R!415A4+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B


05DZ(&EN;&EN93L@1D].5U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q
'!T)SX\9F]N=!S='EL93TS
M1=&3TY4+5-464Q%.B!I=&%L:6
[($1)4U!


M=')U;65N='


@=VAI8V@@;6ET

X
M
C(P.T9$24
F(S@R





1494.B`P

'!T)SX\9F]N=!S='EL93TS1=$25-03$%9

M4TE:13H@

13H@:71A;&EC


@8V]N



@


@:6YC



T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E
63H@5&EM97
@3F5W(%)O;6%N.R!&3TY4




L('=H:6-H(')A;F=E(&9R;VT@-2!T;R`W('EE87)S

]

M8VM=/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL


T0G






]

]
T1T


05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T

@9F]R('1H92!I;7!A







T1T
M;W`^4F5V96YU92!296-O9VYI=&EO;BP@4&]L:6-Y(%M0;VQI8WD@5&5X=!

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E
63H@5&EM97



@9FEX960@





M8V5M8F5R(#
Q+`R,#$S(&%N9`R


C0L(#(P

S$L
M(#(P
3
L('1H92`@(`-B`@(`@(`@(`@($-O;7!A;GD@9&ED(&YO=!R



1494





M9B!T:&4@=6YD96QI=F5R960@:71E;2X\+V9O;G0^/]D:78^/'-P86X^/]S


MB`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1=415A4
M+4%
24=..B!J=7-T:69Y.R!415A4+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B


05DZ(&EN;&EN93L@1D].5U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q
'!T)SX\9F]N=!S='EL93TS
M1=&3TY4+5-464Q%.B!I=&%L:6
[($1)4U!




M8VL@97%U:79A;&5N='
N($%S(&]F($1E8V5M8F5R(#
Q+`R,#$S+!A;F0@
M
C`Q


]

24=..B!J=7-T:69Y.R!415A4+4E.
M1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@

05DZ(&EN
M;&EN93L@1D].5U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%
M.B`Q
'!T)SX\9F]N=!S='EL93TS1=&3TY4+5-464Q%.B!I=&%L:6
[($1)
M4U!

M;65N='


L(&%C8W)U960@
M97AP96YS97




M13H@

M;F4@;V8@=&AE(&9O;&QO=VEN9R!T:')E92!C871E9V]R:65S.CPO9F]N=#X@


05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@




#L\+V9O;G0^(`@(`T*(`@(`@(`@(#PO9&EV/CQB


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@5&EM97
@


M97



M:6YA;F-I86P@:6YS=')U;65N='

M=F%B;&4@:6YP=71S+!S=6-H(&%S(&EN=&5R97-T(')A=&5S(&%N9!Y:65L



05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
3AP=#L@


SH@1FEN86YC:6%L


M9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=B!S='EL93TS1=4
M15A4+4%
24=..B!J=7-T:69Y.R!415A4+4E.1$5.5#H@
'!T.R!$25-03$%9


05DZ(&EN;&EN93L@1D].5U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5U325I%.B`Q
'!T)SX\9F]N=!S='EL
M93TS1=&3TY4+5-464Q%.B!I=&%L:6
[($1)4U!


@8F%S960@
M;VX@=&AE(&9A:7(@=F%L=64@;V8@=&AE(&%W87)D+B!&;W(@96UP;&]Y965S





















@:7
@






M(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/


TS,!C;&%R:69I97






M4T
@5&]P:6
@-S0P+3$P+30P('!R;W9I9&5S(&=U:61A;F-E(&]N(&1E+7)E







M


L(&%S(&1E9FEN960N



L



#M!4U4F(S@R
C$[*2!.;RX@
C`Q
RTQ
M

L(&]R


@5&%S:R!&;W)C92DN(%1H
M92!A;65N9&UE;G1S(&EN('1H:7
@05-5('-T871E('1H870@86X@=6YR96-O
!B96YE9FET+!O<B!A('!O<G1I;VX@;V8@86X@=6YR96-O
!B96YE9FET+!S:&]U;&0@8F4@<')E<V5N=&5D(&EN('1H


@8V%R




M8V%B;&4@:G5R:7-D:6-T:6]N(&1O97



N(%1H92!A;65N9&UE;G1S(&EN('1H:7
@05-5(&%R92!E9F9E





M;&EC871I;VX@:7





]





;V-A=&EO
M;CH@9FEL93HO+R]#.B]D-3`X
C5C
E\Q938R7S1C
39?.6%C8E]F
60S935A



]

T0Q
M(')O=W-P86X]


T0Q/C$R($UO

#$S/&)R/CPO=&@^#0H@












M(`@(`@(`@/'1D(&%L:6=N/3-$;&5F=!V86QI9VX]
T1M:61D;&4@=VED
M=&@]

T0G0D]21$52+4)/5%1/33H@8FQA8VL@
G!X('-O

M#0H@(`@(`@(`@(`@(`@/'1D(&%L:6=N/3-$;&5F=!V86QI9VX]
T1M
M:61D;&4@=VED=&@]

T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&

38P.SPO9F]N=#X@(`@(`T*(`@(`@(`@
M(`@(`@(#PO=&0^(`@#0H@(`@(`@(`@(`@(`@/'1D(&%L:6=N/3-$

'!T.R!$25-03$%9

M(&%L:6=N/3-$;&5F=#X@#0H@(`@(`@(`@(`@(`@(`@(#QF;VYT('-T

05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5U325I%.B`Q


M(T-#145&1CLG/B`@(`@#0H@(`@(`@(`@(`@(`@/'1D(&%L:6=N/3-$
M;&5F=!V86QI9VX],T1M:61D;&4@=VED=&@],T0R-24^(`@#0H@(`@(`@

M4U!
05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T.R!-05)'24XM4DE'2%0Z


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM
M97

M;6%N/]F;VYT/B`@(`-B`@(`@(`@(`@(`@(`@(#PO9&EV/B`-B`@
M(`@(`@(`@(`@(`\+W1D/B`@(`T*(`@(`@(`@(`@(`@(#QT9!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$
24^(`-B`@

'!T.R!$25-03$%9.B!B;&]C


M)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5U325I%.B`Q

M0VAI968@1FEN86YC:6%L($]F9FEC97(L($-H86ER;6%N/]F;VYT/B`@(`@

M=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$
C4E/B`@(`T*(`@(`@(`@(`@

M=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SY-;W)T;VX@0V]L96UA;CPO9F]N
M=#X@#0H@(`@(`@(`@(`@(`@(`\+V1I=CX@#0H@(`@(`@(`@(`@
M(`@/]T9#X@(`-B`@(`@(`@(`@(`@(`\=&0@86QI9VX]
T1L969T
M('9A;&EG;CTS1&UI9&1L92!W:61T:#TS1#$E/B`@#0H@(`@(`@(`@(`@
M(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-


M(`@(`@(`@(`\=&0@86QI9VX]
T1L969T('9A;&EG;CTS1&UI9&1L92!W


'!T)R!A;&EG;CTS1&QE9G0^(`T*

M(`@(`@/]D:78^(`T*(`@(`@(`@(`@(`@(#PO=&0^(`@#0H@(`@

T0G

T1M:61D;&4@=VED=&@]
M

T1L969T/B`-B`@(`@


M4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`@(`-B`@(`@(`@
M(`@(`@(`\+W1D/B`@(`T*(`@(`@(`@(`@(`@(#QT9!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$-#DE/B`@(`T*(`@(`@


M(`@(`@(`\+W1R/B`-B`@(`@(`@(`@(`@/'1R/B`@(`@#0H@(`@


05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@

T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4+5-)

MB`@(`@(`@(`@(`@(`\=&0@86QI9VX]
T1L969T('9A;&EG;CTS1&UI



M=&0@86QI9VX]
T1L969T('9A;&EG;CTS1&UI9&1L92!W:61T:#TS1#0Y)3X@

M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU

M4D=)3BU224=(5#H@
'!T)R!A;&EG;CTS1&QE9G0^(`T*(`@(`@(`@(`@





M;&4]


M4TE:13H@

T1L969T('9A;&EG
M;CTS1&UI9&1L92!W:61T:#TS1#$E/B`@#0H@(`@(`@(`@(`@(`@(`\
M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T


M/B`@(`@#0H@(`@(`@(`@(`@(`@/]T9#X@(`-B`@(`@(`@(`@
M(`@(`\=&0@86QI9VX]
T1L969T('9A;&EG;CTS1&UI9&1L92!W:61T:#TS

1494.B`P

'!T)R!A;&EG;CTS1&QE9G0^(`T*(`@(`@





T1M:61D;&4@
M=VED=&@]

T1L969T/B`-










M97

]
T1T:#Y$96
N(#
Q




M1#`@=VED=&@]

T0G1D].5U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5U325I%.B`Q



M;&4]
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W

38P.SPO9F]N=#X@(`@#0H@
M(`@(`@(`@(`@(`@(`@(#PO=&0^(`-B`@(`@(`@(`@(`@(`@



05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@

M4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5U325I%.B`Q

M=CX@(`@(`T*(`@(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@



3!P=#L@1D].5U714E'
M2%0Z(&)O;&0G/B8C,38P.SPO9F]N=#X@(`-B`@(`@(`@(`@(`@(`@


M4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5U325I%.B`Q


B!V86QI9VX]
T1B;W1T;VT@
M=VED=&@]
T0Q

T0G0D]21$52+4)/5%1/33H@8FQA8VL@
G!X

M;&4]

M9&EV/B`@(`@#0H@(`@(`@(`@(`@(`@(`@(#PO=&0^(`-B`@(`@

T1B
M;W1T;VT@=VED=&@]
T0Q)2!S='EL93TS1=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,G!X)SX@(`@(`T*(`@(`@(`@(`@(`@(`@

M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^(`@(`T*(`@(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@
M(`@(`@(`@(`@(`\+W1R/B`@(`@#0H@(`@(`@(`@(`@(`@(`\


MB`@(`@(`@(`@(`@(`@(`@/'1D(&%L:6=N/3-$;&5F=!V86QI9VX]
M
T1B;W1T;VT@=VED=&@]
T0T-R4^(`-B`@(`@(`@(`@(`@(`@(`@

M9VX]

M(`-B`@(`@(`@(`@(`@(`@(`@(`\+V1I=CX@(`@(`T*(`@(`@
M(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`@(#QT
M9!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@

M(`@(`@(#PO=&0^(`-B`@(`@(`@(`@(`@(`@(`@/'1D('9A;&EG


M;CL@1D].5U325I%.B`Q,'!T)SXD/]F;VYT/B`@(`@#0H@(`@(`@(`@
M(`@(`@(`@(#PO=&0^(`-B`@(`@(`@(`@(`@(`@(`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1=415A4+4%
24=.


C
P+#`P
#PO9F]N=#X@#0H@


T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P




M/3-$


T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P




M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T


M/B`@(`-B`@(`@(`@(`@(`@(`@(`@/]T9#X@(`T*(`@(`@(`@

M9VX]
T1B;W1T;VT@=VED=&@]



05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@

M86X[($9/3E0M4TE:13H@

M(`-B`@(`@(`@(`@(`@(`@(`@/]T9#X@(`T*(`@(`@(`@(`@
M(`@(`@(`\=&0@86QI9VX]
T1R:6=H=!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1=0041$24Y'+4)/5%1/33H@

05DZ
M(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U3
M25I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`@(`T*(`@(`@(`@(`@(`@

M(#PO=&0^(`-B`@(`@(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1=3U)$15(M0D]45$]-.B!B;&%C


T1R:6=H=!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1=0041$24Y'+4)/5%1/33H@
M

M/3-$)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`@(`T*(`@
M(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`@

M(`@(`@(`@(`@(#PO=&0^(`-B`@(`@(`@(`@(`@(`@(`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1=3U)$15(M









T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@
M=&EM97

M07-S971S+!N970\+V9O;G0^(`@#0H@(`@(`@(`@(`@(`@(`@(`@
M/]D:78^(`@(`-B`@(`@(`@(`@(`@(`@(`@/]T9#X@(`T*(`@
M(`@(`@(`@(`@(`@(`\=&0@86QI9VX],T1R:6=H=!V86QI9VX]
T1B
M;W1T;VT@=VED=&@]

M;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`@(`T*(`@(`@
M(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`@(#QT
M9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q)2!S='EL93TS1=3U)$15(M

24=..B!L969T)SX@

M8F]T=&]M('=I9'1H/3-$

30W+#4Y-SPO9F]N=#X@#0H@(`@(`@(`@(`@(`@(`@(#PO



05DZ(&EN;&EN
M93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
M
'!T)SXF(S$V
#L\+V9O;G0^(`@(`T*(`@(`@(`@(`@(`@(`@(`\





M(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`@(#QT
M9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q

T0G0D]21$52

M4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5U325I%.B`Q




T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&

38P.SPO9F]N=#X@(`@#0H@(`@(`@(`@


]


M/'1D(&-L87-S/3-$=&5X=#XG17-T:6UA=&5D(&9U='5R92!A;6]R=&EZ871I
M;VX@:7
@87

M9STS1#`@=VED=&@]

T0G1D].5U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5U325I%.B`Q



M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU

M3BU224=(5#H@
'!T)R!A;&EG;CTS1&QE9G0^(`@(`-B`@(`@(`@(`@

05DZ(&EN;&EN93L@
M1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T

T0G


Q+`R,#$S.CPO9F]N=#X\
M+V9O;G0^(`@#0H@(`@(`@(`@(`@(`@(`@(`@/]D:78^(`@(`-

M#0H@(`@(`@(`@(`@(`@(`@(#PO=&0^(`-B`@(`@(`@(`@(`@


M;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`@(`T*(`@
M(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`@
M(#QT9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q)3X@(`-B`@(`@(`@

Q-C`[/]F;VYT/B`@(`-B`@(`@(`@(`@(`@(`@(`@/]T



M86X[($9/3E0M4TE:13H@



M)B
Q-C`[/]F;VYT/B`@(`-B`@(`@(`@(`@(`@(`@(`@/]T9#X@

M(`@(`@/'1R/B`@(`-B`@(`@(`@(`@(`@(`@(`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#8Q)3X@(`@#0H@(`@(`@(`@(`@(`@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E
63H@=&EM97

38P

M)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`@(`T*(`@(`@
M(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`@(#QT
M9!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1=415A4+4%
M24=..B!L969T)SX@(`-B`@(`@(`@(`@(`@(`@(`@(`\9F]N=!S

Q-C`[/]F;VYT/B`@(`-


M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^(`@(`T*(`@(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@
M(`@(`@(`@(`@(`@(#QT9!N;W=R87`]
T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$



M4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`@(`T*(`@(`@(`@
M(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`\+W1R/B`@



05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T


M13H@

#$T
M/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`@(`@/]D:78^(`@(`-
MB`@(`@(`@(`@(`@(`@(`@/]T9#X@(`T*(`@(`@(`@(`@(`@
M(`@(`\=&0@86QI9VX]

M)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`@(`T*(`@(`@
M(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`@(#QT
M9!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1=415A4+4%
M24=..B!L969T)SX@(`-B`@(`@(`@(`@(`@(`@(`@(`\9F]N=!S

M(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`@


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@
M=&EM97

M=#X@(`@(`T*(`@(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@


M5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`@(`T*(`@(`@(`@(`@
M(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`\+W1R/B`@(`@
M#0H@(`@(`@(`@(`@(`@(`\='(^(`@(`T*(`@(`@(`@(`@(`@
M(`@(`\=&0@86QI9VX]
T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS

1494

'!T)R!A;&EG;CTS1&QE9G0^(`@(`-

M05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5U325I%.B`Q
'!T)SY&;W(@=&AE('EE87(@96YD960@1&5C96UB97(@
S$L
M(#(P
34\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(`@(`\+V1I=CX@
M(`@(`T*(`@(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@
M(`@(`@(`@(#QT9!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W



M;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M(`@(`T*(`@(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@
M(`@(`@(`@(#QT9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q

M;&4]


T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$


M/3-$)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`@(`T*(`@
M(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@(`\



05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@

M#0H@(`@(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-0

M3E0M4TE:13H@

#$V/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`@(`@/]D:78^
M(`@(`-B`@(`@(`@(`@(`@(`@(`@/]T9#X@(`T*(`@(`@(`@
M(`@(`@(`@(`\=&0@86QI9VX]
T1R:6=H=!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X@(`T*(`@(`@(`@(`@(`@(`@(`@(#QF;VYT('-T

05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`@(`T*
M(`@(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@(`@(`@(`@
M(`@(#QT9!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1=4
M15A4+4%







M(`@(`@(`@(`@(`@/'1D(&%L:6=N/3-$;&5F=!V86QI9VX]
T1B;W1T
M;VT@=VED=&@]
T0V

T1L
M969T/B`@(`@#0H@(`@(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL

M8V5M8F5R(#
Q+`R,#$W/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`@
M(`@/]D:78^(`@(`-B`@(`@(`@(`@(`@(`@(`@/]T9#X@(`T*
M(`@(`@(`@(`@(`@(`@(`\=&0@86QI9VX],T1R:6=H=!V86QI9VX]
M
T1B;W1T;VT@=VED=&@]

M('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^(`@(`T*(`@(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@
M(`@(`@(`@(`@(#QT9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q)2!S
M='EL93TS1=415A4+4%,24=..B!L969T)SX@(`-B`@(`@(`@(`@(`@
M(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M


M/3-$


05DZ(&EN
M;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%
M.B`Q
'!T)SXR






M;&4]
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W




M;VYT/B`@(`-B`@(`@(`@(`@(`@(`@(`@/]T9#X@(`T*(`@(`@
M(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
24@


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E
63H@=&EM97

M
38P.SPO9F]N=#X@(`@#0H@(`@(`@(`@(`@(`@(`@(#PO=&0^(`-
MB`@(`@(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$Q)2!S='EL93TS1=415A4+4%


C`L


M15A4+4%
24=..B!L969T)SX@(`@#0H@(`@(`@(`@(`@(`@(`@(`@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@
M=&EM97

38P.SPO9F]N

M(`@#0H@(`@(`@(`@(`@(`@(`@(#QT9!A;&EG;CTS1&QE9G0@=F%L



M
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O

M(`@(`@(#PO=&0^(`-B`@(`@(`@(`@(`@(`@(`@/'1D(&%L:6=N


T0G

M(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-


M(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M

T0G0D]21$52+4)/5%1/33H@8FQA8VL@
G!X('-O;&ED.R!4
M15A4+4%
24=..B!L969T)SX@(`@(`T*(`@(`@(`@(`@(`@(`@(`@

05DZ(&EN;&EN93L@1D].5U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O
M;G0^(`@(`T*(`@(`@(`@(`@(`@(`@(`\+W1D/B`@#0H@(`@(`@

24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@
G!X)SX@(`@(`T*(`@(`@(`@(`@(`@(`@(`@(#QF

05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^

M)2!S='EL93TS1=0041$24Y'+4)/5%1/33H@-'!X)SX@(`T*(`@(`@(`@

05DZ(&EN;&EN93L@
M1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T
M)SXF(S$V
#L\+V9O;G0^(`@(`T*(`@(`@(`@(`@(`@(`@(`\+W1D

M#0H@(`@(`@(`@(`@(`@(`@(#PO=&0^(`-B`@(`@(`@(`@(`@



M86X[($9/3E0M4TE:13H@

M86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q

T0G0D]21$52+4)/

M05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5U325I%.B`Q




T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4

38P.SPO9F]N=#X@(`@#0H@(`@(`@(`@(`@
M(`@(`@(#PO=&0^(`-B`@(`@(`@(`@(`@(`@(#PO='(^(`@(`-



'0O:'1M





S$L(#(P
M
3



]

M/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG5&AE($-O;7!A;GDF
M(S@R



T1B;W1T;VT@=VED=&@]

M



05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@


M8V5M8F5R(#
Q+`R,#$S/]F;VYT/B`@(`@#0H@(`@(`@(`@(`@(`@

M
T1B;W1T;VT@=VED=&@]
T0Q)2!S='EL93TS1=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,G!X)SX@(`-B`@(`@(`@(`@(`@(`@



05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M


T1B;W1T;VT@=VED
M=&@]

M/B`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I

M/3-$)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5U325I%.B`Q



B!V86QI9VX]
T1B;W1T;VT@=VED=&@]
M
T0Q

M86X[($9/3E0M4TE:13H@



05DZ
M(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U3
M25I%.B`Q


Q-C`[/]F;VYT/B`-B`@(`@(`@
M(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!C

B!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q
B4^(`@(`T*
M(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I

M13H@

6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`-B`@
M(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`\



M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU

M($U!4D=)3BU224=(5#H@

T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P


M=&]M('=I9'1H/3-$


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM
M97


M6%0M04Q)1TXZ(')I9VAT)SX@(`-B`@(`@(`@(`@(`@(`@(`@/&9O

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM
M97

34X/]F;VYT/B`@
M#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@



05DZ(&EN;&EN93L@
M1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T
M)SXF(S$V
#L\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@
M(`-B`@(`@(`@(`@(`@(`@(#QT9!A;&EG;CTS1')I9VAT('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/B`@(`@#0H@(`@(`@(`@(`@(`@

M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@
M(`@(`@(`@(`@(#QT9!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1=415A4+4%

05DZ(&EN;&EN93L@1D].5U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXD/]F;VYT
M/B`@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@
M(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL
M93TS1=415A4+4%

05DZ(&EN;&EN93L@1D].5U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXR+#$U.#PO
M9F]N=#X@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@

24=..B!L969T)SX@(`T*




05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@

M/3-$)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5U325I%.B`Q
'!T)SY!8V-U;75L871E9!$97!R96-I871I
M;VX\+V9O;G0^(`@#0H@(`@(`@(`@(`@(`@(`@(#PO9&EV/B`@(`T*

M






M(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXH,2PP-SD\+V9O;G0^(`@



M(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-






M4TE:13H@





T1L969T/B`@


L(&YE=#PO9F]N=#X@#0H@(`@
M(`@(`@(`@(`@(`@(#PO9&EV/B`@(`T*(`@(`@(`@(`@(`@(`@

M:'0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

T0G4$%$1$E.

M(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`-

M)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5U325I%.B`Q

2PP-SD\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^
M(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!N;W=R87`]
T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$


05DZ(&EN;&EN93L@1D].
M5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF
M(S$V
#L\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-
MB`@(`@(`@(`@(`@(`@(#QT9!A;&EG;CTS1')I9VAT('9A;&EG;CTS


Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@
M(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$

T0G0D]21$52+4)/5%1/


M13H@



M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T


M/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@


#@R-6
R7S%E
M-C)?-&







]




S$L
M(#(P
3


]


M(&]F($-O;7!O;F5N='

]
M




63H@=&EM97
@;F5W(')O;6%N



T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4

38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@(`@
M(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D(&%L:6=N/3-$


T0G4$%$

M;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@

M('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SX\9F]N=!S='EL


M8V5N=&5R.R!0041$24Y'+4)/5%1/33H@
G!X)SX@(`@(`T*(`@(`@(`@
M(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/

3!P=#L@
M1D].5U714E'2%0Z(&)O;&0G/B8C,38P.SPO9F]N=#X@#0H@(`@(`@(`@
M(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$


05DZ(&EN;&EN93L@1D].
M5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T.R!&




6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`-B`@
M(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`\

T1B;W1T;VT@=VED=&@]
M
T0T-R4^(`@(`-B`@(`@(`@(`@(`@(`@(`@/&1I=B!S='EL93TS
M1=415A4+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%

M(`@(`@(`@(`@(`@(`@(`\+V1I=CX@(`-B`@(`@(`@(`@(`@
M(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^(`@(`T*(`@(`@

Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@
M(`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
T1L969T(&-O;'-P
M86X]
T0R('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)3X@(`T*(`@(`@

T1L969T/B`@(`T*(`@(`@(`@(`@(`@(`@

M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^(`@(`T*(`@(`@(`@(`@(`@(`@(`\+V1I=CX@(`-B`@
M(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@


T1B
M;W1T;VT@=VED=&@]

M;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@

M($U!4D=)3BU

'!T)R!A;&EG;CTS

M
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O

38P.SPO9F]N=#X@(`@#0H@(`@

T1B;W1T;VT@=VED=&@]



M(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@

T0G8F%C:V=R

T1L969T/B`@(`T*(`@(`@

M(`@(`@(`@/]D:78^(`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@
M(`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]

Q-C`[
M/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@
M(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
24@


M=#X@(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@
M(`@(`@(`@(#QT9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q

M;&4]

M(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-



T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E
63H@=&EM97

M
38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*
M(`@(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS




6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@
M(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`\+W1R/B`@(`T*(`@(`@

T1B;W1T;VT@=VED=&@]

T0G

M8VL[($U!4D=)3BU

'!T)R!A;&EG

M;&4]
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W

38P.R8C
38P.U-T871E/]F
M;VYT/B`@(`-B`@(`@(`@(`@(`@(`@(`@/]D:78^(`@#0H@(`@
M(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\
M=&0@86QI9VX]
T1R:6=H=!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1=0041$24Y'+4)/5%1/33H@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E
63H@=&EM97

M
38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*
M(`@(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS


M;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@



M3E0M4TE:13H@

M(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
M,T1R:6=H=!V86QI9VX]
T1B;W1T;VT@=VED=&@]



M/3-$)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`-B`@(`@
M(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT
M9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q

T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@
G!X('-O;&ED.R!415A4+4%

T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&





M/B`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#0W)3X@(`@(`T*(`@(`@(`@(`@(`@

05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@


05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5U325I%.B`Q

M:78^(`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@
M(`@(`@(`@(`\=&0@86QI9VX]
T1R:6=H=!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X@(`@(`T*(`@(`@(`@(`@(`@(`@(`\9F]N=!S

Q-C`[/]F;VYT/B`@#0H@
M(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@
M(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

T0G5$58


Q-C`[/]F;VYT/B`@#0H@
M(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@
M(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

M6%0M04Q)1TXZ(')I9VAT)SX@(`-B`@(`@(`@(`@(`@(`@(`@/&9O

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM
M97


05DZ(&EN;&EN93L@1D].
M5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF
M(S$V
#L\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-
MB`@(`@(`@(`@(`@(`@(#QT9!A;&EG;CTS1')I9VAT('9A;&EG;CTS

M('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@
M(`@(`@(`@(#QT9!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1=415A4+4%
24=..B!L969T)SX@#0H@(`@(`@(`@(`@(`@(`@

05DZ(&EN;&EN93L@1D].5U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O
M;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@
M(`@(`@(`@(#QT9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q

M;&4]

M(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-


M9#X@(`@(`T*(`@(`@(`@(`@(`@(#PO='(^(`@#0H@(`@(`@(`@
M(`@(`@/'1R/B`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
T1L

M($1)4U!
05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T.R!-05)'24XM4DE'

05DZ(&EN;&EN93L@1D].5U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q

M9!T87@@97AP96YS93H\+V9O;G0^(`@(`-B`@(`@(`@(`@(`@(`@
M(`@/]D:78^(`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@
M(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^(`T*(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-0

M3E0M4TE:13H@




M3E0M4TE:13H@



T1B;W1T;VT@=VED=&@]
T0Q)2!S='EL
M93TS1=415A4+4%,24=..B!L969T)SX@(`T*(`@(`@(`@(`@(`@(`@
M(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9




M;&4]
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W

38P.SPO9F]N=#X@(`T*(`@
M(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@

M(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`-


T1B
M;W1T;VT@=VED=&@]
T0T-R4^(`@(`-B`@(`@(`@(`@(`@(`@(`@
M/&1I=B!S='EL93TS1=415A4+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C

M/3-$;&5F=#X@(`-B`@(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL

Q-C`[)B
Q-C`[1F5D97)A;#PO
M9F]N=#X@#0H@(`@(`@(`@(`@(`@(`@(#PO9&EV/B`@(`T*(`@(`@
M(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D



T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4

38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@(`@
M(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS

M1D].5U325I%.B`Q,'!T)SXH,C4Y+#@W.#PO9F]N=#X@(`@(`T*(`@(`@
M(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D


M=#X@(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@
M(`@(`@(`@(#QT9!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W

M=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`-B`@
M(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@
M(#QT9!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1=415A4
M+4%
24=..B!L969T)SX@#0H@(`@(`@(`@(`@(`@(`@(#QF;VYT('-T

05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`-B`@
M(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@
M(#QT9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q

T0G5$58

M=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE




M(`T*(`@(`@(`@(`@(`@(#PO='(^(`@#0H@(`@(`@(`@(`@(`@
M/'1R/B`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#0W)2!S='EL93TS1=0041$24Y'+4)/
M5%1/33H@
G!X)SX@(`-B`@(`@(`@(`@(`@(`@(`@/&1I=B!S='EL


M3E0M4TE:13H@


M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T


M/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@

M(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@;F]W






Q-C`[/]F;VYT/B`@#0H@
M(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@
M(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@
G!X('-O;&ED.R!415A4+4%
24=..B!L969T

T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&

38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@
M(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1=3U)$15(M0D]45$]-


M13H@

M(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI

M




M(`T*(`@(`@(`@(`@(`@(`@(`\+V1I=CX@(`-B`@(`@(`@(`@





S-RPS
#8\+V9O;G0^(`@(`-B`@(`@
M(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT
6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5U325I%.B`Q,'!T)SXI/]F;VYT/B`@(`T*(`@(`@(`@(`@(`@
M(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D(&%L:6=N/3-$


T0G4$%$

M;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@

M86X[($9/3E0M4TE:13H@




M5U325I%.B`Q,'!T)SXH,3(V+#,S,CPO9F]N=#X@(`@(`T*(`@(`@(`@
M(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D(&YO

24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
G!X)SX@

T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4



M#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
T1R:6=H=!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X@(`@(`T*(`@(`@(`@(`@(`@(`@

Q-C`[/]F
M;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@
M(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

M;&4]


Q-C`[/]F
M;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@
M(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
3$E('-T


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E
63H@=&EM97


M
6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5U325I%.B`Q,'!T)SXI/]F;VYT/B`@(`T*(`@(`@(`@(`@(`@
M(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D(&%L:6=N/3-$

24^(`@(`-B`@(`@


T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P

38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@
M(`@(`T*(`@(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W


M15A4+4%



M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T.R!-05)'24XM4DE'2%0Z(#!P


05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SY686QU871I;VX@86QL
M;W=A;F-E/]F;VYT/B`@(`T*(`@(`@(`@(`@(`@(`@(`\+V1I=CX@
M(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@
M(`@(`@(#QT9!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T

Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D
M/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$

T0G0D]21$52+4)/5%1/33H@8FQA8VL@
G!X
M('-O;&ED.R!415A4+4%
24=..B!L969T)SX@(`-B`@(`@(`@(`@(`@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E
63H@=&EM97

38P
M.SPO9F]N=#X@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@
M(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q

M6%0M04Q)1TXZ(')I9VAT)SX@(`@(`T*(`@(`@(`@(`@(`@(`@(`\
M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T


M=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE


M#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@
M(`@(`\=&0@86QI9VX],T1R:6=H=!V86QI9VX]
T1B;W1T;VT@=VED=&@]
M
T0Q)2!S='EL93TS1=0041$24Y'+4)/5%1/33H@,G!X)SX@(`-B`@(`@


05DZ(&EN;&EN93L@1D].5U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\
M+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@
M(`@(`@(`@(`@(#QT9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q
24@

T0G0D]21$52+4)/5%1/33H@8FQA8VL@
G!X('-O;&ED.R!415A4
M+4%


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM
M97

S(\+V9O;G0^
M(`@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@

T1B;W1T;VT@
M=VED=&@]

M(#PO='(^(`@#0H@(`@(`@(`@(`@(`@/'1R/B`@#0H@(`@(`@(`@
M(`@(`@(`\=&0@86QI9VX]
T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#0W)2!S='EL93TS1=0041$24Y'+4)/5%1/33H@-'!X)SX@(`-B`@
M(`@(`@(`@(`@(`@(`@/&1I=B!S='EL93TS1=415A4+4E.1$5.5#H@
M
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.



M(`-B`@(`@(`@(`@(`@(`@(#QT9!A;&EG;CTS1')I9VAT('9A;&EG



Q-C`[/]F;VYT/B`@#0H@(`@(`@
M(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

T0G0D]21$52+4)/


M4TE:13H@




M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T


M/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@
M(`@(`@(`\=&0@86QI9VX],T1R:6=H=!V86QI9VX]
T1B;W1T;VT@=VED
M=&@]





M(&YE=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXM/]F;VYT/B`@(`T*(`@
M(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@

24=..B!L969T.R!0041$24Y'+4)/5%1/33H@

T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N

38P.SPO9F]N=#X@(`T*(`@(`@(`@
M(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(#PO='(^(`@

'0^)T$@<F5C

M('1H92!#;VUP86YY)B
X
C$W.W




63H@=&EM97
@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P



05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T.R!-05)'

05DZ(&EN;&EN93L@1D].
M5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF
M(S$V
#L\+V9O;G0^(`@(`T*(`@(`@(`@(`@(`@(`@(`\+V1I=CX@
M(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@
M(`@(`@(#QT9!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T


M:6=N/3-$8F]T=&]M('=I9'1H/3-$

MB`@(`@(`@(`@(`@(`@(`@/&1I=B!S='EL93TS1=415A4+4%
24=.

05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@


T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4

M/B`@(`-B`@(`@(`@(`@(`@(`@(`@/]D:78^(`@#0H@(`@(`@


T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N

#L\
M+V9O;G0^(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@
M(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
<^(`@(`T*(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$

M($9/3E0M4TE:13H@
3!P=#L@1D].5U714E'2%0Z(&)O;&0G/B8C,38P.SPO
M9F]N=#X@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@

M9'1H/3-$

M;VQI9#L@5$585U!3$E'3CH@8V5N=&5R)SX@(`-B`@(`@(`@(`@(`@
M(`@(`@/&1I=B!S='EL93TS1=415A4+4%
24=..B!C96YT97([(%1%6%0M

05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T



M(`@(`@(`@(`@/]D:78^(`@#0H@(`@(`@(`@(`@(`@(`\+W1D

M(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/




M


M(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\
M=&0@86QI9VX]

Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@
M(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$


Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@
M(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$


T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N


M/B`@(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@
M(`@(`@(`@(#QT9!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W

M=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`-B`@
M(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@
M(#QT9!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1=415A4
M+4%
24=..B!L969T)SX@#0H@(`@(`@(`@(`@(`@(`@(#QF;VYT('-T

05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`-B`@
M(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@
M(#QT9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q

T0G5$58

M=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE


M(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@

24=..B!L969T)SX@(`T*(`@(`@

M/'1R/B`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#0W)2!S='EL93TS1=0041$24Y'+4)/
M5%1/33H@,G!X)SX@(`-B`@(`@(`@(`@(`@(`@(`@/&1I=B!S='EL
M93TS1=415A4+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.



M05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`-B`@(`@(`@(`@(`@
M(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!V86QI9VX]
M
T1B;W1T;VT@=VED=&@]
T0Q)2!S='EL93TS1=3U)$15(M0D]45$]-.B!B


Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@
M(`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$



05DZ(&EN;&EN93L@1D].5U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXH
3`N
M
3
\+V9O;G0^(`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@




M(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@
M(`@(`@(#QT9!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T

Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D
M/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$

T0G0D]21$52+4)/5%1/33H@8FQA8VL@
G!X
M('-O;&ED.R!415A4+4%
24=..B!L969T)SX@(`-B`@(`@(`@(`@(`@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E
63H@=&EM97

38P
M.SPO9F]N=#X@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@
M(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q

M6%0M04Q)1TXZ(')I9VAT)SX@(`@(`T*(`@(`@(`@(`@(`@(`@(`\
M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T



24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@
G!X)SX@(`-B`@(`@(`@(`@(`@(`@(`@/&9O;G0@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@

M(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@/]T

M86QI9VX]


05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
'!T.R!-


05DZ(&EN;&EN93L@
M1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T

M=#PO9F]N=#X@(`-B`@(`@(`@(`@(`@(`@(`@/]D:78^(`@#0H@
M(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@
M(`\=&0@86QI9VX],T1R:6=H=!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q
M)3X@(`@(`T*(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$

M($9/3E0M4TE:13H@



M($9/3E0M4TE:13H@

SPO9F]N=#X@(`-B`@(`@
M(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT
M9!N;W=R87`]
T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
24@



T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E
63H@=&EM97

M;G0^(`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@
M(`@(`@(`@(`\=&0@86QI9VX]
T1R:6=H=!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X@(`@(`T*(`@(`@(`@(`@(`@(`@(`\9F]N=!S

Q-C`[/]F;VYT/B`@#0H@
M(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@
M(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

T0G5$58


Q-C`[/]F;VYT/B`@#0H@
M(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@
M(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

M6%0M04Q)1TXZ(')I9VAT)SX@(`-B`@(`@(`@(`@(`@(`@(`@/&9O

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM
M97



M='(^(`-B`@(`@(`@(`@(`@(`@(#QT9!A;&EG;CTS1&QE9G0@=F%L


T1L969T/B`@

M5U325I%.B`Q,'!T)SY686QU871I;VX@86QL;W=A;F-E/]F;VYT/B`@(`T*

M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T


M/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@

3
\+V9O;G0^(`-B`@(`@(`@(`@(`@
M(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!N;W=R87`]
M
T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

T0G


05DZ(&EN
M;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%
M.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO
M=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!A;&EG;CTS1')I9VAT



Q-C`[/]F;VYT/B`@#0H@
M(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@
M(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@
G!X('-O;&ED.R!415A4+4%
24=..B!L969T

T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&

38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@
M(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1=3U)$15(M0D]45$]-


M13H@






MB`@(`@(`@(`@(`@(`@(`@/]D:78^(`@#0H@(`@(`@(`@(`@
M(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
M
T1R:6=H=!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1=0
M041$24Y'+4)/5%1/33H@-'!X)SX@(`-B`@(`@(`@(`@(`@(`@(`@

T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@
M=&EM97

38P.SPO9F]N



M;&4]
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W

38P.SPO9F]N=#X@(`T*(`@
M(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1=3U)$

24=..B!R:6=H


M3E0M4TE:13H@


M(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI

M

M86X[($9/3E0M4TE:13H@



Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@
M(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$


05DZ(&EN;&EN93L@
M1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T
M)SXP+C`P/]F;VYT/B`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-
MB`@(`@(`@(`@(`@(`@(#QT9!N;W=R87`]
T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$


05DZ(&EN;&EN93L@1D].5U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T)SXE/]F;VYT
M/B`@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@


]
T1T
M97AT/B=4:&4@=&%X(&5F9F5C='



M;&4]
T0G1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%
M.B`Q



M86X[($9/3E0M4TE:13H@


M3CH@8V5N=&5R)SX@(`-B`@(`@(`@(`@(`@(`@(`@/&1I=B!S='EL



S$L(#(P
M
3
\+V9O;G0^/]F;VYT/B`@(`-B`@(`@(`@(`@(`@(`@(`@/]D
M:78^(`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@




M(&)O;&0G/B8C
38P.SPO9F]N=#X@#0H@(`@(`@(`@(`@(`@(`\+W1D



M13H@

S$L(#(P
3(\+V9O;G0^/]F;VYT
M/B`@(`-B`@(`@(`@(`@(`@(`@(`@/]D:78^(`@#0H@(`@(`@
M(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@






T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4

38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@(`@
M(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D(&-O;'-P86X]
M



T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
M63H@=&EM97

38P.SPO
M9F]N=#X@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@
M(`@(`@(`@(`@/'1D(&-O;'-P86X]
T0R('9A;&EG;CTS1&)O='1O;2!W

M=R!R;VUA;CL@1D].5U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^(`-B`@
M(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@



M(`@(`@(`@(`@(`@/'1D(&%L:6=N/3-$;&5F=!V86QI9VX]
T1B;W1T
M;VT@=VED=&@]
T0T-R4^(`@(`-B`@(`@(`@(`@(`@(`@(`@/&1I
M=B!S='EL93TS1=415A4+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@

M;&5F=#X@(`-B`@(`@(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS



M;&4]
T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W

38P.SPO9F]N=#X@(`T*(`@
M(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@




24=..B!L969T)SX@(`T*(`@(`@(`@
M(`@(`@(`@(`F(S$V,#L@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@
M(`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]

Q-C`[
M/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@
M(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
24@


M=#X@(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@
M(`@(`@(`@(#QT9!V86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q

M;&4]

M(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-


38P.R`-B`@(`@(`@(`@
M(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`\+W1R/B`@(`T*

T1B;W1T;VT@=VED=&@]
T0T-R4^(`@
M(`-B`@(`@(`@(`@(`@(`@(`@/&1I=B!S='EL93TS1=415A4+4E.
M1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@


M(`@(`@(`@(`@(`@(`@(#PO9&EV/B`@(`T*(`@(`@(`@(`@(`@
M(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D(&%L:6=N/3-$

24^(`@(`-B`@(`@


T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P

38P.SPO9F]N=#X@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@
M(`@(`T*(`@(`@(`@(`@(`@(`@/'1D('9A;&EG;CTS1&)O='1O;2!W


38P.R`-

M)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`-B`@(`@(`@
M(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!V
M86QI9VX]
T1B;W1T;VT@=VED=&@]




L
#(R/]F;VYT/B`@(`T*(`@

T1B;W1T;VT@=VED=&@]
T0Q
M)2!S='EL93TS1=415A4+4%,24=..B!L969T)SX@(`T*(`@(`@(`@(`@
M(`@(`@(`F(S$V



G!X

M(`@(`@(`@(`@(`@(`\9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI

M



M($9/3E0M4TE:13H@



M9VX]
T1B;W1T;VT@=VED=&@]


M05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`-B`@(`@(`@(`@(`@
M(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!V86QI9VX]
M
T1B;W1T;VT@=VED=&@]
T0Q)2!S='EL93TS1=3U)$15(M0D]45$]-.B!B


Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@
M(`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$



05DZ(&EN;&EN93L@1D].5U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q

T1B;W1T
M;VT@=VED=&@]

M(`@(`@(`@(`\=&0@86QI9VX]
T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#0W)3X@(`@(`T*(`@(`@(`@(`@(`@(`@(`\9&EV('-T

05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@

M4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5U325I%.B`Q

MB`@(`@(`@(`@(`@(`@(`@/]D:78^(`@#0H@(`@(`@(`@(`@
M(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
M

Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D
M/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$


Q-C`[/]F;VYT/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D
M/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$

T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4+5-)

RPU-C@\+V9O;G0^(`@(`T*(`@(`@(`@(`@(`@

T1B;W1T;VT@=VED=&@]
T0Q)2!S='EL93TS1=4
M15A4+4%,24=..B!L969T)SX@(`T*(`@(`@(`@(`@(`@(`@(`F(S$V
M
#L@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@
M(`@(`@(`\=&0@86QI9VX],T1R:6=H=!V86QI9VX]
T1B;W1T;VT@=VED
M=&@]






M(`T*(`@(`@(`@(`@(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@

24=..B!L969T)SX@(`T*(`@(`@

M/B`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX]
T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#0W)2!S='EL93TS1=0041$24Y'+4)/5%1/
M33H@,G!X)SX@(`-B`@(`@(`@(`@(`@(`@(`@/&1I=B!S='EL93TS
M1=415A4+4E.1$5.5#H@
'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%

M(`@(`@(`@(`@(`@(`@/]D:78^(`@#0H@(`@(`@(`@(`@(`@
M(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX],T1R
M:6=H=!V86QI9VX]
T1B;W1T;VT@=VED=&@]
!S;VQI9#L@5$585U!3$E'3CH@

M)T1)4U!
05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5U325I%.B`Q
'!T)SXF(S$V
#L\+V9O;G0^(`-B`@(`@(`@
M(`@(`@(`@(#PO=&0^(`@(`-B`@(`@(`@(`@(`@(`@(#QT9!V
M86QI9VX]
T1B;W1T;VT@=VED=&@]
T0Q

T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@
G!X('-O;&ED.R!415A4+4%


T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E
63H@=&EM97
@;F5W(')O;6%N.R!&3TY4



M4TE:13H@




M(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@


6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%
M.B`Q,'!T)SXI/]F;VYT/B`@(`T*(`@(`@(`@(`@(`@(`@/]T9#X@
M(`@(`T*(`@(`@(`@(`@(`@(#PO='(^(`@#0H@(`@(`@(`@(`@
M(`@/'1R/B`@#0H@(`@(`@(`@(`@(`@(`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0W)2!S='EL93TS1=0041$24Y'
M+4)/5%1/33H@-'!X)SX@(`-B`@(`@(`@(`@(`@(`@(`@/&1I=B!S


M($9/3E0M4TE:13H@

M#0H@(`@(`@(`@(`@(`@(`@(#PO9&EV/B`@(`T*(`@(`@(`@(`@
M(`@(`@/]T9#X@(`@(`T*(`@(`@(`@(`@(`@(`@/'1D(&%L:6=N


T0G



05DZ(&EN;&EN93L@1D].5U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5U325I%.B`Q


T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$



05DZ(&EN;&EN93L@
M1D].5U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5U325I%.B`Q
'!T
M)SXF(S$V
#L\+V9O;G0^(`-B`@(`@(`@(`@(`@(`@(#PO=&0^(`@
M(`-B`@(`@(`@(`@(`@(`@(#QT9!A;&EG;CTS1')I9VAT('9A;&EG



Q-C`[/]F;VYT/B`@#0H@(`@(`@
M(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@(`@(`@(`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$

T0G0D]21$52+4)/


M4TE:13H@




M9F]N=!S='EL93TS1=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T


M/B`@#0H@(`@(`@(`@(`@(`@(`\+W1D/B`@(`@#0H@(`@(`@(`@


#@R-6
R7S%E
M-C)?-&







]



2P@
M








]




]




]
T1T



#`L



]



T1T;W`^4W1O8VL@4F5P

M;B!3:&%R97
I/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1N=6UP



]


@06-Q=6ER960@86YD($QI86)I;&ET:65S



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P



]




]






]




]
T1T97AT




]





]
T1N=6UP/C(L-3`P+#`P



]






M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^





]



]



#`\




]




64V
E\T
M8S$V7SEA8V)?9C%D
V4U83@Y-#8V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T
Z+V0U
#@R-6
R7S%E-C)?-&
Q-E\Y86-B7V8Q9#-E-6$X.30V-B]7



^+RH@1&\@3F]T(%)E;6]V92!4

$5*34%%/@T*(`@(`@

2!R;W=S


2X@(!/4D=!3DE:051)3TX@04Y$($Y!
M5%5212!/1B!/4$52051)3TY3(A$971A:6QS*2`M(%-C:&5D=6QE(&]F($5X



]
T1T:#Y$96
N(#



T1T;W`^/'-T

M5$E/3E
@*$1E=&%I;'







]
T1R:#X-






]
T1R;SX-



]



2X@3U)'04Y)6D%424].($%.

]





T1T;W`^4F%J($MU;6%R(%1I=V%R


T1T;W`^

M15)!5$E/3E
@*$1E=&%I;'




@3V9F




]



]
M

]
M





]

]


#@R
M-6
R7S%E-C)?-&






]

T1)1#!%54A!



]
T1T:#Y$
M96
N(#

M/D1E8RX@
S$L(#(P
#D\8G(^/]T:#X-B`@(`@(`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S
2P@



]

]
M




]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P



M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$;G5M/B@R.#`L.30W


C(Y+#@S



]



M1'5R:6YG($1E=F5L;W!M96YT(%-T86=E/]T9#X-B`@(`@(`@/'1D(&-L



]



M(&9I;&4Z+R\O0SHO9#4P.#(U8S)?
64V
E\T8S$V7SEA8V)?9C%D
V4U83@Y

O4VAE970R-RYH=&UL#0I#;VYT96YT+51R86YS9F5R


M87-C:6DB#0H-CQH=&UL/@T*(`\:&5A

M

M;W9E(%1H:7


T0Q
M(')O=W-P86X]


24-)15
@*$1E=&%I;'


]
T1T:#Y$96
N(#




]
T1T97AT









]





]




T1T;W`^36EN:6UU


T1T;W`^

N(%-534U!4ED@3T8@4TE'3DE&24-!3E0@04-#3U5.







]


]




]
T1T


]




]
T1T

M04Y'24)
12!!4U-%5%
@*$1E=&%I;'

]
M
T1T:#Y$96
N(#
Q+`R,#$P/&)R/CPO=&@^#0H@(`@(`@(#QT:!C;&%S

S$L(#(P
3
\8G(^/]T:#X-B`@(`@(`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S
2P@
C`Q


#$P/&)R/E)E:6UB=7)S96UE;G0@;V8@4F5S96%R8V@@86YD($1E=F5L



]
T1T:#Y$96
N(#

S$L(#(P




]
T1T:#Y$96
N(#



]
T1T:#Y$96
N(#


]
T1T
M:#Y$96
N(#





]





]




]



]



]



]
T1T





]
T1T97AT/B=B*2`@(%1O(')E:6UB=7)S92`D
C@T+#4P

@:6YC=7)R960@8GD@4')O


]

M8W

#`@

M87-E($D@8VQI;FEC86P@=')I86P@87




]




]
T1N=6UP/B0@









]


]



]


M

]
M



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT


]




]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P




]



]





]


M92!#;VUP86YY)W








]



]





]
T1N=6UP/C
P+#`P


]


]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]



@9&5F:6YE9D@9F]R('-A;&5S
M(&)E='=E96X@)#`@+2`D,C`L,#`P+#`P,P@
B4@9F]R('-A;&5S(&)E='=E
M96X@)#(P+#`P
PP,#$@+2`D-3`L,#`P+#`P,P@86YD(#$E(&]F('-A;&5S

#`P+#`P


BPP
M
#`L

M
#`P+#`P


M



]
T1T




]




]



]





]









BPT
#




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


C5C
E\Q
M938R7S1C
39?.6%C8E]F

M;G0]

^#0H@

M1513(A$971A:6QS*2`M(%-C:&5D=6QE(&]F($9I;FET92U,:79E9!);G1A


S$L(#(P
3
\8G(^/]T:#X-B`@
M(`@(`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
2P@
C`Q



]


]
M

]
T1N=6UP/B0@
C
P+#`P
M

M86QI9VX]

M(`@(`@/'1D(&-L87-S/3-$;G5M/B@X
BPT
#




]
T1N
M=6UP/B0@


64V
E\T8S$V7SEA8V)?9C%D
M
V4U83@Y-#8V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T
Z+V0U
#@R
M-6
R7S%E-C)?-&

M965T

M(G5S+6%S8VEI(@T*#0H\:'1M;#X-B`@/&AE860^#0H@(`@/$U%5$$@:'1T


^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@

$4V2T%#/@T*(`@(`@/'1R/@T*(`@(`@





L($9U

S$L(#(P
3
\
M8G(^/]T:#X-B`@(`@(`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
2P@
C`Q
M

]



]
T1P;!V86QI9VX],T1T;W`^1F]R('1H
M92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+`R
#$T/]T9#X-B`@(`@(`@



]

2P@


T1T;W`^1F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#
Q




S$L(#(P


]





C`L



]



]




C5C
M
E\Q938R7S1C
39?.6%C8E]F

M;G1E;G0]

M
T0Q(')O=W-P86X]



M


#$S/&)R







]
M

]
M
T1N=6UP/B0@


#@R-6
R7S%E-C)?-&
Q-E\Y86-B7V8Q9#-E-6$X.30V



]
T1R97!O


M8RX@
S$L(#(P
3
\8G(^/]T:#X-B`@(`@(`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S
2P@
C`Q

]





T1T;W`^06-C=6UU;&%T



]
T1P
M;!V86QI9VX],T1T;W`^1FEX960@07-S971S+!N970\+W1D/@T*(`@(`@



M+R\O0SHO9#4P.#(U8S)?
64V
E\T8S$V7SEA8V)?9C%D
V4U83@Y-#8V+U=O

O4VAE970S
RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D



T1T97AT

M:7

T0Q(')O=W-P
M86X]

G($5154E462`H
M1$5&24-)14Y#62D@*$1E=&%I;'



]
T1T:#Y$96
N(#

S$L(#(P
3
\8G(^1&ER

M=&@^1&5C+B`S
2P@
C`Q

2P@
C`Q



#$P/&)R

]
T1T:#Y$96
N(#


2P@
C`Q



]
T1T:#Y$96
N(#


]
M
T1T:#Y$96
N(#

]
T1T:#Y$96
N
M(#


#$S




]


]
M




]



]


]
T1N=6UP/C4P
M+#`P

#`L

#`P+#`P



M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]





M


]
T1N=6UP/B0@






]





T1T;W`^4')E9F5R


]



]



]


]
M




]



]





S`L




]





]






]



C$U+#`P




]


]




]






]






]



]
T1N=6UP/B0@

]







]




]
T1T




]



]



]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]

]
T1N
M=6UP/C0S



]



]




]


]
T1N=6UP/C
S

RPS


]
T1T97AT




]



]


]



M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P

M-S`L



]




]






]
T1N=6UP/C
P+#`P



]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^

2PV-C8L

M;7`^






]



]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]


M(#`N










]




]


CDL-3`P



]


]




]




M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]

]
T1N=6UP/B0@
C(U+#`P


]
T1N=6UP/B0@
M.3DY+#4P



]



#DL-3`P/'-P86X^



;V-A=&EO;CH@9FEL93HO+R]#.B]D-3`X
C5C
E\Q938R7S1C
M
39?.6%C8E]F

T+FAT;6P-


M@T*/&AT;6P^#0H@(#QH96%D/@T*(`@(#Q-151!(&AT='`M97%U:78]
T1#

]
T13:&]W







]
T1T:#Y$96
N(#

S$L(#(P
3`\


@06=R965M


]
T1T
M:#Y$96
N(#

]
T1T:#Y$96
N
M(#

]
T1T:#Y$96
N(#

C`L(#(P
3



]
T1T:#Y$96
N(#

M8G(^/]T:#X-B`@(`@(`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
2P@
C`Q
M

@06=R965M96YT(%M-96UB97)=/&)R/CPO=&@^



]

I(%M


]




]





T1T;W`^3F]T97
@

2PW

2PW


2PW
M




]
T1N=6UP/B0@
RPR






]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


\+W1D/@T*(`@(`@



]





]
T1T



]



]

XR,!P97(@




]






]



]



]


]



]




]


]


C
P+#`P




]



]
T1R



]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]



M
C@T+#4P

]
T1P;!V86QI
M9VX],T1T;W`^3F]T97,@4&%Y86)L93PO=&0^#0H@(`@(`@(#QT9!C;&%S


]



]
T1N=6UP/CDW+#`P





]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P






]


]
M



]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]
T1T



;V-A=&EO;CH@9FEL93HO+R]#.B]D-3`X
C5C
E\Q938R7S1C
39?
M.6%C8E]F


T1#;VYT

]
T13:&]W+FIS




]

]

]
T1T:#Y$96
N(#
Q+`R,#$R/&)R/CPO=&@^#0H@(`@








BPR-C(\

M(#0T
2PP


M:6=N/3-$=&]P/D]P97)A=&EN9R!



#


]
T1P


M
64V
E\T8S$V7SEA8V)?9C%D

O4VAE970S


M
M87-C:6DB#0H-CQH=&UL/@T*(`\:&5A9#X-B`@(`\345402!H='1P+65Q







]
M

]
T1T:#Y$
M96
N(#




T1T;W`^1F5D97)A;#PO=&0^






]



T1T

]



]
M







T1T;W`^5&]T86P@


]
T1N=6T^*#$R-BPS





3(V+#
S
CQS



M
64V
E\T8S$V7SEA8V)?9C%D

O4VAE970S


M
M87-C:6DB#0H-CQH=&UL/@T*(`\:&5A9#X-B`@(`\345402!H='1P+65Q





T0Q(')O=W-P86X]



M86X]

#$S

]
T1R




]


]
T1N=6T^*#
T+C`P)2D\


M/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$;G5M/B@Q


R4I/'-P

M
3

]
T1P;!V86QI9VX]
M,T1T;W`^5F%L=6%T:6]N(&%L;&]W86YC93PO=&0^#0H@(`@(`@(#QT9!C

3

3


]

XP,4\




]


S$L(#(P
3
\8G(^/]T:#X-B`@(`@(`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S
2P@
C`Q



]



]
T1N=6UP


]
T1N=6UP/C4U+#0Y
3QS


M







]
T1R;SX-

]
T1N=6T^*#8U
M

M1&YU;3XH
S$V+#(V



]
T1N=6UP/B0@






]

@
M*$1E=&%I;'



B!-;VYT:'

M
2P@
C`Q


]
T1T

#@L(#(P
M




S$L(#(P
3
\8G(^3V9F:6-E(%-P86-E(%M-96UB97)=
M/&)R/DEM;65D:6%T92!&86UI;'D@365M8F5R(&]F($UA;F%G96UE;G0@;W(@



S$L(#(P
3


M/]T:#X-B`@(`@(`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
2P@
C`Q
SQB



]




]





]





]




]
T1N=6UP/B0@
2PR

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]


M/D]P97)A=&EN9R!
96%S97
L(%)E;G0@17AP96YS93PO=&0^#0H@(`@(`@

]



]
T1N=6UP/C$T+#0P


]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^



]
M




]






]




]

]
T1T97AT










]




@87




@

#QS



M=&AE($-O;7!A;GD@:6X@82!R86ES92X@(%1H92!A9W)E96UE;G0@=&5R;6EN

RP@

30L('1H

M=VET:!/8FIE8W1I=F4@17%U:71Y('=H97)E8GD@8F]T:!P87)T:65S(&%G







]





]

#`L



T1T;W`^4')O




BPP





]



]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^




]
T1T





]






]





M

]
M


C4L



2PX




]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T



]





]





]





]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]



M-3`L




]



]




M86QI9VX]
T1T;W`^36%X:6UU;2!#87!I=&%L('1O(%)A:7-E(&EN(%!R:79A

M+#4P




]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]
T1N=6UP/C(U
M+#`P

]




]
T1T





]
M
T1P;!V86QI9VX],T1T;W`^4W1O8VL@27-S=6%B;&4L(%9A;'5E+!$=7)I

]




]
T1T




]


M+2TM/5].97AT4&%R=%]D-3`X
C5C
E\Q938R7S1C
39?.6%C8E]F
60S935A


M
M87-C:6DB#0H-CQH=&UL/@T*(`\:&5A9#X-B`@(`\345402!H='1P+65Q





T0Q(')O=W-P86X]

M3D]412`Q

M87-S/3-$=&@^1&5C+B`S
2P@
C`Q

#$R/&)R/CPO=&@^#0H@(`@(`@(#QT





]



#$S/&)R

M=&EF:6




S$L(#(P
3
\8G(^0V]N



S$L(#(P
3




M;&EN:6-A;!$979E;&]P;65N=!/9F9I8V5R(%M-96UB97)=/&)R/CPO=&@^





]
T1T:#Y$96
N(#

N(%M-96UB97)=/&)R/CPO=&@^#0H@

#$S/&)R/D-O;G-U;'1I




]
T1T




]





]





]





]





]



]



M




]




]
T1T




]
T1N=6UP/B0@-#`L

]
T1N=6UP
M/B0@
C(L



]
T1N=6UP/B0@


]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
M

]

]
T1N=6UP/C
X-BPV
M





]


C`L




]
T1N=6UP/C$P+#`P


]





]


]




2!S
M:&%L;!P87D@1'(N($UI='1E;&UA;B`D-S(L




M:6




BPP

M(&EN8W)E;65N='




M8W)E;65N='









@;V8@)#
U+#`P


]





M('1H92!A9W)E96UE;G0L($1R+B!3=7)I86YO('-H86QL(&)E('!A:60@82!S
M:6=N:6YG(&)O;G5S(&]F(0Q,PP


@;V8@=&AE(&1A=&4@;V8@=&AE






M=VET:!T:&4@97AE8W5T:6]N(&]F('1H92!A9W)E96UE;G0L($)A;F5R:F5E
M('-H86QL(&)E('!A:60@82!S:6=N:6YG(&)O;G5S(&]F(0S-2PP
#`@=&\@




]



@=W)I='1E;B!N;W1I8V4N(%1H


C4E(&1I



#$T+B`@26X@8V]N;F5C=&EO

@86=R965M96YT('1H92!#

3
L(#(P
M
3

#`L


]
T1T




]



]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1N=6UP
M/C$P+#`P






]



]







]




]


]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT



]
M




]






]

3`P+#`P



]

M+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^


]





]




]





]
T1N=6UP/C(P

#`\



]
T1T




]








]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT



]
M








64V
E\T8S$V7SEA8V)?9C%D
M
V4U83@Y-#8V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T
Z+V0U
#@R
M-6
R7S%E-C)?-&


M(G5S+6%S8VEI(@T*#0H\:'1M;#X-B`@/&AE860^#0H@(`@/$U%5$$@:'1T


^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@

$571T%'/@T*(`@(`@/'1R/@T*(`@(`@



M;VYG/DY/5$4@



T0T/C`@36]N=&AS($5N

M

S$L(#(P
3
\8G(^/]T
M:#X-B`@(`@(`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
2P@
C`Q


#$S/&)R

C`Q



]


S$L(#(P



2P@
C`Q


M
2X@4U54T51545.5!%5D5.5%
@*$1E=&%I;'
I(%M
:6YE($ET96US73PO

]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P


]
T1T97AT







]



]





]




]
T1N=6UP/B0@


]

M;CX\+W-P86X^/]T9#X-B`@(`@(`@/'1D(&-L87-S/3-$=&5X=#XG/'-P

]
T1T


L($ES

]
T1T




]







]
T1N=6UP/B0@
BPU
#`L


M


]



T1T;W`^3W1H97(@0V]M;6ET
M;65N='











]








@86=R965D('1H870@=&AE($-O;7!A;GD@=V]U;&0@

@;V8@8V]M;6]N('-T;V-K

M=&AE('1O=&%L('!R;V-E961S(')E8V5I=F5D(&)Y('1H92!#;VUP86YY+CQS

]


]





]
T1T97AT/B=A*2!I;F-R96%S92!T:&4@86UO=6YT
M('1H92!#;VUP86YY(&ES(&]F9F5R:6YG('1O(0S+#4P,PP
#`@9G)O;2`D
M
BPU
#`L







64V
E\T8S$V7SEA8V)?9C%D
V4U
M83@Y-#8V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T
Z+V0U
#@R-6
R
M7S%E-C)?-&



T0B=7)N.G-C:&5M87


T0B4VAE970P
M
2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
#(N:'1M;(O/@T*
M(#QO.D9I;&4@2%)E9CTS1)3:&5E=#`S+FAT;6PB+SX-B`\;SI&:6QE($A2
M968],T0B4VAE970P-YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M
#4N:'1M;(O/@T*(#QO.D9I;&4@2%)E9CTS1)3:&5E=#`V+FAT;6PB+SX-
MB`\;SI&:6QE($A2968],T0B4VAE970P-RYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#@N:'1M;(O/@T*(#QO.D9I;&4@2%)E9CTS1)3:&5E
M=#`Y+FAT;6PB+SX-B`\;SI&:6QE($A2968]
T0B4VAE970Q
YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N:'1M;(O/@T*(#QO.D9I;&4@
M2%)E9CTS1)3:&5E=#$R+FAT;6PB+SX-B`\;SI&:6QE($A2968]
T0B4VAE
M970Q
RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T

T0B4VAE970Q.2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T
C`N:'1M;(O/@T*(#QO.D9I;&4@2%)E9CTS1)3
M:&5E=#(Q+FAT;6PB+SX-B`\;SI&:6QE($A2968],T0B4VAE970R,BYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C,N:'1M;(O/@T*(#QO.D9I
M;&4@2%)E9CTS1)3:&5E=#(T+FAT;6PB+SX-B`\;SI&:6QE($A2968]
T0B
M4VAE970R-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
C8N:'1M
M;(O/@T*(#QO.D9I;&4@2%)E9CTS1)3:&5E=#(W+FAT;6PB+SX-B`\;SI&
M:6QE($A2968],T0B4VAE970R.YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T
CDN:'1M;(O/@T*(#QO.D9I;&4@2%)E9CTS1)3:&5E=#
P+FAT
M;6PB+SX-B`\;SI&:6QE($A2968],T0B4VAE970S,2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,S(N:'1M;(O/@T*(#QO.D9I;&4@2%)E9CTS
M1)3:&5E=#,S+FAT;6PB+SX-B`\;SI&:6QE($A2968]
T0B4VAE970S-YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S4N:'1M;(O/@T*(#QO
M.D9I;&4@2%)E9CTS1)3:&5E=#,V+FAT;6PB+SX-B`\;SI&:6QE($A2968]
M
T0B4VAE970S-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
S@N
M:'1M;(O/@T*(#QO.D9I;&4@2%)E9CTS1)3:&5E=#
Y+FAT;6PB+SX-B`\
M;SI&:6QE($A2968],T0B4VAE970T,YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F

I7V0U
#@R-6
R7S%E-C)?-&
Q-E\Y86-B7V8Q9#-E-6$X.30V-BTM#0H`
`
end











    
  
      

          











        
        
        


        

000

000


        

403)

228)


Intangible Assets
 net

597

772




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 excluding financial assets and goodwill
 lacking physical substance with a finite life.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 excluding financial assets and goodwill
 lacking physical substance with a finite life.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 excluding goodwill
 as of the balance sheet date
 net of accumulated amortization and impairment charges.
              
 -Subparagraph ((a)(1)
(b))
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        
        
        

      


















 2010



          



 2010



          



 2010



          



 2010



          



 2008



          



 2008



          



 2008

          



        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        


Intangible Assets Acquired
 Term of Consideration
 Description
        
        
        
        

000 in four (4) installments through April 1
 2011
 all of which has been paid

500 of research and development expenses incurred by Prostagenics (See Note 7)

000 within fifteen (15) days upon completing a phase I clinical trial as defined by the Food and Drug Administration (FDA)
 and

500
000 within fifteen (15) days upon completing a phase II clinical trial as defined by the FDA.
        
        
        


        
        
        
        

000

000

500

000
        
        
        
        


Debt Instrument
 Face Amount
        
        
        
        
        
        
        

500
000
        
        
        


Debt Instrument
 Maturity Date
 Description
        
        
        
        
        
        
        
        
        
        
        


Debt Instrument
 Interest Rate
 Stated Percentage
        
        
        
        
        
        
        
        
        
        
        


Debt Instrument
 Convertible
 Terms of Conversion Feature
        
        
        
        
        
        
        

 subject to a minimum floor price of $0.50 per share.  If the Company's shares are publicly traded
 Prostagenics will have registration rights with respect to the conversion of the shares subject to a one-year lock-up period and agreed not to liquidate more than 25% of its share per quarter upon expiration of the one-year lock-up period.
        
        
        


        
        
        
        
        
        
        
        
        
        
        

000


        
        
        
        
        
        
        
        
        

000
000
 2% for sales between $20
000
001 - $50
000
000
 and 1% of sales in excess of $50
000
000

000
000
 2% for sales between $2
000
001 - $5
000
000
 and 3% of sales in excess of $5
000
000
        


Intangible Assets
 Explanation of Significant Additions
        
        
        
        
        
        
        
        
        
        

 royalties from sublicenses
 maintenance fees or similar charges received from sublicenses
 the Company will be required to be pay NYMC 17.5% of such fees earned.


Sublicense Fees and Other Fees
 Royalty Percentage
        
        
        
        
        
        
        
        
        
        
        


        

175

174
        

403
        
        
        
        
        
        
        




        
          

        
          
            

 including payment terms
 frequency of payments and other terms of consideration
 for intangible assets acquired.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 type of debt or equity security into which the debt is convertible
 the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into)
 the conversion period
 any contingencies associated with the conversion terms
 and the existence and amount of a beneficial conversion feature.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 under the debt agreement.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 if so
 a brief description of the serial maturities.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 excluding goodwill.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

NOTE 4.   INTANGIBLE ASSETS (Details) - Schedule of Finite-Lived Intangible Assets
 Future Amortization Expense (USD $)











Schedule of Finite-Lived Intangible Assets
 Future Amortization Expense [Abstract]
        
        


For the year ended December 31
 2014

174
        


For the year ended December 31
 2015

174
        


For the year ended December 31
 2016

174
        


For the year ended December 31
 2017

174
        


For the year ended December 31
 2018

174
        


        

727
        


        

597

772




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 excluding financial assets and goodwill
 lacking physical substance with a finite life.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 excluding financial assets and goodwill
 lacking physical substance with a finite life.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 excluding financial assets and goodwill
 lacking physical substance with a finite life.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 excluding financial assets and goodwill
 lacking physical substance with a finite life.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 excluding financial assets and goodwill
 lacking physical substance with a finite life.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 excluding financial assets and goodwill
 lacking physical substance with a finite life.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 excluding goodwill
 as of the balance sheet date
 net of accumulated amortization and impairment charges.
              
 -Subparagraph ((a)(1)
(b))
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        
        

      














Property
 Plant and Equipment [Abstract]
        
        
        


        
        
        

079




        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        

      






        
        


Organization
 Consolidation and Presentation of Financial Statements Disclosure [Text Block]
        
            
          
 &#8211; AV Therapeutics
 Inc. (the &#8220;Company&#8221;) is a Delaware corporation formed on November 14
 2011 under the name &#8220;Aquino Milling Inc.&#8221; Under its initial business plan
 the Company intended to purchase rice milling equipment and commence rice milling operations. On June 10
 2013
 the Company changed its name to &#8220;Code 2 Action
 Inc.&#8221; On July 30
 2013

          
On December 13
 2013 (the &#8220;Closing Date&#8221;)
 the Company along with AVT Acquisitions
 Inc.
 a Delaware corporation and a wholly-owned subsidiary of the Company (the &#8220;Subsidiary&#8221;) entered into and closed an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) with Advanced Vaccine Therapeutics
 Inc.
 a Delaware corporation (formerly known as AV Therapeutics
 Inc.) (&#8220;AVT&#8221;). Pursuant to the Merger Agreement
 (i) the Subsidiary merged into AVT
 such that AVT became a wholly-owned subsidiary of the Company
 and (ii) the Company issued 58
000
000 shares (the &#8220;Acquisition Shares&#8221;)
 of the Company&#8217;s common stock to the shareholders of AVT
 representing approximately 77% of the Company&#8217;s aggregate issued and outstanding common stock following the closing of the Merger Agreement (following
            the Share Cancellation and the&#160;&#160;initial closing under the Private Placement
 each as defined below)

          


          

 70
000

          

320. Shortly after the Merger in 2013
 the holders of the notes agreed to convert the notes payable into shares of the Company&#8217;s common stock at $0.20 per share. The Company has included the $7
320 in shares issuable on the consolidated balance sheet at December 31
 2013 as the 36
596 shares of common stock were not issued until January 8

          

 Mr. Doug Cole resigned as officer of the Company. Mr. Cole resigned as a director of the Company on February 5
 2014. In addition

          
              


                    



                  



                    






                    



                  




 Chief Financial Officer




              


                    



                  



                    






                    



                  








              


                    



                  











                    



                  



                    



              


                    



                  



                    



            

 2013
 the Company changed its name from &#8220;Merica Corp.&#8221; to &#8220;AV Therapeutics

          

 2013 authorizing the Company to sell up to 12
500

          

 as of the Closing Date the Company entered into and closed subscription agreements with accredited investors (the &#8220;Investors&#8221;)
 pursuant to which the Company received an aggregate $709
999 and agreed to issue the Investors 3
550
000 shares of common stock (&#8220;Private Placement&#8221;).&#160;&#160;The Company&#8217;s original private placement memorandum dated September 30
 2013 permitted the Company to sell up to 12
500
000 shares of common stock at $0.20 per share. The Company included the receipt of the proceeds in shares issuable on the consolidated balance sheet at December 31
 2013 as the shares were not issued until January 8
 2014 due to administrative delays. As disclosed in Note 9
 in connection with the Private Placement
 the Company incurred costs of $52
800
 which were paid in common shares on January 8

          
AVT is a Delaware corporation that was formed on February 11
 2011.&#160;&#160;Prior to the date of incorporation
 the activities of AVT were carried out through Applied Vaccine Technology
 LLC (&#8220;AVT
 LLC&#8221;)
 a Delaware limited liability company formed in July 2007 and an entity with common ownership as AVT.&#160;&#160;The operations and net assets of AVT
 LLC were acquired by AVT on February 11
 2011 and AVT

          

 pursuant to the Merger Agreement
 AVT became a wholly owned subsidiary of the Company. The acquisition of AVT has been treated as a reverse acquisition in accordance with ASC 805-40 (the &#8220;Reverse Acquisition&#8221;)
 and the business of AVT became the business of the Company. At the time of the Reverse Acquisition

          
 - The Company is a development stage biopharmaceutical company whose business goals are to discover
 develop and commercialize therapeutics to advance the care of patients suffering from cancer.&#160;&#160;The Company&#8217;s activities are supported by its patents
 patent applications
 provisional patent applications
 and other proprietary intellectual property surrounding capridine and immunogens for treatment of infectious diseases and in specific
 prostate cancer
 amongst others.&#160;&#160;To date

          




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 consolidation and basis of presentation of financial statements disclosure.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

NOTE 5.   PROPERTY AND EQUIPMENT (Details) - Schedule of Property
 Plant and Equipment (USD $)











Schedule of Property
 Plant and Equipment [Abstract]
        
        


        

158

158


        

079)
        


Fixed Assets
 net

079

511




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include
 but are not limited to
 land
 buildings
 machinery and equipment
 office equipment
 and furniture and fixtures.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include
 but are not limited to
 land
 buildings
 machinery and equipment
 office equipment
 and furniture and fixtures.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        
        
        
        
        

      










 2014








 2014








 2014

          



 2013



          



 2013





          



 2013





          



 2013



          



 2013



          



 2013





          



 2013





          



 2013



          



 2013



          



 2013






 2013






 2013






 2013








 2013








 2013

          



 2012

          



 2013

          



        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


Loss Contingency
 Damages Sought
 Shares (in Shares)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

000
000

000
000
        
        
        


        
        
        
        
        
        

000

000

000

000

000

000

000

000

000

000
        
        
        
        

392

600

618


Accrued Liabilities
 Current

618

226
        
        
        
        
        
        

000
        
        
        

000
        

000
        
        
        
        

618
        

618


Other Commitments
 Description
        
        
        
        
        

 2013. The Company shall pay Dr. Mittelman $72
000 per annum in common stock in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses
        
        

 to be the Company's Chief Scientific Officer for a term of 4 years.  The agreement was effective on July 1
 2013. The Company shall pay Tiwari $72
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Tiwari shall be paid a signing bonus of $20
000 to be paid over two years in equal increments not less frequently than monthly.

 2013. The Company shall pay Ms. Geliebter $48
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Dr. Geliebter shall be paid a signing bonus of $35
000 to be paid over two years in equal increments not less frequently than monthly.
        
        

 2013. The Company shall pay Mr. Suriano $24
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Dr. Suriano shall be paid a signing bonus of $10
000 to be paid over two years in equal increments not less frequently than monthly. Payments pursuant to consulting agreement shall accrue as of the date of the consulting agreement and commence once the Company has raised $2.5 million through a financing.

 2013. The Company shall pay Banerjee $48
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Banerjee shall be paid a signing bonus of $35
000 to be paid over two years in equal increments not less frequently than monthly.  Payments pursuant to consulting agreement shall accrue as of the date of the consulting agreement and commence once the Company has raised $2.5 million through a financing.

 LLC (a) $2
500 per month in cash
 (b) a monthly amount of registered common shares having a grant date fair value $2
500 (to be calculated at a 25% discount to market) and (c) all pre-approved expenses.
        

 2014.  In connection with the investor relations agreement the Company agreed to (a) pay RedChip a $60
000 cash payment
 which was made on December 13
 2013
 and (b) issue RedChip 200
000 shares of common stock
 which were issue on January 8
 2014.
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

000
        

000
        
        
        
        
        


Shares Issued
 Price Per Share (in Dollars per share)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


Stock Issuable
 Shares
 During Period (in Shares)
        
        
        
        
        
        
        
        
        
        
        
        
        
        

000

200
        
        
        
        
        
        


Stock Issued During Period
 Value
 Issued for Services
        
        

000
        
        
        
        
        
        
        
        
        
        
        
        

040
        
        
        
        
        
        


Stock Issued During Period
 Shares
 Issued for Services (in Shares)
        
        
        

000

630
200
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


Prepaid Expense
 Current

000
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

000
        
        
        
        
        




        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 pertaining to costs that are statutory in nature
 are incurred on contractual obligations
 or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes
 interest
 rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 if longer.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 outsourced management
 technical and staff support.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 but is not limited to
 shares issued for services contributed by vendors and founders.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 but is not limited to
 services contributed by vendors and founders.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          











        
        
        


        

251

436


        

000
        


        

251

436


        

079

511


        

597

772


        

927

719


        
        
        


        

432

735


        

618

226


        

000

000


        

705

705


        

755

666


        
        
        


        
        
        


Preferred stock
 $0.0001 par value: 50
000
000 shares authorized; none issued and outstanding
        
        


Common stock
 $0.0001 par value: 250
000
000 shares authorized; 72
000
000 and 66
289
644 shares issued and outstanding
 respectively

200

629


        

707
680

543
371


        

056
159
        


        

736
867)

830
947)


        

172

947)


        

927

719




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 pertaining to costs that are statutory in nature
 are incurred on contractual obligations
 or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes
 interest
 rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 use the element additional paid in capital
 common stock. For additional paid-in capital associated with only preferred stock
 use the element additional paid in capital
 preferred stock.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 sold
 or consumed within one year (or the normal operating cycle
 if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 and (2) is exposed to potential losses or
 less frequently
 gains
 arising from (a) possible claims against a company's resources due to future performance under contract terms
 and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
              
 -Subparagraph (SX 210.7-03.(a)
19)
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 the issuer does not initially receive the total proceeds. In general
 the issuer does not issue the shares to the investor until it receives the entire proceeds.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 par value and other disclosure concepts are in another section within stockholders' equity.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 excluding goodwill
 as of the balance sheet date
 net of accumulated amortization and impairment charges.
              
 -Subparagraph ((a)(1)
(b))
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 including the portion of equity attributable to noncontrolling interests
 if any.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 if longer.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
 -Subparagraph (SX 210.5-02.19
 -Paragraph 19
 20
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 par value and other disclosure concepts are in another section within stockholders' equity.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 if longer.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include
 but are not limited to
 land
 buildings
 machinery and equipment
 office equipment
 and furniture and fixtures.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 net of receivables from officers
 directors
 owners
 and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest
 minority interest). This excludes temporary equity and is sometimes called permanent equity.
              
 -Paragraph 29
 30
 31
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          



 2011



          



 2011



          



 2011



          



 2011



          



 2011



          



 2011



          



 2012



          



 2012



          



 2012



          



 2013



          



 2013



          



 2013



          



 2013



          



 2010



          



 2013



          



 2013



          



 2013



          



        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


Conversion of stock
 per share
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        




        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        
        

      










        
        
        


        

162
262

016


Operating Loss Carryforwards
 Expiration Date

				 2033
        


Deferred Tax Assets
 Goodwill and Intangible Assets

000
        




        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 before tax effects
 available to reduce future taxable income under enacted tax laws.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 in CCYY-MM-DD format.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        

      






Property
 Plant and Equipment [Abstract]
        


Property
 Plant and Equipment [Table Text Block]
        
    
                

                    


                    








                    


                    








                    


                

                    


                    


                    


                    


                    


                    


                    





                      



                    


                    






                    


                    


                    






                    


                


                      



                    


                    






                    


                    


                    


                    


                    










                    


                    






                    


                    


                    






                    


              




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 but is not limited to
 balances by class of assets
 depreciation and depletion expense and method used
 including composite depreciation
 and accumulated deprecation.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        

      










        
        
        


        
        
        


        
        
        


        
        
        


        
        
        


        

878)

333)


        

428)

999)


        

306)

332)


        

306)

332)


        

306

332


        
        
        




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
 -Subparagraph (a)
(b)
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        
        
        
        
        

      














 2014








 2013

          



 2013






        
        
        
        
        
        
        


Business Acquisition
 Equity Interest Issued or Issuable
 Number of Shares (in Shares)
        
        
        
        
        

000
000


Business Acquisition
 Percentage of Voting Interests Acquired
        
        
        
        
        
        


Stock Repurchased and Retired During Period
 Shares (in Shares)
        
        
        
        
        

000
000


Business Combination
 Recognized Identifiable Assets Acquired and Liabilities Assumed
 Current Liabilities
 Long-term Debt
        

320
        
        
        
        


Debt Instrument
 Convertible
 Conversion Price (in Dollars per share)
        
        
        
        
        
        


Common Stock
 Value
 Subscriptions
        

056
159
        
        
        

320


Stock Issued During Period
 Shares
 Conversion of Convertible Securities (in Shares)
        
        
        

596
        
        


        

500
000

500
000
        
        

500
000
        


Shares Issued
 Price Per Share (in Dollars per share)
        
        
        
        
        
        


        
        
        
        
        

999
        


Stock Issuable
 Shares
 During Period (in Shares)
        
        
        
        

550
000
        


        
        
        
        
        

800
        




        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 if longer
 assumed at the acquisition date.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 the issuer does not initially receive the total proceeds. In general
 the issuer does not issue the shares to the investor until it receives the entire proceeds.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
 -Paragraph 29
 30
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
 -Paragraph 29
 30
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    


















/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software
 Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */
var Show = {};
Show.LastAR = null
Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};
Show.showAR = function ( link
 id
 win ){
	if( Show.LastAR ){
		Show.hideAR();
	}
	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');
	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);
		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}
	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};
Show.toggleNext = function( link ){
	var ref = link;
	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );
	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';
		if( link.textContent ){
			link.textContent = link.textContent.replace( '+'
 '-' );
		}else{
			link.innerText = link.innerText.replace( '+'
 '-' );
		}
	}else{
		ref.style.display = 'none';
		if( link.textContent ){
			link.textContent = link.textContent.replace( '-'
 '+' );
		}else{
			link.innerText = link.innerText.replace( '-'
 '+' );
		}
	}
};











    
  
      

          

        
        

      














        
        
        
        


        

920)

271)

736
867)


        
        
        
        


        

175

174

403


        
        
        

500


        
        
        

079


        

040
        

131
540


        
        
        
        


        

000)
        

000)


        

089

165

050


        

184)

501)

845
295)


        
        
        
        


        
        
        

158)


        
        
        

000)


        
        
        

158)


        
        
        
        


Proceeds received from issuance of common stock
 net of issuance costs

000

000

500


        

999
        

999


        
        
        

000


        
        
        

205


        

999

000

653
704


        

815

499

251


        

436

937
        


        

251

436

251


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        

320
        

320


        

800
        

800



          

        
        
        


        
        
        
        


        
        
        

869



          

        
        
        


        
        
        
        


        
        
        
        




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 federal
 state
 and local authorities as taxes on income.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on
 and a return of
 their investment; borrowing money and repaying amounts borrowed
 or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property
 plant
 and equipment and other productive assets.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 including discontinued operations. Operating activity cash flows include transactions
 adjustments
 and changes in value not defined as investing or financing activities.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 net of income taxes
 which is attributable to the parent.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 liability
 equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. Part noncash refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 excluding goodwill.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 preferred stock
 treasury stock
 stock options
 and other types of equity.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 owners or officers and their immediate families
 pension trusts
 and so forth. Alternate caption: Proceeds from Advances from Affiliates.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 equity-based employee remuneration. This may include the value of stock or unit options
 amortization of restricted stock or units
 and adjustment for officers' compensation. As noncash
 this element is an add back when calculating net cash generated by operating activities using the indirect method.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          











Preferred stock
 par value (in Dollars per share)
        
        


Preferred stock
 shares authorized

000
000

000
000


Preferred stock
 shares issued
        
        


Preferred stock
 shares outstanding
        
        


Common stock
 par value (in Dollars per share)
        
        


Common stock
 shares authorized

000
000

000
000


Common stock
 shares issued

000
000

289
644


Common stock
 shares outstanding

000
000

289
644




        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners
 and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 repurchased
 and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        

      






        
        


        
        
            
          
            
          

 the Company is subject to legal proceedings arising in the ordinary course of business. Such matters are subject to uncertainties and outcomes are not predictable with assurance. Management believes at this time
 there are no ongoing matters that will have a material adverse effect on the Company's business
 consolidated financial position
 results of operations
 or cash flows

          

 2013
 Highland Global Creek Partners
 Inc. (the &#8220;Plaintiffs&#8221;) brought an action against the Company in the Supreme Court of New York
 County of New York
 alleging a breach of a consulting contract. The Plaintiffs are seeking a judgment directing the Company to issue and deliver 80
000
000 shares of common stock and 10
000
000 shares of Series A Preferred Stock.&#160;&#160;In addition
 the Plaintiffs are also seeking an order enjoining the Company from taking any action requiring shareholder approval without notice to Plaintiffs and/or the Plaintiffs participation
 as well as an order declaring that any action requiring stockholder approval taken by the Company without notice to and/or the participation of the Plaintiffs is null and void.&#160;&#160;The Company has filed counterclaims against the Plaintiffs and has not made any formal settlement demand.&#160;&#160;To date

          
            
          

 the Company considered certain executives to be consultants of the Company rather than employees.&#160; If the executives were treated as employees during the above period
 the Company would have been required to withhold and remit payroll taxes to the respective taxing authorities. This position may be subject to audit by the Internal Revenue Service and other state and local taxing authorities
 which
 upon review
 could result in an unfavorable outcome if it is determined that such individuals&#8217; compensation should have been reported on the basis of an employee rather than a consultant.&#160; The Company has recorded charges of approximately $40
392 and $8
600 for the years ended December 31
 2013 and 2012 and approximately $182
618 for the period from July 24
 2007 (inception) to December 31
 2013 in consulting and research and development fees on the
            statements of operations for additional compensation (including penalties and interest) on behalf of the executives should the Company be challenged by the taxing authorities and it is determined their position is without merit. As of December 31
 2013
 $ 182

          
            
          

 2013 the Company entered into a consulting agreement with Dr. Abraham Mittelman to be the Company&#8217;s Chief Executive Officer for a term of 4 years.&#160;&#160;The agreement was effective on July 1
 2013. The Company shall pay Dr. Mittelman $72
000 per annum in common stock in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In connection with this agreement
 the Company incurred research consulting expense of $36
000 for the year ended December 31
 2013

          

 2013 the Company entered into a consulting agreement with Tiwari
 to be the Company&#8217;s Chief Scientific Officer for a term of 4 years.&#160;&#160;The agreement was effective on July 1
 2013. The Company shall pay Tiwari $72
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Tiwari shall be paid a signing bonus of $20
000 to be paid over two years in equal increments not less frequently than monthly.&#160;&#160;The Company incurred expenses associated with Dr. Tiwari&#8217;s consulting services of $96
000 for the year ended December 31
 2013
 of which $56
000 related to the above agreement and the remaining $40
000 related to payment for services provided before the agreement was entered into.&#160;&#160;Of the total amount
            incurred by the Company
 $20
000 remains in accrued expenses at December 31

          

 2013 the Company entered into a consulting agreement with Dr. Jan Geliebter to be the Company&#8217;s Secretary for a term of 4 years.&#160;&#160;The agreement was effective on July 1
 2013. The Company shall pay Ms. Geliebter $48
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Dr. Geliebter shall be paid a signing bonus of $35
000 to be paid over two years in equal increments not less frequently than monthly. The Company incurred consulting expenses associated with Dr. Geliebter&#8217;s services of $59
000 in connection with the above agreement for the year ended December 31
 2013
 which remains in accrued expenses at December 31

          

 2013 the Company entered into a consulting agreement with Dr. Robert Suriano to be the Company&#8217;s Lab Manager for a term of 2 years.&#160;&#160;The agreement was effective on July 1
 2013. The Company shall pay Mr. Suriano $24
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Dr. Suriano shall be paid a signing bonus of $10
000 to be paid over two years in equal increments not less frequently than monthly. Payments pursuant to consulting agreement shall accrue as of the date of the consulting agreement and commence once the Company has raised $2.5 million through a financing. The Company incurred expenses associated with Dr. Suriano&#8217;s consulting services of $27
000 for the year ended December 31
 2013
 of which
            $22
000 related to the above agreement and the remaining $5
000 related to payment for services provided before the agreement was entered into.&#160;&#160;Of the amount incurred by the Company
 $20
000 remains in accrued expenses at December 31

          

 2013 the Company entered into a consulting agreement with Banerjee&#160;to be a research consultant for the Company for a term of 4 years.&#160;&#160;The agreement was effective on July 1
 2013. The Company shall pay Banerjee $48
000 per annum in equal increments not less frequently than monthly with a five (5) percent annual increase plus normal out of pocket expenses. In addition
 in connection with the execution of the agreement
 Banerjee shall be paid a signing bonus of $35
000 to be paid over two years in equal increments not less frequently than monthly.&#160;&#160;Payments pursuant to consulting agreement shall accrue as of the date of the consulting agreement and commence once the Company has raised $2.5 million through a financing. The Company incurred consulting expenses associated with Dr. Banerjee&#8217;s services of $59
000 for the year ended December 31
 2013 in
            connection with the above agreement
 which remains in accrued expenses at December 31

          


          

 2013
 the Company engaged TotalCFO
 LLC to provide consulting services related to its financial reporting for a period of one year unless sooner terminated by either party upon (90) days written notice. The Company shall pay TotalCFO
 LLC (a) $2
500 per month in cash
 (b) a monthly amount of registered common shares having a grant date fair value $2
500 (to be calculated at a 25% discount to market) and (c) all pre-approved expenses.&#160;&#160;The Company incurred professional fees expense to TotalCFO
 LLC of $20
000 for the year ended December 31
 2013
 of which $10
000 was paid and $10
000 remains in accrued expenses at December 31
 2013. The amount in accrued expenses was originally to be paid in shares of registered common stock
 however since the Company has not filed a registration statement they did not have registered shares to issue. Total CFO
 LLC agreed to settle and
            accept shares of unregistered common stock at an amount calculated using the same per share price as the Private Placement of $0.20
 or 50

          

 2014
 the Company agreed to issue Total CFO
 LLC 100
000 shares of common stock at similar terms to the shares issued in the Private Placement as a one-time bonus for consideration of their services in connection with the Company&#8217;s going-public transaction.&#160;&#160;The Company has determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered. During the year ended December 31
 2013
 the Company recorded $20
000 of consulting expense related to this arrangement. The shares were issued on January 8

          


          

 2012 the Company entered into an agreement with RedChip Companies
 Inc. (&#8220;RedChip&#8221;) to assist the Company with various legal
 professional
 investor relations and other services in connection with a going-public transaction involving the Company.&#160;&#160;In December of 2013
 the Company and RedChip agreed to amend the terms of the agreement whereby the Company would issue RedChip 805
200 shares of common stock in full satisfaction for amounts owed in connection with services performed by RedChip at $0.20 per share.&#160;&#160;&#160;The Company has determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered and as a result
 the Company included $161
040 in consulting fees on the consolidated statements of operations for the year ended December 31
 2013 and a corresponding accrual to shares
            issuable.&#160;&#160;The shares were issued on January 8

          

 in December 2013
 the Company entered into an investor relations agreement with RedChip for a term of three months commencing January 1
 2014.&#160;&#160;In connection with the investor relations agreement the Company agreed to (a) pay RedChip a $60
000 cash payment
 which was made on December 13
 2013
 and (b) issue RedChip 200
000 shares of common stock
 which were issue on January 8
 2014.&#160;&#160;The Company has included the $60
000 in prepaid expenses on its consolidated balance sheet as of December 31

          




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        
        
        

      














        
        
        
        


        

 Inc.
        
        


        
        
        
        


        
        
        
        


Entity Common Stock
 Shares Outstanding
        

480
796
        


        
        
        

000


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        
        
        
        


        

				 2013
        
        


        
        
        
        


        
        
        
        




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 then the document is an amendment to previously-filed/accepted document.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 which may also provide financial information from prior periods
 the first fiscal quarter should be given as the fiscal period focus. Values: FY
 Q1
 Q2
 Q3
 Q4
 H1
 H2
 M9
 T1
 T2
 T3
 M8
 CY.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 which may also provide financial information from prior periods
 fiscal 2006 should be given as the fiscal year focus. Example: 2006.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 it is the date up through which that historical data is presented.  If there is no historical data in the report
 use the filing date. The format of the date is CCYY-MM-DD.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 10-Q
 485BPOS
 etc). The document type is limited to the same value as the supporting SEC submission type
 or the word Other.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member]
 Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings
 Instrument.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 (2) Accelerated Filer
 (3) Non-accelerated Filer
 (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 or average bid and asked price of such common equity
 as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 which is required by forms filed with the SEC.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K
 10-Q
 8-K
 20-F
 6-K
 10-K/A
 10-Q/A
 20-F/A
 6-K/A
 N-CSR
 N-Q
 N-1A.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        

      






        
        


        
        
            
          
On January 8
 2014
 the Company issued (a) 3
550
000 shares of common stock&#160;in connection with the&#160;cash proceeds&#160;received in&#160;the Private Placement received in December 2013
 (b) 36
596&#160;shares of common stock in exchange for the cancellation of $7
520 in notes payable
 (c) 264
000 shares of common stock for placement agent services and (d) 1
630
200 shares of common stock for other services. In connection with the foregoing the Company relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933
 as amended
 for transactions not involving a public offering.
            

 2014
 the Company entered into an agreement with John Carris Investments
 LLC (&#8220;John Carris&#8221;) to act on behalf of the Company as its non-exclusive placement agent and assist the Company in raising up to a maximum of $3.5 million.&#160;&#160;In consideration for such services
 the Company will pay John Carris (a) a cash placement fee of 10% of the total purchase price of securities sold
 including all amounts received by the Company upon exercise of any warrants issued in such raise
 (b) a non-accountable expense allowance in the amount of 2% of the aggregate consideration received by the Company
 and (c) warrants in an aggregate amount equal to 8% of the number of common shares issued by the Company in a raise.&#160;&#160;The agreement terminates on June 10

          

 2014
 the Company amended its original private placement memorandum dated September 30
 2013 to (a) increase the amount the Company is offering to $3
500
000 from $2
500
000 and (b) to add a warrant to the offering to purchase one share of Common Stock at an exercise price of $0.40 and exercisable for a period of sixty (60) months after initial exercise date.&#160;&#160;To date
 no additional proceeds other than as disclosed in Note 1

          




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 purchase of a business
 settlement of litigation
 catastrophic loss
 significant foreign exchange rate changes
 loans to insiders or affiliates
 and transactions not in the ordinary course of business.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        
        

      














        
        
        
        


        
        
        
        


        

476

960

892
019


        

692

335

258
109


        

812

467

557


        

809

976

346


        

607

605

482


        

396

343

733
513


        

396)

343)

733
513)


        
        
        
        


Interest (expense) income
 net
        
        

204


        
        

946)

558)


        
        

928)

354)


        

920)

271)

736
867)


        
        
        
        


        

504
224

242
612
        




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 intangible assets
 or depleting assets to periods that benefit from use of the assets.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 pending or threatened litigation
 including arbitration and mediation proceedings.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 net of income taxes
 which is attributable to the parent.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 excluding major activities considered part of the normal operations of the business).
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 general and administrative expense.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 the components of which are not separately disclosed on the income statement
 resulting from ancillary business-related activities (that is
 excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends
 (b) interest on securities
 (c) net gains or losses on securities
 (d) unusual costs
 (e) gains or losses on foreign exchange transactions
 and (f) miscellaneous other income and expense items.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 lawyers and accountants. The term is often expanded to include other professions
 for example
 pharmacists charging to maintain a medicinal profile of a client or customer.
              
 -Subparagraph (SX 210.6-07.2(a)
(b)
(c)
(d))
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 a new process or technique
 or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use
 during the reporting period charged to research and development projects
 including the costs of developing computer software up to the point in time of achieving technological feasibility
 and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 services rendered
 insurance premiums
 or other activities that constitute an earning process. Includes
 but is not limited to
 investment and interest income before deduction of interest expense when recognized as a component of revenue
 and sales and trading gain (loss).
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 as well as all other general and administrative expenses. Direct selling expenses (for example
 credit
 warranty
 and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products
 for example telephone expenses
 Internet
 and postal charges. General and administrative expenses include salaries of non-sales personnel
 rent
 utilities
 communication
 etc.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        

      






Property
 Plant and Equipment [Abstract]
        


Property
 Plant and Equipment Disclosure [Text Block]
        
            
          
            
          
                

                    


                    








                    


                    








                    


                

                    


                    


                    


                    


                    


                    


                    





                      



                    


                    






                    


                    


                    






                    


                


                      



                    


                    






                    


                    


                    


                    


                    










                    


                    






                    


                    


                    






                    


Depreciation expense amounted to $432 and $431 for the years ended December 31
 2013 and 2012
 respectively. Depreciation expense for the period from July 24
 2007 (inception) to December 31
 2013 was $1
079.




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 physical assets used in the normal conduct of business and not intended for resale. Includes
 but is not limited to
 accounting policies and methodology
 roll forwards
 depreciation
 depletion and amortization expense
 including composite depreciation
 accumulated depreciation
 depletion and amortization expense
 useful lives and method used
 income statement disclosures
 assets held for sale and public utility disclosures.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        

      






        
        


        
        
            
          

 2010
 the Company entered into an assignment and assumption agreement (the &#8220;Prostagenics Agreement&#8221;) with Prostagenics
 LLC (&#8220;Prostagenics&#8221;)
 an entity for which two of the Company&#8217;s stockholders own a non-controlling interest (See Note 9).&#160;&#160;Pursuant to the Prostagenics Agreement
 the Company was assigned
 among other things
 the exclusive license covering certain patent rights
 technology
 know-how and preclinical research data relating to the treatment of certain cancers.&#160;&#160;Pursuant to the Prostagenics Agreement
 as consideration for the intangible assets acquired

          



                    


                


000 in four (4) installments through April 1
 2011




            



                    


                


500 of research and development expenses incurred by Prostagenics (See Note 7)




            



                    


                


000 within fifteen (15) days upon completing a phase I clinical trial as defined by the Food and Drug Administration (&#8220;FDA&#8221;)




            



                    


                


500




            

 and contains a rate of interest of 5% per annum.&#160;&#160;The note is convertible into shares of the Company&#8217;s common stock at a 20% discount of the average closing price of the Company&#8217;s common stock for the ten (10) business days prior to the conversion
 subject to a minimum floor price of $0.50 per share.&#160;&#160;If the Company&#8217;s shares are publicly traded

          

 the Company will add the value of the consideration paid to Prostagenics to the value of the intangible assets.On June 24
 2008
 the Company entered into a Supported Research and License Agreement with New York Medical College (&#8220;NYMC&#8221;)
 a related party (the &#8220;NYMC Agreement&#8221;).&#160;&#160;Pursuant to the NYMC Agreement
 the Company was assigned
 among other things
 the exclusive royalty-bearing license covering certain patent rights
 technology
 and know-how relating to the treatment of certain cancers.&#160;&#160;Pursuant to the NYMC Agreement
 the Company made a payment to NYMC consisting of
            a cash licensing fee of $30

          



                    


                


000
000
 2% for sales between $20
000
001 - $50
000
000
 and 1% of sales in excess of $50
000




            



                    


                


000
000
 2% for sales between $2
000
001 - $5
000
000
 and 3% of sales in excess of $5
000




            



                    


                


 royalties from sublicenses
 maintenance fees or similar charges received from sublicenses




            


          

 2013 and 2012

          
                  

                      


                      








                      


                      








                      





                        



                      


                      






                      


                      


                      






                      


                  


                        



                      


                      






                      


                      


                      






                      










                      


                      






                      


                      


                      






                      


                
                  


Estimated future amortization is as follows at December 31
 2013:



                      


                  

                      


                      


                      


                      


                      


                  

                      


                      


                      


                      


                      










                      


                      






                      


                  







                      


                      






                      










                      


                      






                      


                  







                      


                      






                      










                      


                      






                      


                  


                        



                      


                      






                      




                      


                      


                      






                      


                

175 for the year ended December 31
 2013 and $20
174 for the year ended December 31
 2012. Amortization expense for the period from July 24
 2007 (inception) to December 31
 2013 was $82

          




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        

      






        
        


        
        
    
                

                    


                    



December 31
 2013



                    


                    



December 31
 2012



                    


                


                      



                    



                      



                    


                    



                      



                    





                      



                    


                    


                    


                    


                    


                    


                    


                    


                


                      



                    


                    


                    


                    


                    


                    


                    


                    





                      



                    


                    


                    


                    


                    


                    


                    


                    


                


                      



                    


                    


                    


                    


                    


                    


                    


                    





                      



                    


                    






                    


                    


                    






                    


                


                      



                    


                    






                    


                    


                    






                    





                      



                    


                    






                    


                    


                    






                    


                


                      



                    


                    






                    


                    


                    






                    





                      



                    


                    






                    


                    


                    






                    


                


                      



                    


                    


                    


                    


                    


                    


                    


                    


              


        
        
    
                


                      



                    



December 31
 2013



                    


                    



December 31
 2012



                    





                      



                    


                    


                    


                    


                    


                    


                    


                    


                







                    


                    


                    


                    


                    


                    


                    


                    






 state and local tax rate




                    


                    


                    


                    


                    


                    


                    


                    


                


                      



                    


                    


                    


                    


                    


                    


                    


                    





                      



                    


                    


                    


                    


                    


                    


                    


                    


              


        
        
    
                

                    


                    



December 31
 2013



                    


                    



December 31
 2012



                    


                

                    


                    


                    


                    


                    


                    


                    





                      



                    


                    






                    &#160;


                    


                    






                    &#160;


                


                      



                    


                    






                    &#160;


                    


                    






                    &#160;





                      



                    


                    






                    


                    


                    


                    


                    


                


                      



                    


                    






                    &#160;


                    


                    






                    &#160;





                      



                    


                    






                    


                    


                    






                    


                


                      



                    


                    


                    


                    


                    


                    


                    


                    


              




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 but not limited to: current tax expense (benefit)
 deferred tax expense (benefit)
 investment tax credits
 government grants
 the benefits of operating loss carryforwards
 tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity
 adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity
 and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 including the following: the total of all deferred tax liabilities
 the total of all deferred tax assets
 the total valuation allowance recognized for deferred tax assets.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

Accounting Policies
 by Policy (Policies)

        

      






        
        


Consolidation
 Policy [Policy Text Block]
 The consolidated financial statements include the accounts of AV Therapeutics
 Inc. and its wholly-owned subsidiary
 Advanced Vaccine Therapeutics
 Inc. Intercompany balances and transactions have been eliminated upon consolidation.


Basis of Accounting
 Policy [Policy Text Block]
        
          
and its primary activities since inception have been the research and development of its therapeutics
 negotiating strategic alliances and other agreements

 the Company's activities have been accounted for as those of a Development Stage Company as defined by ASC 915.


Use of Estimates
 Policy [Policy Text Block]
The Company prepares the financial statements in accordance with U.S. GAAP which
 requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;&#160;The Company&#8217;s significant estimates and assumptions include the recoverability and useful lives of long-lived assets
 the fair value of the Company&#8217;s stock
 stock-based compensation
 and the valuation allowance related to the Company&#8217;s deferred tax assets. Certain of the Company&#8217;s estimates
 including the carrying amount of the intangible assets
 could be affected by external conditions
 including those unique to the Company and general economic conditions. It is reasonably
            possible that these external factors could have an effect on the Company&#8217;s estimates and could cause actual results to differ from those estimates.


Cash and Cash Equivalents
 Policy [Policy Text Block]
 Cash equivalents are comprised of all highly liquid investments with an original maturity of three months or less when purchased.&#160;&#160;At December 31
 2013 and 2012
 the Company had no cash equivalents.


Concentration Risk
 Credit Risk
 Policy [Policy Text Block]
 - Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains its cash balances in high quality financial institutions located in the United States which mitigate such risk associated with them. At times
 the Company&#8217;s cash balances may be uninsured or in deposit accounts that exceed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits.


Research and Development Expense
 Policy [Policy Text Block]
 Research and development expenses consist primarily of costs associated with the preclinical and/ or clinical trials of drug candidates
 compensation and other expenses for research and development
 including personnel
 supplies and development materials
 costs for consultants and related contract research and facility costs. Expenditures relating to research and development are expensed as incurred.


Deferred Charges
 Policy [Policy Text Block]
 - Property and equipment are stated at cost
 net of accumulated depreciation which is recorded using the straight line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives
 which range from 5 to 7 years. Maintenance and repairs are charged to operations as incurred.


Intangible Assets
 Finite-Lived
 Policy [Policy Text Block]
Intangible assets are comprised of patents and licenses with original estimated useful lives of 10-15 years.&#160;&#160;Once placed into service
 the Company amortizes the cost of the intangible assets over their estimated useful lives on a straight line basis. As of December 31
 2013 the Company owns one patent that was internally developed and licenses two patents (See Note 4) and also has exclusive rights to two immunological patents related to vaccine development and delivery mechanism. Costs incurred by the Company in connection with developing patents internally are expensed as incurred.


Impairment or Disposal of Long-Lived Assets
 Policy [Policy Text Block]
        


Revenue Recognition
 Policy [Policy Text Block]
 Revenue from license fees and grants is recognized when the following criteria are met: persuasive evidence of an arrangement exists
 services have been rendered
 the contract price is fixed or determinable
 and collection is reasonably assured.&#160;&#160;In licensing arrangements
 delivery does not occur for revenue recognition purposes until the license term begins. Nonrefundable upfront fees received in exchange for products delivered or services performed that do not represent the culmination of a separate earnings process will be deferred and recognized over the term of the agreement using the straight line method or another method if it better represents the timing and pattern of performance. For the years ended December 31
 2013 and 2012 and for the period from July 24
 2007 (inception) to December 31
 2013
 the

          

 revenue arrangements with multiple deliverables are divided into separate units of accounting if the delivered item has value to the customer on a standalone basis and there is objective and reliable evidence of the fair value of the undelivered item.


Earnings Per Share
 Policy [Policy Text Block]
 Basic loss per share was computed using the weighted average number of common shares outstanding. Diluted loss per share includes the effect of diluted common stock equivalents. As of December 31
 2013
 and 2012
 the Company did not have any common stock equivalents outstanding.


Fair Value of Financial Instruments
 Policy [Policy Text Block]
 -&#160;The financial instruments consist of cash
 accounts payables
 accrued expenses
 and short-term credit obligations.&#160;&#160;The carrying amounts of the financial instruments approximate their respective current fair values due to their relatively short maturities.&#160;The carrying amounts of short term credit obligations approximate fair value because the effective yields on these obligations
 which include contractual interest rates

          


          
            
          

 quoted prices from active market exchanges
 including over the counter traded financial instruments. The prices for the financial instruments are determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs

          

 if any
 market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques.


Share-based Compensation
 Option and Incentive Plans Policy [Policy Text Block]
 - The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors
 the fair value of the award is measured on the grant date and for non-employees
 the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award
 usually the vesting period.


Income Tax
 Policy [Policy Text Block]
 - The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740
 Income Taxes. Under this method
 income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity's financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred
            tax assets reported if based on the weight of the available positive and negative evidence

          

 classification
 interest and penalties
 accounting in interim periods
 disclosure
 and transition. The Company will classify as income tax expense any interest and penalties. The Company has no material uncertain tax positions for any of the reporting periods presented. Generally
 the tax authorities may examine the partnership/corporate tax returns for three years from the date of filing. The Company has identified its federal return and its state tax return in New York as &#8220;major&#8221; tax jurisdictions
 as defined.


New Accounting Pronouncements
 Policy [Policy Text Block]
 The FASB has issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2013-11
 Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward
 a Similar Tax Loss
 or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU state that an unrecognized tax benefit
 or a portion of an unrecognized tax benefit
 should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward
 a similar tax loss
 or a tax credit carryforward
 except as follows. To the extent a net operating loss carryforward
 a similar tax loss
 or a tax credit carryforward is not available at the reporting
            date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use
 and the entity does not intend to use
 the deferred tax asset for such purpose
 the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The amendments in this ASU are effective for fiscal years
 and interim periods within those years
 beginning after December 15
 2013. For nonpublic entities
 the amendments are effective for fiscal years
 and interim periods within those years
 beginning after December 15
 2014. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption of this standard is not expected to have a material
            impact on the Company&#8217;s consolidated financial position and consolidated results of operations.


Subsequent Events
 Policy [Policy Text Block]
        




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 or basis of presentation
 used to prepare the financial statements (for example
 US Generally Accepted Accounting Principles
 Other Comprehensive Basis of Accounting
 IFRS).
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents
 (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk
 (3) the classification of any negative balance accounts (overdrafts)
 and (4) the carrying basis of cash equivalents (for example
 at cost) and whether the carrying amount of cash equivalents approximates fair value.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example
 common stock
 a partnership interest or other means of exerting influence) in other entities
 for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions
 noncontrolling interest
 and the income statement treatment in consolidation for issuances of stock by a subsidiary.
              
 -Section 02
 03
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 including any antidilutive items that have been excluded from the computation and takes into account stock dividends
 splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances
 recognizing investment tax credits
 operating loss carryforwards
 tax credit carryforwards
 and other carryforwards
 methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 but is not limited to
 quantification of the expected or actual impact.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 a new process or technique
 or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example
 delivery of multiple products
 services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 and the methodologies and significant assumptions used to determine that measurement.
              
 -Subparagraph (b)
(f)
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        

      






        
        


        
        
            
          

 2013 and 2012
 the Company generated U.S. federal and state net operating loss carryovers for tax purposes of approximately $1
162
262 and $441
016
 respectively. The net operating loss carryover may be used to reduce taxable income through the year 2033. Section 382 of the Internal Revenue Code imposes certain limitations on the utilization of net operating loss carryovers and other tax attributes after a change in control. If the Company has a change in ownership

          
            
          
                

                    


                    



December 31
 2013



                    


                    



December 31
 2012



                    


                


                      



                    



                      



                    


                    



                      



                    





                      



                    


                    


                    


                    


                    


                    


                    


                    


                


                      



                    


                    


                    


                    


                    


                    


                    


                    





                      



                    


                    


                    


                    


                    


                    


                    


                    


                


                      



                    


                    


                    


                    


                    


                    


                    


                    





                      



                    


                    






                    


                    


                    






                    


                


                      



                    


                    






                    


                    


                    






                    





                      



                    


                    






                    


                    


                    






                    


                


                      



                    


                    






                    


                    


                    






                    





                      



                    


                    






                    


                    


                    






                    


                


                      



                    


                    


                    


                    


                    


                    


                    


                    


              
            
          
                


                      



                    



December 31
 2013



                    


                    



December 31
 2012



                    





                      



                    


                    


                    


                    


                    


                    


                    


                    


                







                    


                    


                    


                    


                    


                    


                    


                    






 state and local tax rate




                    


                    


                    


                    


                    


                    


                    


                    


                


                      



                    


                    


                    


                    


                    


                    


                    


                    





                      



                    


                    


                    


                    


                    


                    


                    


                    


              

000. The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely
 a valuation allowance is established. Based upon the Company&#8217;s history of losses since inception
 management believes that it is more likely than not that future benefits of deferred tax assets will not be realized and as a result

          
                

                    


                    



December 31
 2013



                    


                    



December 31
 2012



                    


                

                    


                    


                    


                    


                    


                    


                    





                      



                    


                    






                    &#160;


                    


                    






                    &#160;


                


                      



                    


                    






                    &#160;


                    


                    






                    &#160;





                      



                    


                    






                    


                    


                    


                    


                    


                


                      



                    


                    






                    &#160;


                    


                    






                    &#160;





                      



                    


                    






                    


                    


                    






                    


                


                      



                    


                    


                    


                    


                    


                    


                    


                    


              




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 net change during the year in the total valuation allowance
 approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets
 utilization of a tax carryback
 and tax uncertainties information.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        

      






        
        


        
        
            
          

000
000 authorized shares of blank check preferred stock with a par value of $0.0001. As of December 31
 2013

          

 2007 (inception) and February 11
 2011
 the date that AVT was incorporated
 AVT
 LLC received $930

          

 AVT
 LLC entered into subscription agreements with various accredited investors whereby it received $215
000 and agreed to issue the investors 1
433
339 ($0.15 per share) once AVT was incorporated. The shares were issued on February 11

          

 2011 AVT issued 12
303
336 shares of common stock to various consultants for past professional services and research and development services rendered to the Company.&#160;&#160;The grant date fair value of the shares issued was $1
845
500
 or $0.15 per share
 of which $1
170
250 was included in consulting fees and $ 675
250 was included in research and development expenses on the statements of operations for the period from July 24
 2007 (inception) to December 31
 2013.&#160;&#160;Of the total number of common shares issued
 4
000
000 shares were issued to Mr. Robert Pollack
 the Company&#8217;s current President
 and 6
470
000 were issue to Mr. Morton Coleman
 the Company&#8217;s current Vice President.&#160;&#160;As of December 31
 2013 and 2012

          

 AVT sold 2
196
673 shares of common stock at $0.15 per share for aggregate proceeds of $329
500. AVT incurred issuance costs of $20
000 associated with such offerings
 resulting in net proceeds of $309
500.&#160;&#160;Of the total shares issued in 2011
 30
000 were issued to Mr. Morton Coleman
 the Company&#8217;s current Vice President for $0.15 cents per share
 or gross proceeds of 4

          

 AVT sold 1
666
667 shares of common stock at $0.15 per share for aggregate proceeds of $250

          

 AVT sold 1
166
666 shares of common stock at $0.15 per share for aggregate proceeds of $175

          

 AVT sold 249
998 shares of common stock at $0.20 per share for aggregate proceeds of $50

          




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 including other comprehensive income. Includes
 but is not limited to
 balances of common stock
 preferred stock
 additional paid-in capital
 other capital and retained earnings
 accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
              
 -Paragraph 29
 30
 -Subparagraph (SX 210.4-08.(d)
(e))
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        

      






        
        


        
        
            
          

205 on July
 24
 2007 (inception) which remained outstanding as of December 31

          

 2010
 Prostagenics received various services from three consultants (two of whom are stockholders of the Company) in connection with the continued research and development of cancer treatments supported by the patents identified in the Prostagenics Agreement.&#160;&#160;Through February 5
 2010
 Prostagenics had unpaid consulting fees accrued to these consultants in the amount of $284
500.&#160;&#160;As disclosed in Note 4
 in connection with the Prostagenics Agreement
 AVT reimbursed Prostagenics $284
500 through the assumption of such liabilities.&#160;&#160;The Company has included the $284
500 as research and development expense on the consolidated statements of operations for the period from July 24
 2007 (inception) to December 31

          

 $125
000 and $62
500 are payable to Dr. Raj Tiwari (&#8220;Tiwari&#8221;) and Dr. Debabrata Banerjee (&#8220;Banerjee&#8221;)
 respectively

          

000 is payable to the estate of Daniel Miller

          

 Dr. Abraham Mittelman
 advanced the Company $11
000 in February 2011. The advance is non-interest bearing and the Company has agreed to repay the advance with common stock at $0.20 per share at a future date to be determined.&#160;&#160;As of December 31
 2013 and 2012

          




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 which includes amounts of borrowings under each line of credit
 note payable
 commercial paper issue
 bonds indenture
 debenture issue
 own-share lending arrangements and any other contractual agreement to repay funds
 and about the underlying arrangements
 rationale for a classification as long-term
 including repayment terms
 interest rates
 collateral provided
 restrictions on use of assets and activities
 whether or not in compliance with debt covenants
 and other matters important to users of the financial statements
 such as the effects of refinancing and noncompliance with debt covenants.
              
 -Paragraph 19
 20
 -Subparagraph (SX 210.5-02.19
20
22)
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        

      






        
        


        
        
            
          

 LLC

          
            
          

 an entity owned by the wife of the Company&#8217;s President
 on a month to month basis for $1
200 per month. The arrangement commenced in 2012.&#160;&#160;Rent expense for each of the years ended December 31
 2013 and 2012 was $14
400 in connection with this arrangement
 of which $5
000 is included in accounts payable and accrued expenses as of December 31

          
            
          

 the Company reached an agreement with a member of its Board of Directors
 Mr. Douglas Cole
 whereby the Company agreed to issue 200
000 shares of common stock to Mr. Cole for his past services as a Director at similar terms to the shares issued in the Private Placement.&#160;&#160;The Company has determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered.&#160;&#160;During the year ended December 31
 2013
 the Company recorded $40
000 in connection with this issuance which is included in consulting fees in the statement of operations with a corresponding accrual to shares issuable. Due to administrative delays
 the shares were issued on January 8

 2014
 Mr. Cole resigned as a director of AV Therapeutics
 Inc.
          
            
          

 2013 the Company engaged Sichenzia Ross Friedman Ference LLP (&#8220;SRFF&#8221;) as its legal representative for a going public transaction. The Company agreed to pay SRFF $50
000 and 325
000 shares of common stock for providing this service. Once the Company was able to complete such transaction
 which it did in December 2013
 the Company agreed to pay $4
500 per month for general legal matters
 for which the Company will have the option to pay such fees in registered common stock valued at $6
000. The Company has determined that the fair market value of the stock was more readily available than the fair market value of the services rendered. The Company paid SRFF the $50
000 in cash during the year ended December 31
 2013 and has included the value of the common stock to be issued of $65
000 in&#160;&#160;shares issuable on the consolidated balance sheet as of December 31
 2013
            with a corresponding charge to consulting fees on the statement of operations. The shares were issued on January 8

          

 Paradox Capital Partners
 LLC
 an entity beneficially owned by Mr. Harvey J. Kesner
 a partner at SRFF
 invested $50
000 in the Private Placement and received 250

          


          

 2012
 the Company entered into an agreement with Objective Equity
 LLC (&#8220;Objective Equity&#8221;) to act on behalf of the Company as its non-exclusive placement agent and assist the Company in raising up to a maximum of $25 million.&#160;&#160;In consideration for such services
 the Company will pay Objective Equity (a) a cash placement fee of 8% of the total purchase price of securities sold
 including all amounts received by the Company upon exercise of any warrants issued in such raise and
 (b) warrants in an aggregate amount equal to 8% of the number of common shares issued by the Company in a raise.&#160;&#160;The agreement terminates on December 13
 2014. Mr. Douglas Cole
 a former Director of the Company is a partner in Objective Equity.&#160;&#160;On January 8
 2014
 the Company amended the terms of its agreement with Objective Equity whereby both parties agreed that
            the Company would issue Objective Equity shares of common stock with a grant date fair value equal to 8% of the total proceeds received by the Company.&#160;&#160;The Company has determined that the fair value of the common stock was more readily determinable than the fair value of the services rendered.&#160;&#160;Of the total proceeds received to date in the Private Placement
 Objective Equity assisted the Company in the raising of the initial $660
000 and as a result
 the Company included $52
800 in shares issuable at December 31
 2013.&#160;&#160;On January 8
 2014
 the Company issued 264

          




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        
        
        
        
        
        
        
        
        
        

      














 2010



          



 2013

          



 2012

          



 2013

          



 2013

          



 2011

          



 2010


 2013 [Member]

          



 2013

          



 2010

          



 2013

          



        
        
        
        
        
        
        
        
        
        
        
        
        
        


Notes Payable
 Related Parties
 Current

705

705

705
        

205

205

000

500
        
        
        
        
        


Debt Instrument
 Interest Rate Terms
        
        
        
        
        
        
        
        
        
        
        
        
        


Debt Instrument
 Payment Terms
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        


Accrued Research and Development Fees
 Current
        
        
        
        
        
        
        
        
        

500
        
        
        


        
        
        

000

500
        
        
        
        
        
        
        
        
        


        

692

335

258
109
        
        
        
        
        
        
        
        
        

500


        
        
        
        
        
        
        
        
        
        
        

000
        
        


        
        
        
        
        

500
000
        
        
        
        
        
        
        
        


Debt Instrument
 Face Amount
        
        
        
        
        
        
        
        

000
        
        
        
        




        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 and
 if variable
 identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate
 and other pertinent information
 such as frequency of rate resets.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 aggregate carrying amount of all types of notes payable
 as of the balance sheet date
 with initial maturities beyond one year or beyond the normal operating cycle
 if longer.
              
 -Paragraph 19
 20
 -Paragraph 13
 16
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 excluding goodwill.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 a new process or technique
 or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use
 during the reporting period charged to research and development projects
 including the costs of developing computer software up to the point in time of achieving technological feasibility
 and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        

      






        
        


        

 2013 and 2012

    
                  

                      


                      








                      


                      








                      





                        



                      


                      






                      


                      


                      






                      


                  


                        



                      


                      






                      


                      


                      






                      










                      


                      






                      


                      


                      






                      


                


Schedule of Finite-Lived Intangible Assets
 Future Amortization Expense [Table Text Block]


    
                  


Estimated future amortization is as follows at December 31
 2013:



                      


                  

                      


                      


                      


                      


                      


                  

                      


                      


                      


                      


                      










                      


                      






                      


                  







                      


                      






                      










                      


                      






                      


                  







                      


                      






                      










                      


                      






                      


                  


                        



                      


                      






                      




                      


                      


                      






                      


                




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 excluding financial assets and goodwill
 lacking physical substance with a finite life
 by either major class or business segment.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          



































        
        
        
        
        
        
        
        
        


        

504
        
        
        
        
        
        
        


        

172

947)

676)

832)

878

891

624
        


Development Stage Enterprise
 Deficit Accumulated During Development Stage

736
867

830
947
        
        
        
        
        
        




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 net of receivables from officers
 directors
 owners
 and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest
 minority interest). This excludes temporary equity and is sometimes called permanent equity.
              
 -Paragraph 29
 30
 31
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        
        
        
        
        

      


















 2014



          



 2014



          



 2014

          



 2014

          



 2012

          



        
        
        
        
        
        
        
        
        
        


Development Stage Entities
 Stock Issued
 Shares
 Issued for Cash
        
        
        
        
        
        
        

550
000
        


Debt Conversion
 Converted Instrument
 Shares Issued
        
        
        
        
        
        
        

596
        


Debt Conversion
 Original Debt
 Amount

320
        

320
        
        
        
        

520
        


Stock Issued During Period
 Shares
 Issued for Services
        
        
        
        
        

000
        

630
200
        


        

500
000
        

500
000

500
000

500
000
        
        
        

000
000


Other Commitments
 Description
        
        
        
        

 including all amounts received by the Company upon exercise of any warrants issued in such raise
 (b) a non-accountable expense allowance in the amount of 2% of the aggregate consideration received by the Company
 and (c) warrants in an aggregate amount equal to 8% of the number of common shares issued by the Company in a raise.  The agreement terminates on June 10
 2014.
        
        
        

 including all amounts received by the Company upon exercise of any warrants issued in such raise and
 (b) warrants in an aggregate amount equal to 8% of the number of common shares issued by the Company in a raise.  The agreement terminates on December 13
 2014. Mr. Douglas Cole
 a former Director of the Company is a partner in Objective Equity.  On January 8
 2014
 the Company amended the terms of its agreement with Objective Equity whereby both parties agreed that the Company would issue Objective Equity shares of common stock with a grant date fair value equal to 8% of the total proceeds received by the Company.


Subsequent Event
 Description
        
        
        
        
        
        

500
000 from $2
500
000 and (b) to add a warrant to the offering to purchase one share of Common Stock at an exercise price of $0.40 and exercisable for a period of sixty (60) months after initial exercise date.
        
        




        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 but is not limited to
 shares issued for services contributed by vendors and founders.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          




          




          




          




          




          




          




          




          




          




          




          




          




          


          




          




          




          




          




          




          




          




          




          




          




          




          




          




          


          




          




          




          




          




          




          


          


          


          


          


          


          


          


          


          


          


          


          


          


          


          


          


          


          


          



Balance at Dec. 31
 2006
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


Balance (in Shares) at Dec. 31
 2006
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        

869
        
        
        
        
        
        
        
        
        
        
        
        
        
        

869)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        

689
629
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

000
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

000


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

376)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

376)


Balance at Dec. 31
 2007
        
        
        
        
        
        
        
        
        
        
        
        
        

869
        
        
        
        
        
        
        
        
        
        
        
        
        
        

131
        
        
        
        
        
        
        

376)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

624


Balance (in Shares) at Dec. 31
 2007
        
        
        
        
        
        
        
        
        
        
        
        
        

689
629
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

000
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

000


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

733)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

733)


Balance at Dec. 31
 2008
        
        
        
        
        
        
        
        
        
        
        
        
        

869
        
        
        
        
        
        
        
        
        
        
        
        
        
        

131
        
        
        
        
        
        
        

109)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

891


Balance (in Shares) at Dec. 31
 2008
        
        
        
        
        
        
        
        
        
        
        
        
        

689
629
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

013)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

013)


Balance at Dec. 31
 2009
        
        
        
        
        
        
        
        
        
        
        
        
        

869
        
        
        
        
        
        
        
        
        
        
        
        
        
        

131
        
        
        
        
        
        
        

122)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

878


Balance (in Shares) at Dec. 31
 2009
        
        
        
        
        
        
        
        
        
        
        
        
        

689
629
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

433
339
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

000
        
        
        
        
        
        
        

000
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

710)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

710)


Balance at Dec. 31
 2010
        
        
        
        
        
        
        
        
        
        
        
        
        

869
        
        
        
        
        
        
        
        
        
        
        
        
        
        

131
        
        
        
        
        
        

000

374
832)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

832)


Balance (in Shares) at Dec. 31
 2010
        
        
        
        
        
        
        
        
        
        
        
        
        

689
629
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

857
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

000)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        

433
339
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        

230
        
        
        
        
        
        
        
        
        
        
        
        
        

844
270
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

845
500
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        

303
336
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

303
336
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

480

933

933

933
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

500

000

000

000
        
        
        
        
        
        
        
        
        
        


        
        
        

667

667

667

672
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

169
844)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

169
844)


Balance at Dec. 31
 2011
        
        
        
        
        
        
        
        
        
        
        
        
        

463
        
        
        
        
        
        
        
        
        
        
        
        
        
        

293
537
        
        
        
        
        
        
        

544
676)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

676)


Balance (in Shares) at Dec. 31
 2011
        
        
        
        
        
        
        
        
        
        
        
        
        

622
977
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

983

934

917
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

000

000

000
        
        
        
        
        
        
        


        
        
        
        
        
        
        

667

667

333
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

271)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

271)


Balance at Dec. 31
 2012
        
        
        
        
        
        
        
        
        
        
        
        
        

629
        
        
        
        
        
        
        
        
        
        
        
        
        
        

543
371
        
        
        
        
        
        
        

830
947)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

947)


Balance (in Shares) at Dec. 31
 2012
        
        
        
        
        
        
        
        
        
        
        
        
        

289
644
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

289
644


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

983

967

933

975
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

000

000

000

000
        
        
        


        
        
        
        
        
        
        
        
        
        

667

333

666

998
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

749)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

320)


        
        
        
        
        
        
        
        
        
        
        
        
        
        

293
692
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

800)
        
        
        

040

320

999

800
        
        
        
        

040
        
        
        
        
        
        
        
        
        
        
        

320

999
        


        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

920)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

920)


Balance at Dec. 31
 2013
        
        
        
        
        
        
        
        
        
        
        
        
        

200
        
        
        
        
        
        
        
        
        
        
        
        
        
        

707
680
        
        
        
        
        
        

056
159

736
867)
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

172


Balance (in Shares) at Dec. 31
 2013
        
        
        
        
        
        
        
        
        
        
        
        
        

000
000
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        

000
000




        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 net of income taxes
 which is attributable to the parent.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 net of receivables from officers
 directors
 owners
 and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest
 minority interest). This excludes temporary equity and is sometimes called permanent equity.
              
 -Paragraph 29
 30
 31
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 but is not limited to
 shares issued for services contributed by vendors and founders.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
 -Paragraph 29
 30
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 but is not limited to
 services contributed by vendors and founders.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
 -Paragraph 29
 30
 31
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        

      






        
        


        
        
            
          
 The consolidated financial statements include the accounts of AV Therapeutics
 Inc. and its wholly-owned subsidiary
 Advanced Vaccine Therapeutics

          
            
          
and its primary activities since inception have been the research and development of its therapeutics
 negotiating strategic alliances and other agreements


          
The Company prepares the financial statements in accordance with U.S. GAAP which
 requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;&#160;The Company&#8217;s significant estimates and assumptions include the recoverability and useful lives of long-lived assets
 the fair value of the Company&#8217;s stock
 stock-based compensation
 and the valuation allowance related to the Company&#8217;s deferred tax assets. Certain of the Company&#8217;s estimates
 including the carrying amount of the intangible assets
 could be affected by external conditions
 including those unique to the Company and general economic conditions. It is reasonably

          
 Cash equivalents are comprised of all highly liquid investments with an original maturity of three months or less when purchased.&#160;&#160;At December 31
 2013 and 2012

          
 - Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains its cash balances in high quality financial institutions located in the United States which mitigate such risk associated with them. At times

          
 Research and development expenses consist primarily of costs associated with the preclinical and/ or clinical trials of drug candidates
 compensation and other expenses for research and development
 including personnel
 supplies and development materials

          
 - Property and equipment are stated at cost
 net of accumulated depreciation which is recorded using the straight line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives

          
Intangible assets are comprised of patents and licenses with original estimated useful lives of 10-15 years.&#160;&#160;Once placed into service
 the Company amortizes the cost of the intangible assets over their estimated useful lives on a straight line basis. As of December 31
 2013 the Company owns one patent that was internally developed and licenses two patents (See Note 4) and also has exclusive rights to two immunological patents related to vaccine development and delivery mechanism. Costs incurred by the Company in connection with developing patents internally are expensed as incurred.
          
            
          
 Revenue from license fees and grants is recognized when the following criteria are met: persuasive evidence of an arrangement exists
 services have been rendered
 the contract price is fixed or determinable
 and collection is reasonably assured.&#160;&#160;In licensing arrangements
 delivery does not occur for revenue recognition purposes until the license term begins. Nonrefundable upfront fees received in exchange for products delivered or services performed that do not represent the culmination of a separate earnings process will be deferred and recognized over the term of the agreement using the straight line method or another method if it better represents the timing and pattern of performance. For the years ended December 31
 2013 and 2012 and for the period from July 24
 2007 (inception) to December 31
 2013
 the

          


          
 Basic loss per share was computed using the weighted average number of common shares outstanding. Diluted loss per share includes the effect of diluted common stock equivalents. As of December 31
 2013
 and 2012

          
 -&#160;The financial instruments consist of cash
 accounts payables
 accrued expenses
 and short-term credit obligations.&#160;&#160;The carrying amounts of the financial instruments approximate their respective current fair values due to their relatively short maturities.&#160;The carrying amounts of short term credit obligations approximate fair value because the effective yields on these obligations
 which include contractual interest rates

          


          
            
          

 quoted prices from active market exchanges
 including over the counter traded financial instruments. The prices for the financial instruments are determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs

          

 if any

          
 - The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors
 the fair value of the award is measured on the grant date and for non-employees
 the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award

          
 - The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740
 Income Taxes. Under this method
 income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity's financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred
            tax assets reported if based on the weight of the available positive and negative evidence

          

 classification
 interest and penalties
 accounting in interim periods
 disclosure
 and transition. The Company will classify as income tax expense any interest and penalties. The Company has no material uncertain tax positions for any of the reporting periods presented. Generally
 the tax authorities may examine the partnership/corporate tax returns for three years from the date of filing. The Company has identified its federal return and its state tax return in New York as &#8220;major&#8221; tax jurisdictions

          
 The FASB has issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2013-11
 Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward
 a Similar Tax Loss
 or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU state that an unrecognized tax benefit
 or a portion of an unrecognized tax benefit
 should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward
 a similar tax loss
 or a tax credit carryforward
 except as follows. To the extent a net operating loss carryforward
 a similar tax loss
 or a tax credit carryforward is not available at the reporting
            date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use
 and the entity does not intend to use
 the deferred tax asset for such purpose
 the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The amendments in this ASU are effective for fiscal years
 and interim periods within those years
 beginning after December 15
 2013. For nonpublic entities
 the amendments are effective for fiscal years
 and interim periods within those years
 beginning after December 15
 2014. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption of this standard is not expected to have a material

          
              
            




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        

      







          

        


        
        


        
        



          

        


        
        


        
        



          

        


        
        


        
        



          

        


        
        


Property
 Plant and Equipment
 Useful Life
        


Finite-Lived Intangible Asset
 Useful Life
        



          

        


        
        


Property
 Plant and Equipment
 Useful Life
        


Finite-Lived Intangible Asset
 Useful Life
        




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 in 'PnYnMnDTnHnMnS' format
 for example
 'P1Y5M13D' represents the reported fact of one year
 five months
 and thirteen days.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 physical assets used in the normal conduct of business and not intended for resale
 in 'PnYnMnDTnHnMnS' format
 for example
 'P1Y5M13D' represents the reported fact of one year
 five months
 and thirteen days. Examples include
 but not limited to
 land
 buildings
 machinery and equipment
 office equipment
 furniture and fixtures
 and computer equipment.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















  

  
  
  
  
  
  
  
  
  


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      


      
      




      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      


      
      




      
      
      
      
      
      
      


      
      
      


      
      




      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      
      
      


      
      
      
      
      



    
    














    
    

Dec. 31


Dec. 31


Dec. 31


Dec. 31


Dec. 31

    

 2010


 2011

    


    
    
    
    
    
    



  
  













    
  
      

          











        
        
        


        

465

239


        

491

022


        

612
        


        

568

261


        

568)

261)


        
        
        




        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
 -Subparagraph (b)
(c)
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

 plant
 and equipment.
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    





















    
  
      

          

        

      






        
        


        

 Mr. Doug Cole resigned as officer of the Company. Mr. Cole resigned as a director of the Company on February 5
 2014. In addition

    
              


                    



                  



                    






                    



                  




 Chief Financial Officer




              


                    



                  



                    






                    



                  








              


                    



                  











                    



                  



                    



              


                    



                  



                    



            




        
          

        
          
            
                
              
                
              

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    








        
          

        
          
            

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    

                  
                    
                    













